No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d4fkwA_, 1.0000, 0.00, 1.000, 280, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
2, d4fkuA_, 0.9974, 0.31, 1.000, 293, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3, d5ievA_, 0.9969, 0.34, 0.996, 284, 280, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
4, d4fkvA_, 0.9964, 0.38, 1.000, 282, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
5, d2xnbA_, 0.9959, 0.40, 0.996, 296, 280, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
6, d5ieyA_, 0.9954, 0.43, 0.996, 286, 280, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
7, d3uliA_, 0.9942, 0.56, 0.993, 286, 280, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
8, d3lfnA_, 0.9938, 0.52, 0.993, 285, 280, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
9, d2b52A_, 0.9935, 0.53, 0.996, 283, 280, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
10, d3pj8A1, 0.9927, 0.57, 0.996, 287, 280, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
11, d2c6iA_, 0.9924, 0.40, 0.996, 292, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
12, d2a0cX_, 0.9923, 0.57, 0.993, 294, 280, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
13, d1ykrA_, 0.9923, 0.56, 0.996, 298, 280, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
14, d2xmyA_, 0.9914, 0.62, 0.996, 295, 280, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
15, d4lynA_, 0.9912, 0.46, 0.996, 287, 279, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
16, d1pxjA_, 0.9912, 0.61, 0.993, 294, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
17, d3wblA_, 0.9911, 0.46, 0.996, 283, 279, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
18, d2clxA_, 0.9909, 0.62, 0.996, 293, 280, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
19, d1pxoA_, 0.9909, 0.70, 0.993, 294, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
20, d1di8A_, 0.9909, 0.47, 1.000, 283, 279, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
21, d5iexA_, 0.9907, 0.48, 1.000, 285, 279, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
22, d1pxpA_, 0.9907, 0.63, 0.996, 294, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
23, d2vv9A_, 0.9906, 0.52, 1.000, 279, 279, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
24, d3qxoA_, 0.9902, 0.64, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
25, d1hckA_, 0.9902, 0.66, 0.993, 294, 280, HUMAN CYCLIN-DEPENDENT KINASE 2
26, d2exmA_, 0.9901, 0.63, 0.993, 298, 280, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
27, d2c6kA_, 0.9899, 0.51, 0.996, 292, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
28, d3r1sA_, 0.9895, 0.66, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
29, d2w1hA_, 0.9895, 0.54, 0.996, 283, 279, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
30, d1hclA_, 0.9894, 0.67, 0.993, 294, 280, HUMAN CYCLIN-DEPENDENT KINASE 2
31, d3raiA_, 0.9893, 0.67, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
32, d3qtwA_, 0.9893, 0.68, 0.986, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
33, d2b54A_, 0.9893, 0.66, 0.993, 298, 280, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
34, d3r8uA_, 0.9892, 0.67, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
35, d3r73A_, 0.9892, 0.67, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
36, d2v0dA_, 0.9891, 0.54, 0.996, 292, 279, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
37, d3r6xA_, 0.9890, 0.68, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
38, d2c69A_, 0.9890, 0.55, 0.996, 292, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
39, d1pw2A_, 0.9890, 0.68, 0.993, 294, 280, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
40, d3rkbA_, 0.9888, 0.70, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
41, d3r71A_, 0.9888, 0.68, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
42, d4fkrA_, 0.9886, 0.42, 1.000, 282, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
43, d3r1yA_, 0.9886, 0.69, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
44, d3rk9A_, 0.9885, 0.72, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
45, d3qtqA_, 0.9884, 0.72, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
46, d3rpoA_, 0.9883, 0.70, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
47, d1pxiA_, 0.9883, 0.69, 0.993, 294, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
48, d3royA_, 0.9882, 0.71, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
49, d3rm7A_, 0.9882, 0.71, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
50, d5aneA_, 0.9880, 0.72, 0.993, 294, 280, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
51, d1ke9A_, 0.9880, 0.44, 1.000, 281, 278, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
52, d3qzhA_, 0.9879, 0.72, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
53, d1y8yA_, 0.9879, 0.59, 0.996, 292, 279, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
54, d1ke5A_, 0.9879, 0.45, 0.996, 281, 278, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
55, d3qqfA_, 0.9878, 0.72, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L1
56, d2w06A_, 0.9878, 0.45, 1.000, 282, 278, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
57, d1ke8A_, 0.9878, 0.45, 0.996, 282, 278, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
58, d1ke7A_, 0.9878, 0.45, 0.996, 281, 278, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
59, d3r9dA_, 0.9877, 0.74, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
60, d3qzfA_, 0.9877, 0.72, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
61, d3s0oA_, 0.9876, 0.75, 0.989, 293, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
62, d3r7vA_, 0.9876, 0.71, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
63, d3r28A_, 0.9876, 0.72, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
64, d1wccA_, 0.9876, 0.61, 0.993, 283, 279, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
65, d1fvtA_, 0.9875, 0.46, 0.996, 282, 278, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
66, d3qu0A_, 0.9874, 0.76, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
67, d3rk7A_, 0.9873, 0.77, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
68, d3r7eA_, 0.9873, 0.73, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
69, d3s00A_, 0.9872, 0.72, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L4-14
70, d3rk5A_, 0.9871, 0.78, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
71, d3r7yA_, 0.9871, 0.73, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
72, d2vtoA_, 0.9868, 0.49, 0.996, 283, 278, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
73, d3tiyA_, 0.9866, 0.66, 0.996, 293, 279, CDK2 IN COMPLEX WITH NSC 35676
74, d3r8zA_, 0.9866, 0.77, 0.996, 290, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
75, d2c6lA_, 0.9866, 0.50, 0.996, 291, 278, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
76, d4fkqA_, 0.9863, 0.52, 1.000, 283, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
77, d5k4jA1, 0.9862, 0.54, 0.996, 281, 278, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
78, d3r1qA_, 0.9861, 0.78, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
79, d3rjcA_, 0.9860, 0.78, 0.986, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L4-12
80, d3fz1A_, 0.9858, 0.54, 0.996, 284, 278, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
81, d3ti1A_, 0.9857, 0.80, 0.996, 294, 280, CDK2 IN COMPLEX WITH SUNITINIB
82, d3r8vA_, 0.9856, 0.79, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
83, d3qx2A_, 0.9856, 0.78, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
84, d3qtxA_, 0.9856, 0.80, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
85, d3qqjA_, 0.9854, 0.78, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L2
86, d2w17A_, 0.9853, 0.64, 0.993, 278, 278, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
87, d4kd1A_, 0.9852, 0.78, 0.996, 298, 280, CDK2 IN COMPLEX WITH DINACICLIB
88, d3rpvA_, 0.9852, 0.81, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
89, d1y91A_, 0.9849, 0.57, 0.996, 286, 278, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
90, d3sqqA_, 0.9848, 0.82, 0.996, 288, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
91, d3ql8A_, 0.9848, 0.82, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
92, d1ke6A_, 0.9848, 0.43, 1.000, 280, 277, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
93, d3rniA_, 0.9846, 0.83, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
94, d3qxpA_, 0.9846, 0.83, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
95, d5anjA_, 0.9845, 0.58, 0.996, 291, 278, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
96, d3qtzA_, 0.9845, 0.85, 0.986, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
97, d3qwjA_, 0.9844, 0.82, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
98, d3qqkA_, 0.9842, 0.84, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L4
99, d3pxrA_, 0.9842, 0.83, 0.996, 294, 280, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
100, d4bzdA_, 0.9841, 0.47, 0.996, 277, 277, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
101, d1w0xC_, 0.9841, 0.45, 1.000, 280, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
102, d3r9hA_, 0.9840, 0.85, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
103, d2b53A_, 0.9840, 0.81, 0.993, 294, 280, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
104, d3rm6A_, 0.9839, 0.73, 0.986, 293, 279, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
105, d3qx4A_, 0.9839, 0.83, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
106, d2vtiA_, 0.9838, 0.47, 0.996, 280, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
107, d2uzoA_, 0.9838, 0.47, 1.000, 290, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
108, d3tizA_, 0.9833, 0.74, 0.996, 293, 279, CDK2 IN COMPLEX WITH NSC 111848
109, d3qziA_, 0.9833, 0.85, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
110, d2vtpA_, 0.9831, 0.50, 0.996, 281, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
111, d2c6mA_, 0.9830, 0.51, 0.996, 290, 277, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
112, d1pf8A_, 0.9830, 0.97, 0.989, 298, 280, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
113, d1h08A_, 0.9830, 0.51, 0.996, 283, 277, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
114, d2c6oA_, 0.9829, 0.51, 0.996, 290, 277, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
115, d4ez3A_, 0.9828, 0.89, 0.996, 294, 280, CDK2 IN COMPLEX WITH NSC 134199
116, d3qwkA_, 0.9828, 0.88, 0.986, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
117, d3qqgA_, 0.9828, 0.85, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L2-5
118, d2vtmA_, 0.9825, 0.52, 0.996, 290, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
119, d4erwA_, 0.9824, 0.79, 1.000, 292, 279, CDK2 IN COMPLEX WITH STAUROSPORINE
120, d3r8lA_, 0.9823, 0.87, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L3-4
121, d3qzgA_, 0.9823, 0.89, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
122, d1h0vA_, 0.9823, 0.65, 0.996, 288, 278, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
123, d3r8pA_, 0.9821, 0.88, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
124, d1pxnA_, 0.9821, 0.86, 0.996, 294, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
125, d3r7uA_, 0.9819, 0.55, 0.996, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
126, d2vtsA_, 0.9819, 0.54, 0.996, 282, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
127, d3iggA_, 0.9818, 0.55, 0.996, 290, 277, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
128, d3ezvA_, 0.9817, 0.59, 0.996, 277, 277, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
129, d1h0uA_, 0.9816, 0.68, 0.996, 291, 278,  
130, d1gihA_, 0.9816, 0.41, 1.000, 276, 276, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
131, d2vtrA_, 0.9815, 0.56, 0.996, 290, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
132, d3rmfA_, 0.9814, 0.71, 1.000, 278, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
133, d3r83A_, 0.9814, 0.88, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
134, d3qruA_, 0.9814, 0.91, 0.996, 295, 280, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
135, d3sw7A_, 0.9813, 0.72, 1.000, 278, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
136, d3qtuA_, 0.9813, 0.98, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
137, d3unkA_, 0.9810, 0.91, 0.996, 295, 280, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
138, d3rpyA_, 0.9810, 0.60, 1.000, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
139, d1w8cA_, 0.9810, 0.58, 0.996, 290, 277, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
140, d1b39A_, 0.9809, 0.58, 0.996, 290, 277, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
141, d3rzbA_, 0.9808, 0.61, 1.000, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
142, d2r3rA_, 0.9808, 0.59, 0.996, 290, 277, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
143, d3r9oA_, 0.9807, 0.62, 1.000, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
144, d2r3jA_, 0.9807, 0.45, 0.996, 278, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
145, d2b55A_, 0.9807, 0.47, 1.000, 276, 276, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
146, d1giiA_, 0.9807, 0.45, 0.986, 279, 276, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
147, d4acmA_, 0.9806, 0.45, 1.000, 277, 276, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
148, d1pxmA_, 0.9806, 0.60, 1.000, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
149, d1pxlA_, 0.9806, 0.59, 0.996, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
150, d2vtlA_, 0.9805, 0.60, 0.996, 290, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
151, d2r3kA_, 0.9805, 0.46, 0.996, 277, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
152, d2ds1A_, 0.9804, 0.60, 0.986, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
153, d2c68A_, 0.9804, 0.60, 0.996, 290, 277, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
154, d4fkiA_, 0.9803, 0.61, 0.996, 287, 277, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
155, d3py0A_, 0.9803, 0.91, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR SU9516
156, d2r3fA_, 0.9803, 0.60, 0.996, 290, 277, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
157, d1h07A_, 0.9802, 0.47, 0.996, 285, 276, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
158, d4fkoA_, 0.9797, 0.76, 1.000, 291, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
159, d1h0wA_, 0.9797, 0.79, 0.996, 283, 277, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
160, d3r7iA_, 0.9796, 0.63, 0.996, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
161, d2r3mA_, 0.9795, 0.50, 0.996, 278, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
162, d3qqhA_, 0.9794, 0.94, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L2-2
163, d3pxyA_, 0.9793, 0.94, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR JWS648
164, d3qqlA_, 0.9791, 0.98, 0.989, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L3
165, d1h06A_, 0.9791, 0.52, 0.996, 277, 276,  
166, d1b38A_, 0.9790, 0.65, 0.996, 290, 277, HUMAN CYCLIN-DEPENDENT KINASE 2
167, d3qrtA_, 0.9789, 1.00, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
168, d1h00A_, 0.9786, 0.38, 0.996, 278, 275, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
169, d1pxkA_, 0.9785, 0.67, 0.996, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
170, d1v1kA_, 0.9784, 0.54, 0.996, 277, 276, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
171, d3qtsA_, 0.9783, 0.69, 1.000, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
172, d2r3hA_, 0.9783, 0.55, 0.996, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
173, d4ek8A_, 0.9782, 0.56, 0.996, 280, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
174, d3rahA_, 0.9782, 0.69, 1.000, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
175, d2r3pA_, 0.9782, 0.56, 0.996, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
176, d2r3lA_, 0.9781, 0.41, 1.000, 275, 275, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
177, d4fklA_, 0.9780, 0.68, 0.996, 290, 277, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
178, d4fkpA_, 0.9779, 0.57, 0.996, 279, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
179, d2uznA_, 0.9778, 0.57, 1.000, 279, 276, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
180, d1gz8A_, 0.9777, 0.69, 0.996, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
181, d1e1vA_, 0.9777, 0.69, 0.996, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
182, d4fkjA_, 0.9776, 0.58, 0.996, 278, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
183, d5anoA_, 0.9775, 0.43, 0.996, 277, 275, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
184, d3qtrA_, 0.9775, 0.72, 1.000, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
185, d3rprA_, 0.9774, 0.71, 1.000, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
186, d2vtaA_, 0.9774, 0.44, 0.996, 278, 275, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
187, d3s1hA_, 0.9773, 0.72, 1.000, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
188, d2vthA_, 0.9771, 0.45, 0.996, 278, 275, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
189, d1e1xA_, 0.9771, 0.71, 0.996, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
190, d3sw4A_, 0.9770, 0.46, 1.000, 279, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
191, d3r9nA_, 0.9769, 0.73, 1.000, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
192, d2vtjA_, 0.9769, 0.46, 1.000, 276, 275, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
193, d4fkgA_, 0.9765, 0.61, 0.996, 286, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
194, d2r64A_, 0.9764, 0.63, 0.996, 279, 276, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
195, d2r3oA_, 0.9762, 0.62, 0.996, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
196, d2c5yA_, 0.9759, 0.75, 0.996, 290, 277, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
197, d3ralA_, 0.9758, 0.77, 1.000, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
198, d3rakA_, 0.9758, 0.78, 1.000, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
199, d2r3iA_, 0.9758, 0.63, 0.996, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
200, d3ns9A_, 0.9757, 0.64, 0.996, 289, 276, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
201, d3lfsA_, 0.9757, 0.75, 0.996, 290, 277, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
202, d4bghA_, 0.9754, 0.53, 1.000, 275, 275, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
203, d4ek5A_, 0.9753, 0.66, 0.996, 289, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
204, d3ig7A_, 0.9749, 0.55, 0.996, 278, 275, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
205, d2w05A_, 0.9748, 0.56, 1.000, 276, 275, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
206, d5jq8A_, 0.9746, 0.40, 0.996, 278, 274, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
207, d3s2pA_, 0.9746, 0.68, 0.996, 279, 276, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
208, d1ckpA_, 0.9743, 0.70, 0.996, 279, 276, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
209, d1aq1A_, 0.9742, 0.68, 1.000, 277, 276, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
210, d1g5sA_, 0.9739, 0.59, 0.996, 275, 275, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
211, d3r8mA_, 0.9738, 1.09, 0.982, 286, 279, CDK2 IN COMPLEX WITH INHIBITOR L3-3
212, d2vtnA_, 0.9734, 0.48, 1.000, 274, 274, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
213, d4ek6A_, 0.9732, 0.61, 0.996, 278, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
214, d5aniA_, 0.9731, 0.61, 0.996, 280, 275, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
215, d4fksA_, 0.9731, 0.48, 1.000, 275, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
216, d4gcjA1, 0.9727, 1.10, 0.989, 298, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
217, d2vtqA_, 0.9721, 0.53, 1.000, 274, 274, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
218, d3unjA_, 0.9719, 1.11, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
219, d4nj3A_, 0.9718, 0.83, 1.000, 277, 276, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
220, d1vyzA_, 0.9713, 0.55, 1.000, 279, 274, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
221, d4fktA_, 0.9711, 0.55, 0.996, 278, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
222, d3lfqA_, 0.9707, 0.80, 0.996, 289, 276, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
223, d1r78A_, 0.9707, 0.42, 1.000, 273, 273, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
224, d2r3nA_, 0.9705, 0.70, 0.996, 275, 275, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
225, d2j9mA_, 0.9702, 0.72, 0.996, 275, 275, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
226, d2btrA_, 0.9701, 0.60, 1.000, 275, 274, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
227, d2bheA_, 0.9699, 0.61, 0.996, 274, 274, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
228, d1gijA_, 0.9696, 0.46, 0.989, 273, 273, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
229, d1dm2A_, 0.9693, 0.64, 0.996, 274, 274, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
230, d3ezrA_, 0.9690, 0.49, 1.000, 273, 273, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
231, d2vu3A_, 0.9690, 1.11, 0.986, 285, 276, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
232, d2r3gA_, 0.9688, 0.64, 0.996, 287, 274, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
233, d1jsvA_, 0.9683, 0.65, 0.996, 287, 274, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
234, p5oo0A_, 0.9676, 0.78, 0.996, 288, 275, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
235, d5mhqA1, 0.9675, 0.79, 0.996, 288, 275, CCT068127 IN COMPLEX WITH CDK2
236, d4ek4A_, 0.9666, 0.71, 0.996, 287, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
237, d1urwA_, 0.9660, 0.47, 0.996, 274, 272, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
238, d2r3qA_, 0.9659, 0.61, 0.996, 286, 273, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
239, d5jq5A_, 0.9656, 0.74, 0.993, 287, 274, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
240, d4ek3A_, 0.9652, 0.75, 0.996, 287, 274, CRYSTAL STRUCTURE OF APO CDK2
241, d4rj3A_, 0.9651, 0.75, 0.996, 287, 274, CDK2 WITH EGFR INHIBITOR COMPOUND 8
242, d2bhhA_, 0.9642, 0.79, 0.996, 274, 274, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
243, d2btsA_, 0.9635, 0.80, 0.996, 274, 274, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
244, d2a4lA_, 0.9635, 0.69, 0.996, 286, 273, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
245, d1oitA_, 0.9623, 0.48, 0.993, 273, 271, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
246, d2vttA_, 0.9622, 0.70, 0.996, 272, 272, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
247, d5fp6A_, 0.9599, 0.85, 0.985, 278, 273, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
248, d2fvdA_, 0.9592, 0.87, 0.993, 284, 273, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
249, d1oirA_, 0.9585, 0.84, 0.996, 286, 273, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
250, d4ez7A1, 0.9584, 1.40, 0.975, 298, 280, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
251, d1h01A_, 0.9581, 0.85, 0.996, 286, 273, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
252, d2duvA_, 0.9578, 0.66, 1.000, 272, 271, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
253, d1p2aA_, 0.9577, 0.68, 0.993, 271, 271, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
254, d4d1xA_, 0.9572, 0.54, 1.000, 274, 270, CDK2 IN COMPLEX WITH LUCIFERIN
255, d5andA_, 0.9571, 0.54, 0.996, 273, 270, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
256, d3pxqA1, 0.9548, 1.47, 0.968, 294, 280, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
257, d3le6A_, 0.9539, 0.66, 0.996, 283, 270, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
258, d5ankA_, 0.9532, 0.68, 0.996, 273, 270, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
259, d3py1A1, 0.9531, 1.47, 0.971, 298, 280, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
260, d5angA_, 0.9526, 0.46, 0.996, 268, 268, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
261, d3pxfA1, 0.9526, 1.49, 0.968, 298, 280, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
262, d1jvpP_, 0.9501, 0.63, 0.985, 268, 268, CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365
263, d3pxzA1, 0.9493, 1.55, 0.968, 298, 280, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
264, d1pyeA_, 0.9449, 0.46, 1.000, 266, 266, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
265, d5d1jA_, 0.9440, 0.31, 1.000, 265, 265, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
266, d1oiqA_, 0.9394, 0.38, 1.000, 264, 264, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
267, d1buhA_, 0.9391, 1.39, 0.989, 287, 274, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
268, d5fp5A_, 0.9338, 0.65, 1.000, 264, 264, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
269, d1fvvA_, 0.9334, 2.01, 0.996, 298, 280, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
270, d4fx3A_, 0.9331, 1.88, 0.996, 298, 279, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
271, d4fx3C_, 0.9321, 1.89, 0.996, 298, 279, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
272, d3qhwC1, 0.9298, 1.83, 0.996, 295, 277, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
273, d3qhwA1, 0.9291, 1.84, 0.996, 295, 277, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
274, d3qhrC1, 0.9283, 1.84, 0.996, 295, 277, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
275, d3qhrA1, 0.9279, 1.85, 0.996, 295, 277, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
276, d1h1pA1, 0.9277, 1.83, 0.968, 295, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
277, d2uzdA_, 0.9274, 1.86, 1.000, 295, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
278, d4eokA1, 0.9273, 1.93, 0.989, 292, 278, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
279, d1ob3A_, 0.9263, 1.22, 0.627, 277, 268, STRUCTURE OF P. FALCIPARUM PFPK5
280, d1v0pA_, 0.9257, 1.23, 0.627, 277, 268, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
281, d2c6tA_, 0.9255, 1.90, 1.000, 295, 277, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
282, d4yc6E_, 0.9252, 1.37, 0.652, 285, 270, CDK1/CKS1
283, d1h1pC1, 0.9251, 1.87, 0.968, 295, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
284, d1h1sC1, 0.9247, 1.91, 0.996, 295, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
285, d5if1A_, 0.9239, 2.02, 0.996, 298, 279, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
286, d2cchC2, 0.9238, 1.90, 0.964, 295, 277, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
287, d4ii5A_, 0.9231, 1.94, 0.996, 295, 277, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
288, d2iw8A1, 0.9231, 1.99, 0.989, 296, 278, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
289, d4ii5C_, 0.9229, 1.94, 0.996, 295, 277, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
290, d4eolA1, 0.9225, 1.95, 0.986, 293, 277, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
291, d2wxvA1, 0.9224, 2.03, 0.996, 298, 279, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
292, d1v0bA_, 0.9224, 1.29, 0.616, 286, 268, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
293, d5cyiA1, 0.9222, 2.05, 0.996, 297, 279, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
294, d4yc6A_, 0.9221, 1.43, 0.652, 285, 270, CDK1/CKS1
295, d4i3zA_, 0.9221, 1.97, 0.996, 295, 277, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
296, d1h1rC1, 0.9217, 1.94, 0.993, 295, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
297, d4yc6C_, 0.9216, 1.44, 0.652, 285, 270, CDK1/CKS1
298, d2i40A_, 0.9216, 2.13, 1.000, 291, 279, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
299, d5cyiC1, 0.9215, 1.97, 0.996, 295, 277, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
300, d4i3zC_, 0.9215, 1.97, 0.996, 295, 277, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
301, d4eoiC1, 0.9215, 1.97, 0.993, 295, 277, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
302, d4eonC1, 0.9209, 2.02, 0.989, 296, 278, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
303, d1oiyC1, 0.9209, 1.98, 0.996, 295, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
304, d3eidA_, 0.9202, 2.16, 1.000, 292, 279, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
305, d4eopC1, 0.9201, 1.98, 0.996, 295, 277, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
306, d3ddpC1, 0.9200, 2.07, 0.996, 297, 279, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
307, d1h1qC1, 0.9200, 2.00, 1.000, 295, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
308, d1finA_, 0.9200, 2.08, 0.996, 298, 279, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
309, d1oi9C1, 0.9195, 1.98, 0.996, 295, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
310, d2wihA1, 0.9191, 2.07, 0.996, 298, 279, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
311, d1jstC_, 0.9190, 2.10, 1.000, 297, 279, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
312, d1h1sA1, 0.9187, 2.01, 1.000, 295, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
313, d2iw6C2, 0.9184, 1.97, 0.993, 294, 276, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
314, d1qmzC1, 0.9183, 2.01, 1.000, 295, 277, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
315, d2uzeC_, 0.9178, 1.99, 1.000, 295, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
316, d1qmzA1, 0.9178, 2.02, 1.000, 295, 277, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
317, d4eolC1, 0.9177, 2.05, 0.986, 296, 278, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
318, d2uzlC_, 0.9175, 2.01, 1.000, 295, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
319, d4bcoA1, 0.9173, 2.11, 0.996, 297, 279, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
320, d2uzlA_, 0.9173, 2.01, 1.000, 295, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
321, d2g9xA2, 0.9172, 2.12, 1.000, 297, 279, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
322, d1vywA1, 0.9172, 2.12, 0.996, 298, 279, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
323, d3ddpA1, 0.9171, 2.08, 0.996, 296, 278, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
324, d4yc6G_, 0.9169, 1.55, 0.652, 285, 270, CDK1/CKS1
325, d2uzeA_, 0.9168, 2.00, 1.000, 295, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
326, d3bhuA1, 0.9166, 2.12, 1.000, 295, 279, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
327, d1h1rA1, 0.9166, 2.04, 0.993, 295, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
328, d5hq0A1, 0.9165, 1.53, 0.659, 289, 270, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
329, d4y72A1, 0.9165, 1.53, 0.659, 289, 270, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
330, d1oiuA1, 0.9165, 2.10, 1.000, 293, 278, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
331, d3dogA1, 0.9163, 2.14, 1.000, 296, 279, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
332, d4eonA1, 0.9162, 2.18, 0.986, 297, 279, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
333, d2iw9A2, 0.9162, 2.09, 0.996, 292, 278, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
334, d1oiyA1, 0.9162, 2.06, 1.000, 292, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
335, d4eosC1, 0.9159, 2.04, 1.000, 295, 277, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
336, d4bcpA1, 0.9159, 2.13, 0.996, 297, 279, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
337, d2cchA2, 0.9159, 2.06, 0.996, 295, 277, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
338, d1h1qA1, 0.9159, 2.06, 1.000, 295, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
339, d1gy3C_, 0.9159, 2.03, 1.000, 295, 277, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
340, d4bcnA1, 0.9158, 2.15, 1.000, 295, 279, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
341, d1gy3A_, 0.9158, 2.03, 1.000, 295, 277, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
342, d1oguA1, 0.9156, 2.10, 1.000, 293, 278, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
343, d1oi9A1, 0.9155, 2.06, 1.000, 294, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
344, d5nevA1, 0.9153, 2.02, 0.993, 294, 276, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
345, d5lmkA1, 0.9149, 2.16, 0.996, 295, 279, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
346, d4eoiA1, 0.9144, 2.16, 0.993, 293, 279, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
347, d4cfwC1, 0.9143, 2.06, 0.996, 295, 277, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
348, d3bhtA2, 0.9142, 2.16, 1.000, 295, 279, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
349, d4eokC1, 0.9140, 2.09, 0.986, 296, 278, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
350, d2bpmA2, 0.9140, 2.15, 0.996, 298, 279, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
351, d3ddqA1, 0.9136, 2.18, 0.996, 295, 279, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
352, d3gc0A_, 0.9135, 1.77, 0.554, 278, 271, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
353, d5lqfA1, 0.9132, 1.52, 0.658, 284, 269, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
354, d4d1zA_, 0.9129, 0.63, 1.000, 258, 258, CDK2 IN COMPLEX WITH A LUCIFERIN DERIVATE
355, d4eopA1, 0.9126, 2.13, 0.993, 294, 278, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
356, d4eorA1, 0.9123, 2.14, 1.000, 292, 278, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
357, d2c4gC2, 0.9123, 2.20, 0.996, 298, 279, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
358, d2c5pC_, 0.9119, 2.17, 0.996, 296, 278,  
359, d2bkzA2, 0.9119, 2.32, 0.996, 298, 280, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
360, d2iw6A1, 0.9117, 2.07, 0.996, 291, 276, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
361, d4eooC1, 0.9116, 2.12, 0.996, 295, 277, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
362, d3f5xC_, 0.9116, 2.30, 0.996, 298, 280, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
363, d1h28A1, 0.9116, 2.09, 1.000, 295, 277, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
364, d4cfmA1, 0.9112, 2.12, 1.000, 295, 277, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
365, d2cciC2, 0.9112, 2.12, 1.000, 295, 277, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
366, d4eojA1, 0.9111, 2.22, 0.986, 293, 279, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
367, d4bcnC1, 0.9111, 2.03, 1.000, 293, 275, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
368, d1h28C1, 0.9111, 2.11, 1.000, 295, 277, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
369, d2uzbA_, 0.9110, 2.09, 1.000, 295, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
370, d1fvvC_, 0.9110, 2.29, 0.993, 298, 280, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
371, d2wpaA1, 0.9109, 2.21, 0.996, 298, 279, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
372, d1okuC_, 0.9108, 2.18, 0.996, 296, 278,  
373, d2c5nC_, 0.9107, 2.19, 0.996, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
374, d2c5nA_, 0.9106, 2.20, 1.000, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
375, d5lqfD1, 0.9104, 1.51, 0.657, 282, 268, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
376, d2c5vC_, 0.9104, 2.19, 0.996, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
377, d3f5xA_, 0.9100, 2.29, 0.996, 297, 279, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
378, d1ol2C_, 0.9100, 2.19, 0.996, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
379, d1fq1B_, 0.9100, 2.12, 0.996, 295, 278, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
380, d2c4gA2, 0.9097, 2.15, 0.964, 297, 278, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
381, d1urcC_, 0.9096, 2.23, 0.996, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
382, d4eosA1, 0.9095, 2.18, 1.000, 293, 278, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
383, d3bhvA1, 0.9095, 2.23, 0.996, 295, 279, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
384, d2wevC_, 0.9094, 2.21, 0.996, 296, 278, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
385, d2wxvC1, 0.9092, 2.21, 0.996, 298, 279, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
386, d2uzbC_, 0.9092, 2.12, 1.000, 292, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
387, d1ol1C_, 0.9091, 2.22, 0.996, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
388, d2wmbA1, 0.9089, 2.16, 1.000, 295, 277, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
389, d5nevC1, 0.9083, 2.14, 0.996, 295, 277, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
390, d3my5A1, 0.9083, 2.25, 1.000, 294, 279, CDK2/CYCLINA IN COMPLEX WITH DRB
391, d2v22C_, 0.9082, 2.24, 0.996, 296, 278, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
392, d2c5oC_, 0.9082, 2.24, 0.996, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
393, d4bcmA1, 0.9081, 2.17, 1.000, 292, 277, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
394, d4cfnA1, 0.9080, 2.22, 0.996, 293, 278, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
395, d2c5oA_, 0.9079, 2.24, 0.996, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
396, d4cfnC1, 0.9078, 2.06, 0.996, 293, 275, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
397, d4cfwA1, 0.9076, 2.27, 0.996, 297, 279, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
398, d2bkzC2, 0.9076, 2.34, 0.996, 297, 279, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
399, d3tnwA1, 0.9074, 2.27, 1.000, 294, 279, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
400, d4eooA1, 0.9073, 2.22, 0.996, 292, 278, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
401, d4cfuA1, 0.9073, 2.27, 1.000, 295, 279, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
402, d4cfvA1, 0.9070, 2.27, 0.996, 297, 279, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
403, d4eomA1, 0.9068, 2.24, 0.986, 294, 278, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
404, d2c5vA_, 0.9068, 2.25, 0.996, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
405, d1h26A1, 0.9068, 2.19, 1.000, 295, 277, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
406, d2c5pA_, 0.9066, 2.24, 1.000, 296, 278,  
407, d1okuA_, 0.9066, 2.25, 0.996, 296, 278,  
408, d2cciA2, 0.9065, 2.18, 1.000, 295, 277, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
409, d1pkdA1, 0.9065, 2.20, 1.000, 295, 277, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
410, d4bcmC1, 0.9063, 2.10, 0.996, 293, 275, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
411, d2wevA_, 0.9062, 2.25, 1.000, 296, 278, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
412, d2uueC_, 0.9062, 2.28, 0.996, 296, 278, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
413, d2c5tC_, 0.9061, 2.28, 0.996, 296, 278,  
414, d2x1nC_, 0.9060, 2.28, 0.996, 296, 278, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
415, d2whaC_, 0.9060, 2.28, 0.996, 296, 278,  
416, d2c6tC_, 0.9060, 2.15, 1.000, 295, 277, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
417, d2c5xA_, 0.9058, 2.27, 0.996, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
418, d1urcA_, 0.9057, 2.28, 0.996, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
419, d2c5xC_, 0.9054, 2.26, 0.996, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
420, d2whaA_, 0.9053, 2.30, 0.996, 296, 278,  
421, d2x1nA_, 0.9052, 2.30, 0.996, 296, 278, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
422, d1vywC1, 0.9051, 2.40, 0.996, 298, 280, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
423, d2wipA1, 0.9045, 2.05, 0.996, 293, 274, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
424, d1ua2A_, 0.9045, 1.74, 0.430, 286, 270, CRYSTAL STRUCTURE OF HUMAN CDK7
425, d2wmaA1, 0.9044, 2.23, 0.996, 295, 277, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
426, d4eoqA1, 0.9043, 2.26, 1.000, 293, 278, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
427, d2wihC1, 0.9042, 2.29, 0.996, 298, 279, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
428, d1okvC_, 0.9042, 2.26, 0.996, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
429, d2wfyC_, 0.9039, 2.28, 0.996, 296, 278, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
430, d1e9hC1, 0.9039, 2.20, 1.000, 295, 277, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
431, d5a14A_, 0.9038, 2.25, 0.953, 284, 277, HUMAN CDK2 WITH TYPE II INHIBITOR
432, d1okwC_, 0.9038, 2.28, 0.996, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
433, d5uq2A_, 0.9036, 2.27, 0.996, 296, 277, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
434, d2uzdC_, 0.9034, 2.20, 1.000, 295, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
435, d3gbzA_, 0.9033, 1.78, 0.556, 274, 268, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
436, d2whbA_, 0.9033, 2.33, 0.996, 296, 278, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
437, d5if1C_, 0.9032, 2.30, 0.993, 296, 278, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
438, d1ua2D_, 0.9031, 1.76, 0.433, 286, 270, CRYSTAL STRUCTURE OF HUMAN CDK7
439, d1ua2B_, 0.9022, 1.78, 0.433, 286, 270, CRYSTAL STRUCTURE OF HUMAN CDK7
440, d2whbC_, 0.9020, 2.32, 0.996, 296, 278, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
441, d2v22A_, 0.9020, 2.32, 0.996, 296, 278, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
442, d1pkdC1, 0.9018, 2.23, 1.000, 295, 277, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
443, d3tnwC_, 0.9017, 2.06, 0.996, 291, 273, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
444, d1ol2A_, 0.9016, 2.33, 1.000, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
445, d1p5eA1, 0.9015, 2.25, 1.000, 295, 277, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
446, d2uueA_, 0.9014, 2.34, 0.996, 296, 278, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
447, d2c5tA_, 0.9010, 2.35, 0.996, 296, 278,  
448, d2i40C_, 0.9006, 2.36, 0.996, 296, 278, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
449, d2wpaC1, 0.9004, 2.35, 0.996, 298, 279, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
450, d1f5qA_, 0.9001, 2.32, 0.939, 296, 277, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
451, d1e9hA_, 0.9001, 2.28, 1.000, 295, 277, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
452, d1h27A1, 0.9000, 2.28, 1.000, 295, 277, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
453, d2bpmC2, 0.8999, 2.36, 0.996, 298, 279, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
454, d1p5eC1, 0.8996, 2.26, 1.000, 295, 277, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
455, d1ua2C_, 0.8994, 1.83, 0.433, 286, 270, CRYSTAL STRUCTURE OF HUMAN CDK7
456, d1jstA_, 0.8994, 2.40, 0.993, 297, 279, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
457, d1ol1A_, 0.8986, 2.36, 1.000, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
458, d1okwA_, 0.8975, 2.38, 0.996, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
459, d1finC_, 0.8973, 2.39, 0.993, 298, 279, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
460, d2wfyA_, 0.8962, 2.35, 0.996, 295, 277, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
461, d2wipC1, 0.8959, 2.09, 0.996, 291, 272, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
462, d5l2wA1, 0.8946, 2.10, 0.996, 296, 271, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
463, d4ogrI_, 0.8933, 2.43, 0.399, 318, 278, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
464, d4or5A_, 0.8928, 2.42, 0.401, 319, 277, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
465, d1blxA_, 0.8927, 2.11, 0.498, 305, 271, P19INK4D/CDK6 COMPLEX
466, d4ogrA_, 0.8926, 2.45, 0.399, 314, 278, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
467, d1okvA_, 0.8923, 2.37, 0.924, 295, 275, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
468, d1h25A1, 0.8923, 2.26, 0.993, 292, 274, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
469, d4yc3A1, 0.8922, 1.96, 0.652, 294, 270, CDK1/CYCLINB1/CKS2 APO
470, d3my1A_, 0.8919, 2.32, 0.399, 314, 276, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
471, d2cjmC_, 0.8915, 2.32, 0.993, 294, 276, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
472, d4j71A_, 0.8914, 2.30, 0.332, 347, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
473, d1unlB_, 0.8911, 2.09, 0.585, 292, 270, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
474, d4j1rC_, 0.8906, 2.32, 0.336, 344, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
475, d4bcgA_, 0.8905, 2.31, 0.402, 312, 276, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
476, d4or5F_, 0.8904, 2.47, 0.404, 324, 277, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
477, d4j1rA_, 0.8904, 2.32, 0.336, 343, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
478, d4j1rD_, 0.8903, 2.32, 0.336, 345, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
479, d4bckA1, 0.8900, 2.42, 0.996, 296, 278, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
480, d4bchA_, 0.8889, 2.33, 0.402, 308, 276, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
481, d1v0bB_, 0.8883, 1.22, 0.591, 261, 257, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
482, d1h24A1, 0.8881, 2.33, 0.996, 292, 274, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
483, d4ogrE_, 0.8873, 2.34, 0.398, 310, 274, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
484, d1gngB_, 0.8872, 2.38, 0.332, 355, 274, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
485, d4bcfA_, 0.8869, 2.34, 0.407, 307, 275, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
486, d3eidC_, 0.8862, 2.44, 0.996, 290, 277, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
487, d4j71B_, 0.8860, 2.37, 0.332, 347, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
488, d4au8B_, 0.8860, 2.00, 0.598, 277, 266, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
489, d1w98A2, 0.8857, 2.27, 0.996, 296, 271, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
490, d4bcjA_, 0.8856, 2.40, 0.404, 309, 275, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
491, d3mi9A_, 0.8845, 2.53, 0.401, 328, 277, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
492, d3lq5A_, 0.8843, 2.31, 0.398, 307, 274, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
493, d4pteB_, 0.8840, 2.39, 0.336, 347, 274, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
494, d2jgzA_, 0.8840, 2.12, 0.985, 288, 269, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
495, d4j1rB_, 0.8839, 2.32, 0.338, 346, 272, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
496, d4bcqC1, 0.8836, 2.26, 1.000, 291, 273, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
497, d3g33A_, 0.8835, 1.70, 0.479, 291, 263, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
498, d1f5qC_, 0.8835, 2.22, 0.930, 288, 270, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
499, d3miaA_, 0.8834, 2.54, 0.401, 324, 277, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
500, d5f94B_, 0.8832, 2.41, 0.336, 349, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
501, d3i4bA_, 0.8828, 2.34, 0.339, 359, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
502, d3g33C_, 0.8827, 1.71, 0.479, 291, 263, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
503, d3i4bB_, 0.8826, 2.37, 0.332, 347, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
504, d5f94A_, 0.8825, 2.42, 0.336, 346, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
505, d4ptcB_, 0.8823, 2.41, 0.339, 347, 274, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
506, d4cxaA_, 0.8819, 2.57, 0.424, 329, 278, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
507, d1h27C1, 0.8819, 2.27, 1.000, 290, 272, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
508, d1h24C1, 0.8819, 2.38, 0.996, 292, 274, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
509, d4ptcA_, 0.8817, 2.37, 0.339, 342, 274, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
510, d5l2sA_, 0.8813, 1.43, 0.512, 263, 258, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
511, d4bckC1, 0.8813, 2.31, 1.000, 291, 273, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
512, d4bciA_, 0.8810, 2.41, 0.405, 308, 274, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
513, d2w99B_, 0.8810, 1.78, 0.473, 291, 264, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
514, d5hlnB_, 0.8809, 2.43, 0.336, 346, 274, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
515, d4imyE_, 0.8809, 2.48, 0.408, 313, 277, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
516, d1ob3B_, 0.8807, 1.23, 0.620, 258, 255, STRUCTURE OF P. FALCIPARUM PFPK5
517, d3gb2A_, 0.8803, 2.30, 0.339, 340, 271, GSK3BETA INHIBITOR COMPLEX
518, d1j1bB_, 0.8799, 2.36, 0.339, 364, 274, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
519, d1v0oA_, 0.8798, 1.81, 0.612, 276, 263, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
520, d2w9zB_, 0.8796, 1.64, 0.479, 287, 261, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
521, d1uv5A_, 0.8793, 2.37, 0.336, 348, 274, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
522, d4pteA_, 0.8791, 2.35, 0.342, 341, 272, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
523, d3sayB_, 0.8791, 2.47, 0.332, 347, 274, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
524, d1gngA_, 0.8788, 2.41, 0.330, 348, 273, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
525, d3zrmB_, 0.8784, 2.50, 0.332, 347, 274, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
526, d1v0pB_, 0.8784, 1.28, 0.616, 258, 255, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
527, d3zrmA_, 0.8782, 2.45, 0.333, 344, 273, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
528, d3zrlB_, 0.8781, 2.50, 0.332, 347, 274, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
529, d2o5kA1, 0.8781, 2.42, 0.332, 350, 274, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
530, d3zrkA_, 0.8778, 2.45, 0.333, 345, 273, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
531, d3zrkB_, 0.8777, 2.50, 0.332, 348, 274, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
532, d3sd0B_, 0.8775, 2.48, 0.336, 349, 274, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
533, d2cjmA_, 0.8775, 2.37, 0.993, 285, 272, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
534, d4bbmA1, 0.8772, 2.21, 0.399, 306, 268, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
535, d3sayA_, 0.8772, 2.39, 0.338, 347, 272, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
536, d1j1cB_, 0.8769, 2.40, 0.339, 364, 274, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
537, d1j1bA_, 0.8768, 2.43, 0.336, 354, 274, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
538, d3m1sB_, 0.8766, 2.41, 0.337, 349, 273, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
539, d3nuxA_, 0.8765, 1.44, 0.506, 261, 257, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
540, d3f88B_, 0.8765, 2.35, 0.338, 340, 272, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
541, d3tn8A_, 0.8764, 2.37, 0.407, 304, 273, CDK9/CYCLIN T IN COMPLEX WITH CAN508
542, d5hlnA_, 0.8763, 2.52, 0.336, 346, 274, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
543, d3zrlA_, 0.8762, 2.48, 0.333, 345, 273, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
544, d3f88A_, 0.8761, 2.34, 0.338, 340, 272, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
545, d4imyA_, 0.8759, 2.62, 0.408, 314, 277, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
546, d1h8fB_, 0.8759, 2.49, 0.339, 350, 274, GLYCOGEN SYNTHASE KINASE 3 BETA.
547, d1h8fA_, 0.8758, 2.49, 0.339, 352, 274, GLYCOGEN SYNTHASE KINASE 3 BETA.
548, d1q41B_, 0.8757, 2.44, 0.336, 343, 274, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
549, d4nm0A1, 0.8750, 2.51, 0.336, 355, 274, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
550, d4aaaA1, 0.8745, 2.15, 0.412, 290, 267, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
551, d4acgA_, 0.8744, 2.50, 0.336, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
552, d5acbC_, 0.8738, 2.66, 0.432, 324, 278, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
553, d1j1cA_, 0.8736, 2.44, 0.332, 354, 274, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
554, d4krcA_, 0.8735, 2.41, 0.565, 297, 271, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
555, d3f7zB1, 0.8735, 2.36, 0.337, 338, 270, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
556, d4nstC_, 0.8734, 2.67, 0.424, 317, 278, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
557, d2jldB_, 0.8734, 2.45, 0.337, 349, 273, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
558, d2jldA_, 0.8732, 2.47, 0.337, 349, 273, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
559, d4acdA_, 0.8730, 2.51, 0.336, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
560, d3sd0A_, 0.8730, 2.55, 0.332, 350, 274, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
561, d3nizA1, 0.8730, 2.51, 0.572, 284, 271, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
562, d3m1sA_, 0.8730, 2.45, 0.338, 348, 272, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
563, d1q5kA_, 0.8730, 2.38, 0.336, 345, 271, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
564, d4achA_, 0.8728, 2.51, 0.336, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
565, d2ow3A_, 0.8728, 2.57, 0.336, 346, 274, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
566, d5l2iA_, 0.8727, 1.46, 0.512, 260, 256, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND PALBOCICLIB.
567, d4nstA_, 0.8727, 2.67, 0.424, 322, 278, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
568, d4imyC_, 0.8726, 2.49, 0.405, 310, 274, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
569, d4achB_, 0.8726, 2.48, 0.332, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
570, d1v0oB_, 0.8725, 1.78, 0.613, 274, 261, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
571, d1o9uA_, 0.8725, 2.60, 0.336, 349, 274, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
572, d5hlpA_, 0.8723, 2.39, 0.344, 337, 270, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
573, d5l2tA_, 0.8721, 1.47, 0.512, 261, 256, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.
574, d2ow3B_, 0.8721, 2.59, 0.332, 351, 274, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
575, d4afjA_, 0.8718, 2.40, 0.341, 342, 270, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
576, d4acgB_, 0.8716, 2.49, 0.336, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
577, d4acdB_, 0.8716, 2.53, 0.336, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
578, d4accA_, 0.8711, 2.49, 0.332, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
579, d3pupB_, 0.8708, 2.51, 0.341, 347, 273, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
580, d3pupA_, 0.8707, 2.51, 0.341, 346, 273, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
581, d4au8A1, 0.8705, 1.80, 0.588, 274, 260, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
582, d1r0eB_, 0.8703, 2.57, 0.332, 344, 274, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
583, d1pyxA_, 0.8703, 2.36, 0.341, 343, 270, GSK-3 BETA COMPLEXED WITH AMP-PNP
584, d5f95A_, 0.8702, 2.37, 0.339, 345, 271, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
585, d4accB_, 0.8702, 2.55, 0.336, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
586, d1r0eA_, 0.8700, 2.57, 0.332, 344, 274, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
587, p4gubA_, 0.8699, 2.32, 0.313, 329, 268, CASEIN KINASE II BOUND TO INHIBITOR
588, d4afjB_, 0.8687, 2.46, 0.337, 346, 270, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
589, d4krdA_, 0.8685, 2.39, 0.569, 294, 269, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
590, d5acbD_, 0.8683, 2.74, 0.432, 319, 278, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
591, d4bcqA1, 0.8681, 2.42, 0.996, 289, 271, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
592, d3ofmA_, 0.8680, 2.40, 0.320, 325, 269, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
593, d3od6X_, 0.8679, 1.96, 0.374, 344, 262, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
594, d3gc8A_, 0.8679, 2.32, 0.368, 347, 269, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
595, d5efqC_, 0.8678, 2.76, 0.439, 325, 278, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
596, d4i5hA_, 0.8675, 2.39, 0.379, 335, 269, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
597, p4ib5A_, 0.8674, 2.37, 0.317, 331, 268, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
598, d1g3nE_, 0.8673, 2.10, 0.492, 293, 264, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
599, d4kiqA_, 0.8672, 2.28, 0.381, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
600, d2pk9A_, 0.8672, 2.27, 0.560, 287, 266, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
601, d4nm7A1, 0.8671, 2.69, 0.326, 354, 273, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
602, d5m56A_, 0.8670, 2.43, 0.320, 331, 269, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
603, d5efqA_, 0.8670, 2.78, 0.435, 321, 278, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
604, d4ez5A_, 0.8669, 1.44, 0.512, 258, 254, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
605, d4nm5A1, 0.8668, 2.70, 0.326, 360, 273, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
606, d4kipB_, 0.8666, 2.37, 0.379, 338, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
607, d3wowA_, 0.8664, 2.41, 0.309, 334, 269, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
608, d4un0C_, 0.8663, 2.75, 0.430, 308, 277, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
609, p3be9A_, 0.8663, 2.44, 0.312, 327, 269, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
610, d1g3nA_, 0.8662, 2.12, 0.492, 293, 264, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
611, p4nh1B_, 0.8655, 2.46, 0.312, 332, 269, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
612, p4nh1A_, 0.8655, 2.46, 0.312, 330, 269, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
613, p5n9lA_, 0.8654, 2.48, 0.312, 329, 269, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
614, d3at3A_, 0.8654, 2.47, 0.312, 332, 269, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
615, d1q3wA_, 0.8654, 2.45, 0.341, 344, 270, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
616, d4ubaA_, 0.8652, 2.44, 0.309, 333, 269, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
617, d5kwhB_, 0.8650, 2.48, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2
618, d1pyxB_, 0.8650, 2.35, 0.347, 338, 268, GSK-3 BETA COMPLEXED WITH AMP-PNP
619, d1xo2B_, 0.8649, 2.18, 0.506, 289, 265, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
620, d4md7H_, 0.8646, 2.41, 0.317, 330, 268, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
621, p3o17B_, 0.8646, 2.28, 0.372, 357, 266, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
622, d3q3bA_, 0.8645, 2.45, 0.341, 344, 270, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
623, d3ngaA_, 0.8645, 2.47, 0.312, 331, 269, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
624, d3at4A_, 0.8645, 2.49, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
625, p2h96B_, 0.8645, 2.36, 0.367, 357, 267, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
626, p5v62A_, 0.8643, 2.38, 0.377, 349, 268, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
627, d5h8bA_, 0.8643, 2.45, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
628, d4md7F_, 0.8643, 2.40, 0.317, 332, 268, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
629, d3q9wA_, 0.8643, 2.45, 0.317, 328, 268, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
630, p5v61A_, 0.8642, 2.35, 0.377, 348, 268, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
631, d5h8bB_, 0.8642, 2.49, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
632, d4kiqC_, 0.8642, 2.28, 0.381, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
633, p5ooiA_, 0.8641, 2.44, 0.320, 329, 269, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
634, d4kwpA_, 0.8641, 2.47, 0.312, 329, 269, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
635, d5k5nA_, 0.8638, 2.28, 0.350, 331, 266, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
636, d5h8eB_, 0.8638, 2.49, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
637, p5n9nA_, 0.8637, 2.52, 0.312, 329, 269, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
638, d5buiA_, 0.8637, 2.21, 0.372, 338, 266, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
639, d4qp8B_, 0.8637, 2.28, 0.375, 337, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
640, d4md7E_, 0.8637, 2.41, 0.317, 332, 268, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
641, d3warA_, 0.8637, 2.47, 0.309, 334, 269, CRYSTAL STRUCTURE OF HUMAN CK2A
642, p3u9cA_, 0.8637, 2.42, 0.317, 331, 268, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
643, d3gc9A_, 0.8637, 2.32, 0.362, 335, 268, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
644, d3q9zA_, 0.8635, 2.49, 0.312, 332, 269, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
645, d1q3wB_, 0.8635, 2.41, 0.342, 341, 269, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
646, d5nhjA_, 0.8634, 2.49, 0.383, 345, 269, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
647, d1lpuA_, 0.8634, 2.47, 0.316, 327, 269, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
648, d5cqwA_, 0.8633, 2.47, 0.312, 331, 269, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
649, d4md7G_, 0.8633, 2.43, 0.317, 332, 268, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
650, d4kipA_, 0.8633, 2.32, 0.377, 337, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
651, d4bxaA_, 0.8633, 2.47, 0.312, 331, 269,  
652, d3c13A_, 0.8632, 2.47, 0.317, 328, 268, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
653, d5hlpB_, 0.8631, 2.39, 0.341, 335, 267, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
654, d4rlkA_, 0.8631, 2.47, 0.316, 327, 269, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
655, d3q04A_, 0.8631, 2.49, 0.312, 328, 269, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
656, d5ku8B_, 0.8630, 2.51, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2
657, p4md8F_, 0.8630, 2.46, 0.309, 332, 269, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
658, d3wikA_, 0.8630, 2.45, 0.309, 334, 269, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
659, d3ngaB_, 0.8629, 2.49, 0.312, 331, 269, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
660, d5h8eA_, 0.8628, 2.47, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
661, d3wilA_, 0.8628, 2.39, 0.313, 331, 268, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
662, p2pvhA_, 0.8627, 2.49, 0.312, 327, 269, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
663, d5u6iA_, 0.8626, 2.47, 0.381, 339, 268, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
664, d3f7zA1, 0.8626, 2.36, 0.337, 338, 267, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
665, p2pvnA_, 0.8626, 2.49, 0.312, 327, 269, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
666, p6g97A_, 0.8625, 2.44, 0.381, 344, 268, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
667, p5n9kA_, 0.8625, 2.53, 0.312, 329, 269, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
668, d1ds5A_, 0.8624, 2.48, 0.316, 328, 269, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
669, d4kiqB_, 0.8623, 2.32, 0.381, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
670, d3o2mB_, 0.8623, 2.28, 0.361, 358, 266, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
671, d1dayA_, 0.8623, 2.48, 0.316, 327, 269, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
672, d1dawA_, 0.8623, 2.50, 0.316, 327, 269, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
673, d5cu2A_, 0.8622, 2.41, 0.313, 328, 268, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
674, d4kinB_, 0.8622, 2.37, 0.383, 341, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
675, d3fl5A_, 0.8622, 2.49, 0.316, 324, 269, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
676, p2g01B_, 0.8622, 2.31, 0.357, 356, 266, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
677, d1ds5B_, 0.8622, 2.49, 0.316, 328, 269, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
678, d2zoqB_, 0.8621, 2.39, 0.392, 351, 268, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
679, d1jamA_, 0.8621, 2.50, 0.316, 327, 269, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
680, d3pvgA_, 0.8620, 2.48, 0.316, 326, 269, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
681, d5cx9A_, 0.8619, 2.43, 0.313, 328, 268, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
682, d5b0xA_, 0.8619, 2.49, 0.312, 329, 269, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
683, d3bqcA_, 0.8619, 2.49, 0.317, 328, 268, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
684, d3at2A_, 0.8619, 2.47, 0.309, 334, 269, CRYSTAL STRUCTURE OF CK2ALPHA
685, d1ds5C_, 0.8619, 2.49, 0.316, 328, 269, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
686, p3u9cB_, 0.8618, 2.43, 0.317, 331, 268, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
687, d3u87A_, 0.8618, 2.49, 0.312, 329, 269, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
688, d3kxjA_, 0.8618, 2.48, 0.316, 326, 269,  
689, d1lp4A_, 0.8618, 2.50, 0.316, 327, 269, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
690, p4md8E_, 0.8617, 2.48, 0.312, 332, 269, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
691, d4cjyC_, 0.8617, 2.76, 0.417, 303, 276,  
692, d3pzhA_, 0.8617, 2.50, 0.316, 327, 269, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
693, d5ct0A_, 0.8616, 2.36, 0.311, 326, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
694, p4md9H_, 0.8615, 2.50, 0.309, 328, 269, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
695, p2pvkA_, 0.8615, 2.49, 0.312, 327, 269, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
696, d5mmrA_, 0.8614, 2.36, 0.311, 326, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
697, d5kwhA_, 0.8614, 2.51, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2
698, d5cu0A_, 0.8614, 2.34, 0.315, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
699, d4dgmA_, 0.8614, 2.50, 0.316, 326, 269, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
700, p3e3bX_, 0.8614, 2.50, 0.320, 334, 269, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
701, d3q9xB_, 0.8613, 2.44, 0.317, 330, 268, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
702, d5motA_, 0.8612, 2.40, 0.318, 328, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
703, d5modA_, 0.8612, 2.36, 0.311, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
704, d4qp9A_, 0.8612, 2.29, 0.375, 335, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
705, d3pe1A_, 0.8612, 2.45, 0.313, 327, 268, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
706, d3blrA_, 0.8612, 2.41, 0.400, 300, 270, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
707, d2fysA_, 0.8612, 2.30, 0.375, 348, 267, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
708, d1ds5D_, 0.8612, 2.50, 0.316, 328, 269, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
709, d5mohA_, 0.8610, 2.34, 0.316, 326, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
710, p4md8H_, 0.8610, 2.50, 0.312, 331, 269, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
711, d4aguB_, 0.8610, 2.21, 0.398, 276, 264, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
712, d3q9zB_, 0.8610, 2.46, 0.317, 332, 268, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
713, d3owkA_, 0.8610, 2.55, 0.312, 330, 269, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
714, d3mb7A_, 0.8610, 2.56, 0.312, 330, 269, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
715, d3du8A_, 0.8610, 2.39, 0.340, 336, 268, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
716, d1jwhB_, 0.8610, 2.54, 0.312, 335, 269, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
717, p4md8G_, 0.8609, 2.50, 0.309, 332, 269, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
718, d3o2mA_, 0.8609, 2.29, 0.361, 358, 266, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
719, d3kxgA_, 0.8609, 2.49, 0.316, 326, 269, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
720, d3mb6A_, 0.8608, 2.54, 0.317, 329, 268, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
721, d5t1hB_, 0.8607, 2.53, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2
722, d5cquA_, 0.8607, 2.42, 0.313, 328, 268, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
723, d4mygB_, 0.8607, 2.38, 0.386, 335, 267, MAPK13 ACTIVE FORM
724, d4bxbA_, 0.8607, 2.42, 0.313, 328, 268,  
725, d3axwA_, 0.8607, 2.51, 0.312, 329, 269, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
726, d4dgnA_, 0.8606, 2.51, 0.316, 325, 269, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
727, d3pe2A_, 0.8606, 2.45, 0.313, 327, 268, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
728, d1unlA_, 0.8605, 2.41, 0.572, 292, 269, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
729, d1i09B_, 0.8605, 2.47, 0.338, 341, 269, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
730, d5nhhA_, 0.8604, 2.54, 0.383, 348, 269, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
731, d4rllA_, 0.8604, 2.55, 0.312, 329, 269, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
732, d4dgoA_, 0.8604, 2.52, 0.316, 325, 269, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
733, d3r0tA_, 0.8604, 2.46, 0.313, 327, 268, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
734, p2pvmA_, 0.8604, 2.50, 0.312, 327, 269, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
735, d5ctpB_, 0.8603, 2.46, 0.313, 327, 268, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
736, d5cqwB_, 0.8603, 2.51, 0.312, 331, 269, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
737, p4ib5C_, 0.8603, 2.55, 0.312, 332, 269, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
738, d3q9xA_, 0.8603, 2.53, 0.312, 330, 269, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
739, d5mmfA_, 0.8602, 2.38, 0.311, 326, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
740, d3q3bB_, 0.8602, 2.45, 0.342, 341, 269, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
741, d1q5kB_, 0.8601, 2.43, 0.336, 344, 268, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
742, d5h8gA_, 0.8600, 2.25, 0.313, 324, 265, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
743, d4bxaB_, 0.8600, 2.51, 0.312, 331, 269,  
744, d3owlA_, 0.8600, 2.55, 0.312, 330, 269, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
745, d3owjA_, 0.8600, 2.55, 0.312, 328, 269, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
746, d3fwqB_, 0.8599, 2.49, 0.289, 334, 270, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
747, p2pvlA_, 0.8599, 2.52, 0.312, 327, 269, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
748, d1j91B_, 0.8599, 2.60, 0.315, 327, 270, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
749, d5n1vB_, 0.8598, 2.51, 0.312, 331, 269, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
750, d1q41A_, 0.8598, 2.39, 0.348, 339, 267, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
751, d4anmA1, 0.8597, 2.50, 0.316, 327, 269, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
752, d3du8B_, 0.8597, 2.42, 0.343, 339, 268, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
753, d5csvA_, 0.8596, 2.41, 0.318, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
754, d4qp7A_, 0.8596, 2.33, 0.375, 337, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
755, d4ptgA_, 0.8596, 2.33, 0.353, 333, 266, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
756, p4md9G_, 0.8596, 2.52, 0.312, 329, 269, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
757, p4lfiB_, 0.8596, 2.54, 0.290, 371, 269, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
758, p4lfiA_, 0.8596, 2.54, 0.290, 370, 269, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
759, d4auaA_, 0.8596, 1.39, 0.510, 256, 251, LIGANDED X-RAY CRYSTAL STRUCTURE OF CYCLIN DEPENDENT KINASE 6 (CDK6)
760, d4aguA_, 0.8596, 2.26, 0.398, 277, 264, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
761, d3u87B_, 0.8596, 2.52, 0.312, 329, 269, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
762, d3rp0A_, 0.8596, 2.54, 0.312, 329, 269,  
763, p2pvjA_, 0.8596, 2.51, 0.312, 326, 269, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
764, d1zogA_, 0.8596, 2.51, 0.316, 325, 269, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
765, d1lr4A_, 0.8596, 2.52, 0.316, 327, 269, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
766, d5mo8A_, 0.8595, 2.40, 0.311, 325, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
767, d5v60A_, 0.8594, 2.43, 0.384, 347, 268, PHOSPHO-ERK2 BOUND TO AMP-PCP
768, d4aguC_, 0.8594, 2.22, 0.398, 278, 264, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
769, d3ocgA_, 0.8594, 2.28, 0.372, 336, 266, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
770, p4md9P_, 0.8592, 2.52, 0.309, 328, 269, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
771, d2pvrA_, 0.8592, 2.48, 0.313, 328, 268, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
772, d1m2qA_, 0.8592, 2.59, 0.316, 327, 269, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
773, d1jsuA_, 0.8592, 2.56, 0.924, 285, 264, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
774, d3u4uA_, 0.8591, 2.38, 0.311, 327, 267, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
775, d5nhoA_, 0.8590, 2.53, 0.390, 343, 269, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
776, d5cspA_, 0.8590, 2.41, 0.318, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
777, p4md9E_, 0.8590, 2.52, 0.309, 329, 269, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
778, d4dglD_, 0.8590, 2.55, 0.312, 328, 269, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
779, d3rp0C_, 0.8590, 2.51, 0.312, 329, 269,  
780, d5nqcA_, 0.8589, 2.60, 0.310, 331, 271, CK2ALPHA IN COMPLEX WITH NMR154
781, d5mo5A_, 0.8589, 2.36, 0.312, 326, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
782, d1zohA_, 0.8589, 2.52, 0.316, 326, 269, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
783, d5moeA_, 0.8588, 2.35, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
784, d5mo7A_, 0.8588, 2.41, 0.311, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
785, p3vuiA_, 0.8588, 2.48, 0.360, 355, 267, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
786, p3o17A_, 0.8588, 2.37, 0.361, 357, 266, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
787, d2qc6A_, 0.8588, 2.54, 0.316, 326, 269, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
788, d5t1hA_, 0.8587, 2.51, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2
789, d1na7A_, 0.8587, 2.45, 0.313, 326, 268, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
790, d5k5nB_, 0.8586, 2.21, 0.350, 334, 263, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
791, d3kxmA_, 0.8586, 2.53, 0.316, 326, 269, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
792, d5m4cA_, 0.8585, 2.49, 0.312, 329, 269, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
793, d4qteA_, 0.8585, 2.53, 0.387, 348, 269, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
794, d3qa0A_, 0.8585, 2.55, 0.312, 330, 269, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
795, d1om1A_, 0.8585, 2.53, 0.316, 325, 269, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
796, d5cvhA_, 0.8584, 2.43, 0.311, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA
797, d4kiqD_, 0.8584, 2.41, 0.377, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
798, d5cu0B_, 0.8583, 2.40, 0.311, 325, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
799, d4qp4A_, 0.8583, 2.34, 0.375, 337, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
800, p2gmxB_, 0.8583, 2.45, 0.356, 357, 267, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
801, d4fv6A_, 0.8582, 2.23, 0.371, 332, 264, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
802, p3vugA_, 0.8582, 2.49, 0.360, 356, 267, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
803, d3q9yA_, 0.8582, 2.49, 0.313, 327, 268, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
804, p4md9F_, 0.8581, 2.44, 0.310, 327, 268, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
805, d3qa0B_, 0.8580, 2.49, 0.317, 330, 268, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
806, d2oxxA_, 0.8580, 2.54, 0.316, 325, 269, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
807, d2oxdA_, 0.8580, 2.53, 0.316, 325, 269, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
808, d5cu6A_, 0.8579, 2.44, 0.315, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA
809, d4fv7A_, 0.8579, 2.43, 0.382, 342, 267, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
810, p2h96A_, 0.8579, 2.38, 0.361, 358, 266, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
811, d1j91A_, 0.8579, 2.58, 0.316, 327, 269, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
812, p5otyA_, 0.8578, 2.44, 0.315, 327, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
813, d3w55A_, 0.8578, 2.49, 0.381, 335, 268, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
814, p3vuhA_, 0.8578, 2.49, 0.360, 355, 267, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
815, d2e14A_, 0.8578, 2.49, 0.381, 335, 268,  
816, p5otzA_, 0.8577, 2.47, 0.313, 327, 268, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
817, d5clpB_, 0.8577, 2.47, 0.313, 327, 268, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
818, d2rkpA_, 0.8577, 2.57, 0.310, 334, 271,  
819, d3mvlB_, 0.8576, 2.37, 0.378, 339, 267, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
820, d1m2pA_, 0.8576, 2.54, 0.316, 325, 269, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
821, d3rp0B_, 0.8575, 2.52, 0.312, 329, 269,  
822, d3kxnA_, 0.8575, 2.52, 0.316, 327, 269, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
823, d2zoqA_, 0.8575, 2.52, 0.394, 351, 269, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
824, d2oxyA_, 0.8575, 2.54, 0.316, 327, 269, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
825, d3gc9B_, 0.8573, 2.40, 0.351, 339, 268, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
826, d3rp0D_, 0.8571, 2.56, 0.312, 329, 269,  
827, d5mpjA_, 0.8570, 2.43, 0.311, 326, 267, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
828, p4md9M_, 0.8570, 2.56, 0.309, 331, 269, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
829, d1zoeA_, 0.8570, 2.54, 0.316, 325, 269, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
830, p5owlB_, 0.8569, 2.54, 0.312, 332, 269, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
831, d5movA_, 0.8569, 2.39, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
832, d5m4uA_, 0.8569, 2.51, 0.321, 332, 268, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
833, d3zduA_, 0.8569, 2.45, 0.348, 297, 267, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
834, d5mo6A_, 0.8568, 2.39, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
835, d3gc8B_, 0.8568, 2.42, 0.351, 346, 268, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
836, d5mowA1, 0.8567, 2.39, 0.312, 326, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
837, d5mo7B_, 0.8567, 2.40, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
838, d5ku8A_, 0.8567, 2.54, 0.313, 328, 268, CRYSTAL STRUCTURE OF CK2
839, d3kxhA_, 0.8567, 2.54, 0.316, 326, 269, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
840, p4md9K_, 0.8566, 2.55, 0.312, 328, 269, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
841, p3vukA_, 0.8566, 2.50, 0.360, 355, 267, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
842, d3juhA_, 0.8566, 2.59, 0.317, 334, 271, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
843, p6gihA_, 0.8565, 2.35, 0.318, 324, 264, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
844, p5os8A_, 0.8565, 2.50, 0.313, 327, 268, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
845, d4kinD_, 0.8565, 2.42, 0.376, 339, 266, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
846, d2zjwA_, 0.8564, 2.45, 0.313, 332, 268, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
847, d5n1vA_, 0.8563, 2.54, 0.312, 331, 269, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
848, d5mp8A_, 0.8563, 2.38, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
849, d5k4iA_, 0.8563, 2.31, 0.372, 336, 266, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
850, d4grbA_, 0.8563, 2.41, 0.311, 327, 267, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
851, d5bvdA_, 0.8562, 2.14, 0.370, 330, 262, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
852, d3mvlA_, 0.8562, 2.37, 0.378, 339, 267, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
853, d1pjkA_, 0.8562, 2.48, 0.313, 331, 268, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
854, p5omyA_, 0.8561, 2.41, 0.315, 332, 267, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
855, d5m56B_, 0.8561, 2.58, 0.320, 328, 269, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
856, d3h30B_, 0.8561, 2.62, 0.310, 333, 271, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
857, d4nifE_, 0.8560, 2.47, 0.387, 348, 269, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
858, d1zz2A_, 0.8559, 2.43, 0.381, 337, 268, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
859, p5owlA_, 0.8558, 2.69, 0.312, 331, 269, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
860, d5cu2B_, 0.8558, 2.40, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
861, d5mo8B_, 0.8557, 2.42, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
862, d4nifB_, 0.8557, 2.48, 0.387, 349, 269, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
863, p4md9L_, 0.8557, 2.58, 0.309, 328, 269, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
864, d1q4lA_, 0.8557, 2.43, 0.345, 342, 267, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
865, p5oulA_, 0.8556, 2.46, 0.315, 327, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
866, d4fbxA_, 0.8556, 2.41, 0.315, 333, 267, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
867, d4kinA_, 0.8555, 2.38, 0.386, 338, 267, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
868, d3rpsA_, 0.8555, 2.40, 0.315, 334, 267, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
869, p2gmxA_, 0.8555, 2.39, 0.372, 357, 266, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
870, d1ymiA_, 0.8555, 2.60, 0.317, 334, 271,  
871, d5m4fA_, 0.8554, 2.57, 0.312, 330, 269, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
872, p2g01A_, 0.8554, 2.49, 0.367, 355, 267, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
873, d5cu3A_, 0.8553, 2.42, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
874, d3bw5A_, 0.8553, 2.61, 0.317, 334, 271,  
875, d1f0qA_, 0.8552, 2.60, 0.316, 329, 269, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
876, d5bveA_, 0.8551, 2.15, 0.370, 330, 262, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
877, p4fmqA_, 0.8551, 2.47, 0.381, 350, 268, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
878, d5ke0A_, 0.8550, 2.62, 0.383, 340, 269, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
879, p3vudA_, 0.8550, 2.42, 0.368, 355, 266, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
880, d5cx9B_, 0.8548, 2.41, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
881, d5cvfA_, 0.8547, 2.41, 0.320, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
882, d2oxyB_, 0.8547, 2.57, 0.316, 327, 269, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
883, p2no3A_, 0.8547, 2.43, 0.361, 357, 266, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
884, d2gphA_, 0.8547, 2.47, 0.377, 345, 268, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
885, p4ib5B_, 0.8546, 2.64, 0.312, 329, 269, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
886, d5cu3B_, 0.8544, 2.44, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
887, d4ubaB_, 0.8544, 2.57, 0.309, 333, 269, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
888, d4cxaC_, 0.8541, 2.86, 0.431, 330, 274, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
889, d3h30A_, 0.8541, 2.66, 0.310, 333, 271, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
890, d4iq6B_, 0.8540, 2.42, 0.350, 332, 266, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
891, p3zu7A_, 0.8538, 2.45, 0.352, 344, 267, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
892, d5mmrB_, 0.8537, 2.41, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
893, d4iz5D_, 0.8536, 2.47, 0.366, 347, 268, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
894, d4iz5A_, 0.8536, 2.47, 0.366, 347, 268, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
895, d3gp0A1, 0.8536, 2.28, 0.354, 332, 263, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
896, d5cu4A_, 0.8535, 2.52, 0.313, 327, 268, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
897, d4iz5B_, 0.8535, 2.47, 0.366, 347, 268, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
898, d5mo6B_, 0.8534, 2.44, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
899, d5mmfB_, 0.8534, 2.42, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
900, d4iz5C_, 0.8534, 2.47, 0.366, 347, 268, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
901, p6ehuB_, 0.8533, 2.42, 0.316, 327, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
902, d5cvhB_, 0.8533, 2.44, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA
903, d3oxiA_, 0.8533, 2.29, 0.360, 322, 264, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
904, d5ct0B_, 0.8532, 2.42, 0.312, 326, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
905, d4qnyA_, 0.8532, 2.45, 0.331, 333, 269, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
906, d1h4lA_, 0.8532, 2.18, 0.590, 278, 261, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
907, d4mygA_, 0.8531, 2.55, 0.390, 335, 267, MAPK13 ACTIVE FORM
908, d1di9A_, 0.8531, 2.42, 0.378, 348, 267, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
909, d5mpjB_, 0.8530, 2.42, 0.312, 324, 266, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
910, d1q3dB_, 0.8530, 2.47, 0.343, 339, 268, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
911, d1q3dA_, 0.8530, 2.51, 0.343, 339, 268, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
912, p3zuvC_, 0.8529, 2.51, 0.388, 357, 268, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
913, d3o0gA_, 0.8529, 2.43, 0.577, 289, 267, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
914, p4mwhA_, 0.8528, 2.62, 0.290, 371, 269, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
915, p2no3B_, 0.8528, 2.47, 0.372, 357, 266, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
916, d5moeB_, 0.8527, 2.38, 0.309, 323, 265, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
917, p5etaB_, 0.8527, 2.33, 0.371, 335, 264, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
918, d5cshA_, 0.8527, 2.44, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
919, d3juhB_, 0.8527, 2.80, 0.312, 334, 272, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
920, p4fi1A_, 0.8526, 2.62, 0.290, 371, 269, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
921, d3i60A_, 0.8526, 2.31, 0.379, 335, 264, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
922, d2b9iA_, 0.8526, 2.52, 0.392, 338, 268, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
923, d5mo5B_, 0.8525, 2.43, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
924, d3qyiA_, 0.8525, 2.47, 0.377, 346, 268,  
925, d5cs6A_, 0.8524, 2.53, 0.311, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
926, d3nszA_, 0.8524, 2.46, 0.311, 327, 267, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
927, d3mvmA_, 0.8523, 2.37, 0.376, 335, 263, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
928, d1m2rA_, 0.8523, 2.64, 0.316, 327, 269, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
929, p4h3qA_, 0.8521, 2.53, 0.387, 352, 269, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
930, d3pwdA_, 0.8521, 2.62, 0.316, 327, 269, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
931, d3o8uA_, 0.8521, 2.31, 0.365, 332, 263, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
932, d3blqA_, 0.8521, 2.47, 0.403, 295, 268, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
933, d1w82A_, 0.8521, 2.55, 0.377, 351, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
934, p3zuvA_, 0.8520, 2.52, 0.381, 357, 268, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
935, d3rpsB_, 0.8520, 2.43, 0.293, 334, 266, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
936, d3fklA_, 0.8519, 2.50, 0.379, 344, 269, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
937, d5ctpA_, 0.8518, 2.45, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
938, d2qkrA1, 0.8515, 2.16, 0.570, 269, 258, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
939, p4jqeA_, 0.8514, 2.65, 0.290, 369, 269, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
940, p3v3vA_, 0.8514, 2.50, 0.361, 351, 266, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
941, d5bujA_, 0.8513, 2.18, 0.370, 331, 262, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
942, d4kinC_, 0.8513, 2.42, 0.376, 338, 266, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
943, d3fmhA_, 0.8513, 2.45, 0.378, 347, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
944, d5modB_, 0.8512, 2.46, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
945, p4ux9D_, 0.8511, 2.28, 0.368, 344, 261, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
946, d5mowB_, 0.8508, 2.46, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
947, d5cvgA_, 0.8508, 2.40, 0.313, 326, 265, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
948, d3c9wA2, 0.8508, 2.46, 0.390, 335, 267, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
949, d3hv4B_, 0.8507, 2.63, 0.381, 338, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
950, d2pmiC_, 0.8507, 2.39, 0.567, 285, 263, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
951, d5nhlA_, 0.8506, 2.62, 0.384, 345, 268, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
952, d3fwqA_, 0.8506, 2.65, 0.289, 334, 270, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
953, d5cshB_, 0.8505, 2.35, 0.316, 323, 263, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
954, d3w8lB_, 0.8505, 2.54, 0.313, 326, 268, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
955, d3blhA1, 0.8505, 2.45, 0.410, 291, 266, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
956, d1q99A_, 0.8505, 2.52, 0.302, 354, 268, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
957, d2b9hA_, 0.8503, 2.58, 0.390, 337, 269, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
958, d3nupA_, 0.8502, 1.36, 0.500, 252, 248, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
959, d1wbwA_, 0.8502, 2.60, 0.372, 351, 269, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
960, d2rg6A_, 0.8501, 2.35, 0.379, 335, 264, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
961, d2erkA_, 0.8500, 2.53, 0.381, 351, 268, PHOSPHORYLATED MAP KINASE ERK2
962, d1q8zA_, 0.8500, 2.53, 0.310, 354, 268, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
963, d1q4lB_, 0.8499, 2.37, 0.343, 337, 265, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
964, d1h4lB_, 0.8499, 2.22, 0.590, 278, 261, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
965, d5bueA_, 0.8498, 2.22, 0.370, 329, 262, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
966, d2b9jA_, 0.8498, 2.58, 0.390, 337, 269, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
967, d3c9wB2, 0.8496, 2.49, 0.390, 335, 267, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
968, d5nhvA_, 0.8495, 2.63, 0.384, 345, 268, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
969, d4qnyB_, 0.8495, 2.49, 0.327, 339, 269, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
970, p4f9bA_, 0.8495, 2.37, 0.280, 318, 264, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
971, d2rg5A_, 0.8495, 2.30, 0.380, 333, 263, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
972, d1lewA_, 0.8495, 2.49, 0.386, 341, 267, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
973, d5nhpA_, 0.8494, 2.63, 0.384, 338, 268, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
974, d1unhA_, 0.8494, 2.15, 0.587, 276, 259, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
975, d3ctqA_, 0.8493, 2.49, 0.365, 336, 266, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
976, d3gcuB_, 0.8492, 2.66, 0.381, 337, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
977, d2b9fA_, 0.8491, 2.52, 0.392, 337, 268, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
978, d2jd5A_, 0.8490, 2.48, 0.318, 353, 267, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
979, d3nnxA_, 0.8489, 2.51, 0.385, 336, 265, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
980, d3hllA_, 0.8489, 2.50, 0.384, 337, 268, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
981, d1wbsA_, 0.8489, 2.63, 0.377, 351, 268, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
982, p6ehuA_, 0.8487, 2.58, 0.315, 327, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
983, p3nieA_, 0.8487, 2.69, 0.402, 369, 271, CRYSTAL STRUCTURE OF PF11_0147
984, d2r7iB_, 0.8487, 2.42, 0.316, 322, 263, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
985, d3mvmB_, 0.8484, 2.34, 0.373, 332, 263, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
986, d2r7iD_, 0.8483, 2.43, 0.316, 322, 263, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
987, d2g9xC2, 0.8483, 1.97, 1.000, 273, 255, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
988, d4fv8A_, 0.8482, 2.31, 0.373, 333, 263, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
989, d3d7zA_, 0.8480, 2.58, 0.369, 348, 268, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
990, d1zyjA_, 0.8479, 2.41, 0.373, 331, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
991, d1jwhA_, 0.8478, 2.61, 0.309, 336, 269, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
992, d3hv5B_, 0.8477, 2.68, 0.381, 339, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
993, d3bv2A_, 0.8477, 2.40, 0.374, 337, 265, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
994, d5mz3A_, 0.8476, 2.62, 0.375, 350, 267, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
995, d4ewqA_, 0.8476, 2.50, 0.363, 346, 267, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
996, d3nnwA_, 0.8476, 2.63, 0.373, 349, 268, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
997, p3nieB_, 0.8476, 2.71, 0.402, 367, 271, CRYSTAL STRUCTURE OF PF11_0147
998, p6g9aA_, 0.8475, 2.65, 0.381, 341, 268, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
999, d4qtbA_, 0.8474, 2.65, 0.388, 351, 268, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
1000, d2f9gA_, 0.8474, 2.49, 0.393, 332, 267, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
1001, p6g93A_, 0.8473, 2.65, 0.381, 343, 268, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1002, d5bvfA_, 0.8473, 2.12, 0.367, 327, 259, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1003, d3py3A1, 0.8473, 2.47, 0.383, 352, 266, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
1004, d4izaA_, 0.8472, 2.55, 0.367, 346, 267, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
1005, d1q99B_, 0.8471, 2.75, 0.299, 364, 271, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
1006, d3hl7A_, 0.8469, 2.47, 0.386, 336, 267, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
1007, d2zb0A_, 0.8469, 2.65, 0.379, 349, 269, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1008, d2r7iA_, 0.8469, 2.45, 0.312, 322, 263, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1009, d2onlB1, 0.8469, 2.51, 0.391, 339, 266, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1010, d1q8zB_, 0.8469, 2.76, 0.299, 364, 271, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
1011, d4qtbB_, 0.8468, 2.66, 0.388, 348, 268, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
1012, d3p7cA_, 0.8468, 2.43, 0.365, 332, 263, P38 INHIBITOR-BOUND
1013, d3flyA_, 0.8468, 2.52, 0.375, 347, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1014, d3rocA_, 0.8467, 2.54, 0.388, 337, 268, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
1015, d4fv9A_, 0.8466, 2.30, 0.382, 331, 262, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
1016, d4l7fA1, 0.8465, 2.57, 0.352, 343, 267, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
1017, d1unhB_, 0.8465, 2.18, 0.583, 276, 259, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1018, d5mp8B_, 0.8464, 2.43, 0.311, 323, 264, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1019, d1ouyA_, 0.8464, 2.51, 0.382, 350, 267, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
1020, d1lezA_, 0.8464, 2.51, 0.386, 343, 267, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
1021, d2okrA_, 0.8463, 2.53, 0.391, 339, 266, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1022, d5m4iA_, 0.8462, 2.60, 0.288, 331, 267, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1023, d3flzA_, 0.8462, 2.52, 0.375, 347, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1024, d1howA_, 0.8462, 2.58, 0.317, 346, 268, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
1025, d3p5kA_, 0.8460, 2.49, 0.367, 332, 264, P38 INHIBITOR-BOUND
1026, d4ub7A_, 0.8459, 2.47, 0.298, 334, 265, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
1027, d3ptgA_, 0.8459, 2.48, 0.380, 340, 266, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
1028, d3nnvA_, 0.8459, 2.62, 0.377, 348, 268, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
1029, d3e3pA_, 0.8459, 2.58, 0.362, 337, 265, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1030, d3nwwA_, 0.8458, 2.54, 0.393, 339, 267, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
1031, d4ptgB_, 0.8457, 2.32, 0.345, 332, 261, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
1032, p3vulA_, 0.8457, 2.42, 0.360, 344, 264, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
1033, d1wboA_, 0.8457, 2.58, 0.373, 351, 268, FRAGMENT BASED P38 INHIBITORS
1034, d5f95B_, 0.8456, 2.37, 0.344, 338, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
1035, p4jr7A_, 0.8455, 2.54, 0.284, 367, 264, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1036, d1wbtA_, 0.8455, 2.64, 0.371, 351, 267, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1037, p5xyyA_, 0.8454, 2.67, 0.375, 350, 269, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1038, d3iphA_, 0.8454, 2.62, 0.377, 345, 268, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
1039, d1oukA_, 0.8454, 2.45, 0.357, 348, 266, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
1040, d2balA_, 0.8453, 2.53, 0.393, 337, 267, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
1041, d3odzX_, 0.8451, 2.35, 0.385, 335, 262, CRYSTAL STRUCTURE OF P38ALPHA Y323R ACTIVE MUTANT
1042, d3kf7A_, 0.8451, 2.51, 0.386, 337, 267, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
1043, d4ka3A_, 0.8449, 2.50, 0.383, 340, 266, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
1044, d3dt1A2, 0.8449, 2.60, 0.381, 352, 268, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
1045, d2pkjA_, 0.8449, 2.49, 0.379, 332, 264,  
1046, d3mptA_, 0.8448, 2.60, 0.381, 347, 268, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
1047, d1q97B_, 0.8448, 2.78, 0.299, 361, 271, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
1048, d3nnuA_, 0.8446, 2.69, 0.377, 348, 268, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
1049, d3bv3A_, 0.8446, 2.52, 0.380, 338, 266, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
1050, d5xvuB_, 0.8445, 2.54, 0.311, 321, 267, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1051, d3bx5A_, 0.8445, 2.51, 0.383, 338, 266, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
1052, d2onlA1, 0.8445, 2.50, 0.396, 338, 265, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1053, d2jd5B_, 0.8445, 2.77, 0.299, 360, 271, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
1054, d2ozaB_, 0.8443, 2.53, 0.365, 340, 266, STRUCTURE OF P38ALPHA COMPLEX
1055, d3mh0A_, 0.8441, 2.47, 0.369, 332, 263, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1056, d3w8lA_, 0.8438, 2.59, 0.310, 326, 268, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1057, d2r7iC_, 0.8438, 2.45, 0.313, 321, 262, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1058, d3p78A_, 0.8437, 2.52, 0.367, 332, 264, P38 INHIBITOR-BOUND
1059, d3p7bA_, 0.8435, 2.52, 0.367, 332, 264, P38 INHIBITOR-BOUND
1060, d5hd7A_, 0.8434, 2.77, 0.379, 347, 269, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
1061, d3uvpA_, 0.8434, 2.61, 0.374, 334, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZAMIDE SUBSTITUTED BENZOSUBERONE
1062, d3p79A_, 0.8434, 2.52, 0.367, 332, 264, P38 INHIBITOR-BOUND
1063, d3gcvA_, 0.8433, 2.50, 0.373, 338, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL62
1064, d2zb1A_, 0.8432, 2.68, 0.373, 345, 268, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1065, d3e92A_, 0.8430, 2.66, 0.369, 348, 268, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1066, d1w83A_, 0.8430, 2.68, 0.371, 351, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1067, d4eojC1, 0.8429, 2.35, 0.973, 278, 260, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
1068, d1r3cA_, 0.8429, 2.63, 0.377, 349, 268, THE STRUCTURE OF P38ALPHA C162S MUTANT
1069, d5tbeA_, 0.8427, 2.30, 0.368, 332, 261, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
1070, d3lffA_, 0.8427, 2.57, 0.370, 335, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
1071, d3kq7A_, 0.8426, 2.69, 0.375, 348, 267, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
1072, d4f9yA_, 0.8425, 2.58, 0.382, 339, 267, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1073, d4ehvA_, 0.8425, 2.53, 0.377, 337, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
1074, d4eh2A_, 0.8425, 2.46, 0.383, 337, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
1075, p4looA_, 0.8423, 2.57, 0.384, 349, 268, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
1076, d3flwA_, 0.8423, 2.61, 0.371, 345, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
1077, d2ghmA_, 0.8423, 2.51, 0.380, 336, 266, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
1078, d4fa2A_, 0.8422, 2.61, 0.386, 339, 267, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
1079, p6gdqA_, 0.8421, 2.61, 0.378, 339, 267, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1080, d4ic7A_, 0.8421, 2.68, 0.401, 355, 269, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
1081, d3flsA_, 0.8421, 2.44, 0.375, 343, 264, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1082, d1w84A_, 0.8420, 2.53, 0.357, 351, 266, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1083, d1h25C1, 0.8420, 2.27, 0.992, 277, 259, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
1084, p3vumA_, 0.8419, 2.46, 0.348, 347, 264, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
1085, d3hv4A_, 0.8419, 2.92, 0.387, 339, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1086, d3e3pB_, 0.8419, 2.66, 0.362, 337, 265, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1087, d1q97A_, 0.8417, 2.52, 0.316, 351, 266, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
1088, d3uvrA_, 0.8416, 2.65, 0.370, 331, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH KM064
1089, d3p4kA_, 0.8415, 2.49, 0.374, 338, 265, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
1090, p4h3pA_, 0.8413, 2.73, 0.379, 342, 269, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
1091, d3mgyA_, 0.8413, 2.25, 0.375, 329, 259, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1092, d5xvuA_, 0.8412, 2.59, 0.311, 321, 267, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1093, d3e93A_, 0.8412, 2.72, 0.371, 346, 267, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1094, d5xvuC_, 0.8411, 2.59, 0.311, 321, 267, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1095, d5clpA_, 0.8411, 2.49, 0.316, 322, 263, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1096, p4ux9A_, 0.8411, 2.58, 0.374, 343, 265, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1097, p5lw1H_, 0.8408, 2.66, 0.351, 355, 268, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1098, d2okrD_, 0.8408, 2.51, 0.383, 339, 264, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1099, p5lw1B_, 0.8407, 2.65, 0.362, 355, 268, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1100, d2pv5A_, 0.8407, 2.26, 0.367, 329, 259,  
1101, d1bl6A_, 0.8406, 2.60, 0.360, 351, 267, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
1102, p5nzzE_, 0.8405, 2.43, 0.376, 343, 263, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1103, d4f9wA_, 0.8405, 2.49, 0.377, 336, 265, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1104, d3o8tA_, 0.8405, 2.56, 0.364, 332, 264, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1105, d1ungA_, 0.8404, 2.50, 0.570, 288, 265, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1106, p5lw1E_, 0.8403, 2.67, 0.362, 355, 268, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1107, d3s3iA_, 0.8401, 2.65, 0.381, 349, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1108, d5larA_, 0.8400, 2.71, 0.348, 350, 267, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
1109, d4yr8C_, 0.8399, 2.21, 0.345, 318, 258, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1110, d3e7oA_, 0.8399, 2.57, 0.356, 342, 267, CRYSTAL STRUCTURE OF JNK2
1111, p5nzzF_, 0.8398, 2.39, 0.378, 341, 262, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1112, d1q8yA_, 0.8397, 2.54, 0.316, 351, 266, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
1113, p4ux9C_, 0.8396, 2.74, 0.371, 333, 267, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1114, p3n9xB_, 0.8395, 2.78, 0.413, 362, 271, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1115, d1ywrA_, 0.8393, 2.58, 0.380, 338, 266, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
1116, d5hd4A_, 0.8392, 2.75, 0.384, 347, 268, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
1117, d1wbnA_, 0.8391, 2.73, 0.375, 351, 267, FRAGMENT BASED P38 INHIBITORS
1118, d2gtnA_, 0.8390, 2.63, 0.380, 337, 266, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
1119, d4aa4A_, 0.8389, 2.51, 0.394, 347, 264, P38ALPHA MAP KINASE BOUND TO CMPD 22
1120, d1m7qA_, 0.8389, 2.60, 0.371, 348, 267, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1121, d4qyyA_, 0.8388, 2.71, 0.353, 337, 266, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
1122, d4zthA_, 0.8387, 2.65, 0.380, 339, 266, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
1123, d2zazA_, 0.8387, 2.52, 0.375, 345, 264, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
1124, d3hp2A_, 0.8385, 2.63, 0.383, 341, 266, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
1125, d3i5zA_, 0.8384, 2.40, 0.378, 331, 262, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
1126, d1bl7A_, 0.8384, 2.61, 0.371, 351, 267, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
1127, p3lhjA_, 0.8383, 2.63, 0.368, 341, 266, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
1128, d3ds6D_, 0.8383, 2.64, 0.381, 349, 268, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1129, d2lgcA1, 0.8383, 2.57, 0.372, 353, 266, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
1130, d1wbvA_, 0.8383, 2.73, 0.375, 351, 267, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1131, d4fv4A_, 0.8381, 2.29, 0.378, 329, 259, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
1132, d3gcuA_, 0.8378, 2.81, 0.376, 339, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1133, d4iz7C_, 0.8377, 2.67, 0.352, 340, 267, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
1134, d2zduA_, 0.8377, 2.70, 0.378, 330, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1135, d5m44A_, 0.8376, 2.62, 0.291, 329, 265, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1136, d4aa5A_, 0.8375, 2.48, 0.395, 340, 263, P38ALPHA MAP KINASE BOUND TO CMPD 33
1137, d3newA_, 0.8375, 2.47, 0.373, 334, 263, P38-ALPHA COMPLEXED WITH COMPOUND 10
1138, d3fmkA_, 0.8375, 2.57, 0.383, 346, 266, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1139, d3fmjA_, 0.8375, 2.54, 0.371, 344, 264, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
1140, d3kvxA_, 0.8374, 2.46, 0.373, 327, 263, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
1141, d1bmkA_, 0.8374, 2.59, 0.357, 351, 266, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
1142, p4ux9B_, 0.8373, 2.64, 0.369, 327, 263, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1143, d4qp8A_, 0.8373, 2.57, 0.375, 335, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
1144, d4ic7D_, 0.8373, 2.76, 0.398, 353, 269, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
1145, p3n9xA_, 0.8373, 2.83, 0.410, 374, 271, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1146, d4fv5A_, 0.8370, 2.42, 0.378, 330, 262, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
1147, d4bgqA_, 0.8370, 2.43, 0.388, 276, 263, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
1148, d4aacA_, 0.8369, 2.50, 0.395, 350, 263, P38ALPHA MAP KINASE BOUND TO CMPD 29
1149, d2pmiA_, 0.8369, 2.32, 0.568, 284, 257, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
1150, d4eh7A_, 0.8367, 2.62, 0.385, 337, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
1151, d1q8yB_, 0.8367, 2.78, 0.295, 357, 268, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
1152, d3hv5A_, 0.8365, 2.82, 0.376, 339, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1153, d3c5uA_, 0.8365, 2.58, 0.376, 338, 266, P38 ALPHA MAP KINASE COMPLEXED WITH A BENZOTHIAZOLE BASED INHIBITOR
1154, d3gfeA_, 0.8364, 2.63, 0.368, 352, 266, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
1155, d4eh8A_, 0.8363, 2.50, 0.380, 336, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
1156, d3fv8A_, 0.8362, 2.52, 0.367, 331, 264, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
1157, d4o2zA1, 0.8359, 2.62, 0.347, 357, 265, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
1158, d5nguA_, 0.8358, 2.74, 0.386, 339, 267, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1159, d2yixA_, 0.8357, 2.65, 0.356, 351, 267, TRIAZOLOPYRIDINE INHIBITORS OF P38
1160, d1wzyA_, 0.8357, 2.79, 0.379, 350, 269, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
1161, d1cm8B_, 0.8357, 2.47, 0.377, 327, 260, PHOSPHORYLATED MAP KINASE P38-GAMMA
1162, d4dglC_, 0.8356, 2.81, 0.309, 334, 269, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1163, d3qudA_, 0.8356, 2.70, 0.387, 345, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
1164, d2xrwA1, 0.8356, 2.48, 0.347, 346, 262, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1165, d2eufB_, 0.8356, 2.18, 0.525, 282, 255, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
1166, d1cm8A_, 0.8356, 2.47, 0.377, 327, 260, PHOSPHORYLATED MAP KINASE P38-GAMMA
1167, d4o6eA_, 0.8354, 2.65, 0.387, 328, 266, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
1168, d3flnC_, 0.8354, 2.44, 0.388, 343, 263, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
1169, d1zzlA_, 0.8354, 2.66, 0.360, 351, 267, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
1170, d3fmmA_, 0.8353, 2.57, 0.358, 346, 265, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
1171, d3ds6A_, 0.8353, 2.70, 0.367, 343, 267, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1172, d3flqA_, 0.8352, 2.48, 0.376, 345, 263, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
1173, d4iz7A_, 0.8351, 2.63, 0.351, 344, 265, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
1174, d3fknA_, 0.8351, 2.73, 0.367, 346, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
1175, d3o0gB_, 0.8350, 1.78, 0.593, 264, 248, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
1176, d2f49A_, 0.8350, 2.80, 0.356, 335, 267, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
1177, d1p38A_, 0.8350, 2.65, 0.358, 351, 265, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
1178, d4l8mA_, 0.8349, 2.71, 0.376, 339, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
1179, d3l1sA_, 0.8349, 2.33, 0.351, 336, 259, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1180, d1w7hA_, 0.8349, 2.62, 0.370, 351, 265, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1181, d5mtxA_, 0.8348, 2.54, 0.376, 331, 263, DIBENZOOXEPINONE INHIBITOR 12B IN COMPLEX WITH P38 MAPK
1182, d4eh6A_, 0.8347, 2.47, 0.378, 335, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
1183, d3hecA_, 0.8344, 2.53, 0.364, 329, 261, P38 IN COMPLEX WITH IMATINIB
1184, d4awiA_, 0.8343, 2.65, 0.371, 352, 267, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
1185, d5uojA_, 0.8342, 2.65, 0.358, 343, 265, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION
1186, d3rinA_, 0.8339, 2.83, 0.379, 349, 269, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1187, d1yw2A_, 0.8338, 2.75, 0.378, 341, 267, MUTATED MUS MUSCULUS P38 KINASE (MP38)
1188, d4eh3A_, 0.8337, 2.64, 0.383, 339, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
1189, d3queA_, 0.8336, 2.71, 0.387, 343, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
1190, d2zdtA_, 0.8336, 2.67, 0.382, 342, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1191, p4lopD_, 0.8335, 2.57, 0.376, 351, 266, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1192, d3zyaA1, 0.8335, 2.55, 0.364, 341, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
1193, d4qp1B_, 0.8334, 2.64, 0.381, 343, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1194, d3p7aA_, 0.8334, 2.55, 0.369, 332, 263, P38 INHIBITOR-BOUND
1195, d2ojjA_, 0.8334, 2.81, 0.346, 344, 266, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1196, d1oguC1, 0.8331, 2.01, 0.992, 269, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1197, d3u8wA_, 0.8330, 2.65, 0.368, 349, 266, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
1198, p6g9hA_, 0.8328, 2.78, 0.368, 343, 266, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1199, d4r3cA_, 0.8328, 2.57, 0.354, 335, 263, CRYSTAL STRUCTURE OF P38 ALPHA MAP KINASE IN COMPLEX WITH A NOVEL ISOFORM SELECTIVE DRUG CANDIDATE
1200, d4bbmB1, 0.8328, 2.22, 0.416, 288, 255, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
1201, d3hp5A_, 0.8328, 2.45, 0.375, 330, 261, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIMIDOPYRIDAZINONE COMPOUND
1202, d2ojgA_, 0.8328, 2.83, 0.352, 337, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1203, d5etcA_, 0.8326, 2.69, 0.361, 355, 266, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
1204, d4qp7B_, 0.8325, 2.62, 0.375, 335, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
1205, d5byyA_, 0.8324, 2.64, 0.402, 338, 266, ERK5 IN COMPLEX WITH SMALL MOLECULE
1206, d5cs6B_, 0.8323, 2.35, 0.318, 316, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1207, d4qtaA_, 0.8322, 2.66, 0.340, 335, 265, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
1208, d3uvqA_, 0.8321, 2.52, 0.392, 333, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
1209, d5n66A_, 0.8319, 2.52, 0.382, 332, 262, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9J
1210, d4fv3A_, 0.8319, 2.84, 0.382, 346, 267, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
1211, p6g8xA_, 0.8318, 2.75, 0.378, 338, 267, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1212, d4xj0A_, 0.8317, 2.69, 0.381, 345, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
1213, d3oefX_, 0.8317, 2.81, 0.389, 334, 265, CRYSTAL STRUCTURE OF Y323F INACTIVE MUTANT OF P38ALPHA MAP KINASE
1214, d3fkoA_, 0.8317, 2.52, 0.361, 343, 263, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
1215, d2fysB_, 0.8317, 2.69, 0.377, 338, 268, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
1216, d3o8pA_, 0.8316, 2.67, 0.348, 336, 264, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1217, d3l1sB_, 0.8316, 2.39, 0.347, 330, 259, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1218, d4iq6A_, 0.8315, 2.37, 0.349, 324, 258, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
1219, d3gi3A_, 0.8315, 2.51, 0.368, 330, 261, CRYSTAL STRUCTURE OF A N-PHENYL-N -NAPHTHYLUREA ANALOG IN COMPLEX WITH P38 MAP KINASE
1220, d3d83A_, 0.8312, 2.75, 0.377, 347, 265, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1221, d4xrlA_, 0.8311, 2.76, 0.361, 337, 266, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1222, d3erkA_, 0.8311, 2.86, 0.377, 350, 268, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
1223, p6cpwA_, 0.8310, 2.68, 0.338, 328, 263, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
1224, d4qp4B_, 0.8309, 2.68, 0.373, 335, 268, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1225, d4fuxA_, 0.8309, 2.79, 0.382, 342, 267, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
1226, d2ojiA_, 0.8309, 2.83, 0.352, 344, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1227, p3teiA_, 0.8308, 2.70, 0.387, 339, 266, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
1228, p5nzzG_, 0.8307, 2.55, 0.388, 342, 263, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1229, d4qtdA_, 0.8307, 2.70, 0.371, 355, 267, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
1230, d3mpaA_, 0.8306, 2.47, 0.375, 331, 261, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1231, d1a9uA_, 0.8306, 2.70, 0.343, 351, 265, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
1232, d4dljA_, 0.8305, 2.56, 0.363, 336, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH RL163
1233, d3fskA_, 0.8305, 2.63, 0.370, 342, 265, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6257
1234, d3cgfA_, 0.8305, 2.78, 0.381, 346, 268, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1235, p6g91A_, 0.8304, 2.75, 0.371, 344, 267, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1236, p4h3pD_, 0.8302, 2.75, 0.386, 338, 267, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
1237, d4eorC1, 0.8302, 2.04, 0.956, 269, 251, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
1238, d3obgA_, 0.8301, 2.58, 0.380, 332, 263, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1239, d3bhuC1, 0.8301, 2.05, 1.000, 269, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
1240, d3cg2A_, 0.8299, 2.35, 0.376, 327, 258,  
1241, d4y46A_, 0.8298, 2.70, 0.382, 340, 267, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1242, d4qpaB_, 0.8298, 2.65, 0.352, 345, 264, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
1243, d3itzA1, 0.8298, 2.86, 0.366, 353, 268, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
1244, d5ci6B_, 0.8297, 2.60, 0.352, 350, 264, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1245, d2gfsA_, 0.8296, 2.58, 0.357, 344, 263, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
1246, d4zzoA_, 0.8295, 2.73, 0.361, 339, 266, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
1247, d4ditA_, 0.8295, 2.24, 0.344, 328, 256, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
1248, d2ghlA_, 0.8294, 2.53, 0.385, 334, 262, MUTANT MUS MUSCULUS P38 KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-874743
1249, d4eh4A_, 0.8293, 2.60, 0.378, 337, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
1250, d1oveA_, 0.8293, 2.72, 0.368, 349, 266, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
1251, d4eomC1, 0.8292, 2.18, 0.984, 271, 253, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
1252, d3eljA_, 0.8292, 2.74, 0.367, 347, 267, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
1253, p6g9nA_, 0.8290, 2.71, 0.352, 344, 264, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1254, d1oz1A_, 0.8290, 2.65, 0.371, 344, 264, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
1255, p6g9dA_, 0.8289, 2.80, 0.368, 345, 266, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1256, d5etiA1, 0.8289, 2.69, 0.355, 352, 265, STRUCTURE OF DEAD KINASE MAPK14
1257, d4erkA_, 0.8288, 2.85, 0.360, 350, 267, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
1258, d4yr8A_, 0.8287, 2.57, 0.370, 320, 262, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1259, d3hv3A_, 0.8286, 2.59, 0.370, 335, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH RL49
1260, p6g9mA_, 0.8285, 2.85, 0.368, 341, 266, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1261, d3amyA_, 0.8285, 2.46, 0.308, 318, 260, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
1262, d1ungB_, 0.8285, 2.15, 0.586, 268, 251, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1263, d1i09A_, 0.8285, 2.38, 0.357, 338, 258, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
1264, d4qp1A_, 0.8284, 2.73, 0.366, 342, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1265, d3fmnA_, 0.8284, 2.48, 0.375, 341, 261, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO2530
1266, d4fv1A_, 0.8283, 2.89, 0.342, 342, 266, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
1267, d3pzeA_, 0.8283, 2.78, 0.352, 347, 267, JNK1 IN COMPLEX WITH INHIBITOR
1268, d4fv2A_, 0.8282, 2.93, 0.381, 344, 268, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
1269, d2gtmA_, 0.8282, 2.64, 0.384, 341, 263, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
1270, d1wfcA_, 0.8281, 2.62, 0.350, 340, 263, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
1271, d1r39A_, 0.8280, 2.70, 0.364, 345, 264, THE STRUCTURE OF P38ALPHA
1272, d4un0D_, 0.8279, 2.64, 0.452, 276, 263, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
1273, d3gcqA_, 0.8279, 2.62, 0.366, 337, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH RL45
1274, d3bhtC1, 0.8279, 2.06, 0.976, 269, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
1275, d1jnkA_, 0.8279, 2.73, 0.382, 346, 267, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
1276, d3pg1A_, 0.8278, 2.81, 0.331, 341, 266, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR (1.95 ANGS RESOLUTION)
1277, d3hegA_, 0.8278, 2.56, 0.356, 333, 261, P38 IN COMPLEX WITH SORAFENIB
1278, d1ukiA_, 0.8278, 2.64, 0.352, 328, 264, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1279, d4bcoC1, 0.8277, 2.04, 1.000, 268, 250, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1280, d3s4qA_, 0.8276, 2.24, 0.383, 326, 256, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-TRIAZINE BASED INHIBITOR
1281, d2fa2A_, 0.8276, 2.88, 0.356, 333, 267, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
1282, d1golA_, 0.8276, 2.88, 0.356, 357, 267, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
1283, p6ge0A_, 0.8275, 2.84, 0.368, 343, 266, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1284, d5lcjA_, 0.8274, 2.73, 0.357, 345, 266, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
1285, d4xp3A_, 0.8273, 2.78, 0.361, 339, 266, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1286, d3mh1A_, 0.8272, 2.66, 0.342, 337, 263, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1287, d4tyhB_, 0.8270, 2.53, 0.368, 335, 261, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
1288, d2r9sA_, 0.8270, 2.54, 0.368, 325, 261, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1289, d1erkA_, 0.8270, 2.94, 0.348, 357, 267, STRUCTURE OF SIGNAL-REGULATED KINASE
1290, d5nhfA_, 0.8269, 2.87, 0.386, 339, 267, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1291, d4zzmA_, 0.8269, 2.82, 0.382, 344, 267, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
1292, d3cgoA_, 0.8269, 2.74, 0.382, 332, 267, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1293, d2pv8A_, 0.8269, 2.67, 0.342, 337, 263,  
1294, d2iw9C2, 0.8269, 2.00, 0.996, 267, 249, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
1295, d5umoA_, 0.8268, 2.89, 0.352, 347, 267, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
1296, d4x21B_, 0.8268, 2.61, 0.370, 336, 265, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1297, d2r9sB_, 0.8267, 2.53, 0.368, 325, 261, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1298, d1tvoA_, 0.8267, 2.92, 0.381, 350, 268, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1299, d4y5hA_, 0.8266, 2.75, 0.382, 349, 267, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1300, d3tg1A_, 0.8266, 2.61, 0.363, 334, 262, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH A MAPK DOCKING PARTNER
1301, d3ds6B_, 0.8266, 2.77, 0.382, 343, 267, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1302, d4xp2A_, 0.8264, 2.89, 0.363, 337, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1303, d4s34A_, 0.8263, 2.87, 0.342, 343, 266, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
1304, d1yqjA2, 0.8263, 2.75, 0.355, 351, 265, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
1305, d4s2zA_, 0.8262, 2.92, 0.348, 346, 267, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
1306, d2p33A_, 0.8262, 2.74, 0.382, 332, 267, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1307, d3lfbA_, 0.8261, 2.61, 0.379, 333, 261, HUMAN P38 MAP KINASE IN COMPLEX WITH RL98
1308, d4s33A_, 0.8259, 2.93, 0.341, 347, 267, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
1309, p4lopA_, 0.8259, 2.68, 0.383, 351, 266, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1310, d3g90X_, 0.8259, 2.70, 0.381, 345, 265, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
1311, d3fmlA_, 0.8258, 2.54, 0.364, 342, 261, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6224
1312, d4x21A_, 0.8257, 2.75, 0.361, 336, 266, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1313, p4lopB_, 0.8257, 2.69, 0.383, 350, 266, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1314, d4kkhA_, 0.8257, 2.86, 0.381, 351, 268, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
1315, p5nzzH_, 0.8255, 2.51, 0.378, 335, 259, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1316, d4kkeA_, 0.8253, 2.76, 0.382, 354, 267, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
1317, d3objA_, 0.8253, 2.78, 0.357, 332, 263, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1318, d4izaC_, 0.8252, 2.70, 0.341, 335, 264, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
1319, d4s31A_, 0.8251, 2.91, 0.342, 347, 266, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
1320, d4eoqC1, 0.8251, 2.23, 1.000, 271, 253, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
1321, d3qywA_, 0.8251, 2.79, 0.361, 340, 266, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1322, d2i6lA_, 0.8251, 2.63, 0.330, 292, 261, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1323, d1kv1A_, 0.8251, 2.57, 0.387, 331, 261, P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1
1324, d4w4wA_, 0.8250, 2.86, 0.381, 349, 268, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
1325, d4b99A_, 0.8250, 2.68, 0.409, 335, 264, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
1326, d4zznA_, 0.8249, 2.78, 0.368, 338, 266, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
1327, d3fl4A_, 0.8248, 2.57, 0.383, 339, 261, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
1328, d2fa2B_, 0.8248, 2.97, 0.356, 332, 267, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
1329, d3bhvC1, 0.8245, 2.14, 1.000, 269, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
1330, d2puuA_, 0.8245, 2.49, 0.375, 330, 259, CRYSTAL STRUCTURE OF P38 COMPLEX WITH 1-(5-TERT-BUTYL-2-P- TOLYL-2H-PYRAZOL-3-YL)-3-[4-(6-MORPHOLIN-4-YLMETHYL- PYRIDIN-3-YL)NAPHTHALEN-1-YL]UREA
1331, d3fi4A_, 0.8243, 2.43, 0.390, 339, 259, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
1332, d2z7lA_, 0.8243, 2.85, 0.387, 329, 266, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
1333, d2f49B_, 0.8243, 2.94, 0.356, 337, 267, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
1334, d4n4sA_, 0.8242, 2.84, 0.348, 342, 267, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
1335, d3v6sB_, 0.8242, 2.61, 0.367, 340, 264, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1336, d3ttiA_, 0.8238, 2.79, 0.382, 341, 267, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
1337, d3r63A_, 0.8238, 2.98, 0.341, 347, 267, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
1338, d3k3iA_, 0.8238, 2.62, 0.379, 332, 261, P38ALPHA BOUND TO NOVEL DGF-OUT COMPOUND PF-00215955
1339, d4s32A_, 0.8237, 2.96, 0.341, 346, 267, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
1340, d4qp3B_, 0.8236, 2.50, 0.390, 331, 259, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
1341, d3g9nA_, 0.8236, 2.75, 0.383, 346, 266, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
1342, d3ds6C_, 0.8236, 2.74, 0.368, 349, 266, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1343, d2qd9A_, 0.8236, 2.57, 0.391, 330, 261, P38 ALPHA MAP KINASE INHIBITOR BASED ON HETEROBICYCLIC SCAFFOLDS
1344, d2o0uA_, 0.8236, 2.76, 0.382, 331, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
1345, d4eh9A_, 0.8234, 2.56, 0.385, 334, 260, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F11 AND RL87
1346, d3v6sA_, 0.8234, 2.75, 0.368, 349, 266, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1347, d4qp3A_, 0.8233, 2.67, 0.366, 339, 262, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
1348, d4kkgA_, 0.8233, 2.77, 0.382, 353, 267, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
1349, d4g6oA_, 0.8233, 2.92, 0.380, 339, 266, CRYSTAL STRUCTURE OF THE ERK2
1350, d4g6nA_, 0.8233, 2.91, 0.350, 341, 266, CRYSTAL STRUCTURE OF THE ERK2
1351, d3l8xA_, 0.8233, 2.24, 0.373, 326, 255, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-PYRIMIDINE BASED INHIBITOR
1352, d2ptoA_, 0.8231, 2.50, 0.375, 330, 259,  
1353, p6g9jA_, 0.8230, 2.78, 0.357, 347, 263, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1354, d5mtyA_, 0.8230, 2.51, 0.372, 328, 258, DIBENZOSUBERONE INHIBITOR 8E IN COMPLEX WITH P38 MAPK
1355, d4cfuC1, 0.8230, 2.17, 1.000, 269, 251, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1356, d5tcoA_, 0.8228, 2.63, 0.367, 327, 259, HUMAN P38 MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 1
1357, d5lckA_, 0.8228, 2.77, 0.366, 345, 265, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
1358, d4h36A_, 0.8226, 2.88, 0.382, 353, 267, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH ATF2 PEPTIDE
1359, d3oc1A_, 0.8226, 2.49, 0.371, 330, 259, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1360, d4xneA_, 0.8225, 2.88, 0.351, 344, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1361, p4h3bC_, 0.8225, 2.89, 0.382, 351, 267, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1362, p4h3bA_, 0.8225, 2.89, 0.382, 351, 267, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1363, d5byzA_, 0.8224, 2.96, 0.398, 348, 269, ERK5 IN COMPLEX WITH SMALL MOLECULE
1364, d3e7oB_, 0.8224, 2.61, 0.333, 326, 261, CRYSTAL STRUCTURE OF JNK2
1365, d2pk9C_, 0.8224, 2.00, 0.565, 266, 248, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
1366, d4yr8E_, 0.8223, 2.66, 0.366, 317, 262, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1367, d3ttjA_, 0.8222, 2.97, 0.377, 333, 268, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
1368, d2iw8C2, 0.8222, 1.91, 0.984, 264, 246, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
1369, d1pmuA_, 0.8222, 2.77, 0.383, 342, 266, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
1370, d4zsjA_, 0.8221, 2.74, 0.356, 344, 264, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
1371, d2ptjA_, 0.8221, 2.56, 0.350, 334, 260,  
1372, d4bcpC1, 0.8220, 2.02, 1.000, 266, 248, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1373, d3gc7A_, 0.8220, 2.83, 0.365, 349, 266, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1374, d4gt3A_, 0.8219, 2.97, 0.346, 347, 266, ATP-BOUND FORM OF THE ERK2 KINASE
1375, d3mh2A_, 0.8219, 2.52, 0.375, 330, 259, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1376, d4dliA_, 0.8218, 2.59, 0.358, 334, 260, HUMAN P38 MAP KINASE IN COMPLEX WITH RL87
1377, p6g92A_, 0.8217, 2.87, 0.378, 343, 267, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1378, p5o90A_, 0.8217, 2.53, 0.398, 330, 261, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
1379, d3mh3A_, 0.8216, 2.58, 0.358, 334, 260, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1380, d3npcA_, 0.8215, 3.02, 0.371, 357, 267, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1381, d3o71A_, 0.8214, 2.94, 0.360, 340, 267, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
1382, d1ukhA_, 0.8214, 2.58, 0.341, 321, 261, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1383, d4xozA_, 0.8213, 2.93, 0.350, 341, 266, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1384, d3hvcA_, 0.8212, 2.45, 0.388, 327, 258, CRYSTAL STRUCTURE OF HUMAN P38ALPHA MAP KINASE
1385, d3hv6A_, 0.8212, 2.57, 0.378, 331, 259, HUMAN P38 MAP KINASE IN COMPLEX WITH RL39
1386, d2p5aA_, 0.8212, 2.45, 0.388, 327, 258,  
1387, d4yr8F_, 0.8211, 2.11, 0.364, 300, 250, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1388, d2f2cB_, 0.8211, 2.27, 0.514, 280, 253, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
1389, d4a9yA_, 0.8210, 2.77, 0.378, 334, 262, P38ALPHA MAP KINASE BOUND TO CMPD 8
1390, d2bakA_, 0.8210, 2.77, 0.378, 334, 262, P38ALPHA MAP KINASE BOUND TO MPAQ
1391, d1ianA_, 0.8210, 2.56, 0.382, 328, 259, HUMAN P38 MAP KINASE INHIBITOR COMPLEX
1392, d1h26C1, 0.8210, 2.05, 1.000, 266, 248, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
1393, d4s30A_, 0.8209, 2.94, 0.350, 342, 266, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
1394, d5o8uA_, 0.8208, 2.61, 0.373, 331, 260, COVALENT INHIBITOR 4B BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S252C
1395, p5o7iA_, 0.8208, 2.77, 0.373, 340, 263, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
1396, d1pmnA_, 0.8207, 2.78, 0.383, 344, 266, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
1397, d2wajA_, 0.8205, 2.75, 0.385, 348, 265, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
1398, p2xs0A_, 0.8204, 2.80, 0.361, 346, 266, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1399, d4qp6A_, 0.8203, 2.66, 0.352, 339, 261, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
1400, d1pmeA_, 0.8203, 2.76, 0.379, 333, 264, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
1401, p4loqD_, 0.8202, 2.76, 0.383, 351, 266, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1402, d4zsgA_, 0.8201, 2.75, 0.356, 347, 264, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
1403, d3v6rA_, 0.8201, 2.90, 0.363, 349, 267, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1404, p6gdmA_, 0.8198, 2.88, 0.358, 341, 265, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1405, p4whzA_, 0.8197, 2.92, 0.381, 342, 268, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
1406, d2i0hA_, 0.8197, 2.89, 0.347, 349, 265, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH AN ARYLPYRIDAZINONE
1407, d3pg3A_, 0.8196, 2.82, 0.357, 337, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL182
1408, d3fc1X_, 0.8196, 2.65, 0.365, 330, 260, CRYSTAL STRUCTURE OF P38 KINASE BOUND TO PYRIMIDO-PYRIDAZINONE INHIBITOR
1409, d3mw1A_, 0.8195, 2.76, 0.373, 342, 263, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1410, d4w4yA_, 0.8192, 2.82, 0.376, 350, 266, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1411, d4ynoA_, 0.8191, 2.93, 0.368, 342, 266, CRYSTAL STRUCTURE OF MAPK13 AT INACTIVE FORM
1412, d3v6rB_, 0.8191, 2.67, 0.367, 346, 264, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1413, d5awmA_, 0.8190, 2.67, 0.361, 345, 263, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
1414, d2wmbC1, 0.8189, 2.02, 1.000, 265, 247, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
1415, d3dogC1, 0.8188, 2.08, 0.996, 266, 248, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
1416, d3uibA_, 0.8187, 2.36, 0.332, 309, 256, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR IN COMPLEX WITH SB203580
1417, d3qyzA_, 0.8183, 2.95, 0.382, 339, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1418, d4xrjA_, 0.8182, 2.94, 0.351, 344, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1419, d4qp2A_, 0.8182, 2.70, 0.352, 336, 261, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
1420, d5n65A_, 0.8181, 2.75, 0.378, 333, 262, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9H
1421, d4xj0B_, 0.8181, 2.68, 0.387, 338, 261, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
1422, d3ha8A_, 0.8181, 2.92, 0.347, 342, 265, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/COMPOUND 14B
1423, d4xp0A_, 0.8180, 2.81, 0.371, 336, 264, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1424, d4qpaA_, 0.8180, 2.59, 0.390, 331, 259, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
1425, d5lmkC1, 0.8179, 2.00, 1.000, 264, 246, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
1426, d4w4xA_, 0.8179, 2.84, 0.376, 342, 266, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1427, d2excX_, 0.8177, 2.72, 0.380, 335, 263, INHIBITOR COMPLEX OF JNK3
1428, d4qp2B_, 0.8176, 2.53, 0.384, 329, 258, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
1429, d3hrbA_, 0.8176, 2.82, 0.371, 344, 264, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1430, p5ax3A_, 0.8175, 2.49, 0.385, 329, 257, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
1431, p4loqB_, 0.8175, 2.80, 0.383, 351, 266, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1432, d3fsfA_, 0.8175, 2.67, 0.369, 340, 260, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 3-(26- DICHLORO-PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]- 1-METHYL-34-DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
1433, d4ic8B_, 0.8174, 2.99, 0.348, 336, 267, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1434, d3iw6A_, 0.8174, 2.95, 0.377, 337, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZYLPIPERAZIN- PYRROL
1435, d2w96B_, 0.8174, 1.62, 0.496, 267, 242, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1436, d3hv7A_, 0.8173, 2.62, 0.386, 330, 259, HUMAN P38 MAP KINASE IN COMPLEX WITH RL38
1437, d5n68A_, 0.8172, 2.56, 0.384, 328, 258, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9M
1438, d4qp6B_, 0.8172, 2.58, 0.390, 334, 259, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
1439, p5xyxA_, 0.8171, 2.62, 0.364, 337, 258, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1440, d1pmvA_, 0.8171, 2.86, 0.382, 347, 267, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
1441, d4cjyD_, 0.8170, 2.63, 0.452, 272, 259,  
1442, d2o2uA_, 0.8170, 2.75, 0.386, 319, 264, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4567- TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE
1443, d4z9lA_, 0.8168, 2.97, 0.375, 333, 267, THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
1444, d5ci6A_, 0.8167, 2.76, 0.376, 335, 263, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1445, d4gvaA_, 0.8167, 3.01, 0.350, 345, 266, ADP-BOUND FORM OF THE ERK2 KINASE
1446, d1oiuC1, 0.8167, 2.01, 0.996, 264, 246, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1447, d4zslA_, 0.8166, 2.89, 0.360, 341, 264, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
1448, d4w4vA_, 0.8163, 2.86, 0.372, 342, 266, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1449, d3da6A_, 0.8162, 2.88, 0.383, 328, 266, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
1450, d3iw7A_, 0.8161, 2.92, 0.375, 335, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH AN IMIDAZO-PYRIDINE
1451, d5o8vA_, 0.8160, 2.47, 0.375, 328, 256, COVALENT INHIBITOR 4A BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S251C
1452, p4loqA_, 0.8160, 2.81, 0.383, 352, 266, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1453, d4fuyA_, 0.8160, 2.82, 0.390, 329, 264, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
1454, d3k3jA_, 0.8159, 2.62, 0.382, 329, 259, P38ALPHA BOUND TO NOVEL DFG-OUT COMPOUND PF-00416121
1455, d2ok1A_, 0.8159, 2.88, 0.377, 333, 265, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1456, d4cfmC1, 0.8154, 2.09, 1.000, 265, 247, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1457, d3zsiA_, 0.8154, 2.74, 0.388, 326, 260, X-RAY STRUCTURE OF P38ALPHA BOUND TO VX-745
1458, d3ddqC1, 0.8150, 2.08, 0.996, 265, 247, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
1459, d3zshA_, 0.8148, 2.84, 0.365, 331, 263, X-RAY STRUCTURE OF P38ALPHA BOUND TO SCIO-469
1460, p4lopC_, 0.8145, 2.63, 0.371, 341, 259, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1461, d3npcB_, 0.8142, 3.12, 0.371, 356, 267, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1462, d3hucA_, 0.8142, 2.89, 0.361, 337, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL40
1463, d4fv0A_, 0.8139, 3.03, 0.332, 341, 265, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
1464, d3hubA_, 0.8139, 2.75, 0.366, 335, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH SCIOS-469
1465, d3odyX_, 0.8138, 2.37, 0.401, 321, 252, CRYSTAL STRUCTURE OF P38ALPHA Y323Q ACTIVE MUTANT
1466, d5n63A_, 0.8135, 2.41, 0.386, 325, 254, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9C
1467, d3rtpA_, 0.8135, 2.68, 0.372, 331, 261, DESIGN AND SYNTHESIS OF BRAIN PENETRANT SELECTIVE JNK INHIBITORS WITH IMPROVED PHARMACOKINETIC PROPERTIES FOR THE PREVENTION OF NEURODEGENERATION
1468, d4xoyA_, 0.8134, 2.76, 0.364, 326, 261, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1469, d3l8sA_, 0.8132, 2.79, 0.379, 334, 261, HUMAN P38 MAP KINASE IN COMPLEX WITH CP-547632
1470, d3lfaA_, 0.8131, 2.73, 0.373, 333, 260, HUMAN P38 MAP KINASE IN COMPLEX WITH DASATINIB
1471, d4eh5A_, 0.8130, 2.50, 0.383, 329, 256, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F4 AND RL87
1472, d5n67A_, 0.8128, 2.54, 0.383, 327, 256, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9L
1473, d1kv2A_, 0.8126, 2.48, 0.395, 325, 256, HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796
1474, d3lfeA_, 0.8125, 2.84, 0.378, 334, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH RL116
1475, d4n0sA_, 0.8119, 3.04, 0.355, 348, 265, COMPLEX OF ERK2 WITH CAFFEIC ACID
1476, p4h39A_, 0.8118, 2.95, 0.377, 340, 265, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH JIP1 PEPTIDE
1477, d4gsbA_, 0.8116, 2.92, 0.379, 343, 264, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
1478, d3sa0A_, 0.8116, 3.05, 0.351, 354, 265, COMPLEX OF ERK2 WITH NORATHYRIOL
1479, d5d7aB_, 0.8113, 2.36, 0.262, 286, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1480, d4e5aX_, 0.8113, 2.64, 0.368, 332, 258, THE W197A MUTANT OF P38A MAP KINASE
1481, d4n4sB_, 0.8112, 2.97, 0.346, 337, 266, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
1482, d5d7aA_, 0.8110, 2.37, 0.266, 289, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1483, d3oy1A_, 0.8110, 2.69, 0.364, 329, 261, HIGHLY SELECTIVE C-JUN N-TERMINAL KINASE (JNK) 2 AND 3 INHIBITORS WITH IN VITRO CNS-LIKE PHARMACOKINETIC PROPERTIES
1484, d2w9fB_, 0.8110, 1.76, 0.481, 261, 241, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1485, d2fslX_, 0.8109, 2.70, 0.384, 332, 258, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-A
1486, d4e6cA_, 0.8106, 2.80, 0.381, 330, 260, P38A-PERIFOSINE COMPLEX
1487, d3oz6B_, 0.8102, 2.97, 0.387, 341, 266, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1488, d2baqA_, 0.8102, 2.78, 0.398, 329, 259, P38ALPHA BOUND TO RO3201195
1489, d5ekoA_, 0.8101, 3.04, 0.366, 341, 265, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1490, d2ewaA_, 0.8100, 2.64, 0.381, 330, 257, DUAL BINDING MODE OF PYRIDINYLIMIDAZOLE TO MAP KINASE P38
1491, d3my5C1, 0.8099, 2.18, 0.996, 265, 247, CDK2/CYCLINA IN COMPLEX WITH DRB
1492, d4zxtA_, 0.8098, 3.10, 0.351, 348, 265, COMPLEX OF ERK2 WITH CATECHOL
1493, d3g9lX_, 0.8097, 2.84, 0.374, 336, 262, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-STYRYLINDOLIN-2-ONE
1494, d2yiwA_, 0.8096, 2.49, 0.388, 325, 255, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE
1495, d3lfcA_, 0.8094, 2.74, 0.367, 334, 259, HUMAN P38 MAP KINASE IN COMPLEX WITH RL99
1496, d1jowB_, 0.8093, 2.26, 0.516, 277, 250, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
1497, d4u79A_, 0.8092, 2.84, 0.383, 337, 264, CRYSTAL STRUCTURE OF HUMAN JNK3 IN COMPLEX WITH A BENZENESULFONAMIDE INHIBITOR.
1498, d5n64A_, 0.8091, 2.59, 0.383, 329, 256, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9G
1499, d4eymA_, 0.8090, 3.05, 0.366, 340, 265, MAPK13 COMPLEX WITH INHIBITOR
1500, d5d7aC_, 0.8087, 2.25, 0.272, 286, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1501, d5cwzB_, 0.8085, 2.30, 0.256, 284, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1502, d4eyjA_, 0.8085, 3.02, 0.356, 338, 264, MAPK13 COMPLEX WITH INHIBITOR
1503, d4aa0A_, 0.8085, 2.74, 0.388, 328, 258, P38ALPHA MAP KINASE BOUND TO CMPD 2
1504, p6f5eB_, 0.8084, 2.86, 0.347, 346, 262, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1505, p5lenB_, 0.8084, 2.86, 0.347, 346, 262, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX WITH JNK1A1 AND JIP1 PEPTIDE
1506, d3iw5A_, 0.8084, 3.10, 0.377, 336, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH AN INDOLE DERIVATIVE
1507, d1bi7A_, 0.8081, 2.21, 0.468, 269, 248, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURE OF THE CDK6-P16INK4A TUMOR SUPPRESSOR COMPLEX
1508, d4u43A_, 0.8078, 2.38, 0.274, 287, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
1509, d4geoA_, 0.8077, 2.52, 0.378, 326, 254, P38A MAP KINASE DEF-POCKET PENTA MUTANT (M194A L195A H228A I229A Y258A)
1510, d5cwzA_, 0.8076, 2.32, 0.260, 284, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1511, d1s9iA_, 0.8074, 2.18, 0.297, 303, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
1512, d2b1pA_, 0.8068, 2.89, 0.361, 331, 263, INHIBITOR COMPLEX OF JNK3
1513, d1bi8C_, 0.8067, 2.20, 0.484, 264, 248, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
1514, d1bi8A_, 0.8067, 2.20, 0.484, 264, 248, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
1515, d3iw8A_, 0.8066, 2.89, 0.364, 334, 261, STRUCTURE OF INACTIVE HUMAN P38 MAP KINASE IN COMPLEX WITH A THIAZOLE-UREA
1516, d4lmnA1, 0.8062, 2.35, 0.288, 291, 250, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
1517, d3gcsA_, 0.8062, 2.87, 0.379, 331, 261, HUMAN P38 MAP KINASE IN COMPLEX WITH SORAFENIB
1518, d4zp5A_, 0.8060, 2.42, 0.267, 284, 251, MAP4K4 IN COMPLEX WITH INHIBITOR
1519, d5ax9C_, 0.8056, 2.32, 0.267, 282, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1520, d5ax9A_, 0.8051, 2.33, 0.263, 282, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1521, d4u40A_, 0.8049, 2.40, 0.274, 295, 252, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
1522, d3zsgA_, 0.8049, 3.00, 0.347, 337, 262, X-RAY STRUCTURE OF P38ALPHA BOUND TO TAK-715
1523, d3zs5A1, 0.8045, 2.98, 0.347, 339, 262, STRUCTURAL BASIS FOR KINASE SELECTIVITY OF THREE CLINICAL P38ALPHA INHIBITORS
1524, d3mblA_, 0.8042, 2.28, 0.285, 290, 249, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
1525, d4cfvC1, 0.8041, 2.15, 0.996, 263, 245, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1526, d5eknA_, 0.8040, 2.99, 0.359, 336, 262, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1527, d5di1A_, 0.8039, 2.46, 0.267, 285, 251, MAP4K4 IN COMPLEX WITH AN INHIBITOR
1528, d4u81A1, 0.8036, 2.36, 0.296, 288, 250, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
1529, d2yisA_, 0.8036, 2.54, 0.390, 325, 254, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE.
1530, d2p55A2, 0.8034, 2.26, 0.293, 288, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1531, d3v04A1, 0.8033, 2.28, 0.289, 288, 249, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
1532, d5j95A_, 0.8032, 2.47, 0.267, 284, 251, MAP4K4 IN COMPLEX WITH INHIBITOR
1533, d4u7zA1, 0.8026, 2.36, 0.296, 290, 250, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
1534, d4u44A_, 0.8026, 2.48, 0.278, 286, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
1535, d4arkA1, 0.8026, 2.38, 0.288, 290, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
1536, d3dv3A_, 0.8026, 2.44, 0.288, 288, 250, MEK1 WITH PF-04622664 BOUND
1537, d2wmaC1, 0.8023, 2.20, 0.972, 264, 246, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
1538, d3e8nA1, 0.8022, 2.37, 0.292, 290, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
1539, d3pp1A1, 0.8019, 2.40, 0.288, 290, 250, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
1540, d3v01A1, 0.8018, 2.40, 0.296, 288, 250, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
1541, d3oz6A_, 0.8018, 2.88, 0.383, 343, 261, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1542, d4u80A_, 0.8017, 2.39, 0.292, 286, 250, MEK 1 KINASE BOUND TO G799
1543, d3fi2A_, 0.8017, 2.69, 0.367, 326, 259, CRYSTAL STRUCTURE OF JNK3 WITH AMINO-PYRAZOLE INHIBITOR SR- 3451
1544, d4zk5A_, 0.8016, 2.42, 0.263, 286, 251, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
1545, d4u45A_, 0.8014, 2.50, 0.274, 289, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
1546, d3is5F1, 0.8012, 2.00, 0.292, 259, 243, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
1547, d3eqbA1, 0.8011, 2.39, 0.292, 288, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1548, p4loqC_, 0.8010, 2.69, 0.375, 337, 256, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1549, d3eqgA_, 0.8010, 2.31, 0.285, 314, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
1550, d3eqfA_, 0.8010, 2.31, 0.285, 314, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
1551, d3fi3A_, 0.8006, 2.63, 0.366, 328, 257, CRYSTAL STRUCTURE OF JNK3 WITH INDAZOLE INHIBITOR SR-3737
1552, d1s9jA1, 0.8006, 2.40, 0.292, 288, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1553, d5ml5A_, 0.8004, 2.88, 0.384, 326, 258, HUMAN P38ALPHA MAPK IN COMPLEX WITH IMIDAZOLYL PYRIDINE INHIBITOR 11B
1554, d3gcpA_, 0.8002, 3.12, 0.354, 337, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH SB203580
1555, d3eqhA_, 0.8001, 2.32, 0.281, 314, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
1556, d4e6aA_, 0.8000, 2.71, 0.380, 324, 255, P38A-PIA23 COMPLEX
1557, d4u42A_, 0.7999, 2.33, 0.265, 282, 249, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
1558, d4e8aA_, 0.7999, 2.85, 0.381, 327, 257, THE CRYSTAL STRUCTURE OF P38A MAP KINASE IN COMPLEX WITH PIA24
1559, d2fsmX_, 0.7994, 2.72, 0.380, 326, 255, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-B
1560, d2npqA_, 0.7993, 2.69, 0.380, 326, 255, A NOVEL LIPID BINDING SITE IN THE P38 ALPHA MAP KINASE
1561, d4e5bA_, 0.7991, 2.73, 0.380, 324, 255, STRUCTURE OF P38A MAP KINASE WITHOUT BOG
1562, d2fstX_, 0.7990, 2.70, 0.378, 324, 254, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327L) ACTIVATING MUTANT
1563, d4obpA_, 0.7988, 2.55, 0.274, 285, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
1564, d2fsoX_, 0.7983, 2.61, 0.383, 325, 253, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A) ACTIVATING MUTANT
1565, d4rvtA_, 0.7981, 2.46, 0.280, 281, 250, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
1566, d4u41A_, 0.7977, 2.40, 0.266, 275, 248, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
1567, p3lfdA_, 0.7977, 2.90, 0.364, 331, 258, HUMAN P38 MAP KINASE IN COMPLEX WITH RL113
1568, d3eqcA_, 0.7975, 2.37, 0.285, 312, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
1569, d4oboA_, 0.7973, 2.42, 0.266, 275, 248, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
1570, d3an0A_, 0.7970, 2.58, 0.250, 291, 252,  
1571, d3vn9A_, 0.7969, 2.58, 0.250, 291, 252, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
1572, d3zlsA_, 0.7965, 2.38, 0.281, 315, 249, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
1573, d3eqiA_, 0.7950, 2.41, 0.285, 315, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
1574, d5bx0A_, 0.7949, 2.41, 0.281, 315, 249, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
1575, d2x7fB_, 0.7949, 2.49, 0.267, 288, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
1576, d3eqdA_, 0.7946, 2.40, 0.285, 315, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
1577, d3zh8A_, 0.7943, 2.35, 0.304, 318, 247, A NOVEL SMALL MOLECULE APKC INHIBITOR
1578, d4fzaB1, 0.7942, 2.32, 0.271, 280, 247, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
1579, d3zh8B_, 0.7939, 2.35, 0.304, 317, 247, A NOVEL SMALL MOLECULE APKC INHIBITOR
1580, d3slsA1, 0.7938, 2.37, 0.282, 289, 248, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
1581, d2gfcA_, 0.7935, 2.43, 0.283, 335, 247, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1582, d2i6lB_, 0.7934, 2.82, 0.304, 269, 253, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1583, d3zlwA_, 0.7932, 2.43, 0.281, 312, 249, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
1584, d4zjiA_, 0.7930, 2.41, 0.304, 278, 247, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
1585, d2q0nA_, 0.7930, 2.57, 0.274, 293, 248, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
1586, d3coiA1, 0.7928, 3.28, 0.365, 342, 266, CRYSTAL STRUCTURE OF P38DELTA KINASE
1587, d4mneE_, 0.7927, 2.46, 0.285, 286, 249, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1588, d3zlyA_, 0.7927, 2.39, 0.286, 310, 248, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
1589, d3zh8C_, 0.7927, 2.32, 0.305, 312, 246, A NOVEL SMALL MOLECULE APKC INHIBITOR
1590, d3vvhA1, 0.7926, 2.44, 0.282, 286, 248, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1591, d2gniA_, 0.7926, 2.43, 0.300, 338, 247, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
1592, d1s9iB_, 0.7926, 2.34, 0.287, 291, 247, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
1593, d2gnjA_, 0.7924, 2.45, 0.296, 335, 247, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
1594, d3zlxA_, 0.7922, 2.43, 0.285, 312, 249, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
1595, d2i0eB_, 0.7921, 2.31, 0.255, 300, 247, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1596, d1o6kA_, 0.7920, 2.41, 0.296, 317, 247, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
1597, d4zjjA_, 0.7919, 2.48, 0.306, 280, 248, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
1598, d3aglB_, 0.7919, 2.48, 0.287, 335, 247, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1599, d4ic8A_, 0.7918, 2.97, 0.353, 325, 258, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1600, d2f7eE_, 0.7917, 2.46, 0.283, 336, 247, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
1601, d3qamE_, 0.7916, 2.47, 0.279, 348, 247, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1602, d1jbpE_, 0.7916, 2.45, 0.283, 339, 247, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
1603, d3zm4A_, 0.7915, 2.34, 0.283, 309, 247, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
1604, d1rejA_, 0.7915, 2.47, 0.283, 333, 247, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
1605, d2bajA2, 0.7914, 2.78, 0.386, 334, 254, P38ALPHA BOUND TO PYRAZOLOUREA
1606, d1fmoE_, 0.7914, 2.46, 0.283, 336, 247, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
1607, d4zjiD_, 0.7913, 2.41, 0.298, 280, 248, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
1608, d1re8A_, 0.7913, 2.46, 0.283, 337, 247, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
1609, d1rekA_, 0.7912, 2.47, 0.283, 336, 247, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
1610, d2ojfE_, 0.7911, 2.47, 0.283, 336, 247, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1611, d2f7xE_, 0.7911, 2.46, 0.283, 336, 247, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
1612, d1q24A_, 0.7911, 2.48, 0.279, 335, 247, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
1613, d4zjiB_, 0.7909, 2.45, 0.308, 276, 247, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
1614, d3slsB1, 0.7909, 2.44, 0.282, 291, 248, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
1615, d3fhiA_, 0.7909, 2.49, 0.283, 336, 247, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
1616, d2oh0E_, 0.7909, 2.45, 0.283, 336, 247, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1617, d1u7eA_, 0.7909, 2.49, 0.283, 338, 247,  
1618, d1o6lA_, 0.7909, 2.43, 0.296, 316, 247, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
1619, d4l44A_, 0.7908, 2.44, 0.310, 321, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
1620, d2uzuE_, 0.7908, 2.46, 0.283, 336, 247, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1621, d2uvxA_, 0.7908, 2.47, 0.279, 335, 247, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
1622, d2gnfA_, 0.7907, 2.46, 0.300, 339, 247, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
1623, d2uzvA_, 0.7905, 2.49, 0.283, 336, 247, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1624, d3fjqE_, 0.7903, 2.48, 0.283, 334, 247, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
1625, d2gcdB_, 0.7902, 2.55, 0.288, 308, 250, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1626, d1apmE_, 0.7901, 2.47, 0.283, 338, 247, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
1627, d1q61A_, 0.7900, 2.48, 0.283, 335, 247, PKA TRIPLE MUTANT MODEL OF PKB
1628, d3d0eB_, 0.7899, 2.46, 0.296, 322, 247, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1629, d3d0eA_, 0.7899, 2.45, 0.296, 322, 247, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1630, d3vvhC1, 0.7898, 2.46, 0.285, 282, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1631, d4yxrA_, 0.7897, 2.50, 0.283, 334, 247, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
1632, d3mvjA_, 0.7897, 2.49, 0.287, 334, 247, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1633, d4zjjB_, 0.7895, 2.46, 0.308, 277, 247, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
1634, d4mneA_, 0.7895, 2.49, 0.285, 286, 249, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1635, d3vvhB1, 0.7895, 2.45, 0.285, 289, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1636, d1q62A_, 0.7895, 2.50, 0.279, 336, 247, PKA DOUBLE MUTANT MODEL OF PKB
1637, d1bkxA_, 0.7895, 2.45, 0.283, 337, 247, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
1638, d4mneH_, 0.7894, 2.43, 0.286, 275, 248, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1639, d2uw7A_, 0.7894, 2.49, 0.279, 335, 247, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1640, d2jdrA_, 0.7894, 2.46, 0.296, 316, 247, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1641, d2c1bA_, 0.7894, 2.50, 0.283, 335, 247, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
1642, d3nx8A_, 0.7893, 2.47, 0.287, 333, 247, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
1643, d3aglA_, 0.7893, 2.48, 0.287, 338, 247, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1644, d2x7fC_, 0.7893, 2.52, 0.276, 285, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
1645, d2jdtA_, 0.7893, 2.50, 0.279, 334, 247, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1646, d2c1aA_, 0.7893, 2.49, 0.283, 335, 247, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
1647, d1atpE_, 0.7893, 2.48, 0.283, 334, 247, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
1648, d2uw4A_, 0.7892, 2.44, 0.285, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1649, d2gngA_, 0.7892, 2.47, 0.300, 338, 247, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
1650, d1jluE_, 0.7892, 2.49, 0.283, 337, 247, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
1651, d4l46A_, 0.7891, 2.47, 0.315, 317, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
1652, d2vo7A_, 0.7890, 2.50, 0.283, 335, 247, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
1653, d3e8eP_, 0.7889, 2.52, 0.283, 341, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1654, d3dneA_, 0.7888, 2.51, 0.283, 336, 247, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1655, d4o0xA1, 0.7886, 2.68, 0.274, 289, 248, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1656, d3ma6B_, 0.7886, 2.19, 0.322, 266, 242, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
1657, d3e8eB_, 0.7886, 2.52, 0.283, 337, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1658, d3e8eA_, 0.7886, 2.53, 0.283, 341, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1659, d1cdkB_, 0.7886, 2.50, 0.287, 342, 247, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
1660, d5ng3A_, 0.7885, 2.63, 0.226, 283, 248, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1661, d4nw6A1, 0.7885, 2.40, 0.301, 296, 246, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
1662, d4o22A1, 0.7884, 2.45, 0.285, 333, 246, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
1663, d4nw5A1, 0.7884, 2.41, 0.301, 296, 246, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
1664, d3oogA_, 0.7884, 2.50, 0.287, 333, 247, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
1665, d3idbA_, 0.7884, 2.52, 0.283, 341, 247, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1666, d2f7zE_, 0.7884, 2.51, 0.283, 336, 247, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
1667, d1ydsE_, 0.7884, 2.50, 0.283, 334, 247, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
1668, d1svgA_, 0.7884, 2.51, 0.283, 338, 247, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
1669, d4mneD_, 0.7883, 2.44, 0.286, 285, 248, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1670, d1ydrE_, 0.7882, 2.50, 0.283, 334, 247, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
1671, d1l3rE_, 0.7882, 2.48, 0.285, 338, 246, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1672, p2y4iC_, 0.7881, 2.35, 0.280, 313, 246, KSR2-MEK1 HETERODIMER
1673, d3e88B_, 0.7880, 2.49, 0.296, 319, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1674, d3e88A_, 0.7880, 2.49, 0.296, 319, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1675, d2uw8A_, 0.7880, 2.47, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
1676, d2uw3A_, 0.7879, 2.47, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
1677, d4o21A_, 0.7878, 2.47, 0.285, 333, 246, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
1678, d4zjiC_, 0.7877, 2.37, 0.301, 281, 246, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
1679, d4l3lA_, 0.7877, 2.48, 0.319, 291, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
1680, d3amaA_, 0.7877, 2.51, 0.291, 342, 247, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
1681, d5cwzC_, 0.7876, 2.26, 0.266, 271, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1682, d3qalE_, 0.7876, 2.52, 0.279, 339, 247, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1683, d1cdkA_, 0.7876, 2.51, 0.287, 342, 247, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
1684, d3e8eE_, 0.7875, 2.52, 0.283, 341, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1685, d2gnhA_, 0.7875, 2.51, 0.300, 338, 247, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
1686, d2erzE_, 0.7875, 2.52, 0.283, 334, 247, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
1687, d3is5A1, 0.7874, 2.08, 0.308, 254, 240, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
1688, d3e8eL_, 0.7874, 2.54, 0.283, 336, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1689, d2x39A_, 0.7874, 2.50, 0.296, 316, 247, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
1690, d2uvyA_, 0.7874, 2.47, 0.280, 333, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
1691, d4u40B_, 0.7873, 2.48, 0.229, 299, 249, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
1692, d3wf7A_, 0.7873, 2.53, 0.315, 288, 248, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
1693, d3mvjE_, 0.7873, 2.48, 0.287, 334, 247, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1694, d1rdqE_, 0.7873, 2.54, 0.279, 340, 247, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
1695, d5ajqA_, 0.7872, 2.67, 0.315, 280, 251, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
1696, d3is5B1, 0.7872, 2.02, 0.301, 255, 239, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
1697, d2jdvA_, 0.7872, 2.51, 0.279, 334, 247, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
1698, d3iw4B_, 0.7871, 2.47, 0.275, 325, 247, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1699, d3idcA_, 0.7871, 2.52, 0.283, 341, 247, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1700, d3e8eI_, 0.7871, 2.53, 0.283, 345, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1701, d2jdsA_, 0.7871, 2.48, 0.285, 334, 246, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
1702, d2i0eA_, 0.7871, 2.40, 0.263, 326, 247, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1703, d2cpkE_, 0.7871, 2.48, 0.285, 333, 246, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
1704, d1xh9A_, 0.7871, 2.54, 0.287, 336, 247, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1705, d5li1A1, 0.7870, 2.36, 0.306, 329, 245, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
1706, d1sveA_, 0.7870, 2.52, 0.283, 341, 247, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
1707, d4o0yA1, 0.7868, 2.70, 0.274, 289, 248, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1708, d3e8cF_, 0.7868, 2.54, 0.283, 341, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1709, d3e8cC_, 0.7868, 2.54, 0.283, 341, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1710, d3e8cA_, 0.7868, 2.54, 0.283, 341, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1711, d2vnyA_, 0.7868, 2.49, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
1712, d2uw5A_, 0.7868, 2.50, 0.280, 333, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1713, d3oxtA_, 0.7867, 2.58, 0.287, 335, 247, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1714, d3iw4C_, 0.7867, 2.46, 0.275, 332, 247, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1715, d3e8cD_, 0.7867, 2.54, 0.283, 344, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1716, d3e8cE_, 0.7866, 2.54, 0.283, 336, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1717, d3e8cB_, 0.7866, 2.54, 0.283, 344, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1718, d2uzwE_, 0.7866, 2.53, 0.283, 336, 247, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1719, d1ydtE_, 0.7866, 2.53, 0.283, 334, 247, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
1720, d5ar8B_, 0.7865, 2.64, 0.225, 274, 249, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
1721, d3pooA_, 0.7865, 2.54, 0.287, 331, 247, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1722, d1xh6A_, 0.7865, 2.56, 0.283, 331, 247, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1723, d4o0vA1, 0.7864, 2.69, 0.278, 289, 248, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1724, d3agmA_, 0.7864, 2.54, 0.287, 337, 247, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
1725, d1xh8A_, 0.7864, 2.50, 0.283, 337, 247, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1726, d1xh5A_, 0.7864, 2.53, 0.283, 335, 247, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1727, d1vebA_, 0.7863, 2.53, 0.283, 338, 247, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
1728, d1svhA_, 0.7863, 2.53, 0.283, 335, 247, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
1729, d2vo6A_, 0.7862, 2.51, 0.285, 335, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
1730, d4x6rA_, 0.7861, 2.49, 0.285, 347, 246, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1731, d3dndA_, 0.7861, 2.52, 0.283, 334, 247, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1732, d2uvzA_, 0.7860, 2.50, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
1733, d4l43A_, 0.7859, 2.52, 0.310, 316, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
1734, d1u5qB_, 0.7858, 2.60, 0.288, 308, 250, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1735, d5i0bA_, 0.7856, 2.71, 0.274, 288, 248, STRUCTURE OF PAK4
1736, d5ax9B_, 0.7856, 2.43, 0.268, 274, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1737, d3thbA_, 0.7855, 2.50, 0.276, 287, 246, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
1738, d3iw4A_, 0.7855, 2.49, 0.275, 330, 247, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1739, d2z7rA_, 0.7855, 2.09, 0.321, 265, 240, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
1740, d2vnwA_, 0.7855, 2.50, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
1741, d2gu8A_, 0.7855, 2.55, 0.283, 335, 247, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
1742, d1smhA_, 0.7855, 2.53, 0.283, 348, 247, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
1743, d1q8tA_, 0.7855, 2.53, 0.283, 338, 247, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
1744, d4tthB_, 0.7854, 2.12, 0.544, 256, 239, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
1745, d4l3jA_, 0.7854, 2.54, 0.315, 291, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
1746, d2uztA_, 0.7854, 2.55, 0.283, 336, 247, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
1747, d1xhaA_, 0.7854, 2.52, 0.283, 348, 247, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1748, d2vo3A_, 0.7853, 2.50, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1749, d2qcsA_, 0.7853, 2.52, 0.285, 335, 246, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
1750, d3p0mA_, 0.7852, 2.54, 0.287, 335, 247, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1751, d2vo0A_, 0.7852, 2.54, 0.279, 340, 247, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1752, d4p41B_, 0.7851, 2.13, 0.544, 256, 239,  
1753, d3ow3A_, 0.7851, 2.56, 0.283, 334, 247, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1754, d3e8dB_, 0.7851, 2.53, 0.296, 317, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1755, d2x7fA_, 0.7851, 2.44, 0.279, 276, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
1756, d1stcE_, 0.7851, 2.50, 0.279, 334, 247, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
1757, d3e8dA_, 0.7850, 2.53, 0.296, 315, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1758, d2gnlA_, 0.7850, 2.56, 0.296, 338, 247, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
1759, d3e87B_, 0.7847, 2.52, 0.296, 321, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1760, d3e87A_, 0.7847, 2.52, 0.296, 321, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1761, d3cquA_, 0.7846, 2.53, 0.296, 318, 247, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1762, d2cdzA_, 0.7846, 2.64, 0.280, 289, 246, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
1763, d4njdA1, 0.7845, 2.65, 0.275, 289, 247, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
1764, d4l45A_, 0.7845, 2.53, 0.315, 317, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
1765, d5ng3D_, 0.7844, 2.59, 0.228, 278, 246, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1766, d3we4A_, 0.7844, 2.54, 0.315, 286, 248, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
1767, d2uw0A_, 0.7842, 2.52, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
1768, d2qurA_, 0.7842, 2.55, 0.283, 338, 247, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
1769, d3tnpF_, 0.7841, 2.52, 0.285, 334, 246, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1770, d3tnpC_, 0.7841, 2.52, 0.285, 334, 246, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1771, d1bx6A_, 0.7841, 2.52, 0.279, 337, 247, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1772, d4obqA_, 0.7840, 2.30, 0.272, 275, 243, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
1773, d4x6qC_, 0.7839, 2.52, 0.285, 334, 246, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1774, d2uw9A_, 0.7839, 2.54, 0.296, 316, 247, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1775, d2uw6A_, 0.7837, 2.53, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1776, d2jedA_, 0.7837, 2.54, 0.296, 324, 247, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1777, d2gcdA_, 0.7835, 2.63, 0.288, 308, 250, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1778, d1q8uA_, 0.7834, 2.55, 0.283, 341, 247, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
1779, d3ambA_, 0.7833, 2.56, 0.291, 340, 247, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
1780, d2weiA1, 0.7832, 2.37, 0.317, 269, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
1781, d1xh7A_, 0.7830, 2.54, 0.285, 337, 246, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1782, d4l42A_, 0.7829, 2.38, 0.314, 299, 245, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
1783, d1xh4A_, 0.7829, 2.55, 0.285, 334, 246, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1784, d3mv5A_, 0.7826, 2.57, 0.296, 315, 247, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1785, d3bwjA_, 0.7821, 2.57, 0.285, 338, 246, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
1786, d3mvhA_, 0.7820, 2.60, 0.296, 311, 247, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1787, d3l9lA_, 0.7820, 2.55, 0.287, 338, 247, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1788, d2jdoA_, 0.7818, 2.57, 0.296, 314, 247, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1789, d3w2sA_, 0.7817, 2.65, 0.210, 307, 248, EGFR KINASE DOMAIN WITH COMPOUND4
1790, d3ocbB_, 0.7815, 2.59, 0.296, 319, 247, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1791, d2hy81_, 0.7815, 2.60, 0.306, 293, 248, PAK1 COMPLEX WITH ST2001
1792, d5hzeA_, 0.7813, 2.39, 0.269, 305, 245, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
1793, d4jdiA_, 0.7812, 2.75, 0.274, 289, 248, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1794, d1u5qA_, 0.7812, 2.66, 0.288, 308, 250, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1795, p3hdmA_, 0.7808, 2.29, 0.269, 285, 242, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
1796, d5vedA_, 0.7807, 2.75, 0.274, 289, 248, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1797, d3fmeA1, 0.7806, 2.74, 0.245, 267, 249, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (MEK6) ACTIVATED MUTANT (S207D T211D)
1798, d4l67A_, 0.7805, 2.71, 0.275, 289, 247, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
1799, d3l9lB_, 0.7805, 2.58, 0.287, 337, 247, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1800, d4a4oA_, 0.7804, 2.57, 0.276, 290, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
1801, d3is5C1, 0.7804, 2.02, 0.304, 254, 237, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
1802, d4u44B_, 0.7803, 2.54, 0.250, 296, 248, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
1803, d4fijA_, 0.7803, 2.81, 0.270, 291, 248, CATALYTIC DOMAIN OF HUMAN PAK4
1804, d3wf6A_, 0.7803, 2.39, 0.321, 277, 243, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
1805, d3wf5A_, 0.7803, 2.35, 0.321, 277, 243, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
1806, d3kb7A_, 0.7803, 2.57, 0.276, 289, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1807, d1u5rB_, 0.7802, 2.70, 0.288, 308, 250, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1808, d3ocbA_, 0.7801, 2.61, 0.296, 315, 247, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1809, d3w2rA_, 0.7798, 2.46, 0.222, 297, 243, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
1810, d5d9kA_, 0.7795, 2.64, 0.294, 280, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
1811, d4fihA_, 0.7795, 2.83, 0.270, 291, 248, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
1812, d3a62A_, 0.7795, 2.25, 0.332, 263, 241, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
1813, d4zy5B_, 0.7794, 2.67, 0.316, 287, 250, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
1814, d4a4lA_, 0.7793, 2.57, 0.276, 290, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
1815, d4zy6B_, 0.7792, 2.62, 0.313, 280, 249, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1816, d3l9mB_, 0.7792, 2.59, 0.287, 336, 247, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1817, d2yacA_, 0.7792, 2.66, 0.271, 290, 247, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
1818, d5ho8A_, 0.7791, 2.51, 0.298, 278, 245, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1819, d3l9mA_, 0.7791, 2.59, 0.287, 338, 247, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1820, d5vefA_, 0.7789, 2.83, 0.270, 289, 248, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
1821, d3orxA_, 0.7789, 2.58, 0.297, 283, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1822, d3orxC_, 0.7788, 2.58, 0.297, 283, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1823, d3orxB_, 0.7788, 2.58, 0.297, 280, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1824, d3h9oA_, 0.7787, 2.62, 0.297, 275, 246, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
1825, d3cqwA_, 0.7787, 2.62, 0.296, 318, 247, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1826, d4jdjA_, 0.7786, 2.78, 0.271, 288, 247, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1827, d3orxD_, 0.7786, 2.58, 0.297, 282, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1828, d2j0iA_, 0.7786, 2.78, 0.275, 289, 247, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
1829, d5ng3B_, 0.7784, 2.58, 0.230, 275, 244, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1830, d4eqmD_, 0.7784, 2.37, 0.249, 268, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
1831, d3ionA_, 0.7784, 2.63, 0.297, 274, 246, PDK1 IN COMPLEX WITH COMPOUND 8H
1832, d4usdA_, 0.7783, 2.46, 0.321, 268, 246, HUMAN STK10 (LOK) WITH SB-633825
1833, d4eqmF_, 0.7782, 2.36, 0.249, 268, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
1834, d3w33A_, 0.7781, 2.69, 0.206, 297, 247, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
1835, d3iopA_, 0.7781, 2.64, 0.297, 275, 246, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
1836, d2fumB_, 0.7781, 2.34, 0.277, 262, 242, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
1837, d4eqmE_, 0.7780, 2.36, 0.249, 268, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
1838, p5w5qB_, 0.7779, 2.52, 0.231, 297, 247, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
1839, d5hkmA_, 0.7778, 2.53, 0.298, 272, 245, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1840, d4jdkA_, 0.7778, 2.78, 0.271, 288, 247, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1841, d5bmsA1, 0.7776, 2.79, 0.274, 289, 248, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1842, d4gv1A1, 0.7776, 2.64, 0.300, 328, 247, PKB ALPHA IN COMPLEX WITH AZD5363
1843, d4jdhA_, 0.7775, 2.83, 0.270, 289, 248, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1844, d5ar4B_, 0.7773, 2.81, 0.227, 279, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
1845, d4b9dB1, 0.7773, 2.35, 0.272, 291, 239, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
1846, d3pp0B_, 0.7773, 2.76, 0.215, 296, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
1847, d2pe0A_, 0.7773, 2.64, 0.293, 275, 246, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
1848, d4zseA_, 0.7772, 2.73, 0.203, 297, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
1849, d3wf8A_, 0.7772, 2.65, 0.319, 287, 248, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
1850, d4apcB1, 0.7770, 2.40, 0.271, 291, 240, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
1851, d4aotA1, 0.7770, 2.61, 0.329, 276, 246, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
1852, d3tnqB_, 0.7770, 2.64, 0.285, 331, 246, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1853, d5j7bB_, 0.7769, 2.83, 0.227, 281, 251, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
1854, d4o0tB_, 0.7769, 2.59, 0.316, 280, 247, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1855, d4ks7A_, 0.7769, 2.80, 0.275, 286, 247, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
1856, d3wf9A_, 0.7769, 2.66, 0.319, 287, 248, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
1857, d3nuuA_, 0.7769, 2.54, 0.298, 276, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
1858, d2fumA_, 0.7769, 2.29, 0.274, 263, 241, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
1859, d1z5mA_, 0.7769, 2.65, 0.293, 275, 246, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
1860, d3sc1A_, 0.7768, 2.64, 0.297, 278, 246, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
1861, d2xchA_, 0.7768, 2.65, 0.293, 278, 246, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1862, d5deyB_, 0.7767, 2.67, 0.313, 281, 249, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
1863, d4u8zA_, 0.7767, 2.62, 0.280, 289, 246, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
1864, d4figB_, 0.7766, 2.74, 0.274, 292, 248, CATALYTIC DOMAIN OF HUMAN PAK4
1865, d4figA_, 0.7766, 2.74, 0.274, 292, 248, CATALYTIC DOMAIN OF HUMAN PAK4
1866, d3rwqA_, 0.7766, 2.67, 0.293, 283, 246, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1867, d1okzA_, 0.7766, 2.54, 0.298, 276, 245, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
1868, d5ho7A_, 0.7765, 2.66, 0.293, 280, 246, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1869, d4b6lA_, 0.7764, 2.69, 0.291, 281, 247, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
1870, d1okyA_, 0.7764, 2.64, 0.293, 281, 246, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1871, d2r7bA_, 0.7763, 2.65, 0.293, 274, 246, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
1872, d1xkkA_, 0.7762, 2.72, 0.211, 289, 246, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
1873, d6b16B_, 0.7761, 2.61, 0.319, 281, 248, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
1874, d5d9kB_, 0.7760, 2.65, 0.296, 280, 247, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
1875, d4zy4B_, 0.7760, 2.72, 0.316, 292, 250, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
1876, d2pe2A_, 0.7759, 2.66, 0.293, 275, 246, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
1877, d5ta6A_, 0.7758, 2.69, 0.271, 294, 247, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
1878, d3nusA_, 0.7757, 2.56, 0.298, 276, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
1879, d5cnnB_, 0.7756, 2.55, 0.209, 304, 244, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
1880, d3rwpA_, 0.7756, 2.68, 0.293, 277, 246, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1881, d3dxnA_, 0.7755, 2.37, 0.325, 258, 240, CRYSTAL STRUCTURE OF THE CALCIUM-DEPENDENT KINASE FROM TOXOPLASMA GONDII 541.M00134 KINASE DOMAIN.
1882, d3a8xA1, 0.7755, 2.57, 0.296, 331, 247, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1883, d4usdB_, 0.7754, 2.47, 0.327, 267, 245, HUMAN STK10 (LOK) WITH SB-633825
1884, d3qcqA_, 0.7754, 2.58, 0.298, 276, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
1885, d2owbA_, 0.7754, 2.69, 0.271, 294, 247, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1886, d5j7bA_, 0.7753, 2.79, 0.228, 277, 250, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
1887, d5d41B_, 0.7753, 2.65, 0.208, 302, 245, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
1888, d4wbbB_, 0.7753, 2.66, 0.285, 334, 246, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
1889, d3a7fA_, 0.7753, 2.66, 0.280, 283, 246, HUMAN MST3 KINASE
1890, d3nunA_, 0.7752, 2.59, 0.298, 278, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
1891, d5dh3B_, 0.7751, 2.82, 0.296, 283, 250, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1892, d4zk5B_, 0.7751, 2.48, 0.245, 294, 245, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
1893, d3ggfA_, 0.7751, 2.55, 0.283, 275, 247, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
1894, d5hngA_, 0.7749, 2.67, 0.297, 280, 246, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1895, d3l9nA_, 0.7749, 2.68, 0.283, 332, 247, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
1896, d2jedB1, 0.7749, 2.67, 0.296, 315, 247, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1897, d4u3yA_, 0.7748, 2.84, 0.227, 295, 251, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
1898, d3fc2A_, 0.7748, 2.62, 0.276, 293, 246, PLK1 IN COMPLEX WITH BI6727
1899, d5dewB_, 0.7747, 2.63, 0.319, 281, 248, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
1900, d5ar7B_, 0.7747, 2.81, 0.224, 278, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
1901, d3lm0A1, 0.7747, 2.88, 0.242, 271, 248, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
1902, d5fd2A_, 0.7745, 2.38, 0.217, 264, 240, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
1903, d4zseD_, 0.7745, 2.75, 0.212, 297, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
1904, d4qmoA_, 0.7745, 2.66, 0.280, 288, 246, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
1905, d3nuyA_, 0.7745, 2.58, 0.298, 276, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
1906, d4j52A_, 0.7744, 2.64, 0.276, 293, 246, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
1907, d4eklA_, 0.7743, 2.68, 0.296, 329, 247, AKT1 WITH GDC0068
1908, d3qcsA_, 0.7743, 2.60, 0.298, 276, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
1909, d5veeA_, 0.7742, 2.86, 0.277, 289, 249, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
1910, d4crsA1, 0.7742, 2.52, 0.302, 329, 245, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
1911, d3qklA_, 0.7742, 2.69, 0.296, 317, 247, SPIROCHROMANE AKT INHIBITORS
1912, d4ks8A_, 0.7741, 2.81, 0.287, 286, 247, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
1913, d4rvtB_, 0.7740, 2.83, 0.233, 297, 249, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
1914, d4qmpA_, 0.7740, 2.68, 0.280, 289, 246, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
1915, d4appA1, 0.7740, 2.83, 0.259, 290, 247, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
1916, d4nusA_, 0.7738, 2.75, 0.291, 301, 247, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
1917, d3dy7A_, 0.7737, 2.34, 0.287, 260, 240, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1918, d2pe1A_, 0.7737, 2.69, 0.293, 275, 246, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
1919, d3qcxA_, 0.7735, 2.62, 0.294, 276, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
1920, d3ow4A_, 0.7735, 2.70, 0.296, 317, 247, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1921, d2xh5A_, 0.7735, 2.72, 0.296, 316, 247, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
1922, d1uu7A_, 0.7735, 2.60, 0.298, 280, 245, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
1923, d4u3yB_, 0.7733, 2.83, 0.229, 300, 249, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
1924, d4aw1A_, 0.7733, 2.63, 0.294, 283, 245, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
1925, d4w8eA_, 0.7732, 2.69, 0.280, 290, 246, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
1926, d3w32A_, 0.7732, 2.81, 0.202, 317, 248, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
1927, d3o7lB_, 0.7732, 2.56, 0.275, 326, 244, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
1928, d4apcA1, 0.7731, 2.36, 0.269, 289, 238, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
1929, d2xckA_, 0.7731, 2.73, 0.289, 275, 246, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1930, d1uu8A_, 0.7731, 2.54, 0.295, 277, 244, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
1931, d4i24B_, 0.7730, 2.81, 0.203, 304, 246, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
1932, d5hg5A_, 0.7729, 2.84, 0.206, 302, 247, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
1933, d4j53A_, 0.7729, 2.72, 0.271, 293, 247, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
1934, d4b9dA1, 0.7729, 2.37, 0.269, 286, 238, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
1935, d3qkkA_, 0.7729, 2.70, 0.300, 326, 247, SPIROCHROMANE AKT INHIBITORS
1936, d5m57A1, 0.7728, 1.96, 0.311, 253, 235, NEK2 BOUND TO ARYLAMINOPURINE 6
1937, d4o0tA_, 0.7728, 2.77, 0.287, 292, 247, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1938, d3ow4B_, 0.7728, 2.73, 0.296, 317, 247, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1939, d3mftA_, 0.7728, 2.78, 0.306, 302, 245, CASK-4M CAM KINASE DOMAIN MN2+
1940, d3qd3A_, 0.7727, 2.64, 0.294, 278, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
1941, d1uu3A_, 0.7727, 2.71, 0.293, 276, 246, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
1942, d6aywB_, 0.7726, 2.68, 0.320, 293, 244, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1943, d3qcyA_, 0.7726, 2.63, 0.298, 275, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
1944, d3q53A_, 0.7726, 2.78, 0.309, 291, 249, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
1945, d2rkuA_, 0.7726, 2.66, 0.276, 294, 246, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
1946, d1u5rA_, 0.7726, 2.78, 0.284, 308, 250, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1947, d5vloB_, 0.7725, 2.68, 0.320, 293, 244, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1948, d4u3zA_, 0.7724, 2.63, 0.241, 282, 245, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
1949, d3gt8B_, 0.7724, 2.75, 0.197, 292, 244, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1950, d5m51A1, 0.7723, 1.97, 0.302, 253, 235, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
1951, d3dfaA1, 0.7723, 2.28, 0.301, 262, 239, CRYSTAL STRUCTURE OF KINASE DOMAIN OF CALCIUM-DEPENDENT PROTEIN KINASE CGD3_920 FROM CRYPTOSPORIDIUM PARVUM
1952, d5f9eB_, 0.7722, 2.70, 0.289, 293, 246, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1953, d5cnoA_, 0.7722, 2.66, 0.213, 300, 244, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
1954, d4w8dA_, 0.7722, 2.69, 0.280, 289, 246, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
1955, d5hg8A_, 0.7721, 2.86, 0.211, 300, 247, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
1956, d5gtyH_, 0.7720, 2.80, 0.211, 300, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1957, d4otdA_, 0.7720, 2.61, 0.297, 334, 246, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
1958, d1uvrA_, 0.7720, 2.72, 0.297, 284, 246, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
1959, d5ta8A_, 0.7719, 2.77, 0.271, 294, 247, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
1960, d5j95B_, 0.7719, 2.76, 0.239, 300, 247, MAP4K4 IN COMPLEX WITH INHIBITOR
1961, d5ajqB_, 0.7719, 2.59, 0.327, 267, 245, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
1962, d3qkmA_, 0.7719, 2.71, 0.300, 329, 247, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
1963, d3qd4A_, 0.7719, 2.65, 0.294, 276, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
1964, d1vzoA_, 0.7719, 2.44, 0.261, 319, 241, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
1965, d3ag9B_, 0.7718, 2.74, 0.287, 317, 247, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
1966, d1uu9A_, 0.7718, 2.56, 0.295, 276, 244, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
1967, d4qmmA_, 0.7717, 2.70, 0.280, 288, 246, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
1968, d4at5A1, 0.7716, 2.71, 0.239, 291, 247, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
1969, d4c8bB_, 0.7715, 2.87, 0.232, 281, 250, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
1970, d3gubA1, 0.7715, 2.51, 0.286, 276, 241, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
1971, d1phkA_, 0.7715, 2.52, 0.302, 277, 242, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
1972, d1h1wA_, 0.7715, 2.74, 0.293, 284, 246, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
1973, d5di1B_, 0.7714, 2.76, 0.239, 300, 247, MAP4K4 IN COMPLEX WITH AN INHIBITOR
1974, d4o0rB_, 0.7714, 2.68, 0.316, 282, 247, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1975, d1q8wA_, 0.7714, 2.65, 0.280, 334, 246, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
1976, d4obqB_, 0.7713, 2.50, 0.246, 293, 244, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
1977, d3c0gA_, 0.7713, 2.81, 0.298, 309, 245, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
1978, d2xikA_, 0.7713, 2.72, 0.289, 288, 246, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
1979, d5gtyG_, 0.7711, 2.76, 0.212, 299, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1980, d5ar2B_, 0.7711, 2.90, 0.223, 285, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
1981, d4zp5B_, 0.7711, 2.76, 0.239, 300, 247, MAP4K4 IN COMPLEX WITH INHIBITOR
1982, d4q9zB_, 0.7711, 2.72, 0.285, 308, 246, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1983, d5ar5A_, 0.7710, 2.85, 0.232, 284, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
1984, d4qmqA_, 0.7710, 2.74, 0.276, 289, 246, MST3 IN COMPLEX WITH CP-673451
1985, d4zloA_, 0.7709, 2.51, 0.313, 277, 243, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
1986, d4zjjC_, 0.7709, 2.49, 0.306, 276, 242, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
1987, d5f9eA1, 0.7708, 2.75, 0.296, 331, 247, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1988, d5cnnA_, 0.7708, 2.73, 0.212, 300, 245, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
1989, d3orxG_, 0.7708, 2.69, 0.293, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1990, d3orxE_, 0.7707, 2.69, 0.293, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1991, d2rgpA_, 0.7707, 2.57, 0.210, 284, 243, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
1992, d4zseB_, 0.7706, 2.77, 0.207, 313, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
1993, d4u45B_, 0.7706, 2.65, 0.233, 295, 245, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
1994, d4j7bA_, 0.7706, 2.76, 0.287, 284, 247, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
1995, d5cnoB_, 0.7705, 2.72, 0.216, 302, 245, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
1996, d3c0iA_, 0.7705, 2.83, 0.298, 298, 245, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
1997, d3bhyA1, 0.7704, 2.55, 0.289, 267, 242, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
1998, d3qd0A_, 0.7703, 2.67, 0.294, 274, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
1999, d3c0gB_, 0.7703, 2.82, 0.298, 320, 245, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2000, d2jiuB_, 0.7703, 2.82, 0.185, 309, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
2001, d4ypdA1, 0.7701, 2.54, 0.286, 276, 241, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
2002, d4q9zA1, 0.7701, 2.76, 0.296, 330, 247, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
2003, d3orxH_, 0.7701, 2.70, 0.293, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2004, d3lm5A1, 0.7701, 2.79, 0.248, 267, 246, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2005, d2fumD_, 0.7701, 2.38, 0.270, 258, 241, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2006, d2biyA_, 0.7701, 2.76, 0.297, 287, 246, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
2007, d1yrpA_, 0.7701, 2.46, 0.283, 275, 240, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2008, d4ra5B_, 0.7700, 2.75, 0.289, 310, 246, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2009, d1yrpB_, 0.7700, 2.46, 0.283, 275, 240, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2010, d5d9lA_, 0.7699, 2.56, 0.273, 299, 245, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
2011, d3gu6A1, 0.7699, 2.54, 0.286, 276, 241, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
2012, d1xjdA_, 0.7699, 2.51, 0.289, 280, 242, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
2013, d3gu4A1, 0.7698, 2.53, 0.286, 276, 241, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
2014, d2x4zA1, 0.7698, 2.84, 0.244, 289, 246, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
2015, d4ty1A_, 0.7697, 2.47, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
2016, d3rcjA_, 0.7697, 2.69, 0.294, 281, 245, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
2017, d1gzkA_, 0.7697, 2.57, 0.303, 271, 241, MOLECULAR MECHANISM FOR THE REGULATION OF PROTEIN KINASE B/ AKT BY HYDROPHOBIC MOTIF PHOSPHORYLATION
2018, d4u41B_, 0.7696, 2.70, 0.232, 297, 246, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
2019, d3q4zB_, 0.7696, 2.66, 0.305, 279, 246, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
2020, d3mfrA_, 0.7696, 2.83, 0.306, 302, 245, CASK-4M CAM KINASE DOMAIN NATIVE
2021, d4yo4A1, 0.7695, 2.54, 0.286, 276, 241, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
2022, d4oboB_, 0.7695, 2.72, 0.232, 297, 246, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
2023, d4ixpA_, 0.7695, 2.38, 0.320, 334, 241, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
2024, d3orxF_, 0.7695, 2.70, 0.293, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2025, d3gu8A1, 0.7695, 2.52, 0.286, 276, 241, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
2026, d3dfcB1, 0.7695, 2.52, 0.286, 276, 241, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
2027, d5imeB_, 0.7694, 2.69, 0.313, 280, 246, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
2028, d3g51A_, 0.7694, 2.38, 0.312, 280, 240, STRUCTURAL DIVERSITY OF THE ACTIVE CONFORMATION OF THE N- TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2
2029, d4zseC_, 0.7693, 2.69, 0.205, 301, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
2030, d3gt8D_, 0.7693, 2.69, 0.202, 295, 243, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2031, d1szmA_, 0.7693, 2.61, 0.286, 317, 245, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2032, d5ng3C_, 0.7692, 2.58, 0.232, 272, 241, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2033, d1gzoA_, 0.7692, 2.58, 0.303, 271, 241, STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
2034, d6aywA_, 0.7691, 2.58, 0.309, 293, 243, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2035, d5d7vC1, 0.7691, 2.39, 0.254, 262, 240, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
2036, d3uohB_, 0.7691, 2.46, 0.315, 264, 241, AURORA A IN COMPLEX WITH RPM1722
2037, d3uohA_, 0.7691, 2.46, 0.315, 264, 241, AURORA A IN COMPLEX WITH RPM1722
2038, d3gt8C_, 0.7691, 2.80, 0.201, 296, 244, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2039, d5d7vB1, 0.7690, 2.45, 0.261, 262, 241, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
2040, d4ynzB1, 0.7690, 2.43, 0.289, 316, 242, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
2041, d4j7bD_, 0.7690, 2.74, 0.293, 281, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
2042, d1jklA_, 0.7689, 2.55, 0.286, 280, 241, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
2043, d5w5oM_, 0.7688, 2.72, 0.228, 276, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2044, d3gu7A1, 0.7688, 2.54, 0.286, 276, 241, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
2045, d2oi4X_, 0.7688, 2.42, 0.270, 275, 241, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
2046, d4ra5A1, 0.7687, 2.80, 0.296, 331, 247, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2047, d3gu5A1, 0.7687, 2.54, 0.286, 276, 241, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
2048, d1ql6A_, 0.7687, 2.65, 0.300, 281, 243, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
2049, d5dh3A_, 0.7686, 2.92, 0.296, 287, 250, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
2050, d5d7vD1, 0.7686, 2.40, 0.254, 262, 240, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
2051, d4k0yA_, 0.7686, 2.46, 0.274, 274, 241, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2052, d3gt8A_, 0.7686, 2.50, 0.195, 300, 241, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2053, d3a8xB1, 0.7686, 2.62, 0.285, 325, 246, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2054, d3orzA_, 0.7685, 2.73, 0.294, 276, 245, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2055, d3dgkA1, 0.7685, 2.54, 0.286, 276, 241, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
2056, d3ckxA_, 0.7685, 2.81, 0.280, 276, 246, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
2057, d4ra4A_, 0.7683, 2.70, 0.264, 317, 246, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2058, d3c0hA_, 0.7683, 2.83, 0.298, 300, 245, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2059, d5v82A_, 0.7682, 2.46, 0.274, 273, 241, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
2060, d4otgA_, 0.7682, 2.64, 0.305, 322, 246, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
2061, d5w5oO_, 0.7681, 2.74, 0.228, 276, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2062, d4zjjD_, 0.7681, 2.61, 0.307, 274, 244, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
2063, d3uokA_, 0.7681, 2.57, 0.298, 265, 242, AURORA A IN COMPLEX WITH YL5-81-1
2064, d3orzC_, 0.7681, 2.80, 0.297, 276, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2065, d5kziA_, 0.7680, 2.50, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
2066, d3uokB_, 0.7680, 2.57, 0.298, 265, 242, AURORA A IN COMPLEX WITH YL5-81-1
2067, d1ig1A_, 0.7680, 2.55, 0.286, 280, 241, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
2068, d1gznA_, 0.7680, 2.48, 0.304, 271, 240, STRUCTURE OF PKB KINASE DOMAIN
2069, d4qmvA_, 0.7679, 2.76, 0.280, 288, 246, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
2070, d3orzB_, 0.7679, 2.81, 0.297, 278, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2071, d1jksA_, 0.7679, 2.55, 0.286, 280, 241, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2072, d5gtyA_, 0.7678, 2.87, 0.211, 300, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2073, d3orzD_, 0.7678, 2.81, 0.297, 278, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2074, d3c0hB_, 0.7678, 2.83, 0.298, 300, 245, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2075, d5gtyB_, 0.7677, 2.76, 0.208, 299, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2076, d4qmyA_, 0.7676, 2.79, 0.280, 287, 246, MST3 IN COMPLEX WITH STAUROSPORINE
2077, d4jx7A_, 0.7675, 2.48, 0.274, 274, 241, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
2078, d3pozA_, 0.7675, 2.74, 0.208, 293, 245, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
2079, d2z7sA_, 0.7675, 2.02, 0.321, 256, 234, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
2080, d4u42B_, 0.7674, 2.39, 0.264, 265, 239, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
2081, d4mtaA_, 0.7674, 2.50, 0.282, 273, 241, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
2082, d3uo6B_, 0.7674, 2.48, 0.307, 264, 241, AURORA A IN COMPLEX WITH YL5-083
2083, d3uo6A_, 0.7674, 2.48, 0.307, 264, 241, AURORA A IN COMPLEX WITH YL5-083
2084, d1jkkA_, 0.7673, 2.56, 0.286, 277, 241, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
2085, d5lvlA_, 0.7672, 2.81, 0.293, 285, 246, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
2086, d4btjB_, 0.7672, 3.04, 0.193, 293, 249, TTBK1 IN COMPLEX WITH ATP
2087, d2w4jA_, 0.7672, 2.57, 0.286, 276, 241, X-RAY STRUCTURE OF A DAP-KINASE 2-277
2088, d5h9bA_, 0.7670, 2.55, 0.344, 269, 241, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
2089, d4dawA_, 0.7670, 2.82, 0.294, 293, 248, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
2090, d3nayB_, 0.7670, 2.72, 0.290, 278, 245, PDK1 IN COMPLEX WITH INHIBITOR MP6
2091, d2ou7A_, 0.7670, 2.76, 0.268, 292, 246, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
2092, d3belA_, 0.7669, 2.50, 0.212, 280, 241, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
2093, d4pf4A1, 0.7668, 2.57, 0.286, 277, 241, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
2094, d4btmB_, 0.7668, 2.97, 0.197, 293, 249, TTBK1 IN COMPLEX WITH INHIBITOR
2095, d3mfuA_, 0.7668, 2.86, 0.306, 302, 245, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
2096, d3vbqA_, 0.7667, 2.53, 0.278, 271, 241, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2097, d3uolB_, 0.7667, 2.46, 0.315, 263, 241, AURORA A IN COMPLEX WITH SO2-162
2098, d3uolA_, 0.7667, 2.46, 0.315, 263, 241, AURORA A IN COMPLEX WITH SO2-162
2099, d3jpvA_, 0.7667, 2.48, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
2100, d2xj0A_, 0.7667, 2.54, 0.278, 274, 241, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2101, d2bzhB_, 0.7667, 2.46, 0.270, 275, 241, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
2102, d4aotB1, 0.7666, 2.73, 0.321, 277, 246, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
2103, d4alvA_, 0.7666, 2.53, 0.274, 274, 241, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2104, d5es1A_, 0.7665, 2.46, 0.333, 304, 240, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2105, d5diaA_, 0.7665, 2.44, 0.275, 273, 240, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
2106, d4wrsA_, 0.7665, 2.50, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
2107, d2o64A_, 0.7665, 2.53, 0.270, 274, 241, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
2108, d2jitB_, 0.7665, 2.86, 0.186, 312, 247, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
2109, d5w5oJ_, 0.7664, 2.78, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2110, d4qmsA_, 0.7664, 2.75, 0.253, 283, 245, MST3 IN COMPLEX WITH DASATINIB
2111, d3f5uA1, 0.7664, 2.52, 0.283, 275, 240, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
2112, d3f2aA_, 0.7663, 2.50, 0.274, 276, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
2113, d3ehaA1, 0.7663, 2.52, 0.287, 275, 240, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
2114, d5ipjA_, 0.7662, 2.44, 0.275, 273, 240, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
2115, d2z7qA_, 0.7662, 2.00, 0.326, 255, 233, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP
2116, d2xj2A_, 0.7662, 2.49, 0.275, 273, 240, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2117, d5ar4A_, 0.7661, 2.78, 0.231, 274, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
2118, d4mblA_, 0.7661, 2.49, 0.270, 274, 241, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2119, d3f5gA1, 0.7661, 2.53, 0.287, 275, 240, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
2120, d6babD_, 0.7660, 2.76, 0.320, 291, 244, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2121, d5dgzA_, 0.7660, 2.49, 0.282, 273, 241, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
2122, d3r00A_, 0.7660, 2.54, 0.274, 274, 241, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2123, d3eh9A1, 0.7660, 2.54, 0.287, 274, 240, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
2124, d5dhjA_, 0.7659, 2.42, 0.275, 273, 240, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
2125, d4n6zA_, 0.7659, 2.51, 0.283, 272, 240, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2126, d3vc4A_, 0.7659, 2.54, 0.270, 274, 241, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2127, d1yxtA_, 0.7659, 2.57, 0.270, 274, 241, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
2128, d4u3zB_, 0.7658, 2.65, 0.245, 294, 245, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
2129, d5fg8A_, 0.7657, 2.58, 0.344, 269, 241, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2130, d4rqvA_, 0.7657, 2.82, 0.293, 288, 246, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
2131, d4g5pB_, 0.7657, 2.90, 0.190, 303, 248, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
2132, d4at3A1, 0.7657, 2.82, 0.229, 286, 249, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
2133, d3unzB_, 0.7657, 2.51, 0.307, 263, 241, AURORA A IN COMPLEX WITH RPM1679
2134, d3unzA_, 0.7657, 2.51, 0.307, 263, 241, AURORA A IN COMPLEX WITH RPM1679
2135, d3nayA_, 0.7657, 2.73, 0.294, 278, 245, PDK1 IN COMPLEX WITH INHIBITOR MP6
2136, d1zrzA_, 0.7657, 2.72, 0.298, 310, 245, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
2137, d5av0A_, 0.7656, 2.53, 0.287, 275, 240, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
2138, d4a06A_, 0.7656, 2.76, 0.294, 282, 245, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
2139, d3q52A_, 0.7656, 2.85, 0.279, 292, 247, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
2140, d5w5oK_, 0.7655, 2.79, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2141, d5lvnA_, 0.7655, 2.83, 0.293, 283, 246, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
2142, d5kgdA_, 0.7655, 2.50, 0.282, 273, 241, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
2143, d5h2uC1, 0.7655, 2.40, 0.255, 261, 239, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
2144, d4wt6A_, 0.7655, 2.52, 0.286, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
2145, d3mfsA_, 0.7655, 2.88, 0.306, 303, 245, CASK-4M CAM KINASE DOMAIN AMPPNP
2146, d1xqzA_, 0.7654, 2.60, 0.281, 277, 242, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
2147, d5jsmA1, 0.7653, 2.65, 0.212, 262, 241, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2148, d5h2uB1, 0.7653, 2.46, 0.262, 261, 240, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
2149, d4xx9A_, 0.7653, 2.83, 0.293, 288, 246, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
2150, d4wsyA_, 0.7653, 2.52, 0.286, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
2151, d4u43B_, 0.7653, 2.91, 0.235, 302, 247, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
2152, d4n70A_, 0.7653, 2.50, 0.275, 274, 240, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2153, d4i22A_, 0.7653, 2.60, 0.211, 297, 242, STRUCTURE OF THE MONOMERIC (V948R)GEFITINIB/ERLOTINIB RESISTANT DOUBLE MUTANT (L858R+T790M) EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH GEFITINIB
2154, d4alwA_, 0.7653, 2.58, 0.270, 273, 241, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2155, d2xj1A_, 0.7653, 2.51, 0.275, 273, 240, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
2156, d5h2uD1, 0.7652, 2.41, 0.255, 261, 239, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
2157, d4qmxA_, 0.7652, 2.82, 0.280, 287, 246, MST3 IN COMPLEX WITH SARACATINIB
2158, d3d5wA_, 0.7652, 2.78, 0.289, 284, 246, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
2159, d6babA_, 0.7651, 2.66, 0.317, 290, 243, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2160, d5w5oD_, 0.7651, 2.78, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2161, d4rqkA_, 0.7651, 2.82, 0.293, 285, 246, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
2162, d4k18A_, 0.7651, 2.59, 0.277, 277, 242, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2163, d3uojB_, 0.7651, 2.50, 0.315, 263, 241, AURORA A IN COMPLEX WITH RPM1715
2164, d3uojA_, 0.7651, 2.50, 0.315, 263, 241, AURORA A IN COMPLEX WITH RPM1715
2165, d5eakA_, 0.7650, 2.63, 0.322, 305, 242, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
2166, d4yhfB_, 0.7650, 2.52, 0.204, 269, 240, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
2167, d4obpB_, 0.7650, 2.50, 0.244, 290, 242, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
2168, d3a8wA1, 0.7650, 2.62, 0.302, 323, 245, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2169, d5gtyE_, 0.7649, 2.83, 0.212, 297, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2170, d5eolA_, 0.7649, 2.54, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
2171, d5ackA_, 0.7649, 2.84, 0.293, 286, 246, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
2172, d3r04A_, 0.7649, 2.53, 0.278, 271, 241, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2173, d3c4eD_, 0.7649, 2.53, 0.278, 273, 241, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2174, d3bbtB_, 0.7649, 2.43, 0.226, 274, 239, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
2175, d2xuuA_, 0.7649, 2.58, 0.285, 301, 242, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
2176, d2j2iB_, 0.7649, 2.49, 0.278, 273, 241, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
2177, d5d7vA1, 0.7648, 2.51, 0.261, 262, 241, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
2178, d5av1A_, 0.7648, 2.55, 0.287, 275, 240, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
2179, d4n6yA_, 0.7648, 2.46, 0.283, 273, 240, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
2180, d4dtkA_, 0.7648, 2.53, 0.282, 273, 241, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
2181, d2phkA_, 0.7648, 2.58, 0.303, 277, 241, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
2182, d1wvxA_, 0.7648, 2.49, 0.287, 275, 240, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2183, d5gtyD_, 0.7647, 2.82, 0.208, 297, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2184, d5dwrA_, 0.7647, 2.51, 0.275, 273, 240, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
2185, d4utdA_, 0.7647, 2.67, 0.314, 266, 242, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
2186, d3vbtA_, 0.7647, 2.53, 0.278, 267, 241, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2187, d2r4bA_, 0.7647, 2.61, 0.225, 292, 240, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
2188, d1yxxA_, 0.7647, 2.65, 0.281, 274, 242, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
2189, d5op2A_, 0.7646, 2.61, 0.288, 263, 243, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2190, d4jx3A_, 0.7646, 2.50, 0.274, 274, 241, CRYSTAL STRUCTURE OF PIM1 KINASE
2191, d4eqcA1, 0.7646, 2.90, 0.313, 292, 249, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
2192, d4ct2A_, 0.7646, 2.87, 0.297, 277, 246, HUMAN PDK1-PKCZETA KINASE CHIMERA
2193, d3r02A_, 0.7646, 2.54, 0.278, 271, 241, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2194, d1yvjA_, 0.7646, 2.92, 0.261, 288, 245, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
2195, d3vbvA_, 0.7645, 2.54, 0.278, 268, 241, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2196, d5d41A_, 0.7644, 2.71, 0.210, 300, 243, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
2197, d3f69B_, 0.7644, 2.55, 0.262, 282, 240, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
2198, d5w5oE_, 0.7643, 2.79, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2199, d5vuaB_, 0.7643, 2.43, 0.272, 270, 239, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2200, d5av3A_, 0.7643, 2.55, 0.287, 275, 240, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
2201, d4qnaA_, 0.7643, 2.85, 0.280, 284, 246, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
2202, d4eqmA_, 0.7643, 2.62, 0.253, 269, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2203, d4aluA_, 0.7643, 2.56, 0.274, 274, 241, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2204, d4ae6A_, 0.7643, 2.74, 0.272, 319, 246, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
2205, d5w5oA_, 0.7642, 2.80, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2206, d4ythA_, 0.7642, 2.70, 0.258, 287, 244, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
2207, d5w5oG_, 0.7641, 2.80, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2208, d4xhkB_, 0.7641, 2.49, 0.283, 269, 240, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
2209, d4eqmC_, 0.7641, 2.63, 0.253, 269, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2210, d4eqmB_, 0.7641, 2.63, 0.253, 269, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2211, d5iisA_, 0.7640, 2.51, 0.283, 273, 240, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
2212, d3vbxA_, 0.7640, 2.54, 0.278, 268, 241, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2213, d4ll5A_, 0.7639, 2.52, 0.282, 268, 241, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
2214, d4as0A_, 0.7639, 2.43, 0.275, 273, 240, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
2215, d3d5uA_, 0.7639, 2.80, 0.289, 288, 246, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
2216, d1yxuD_, 0.7639, 2.54, 0.278, 273, 241, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2217, d4xh6A_, 0.7638, 2.53, 0.282, 273, 241, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
2218, d3vbyA_, 0.7638, 2.54, 0.282, 267, 241, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2219, d3a8wB1, 0.7638, 2.58, 0.279, 324, 244, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2220, d2xizA_, 0.7638, 2.51, 0.275, 273, 240, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2221, d2ckeD_, 0.7638, 2.70, 0.280, 300, 243, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2222, d5jrqA1, 0.7637, 2.46, 0.214, 257, 238, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
2223, d5auvA_, 0.7637, 2.56, 0.287, 275, 240, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
2224, d3r01A_, 0.7637, 2.57, 0.274, 274, 241, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2225, d3bgzA_, 0.7637, 2.42, 0.276, 267, 239, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
2226, d5w5oB_, 0.7636, 2.80, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2227, d5j79B_, 0.7636, 2.84, 0.227, 277, 247, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
2228, d5auxA_, 0.7636, 2.56, 0.287, 275, 240, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
2229, d4uy9A_, 0.7636, 2.48, 0.277, 313, 238, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
2230, d4bznA_, 0.7636, 2.52, 0.283, 272, 240, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
2231, d3bbtD_, 0.7636, 2.45, 0.226, 259, 239, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
2232, d2clqA_, 0.7636, 2.66, 0.303, 263, 241, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2233, d2a2aD_, 0.7636, 2.70, 0.280, 303, 243, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2234, d5kgiA_, 0.7635, 2.53, 0.282, 273, 241, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
2235, d5dfpA_, 0.7635, 2.90, 0.313, 292, 249, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
2236, d4mbiA_, 0.7635, 2.53, 0.270, 274, 241, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2237, p4d28C_, 0.7635, 2.63, 0.339, 279, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
2238, d3krwA2, 0.7635, 2.88, 0.262, 349, 248, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
2239, d3dkcA1, 0.7635, 2.77, 0.218, 310, 243, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
2240, d5av2A_, 0.7634, 2.57, 0.287, 275, 240, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2241, d5kgeA_, 0.7633, 2.54, 0.282, 273, 241, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
2242, d5gtyF_, 0.7633, 2.78, 0.209, 297, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2243, d5auyA_, 0.7633, 2.55, 0.287, 275, 240, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2244, d3h0zA_, 0.7633, 2.42, 0.310, 248, 239, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
2245, d5w5oF_, 0.7632, 2.81, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2246, d5opbA_, 0.7632, 2.62, 0.288, 262, 243, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
2247, d1j3hB_, 0.7632, 2.77, 0.268, 327, 246, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2248, d5kcxA_, 0.7631, 2.57, 0.282, 272, 241, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
2249, d4k1bA_, 0.7631, 2.47, 0.275, 273, 240, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2250, d3bhhB1, 0.7631, 2.66, 0.328, 288, 241, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2251, d5vloA_, 0.7630, 2.47, 0.314, 290, 239, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2252, d5telA_, 0.7630, 2.56, 0.274, 273, 241, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2253, d5dbxB_, 0.7630, 2.49, 0.285, 282, 239, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
2254, d4i24A_, 0.7630, 2.65, 0.207, 295, 241, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
2255, d3hrfA_, 0.7630, 2.79, 0.294, 284, 245, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
2256, d5xgnB_, 0.7629, 2.91, 0.174, 308, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
2257, d5lwmA_, 0.7629, 3.03, 0.252, 290, 246, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
2258, d4b4lA_, 0.7629, 2.70, 0.284, 299, 243, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
2259, d1yxvA_, 0.7629, 2.67, 0.281, 274, 242, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
2260, d5w5oH_, 0.7628, 2.81, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2261, d2objA_, 0.7628, 2.51, 0.283, 272, 240, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
2262, d4qmuA_, 0.7627, 2.83, 0.253, 286, 245, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
2263, d4nfnA_, 0.7627, 3.04, 0.189, 293, 249, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
2264, d3bgpA_, 0.7627, 2.52, 0.287, 272, 240, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
2265, d2o3pA_, 0.7627, 2.57, 0.270, 274, 241, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
2266, d5turA_, 0.7626, 2.56, 0.274, 270, 241, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2267, d5lwnA_, 0.7626, 3.03, 0.252, 290, 246, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
2268, d4btjA_, 0.7626, 3.16, 0.193, 292, 249, TTBK1 IN COMPLEX WITH ATP
2269, d3krxA2, 0.7626, 2.89, 0.266, 349, 248, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
2270, d3jxwA_, 0.7626, 2.59, 0.274, 274, 241, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2271, d2ckeC_, 0.7626, 2.72, 0.280, 300, 243, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2272, d2bzjA_, 0.7626, 2.53, 0.278, 273, 241, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
2273, d5lvoA_, 0.7625, 2.85, 0.293, 285, 246, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
2274, d5ar5B_, 0.7625, 2.82, 0.243, 279, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
2275, d4qmzA_, 0.7625, 2.91, 0.291, 286, 247, MST3 IN COMPLEX WITH SUNITINIB
2276, d3ma6A_, 0.7625, 2.63, 0.313, 267, 243, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
2277, d2ckeA_, 0.7625, 2.72, 0.280, 301, 243, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2278, d2bujA1, 0.7625, 2.73, 0.252, 283, 242, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2279, d1yxuC_, 0.7625, 2.56, 0.282, 272, 241, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2280, d1yhwA_, 0.7625, 2.89, 0.294, 293, 248, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
2281, d5w5oP_, 0.7624, 2.80, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2282, d5vucB_, 0.7624, 2.43, 0.273, 269, 238, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2283, d5os2A_, 0.7624, 2.66, 0.314, 261, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2284, d3qc4A_, 0.7624, 2.72, 0.279, 276, 244, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
2285, d2xiyA_, 0.7624, 2.55, 0.275, 273, 240, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2286, d5h2uA1, 0.7623, 2.52, 0.262, 261, 240, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
2287, d5dt3A_, 0.7623, 2.75, 0.313, 263, 243, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2288, d4enxA_, 0.7623, 2.48, 0.280, 266, 239, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
2289, d3hrcA_, 0.7623, 2.86, 0.293, 279, 246, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
2290, d3c4dA1, 0.7623, 2.52, 0.213, 257, 239,  
2291, d1yxuA_, 0.7623, 2.56, 0.278, 273, 241, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2292, d5os4A_, 0.7622, 2.67, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2293, d3a7iA_, 0.7622, 2.93, 0.291, 286, 247, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
2294, d2a2aA_, 0.7622, 2.74, 0.280, 304, 243, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2295, d5ih5A_, 0.7621, 2.94, 0.198, 286, 248, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
2296, d4qmnA_, 0.7621, 2.83, 0.253, 283, 245, MST3 IN COMPLEX WITH BOSUTINIB
2297, d4bicA_, 0.7621, 2.59, 0.305, 260, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2298, d2f57B1, 0.7621, 2.97, 0.249, 293, 245, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
2299, d1yhsA_, 0.7621, 2.48, 0.285, 267, 239, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
2300, d5orzA_, 0.7620, 2.66, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2301, d3e63A_, 0.7620, 2.74, 0.262, 290, 244, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2302, d3bgqA_, 0.7620, 2.55, 0.283, 272, 240, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
2303, d5he0A2, 0.7619, 2.90, 0.255, 346, 247, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
2304, d5drdA_, 0.7618, 2.81, 0.313, 259, 243, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2305, d4ct1A_, 0.7618, 2.87, 0.297, 283, 246, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
2306, d3vs3B3, 0.7618, 2.57, 0.246, 271, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
2307, d1yhvA_, 0.7618, 2.89, 0.294, 293, 248, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
2308, d5m53A1, 0.7617, 1.95, 0.303, 248, 231, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
2309, d3e62A_, 0.7617, 2.75, 0.262, 291, 244, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2310, d3c4cA1, 0.7617, 2.62, 0.212, 257, 240, B-RAF KINASE IN COMPLEX WITH PLX4720
2311, d1yi3A_, 0.7617, 2.49, 0.285, 267, 239, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
2312, d5orvA_, 0.7616, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2313, d5orpA_, 0.7616, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2314, d5av4A_, 0.7616, 2.55, 0.289, 274, 239, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2315, d4bzoA_, 0.7616, 2.54, 0.283, 272, 240, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
2316, d3qc4B1, 0.7616, 2.67, 0.292, 268, 243, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
2317, d1yxuB_, 0.7616, 2.57, 0.278, 273, 241, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2318, d5w5oL_, 0.7615, 2.82, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2319, d5osdA_, 0.7615, 2.68, 0.314, 266, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2320, d4gfmA_, 0.7615, 2.76, 0.262, 289, 244, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
2321, d3bwfA_, 0.7615, 2.55, 0.278, 273, 241, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
2322, d3jyaA_, 0.7614, 2.58, 0.282, 274, 241, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2323, d2jiuA_, 0.7614, 2.80, 0.221, 303, 244, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
2324, d5vubB_, 0.7613, 2.51, 0.280, 269, 239, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2325, d5toeA_, 0.7613, 2.60, 0.274, 272, 241, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2326, d5lvmA_, 0.7613, 2.89, 0.293, 283, 246, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
2327, d2yabA_, 0.7613, 2.74, 0.288, 299, 243, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2328, d2gs7A_, 0.7613, 2.61, 0.216, 281, 241, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2329, d1cmkE_, 0.7613, 2.82, 0.276, 348, 246, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
2330, d5oseA_, 0.7612, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2331, d5os5A_, 0.7612, 2.68, 0.314, 267, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2332, d5li9A1, 0.7611, 2.73, 0.299, 328, 244, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
2333, d5gtyC_, 0.7611, 2.87, 0.213, 295, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2334, d5auwA_, 0.7611, 2.55, 0.289, 274, 239, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
2335, d1mruB_, 0.7611, 2.58, 0.274, 271, 241, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
2336, d5os0A_, 0.7610, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2337, d5orrA_, 0.7610, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2338, d5kggA_, 0.7610, 2.58, 0.282, 273, 241, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
2339, d2hckA3, 0.7610, 2.51, 0.243, 271, 239, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
2340, d1ol7A_, 0.7610, 2.71, 0.314, 261, 242, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
2341, d5osfA_, 0.7609, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2342, d5os1A_, 0.7609, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2343, d4hnfB_, 0.7609, 2.96, 0.190, 290, 248, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
2344, d3umwA_, 0.7609, 2.44, 0.282, 264, 238, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
2345, d2r4bB_, 0.7609, 2.50, 0.227, 291, 238, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
2346, d5u94A_, 0.7608, 2.63, 0.273, 263, 242, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
2347, d5os6A_, 0.7608, 2.69, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2348, d5oryA_, 0.7608, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2349, d5kbqB_, 0.7608, 2.64, 0.310, 273, 242, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
2350, d5auzA_, 0.7608, 2.56, 0.289, 274, 239, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
2351, d4jboA_, 0.7608, 2.66, 0.306, 266, 242, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2352, d2ckeB_, 0.7608, 2.76, 0.280, 300, 243, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2353, d2a2aC_, 0.7608, 2.76, 0.280, 303, 243, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2354, d1zwsD_, 0.7608, 2.65, 0.285, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2355, d5dt4A_, 0.7607, 2.80, 0.313, 259, 243, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2356, d4lmuA_, 0.7607, 2.47, 0.280, 265, 239, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
2357, d1mryA_, 0.7607, 2.47, 0.303, 270, 238, CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN
2358, d5orxA_, 0.7606, 2.69, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2359, d4rc4A_, 0.7606, 2.53, 0.283, 272, 240, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2360, d4jbpA_, 0.7606, 2.62, 0.307, 255, 241, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2361, d4a7cA_, 0.7605, 2.53, 0.283, 273, 240, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
2362, d1zwsC_, 0.7605, 2.67, 0.285, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2363, d5os3A_, 0.7604, 2.69, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2364, d5ih6A_, 0.7604, 2.98, 0.202, 286, 248, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
2365, d4ytiA_, 0.7604, 2.71, 0.259, 284, 243, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
2366, d4twcA_, 0.7604, 3.00, 0.194, 293, 248, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
2367, d3fxzA_, 0.7604, 2.94, 0.294, 292, 248, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
2368, d2xixA_, 0.7604, 2.53, 0.276, 272, 239, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2369, d1wvyA_, 0.7604, 2.53, 0.287, 273, 240, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2370, d1ctpE_, 0.7604, 2.82, 0.280, 332, 246, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
2371, d5xgnA_, 0.7603, 2.89, 0.234, 302, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
2372, d5orwA_, 0.7603, 2.69, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2373, d5oroA_, 0.7603, 2.69, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2374, d5ornA_, 0.7603, 2.69, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2375, d5cf5B1, 0.7603, 2.78, 0.262, 292, 244, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2376, d3c4eC_, 0.7603, 2.57, 0.278, 272, 241, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2377, d5kgkA_, 0.7602, 2.56, 0.282, 273, 241, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
2378, d5dr2A1, 0.7602, 2.84, 0.309, 263, 243, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
2379, d5dbxA_, 0.7602, 2.67, 0.282, 284, 241, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
2380, d4txcA_, 0.7602, 2.60, 0.286, 276, 241, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
2381, d4tw9A_, 0.7602, 2.98, 0.198, 290, 248, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
2382, d4hjoA_, 0.7602, 2.63, 0.212, 278, 241, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
2383, d4ae9A_, 0.7602, 2.75, 0.273, 321, 245, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
2384, d3fy0A_, 0.7602, 2.83, 0.265, 292, 245, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
2385, d5w5oI_, 0.7601, 2.83, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2386, d5c1qB_, 0.7601, 2.56, 0.290, 273, 241, SERINE/THREONINE-PROTEIN KINASE PIM-1
2387, d4uy9B_, 0.7601, 2.49, 0.277, 315, 238, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
2388, d4btmA_, 0.7601, 3.10, 0.194, 292, 248, TTBK1 IN COMPLEX WITH INHIBITOR
2389, d3kexA_, 0.7601, 2.56, 0.208, 292, 240, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
2390, d2rfeD_, 0.7601, 2.73, 0.219, 278, 242, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
2391, d1ad5B3, 0.7601, 2.55, 0.243, 271, 239, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
2392, d5dnrA_, 0.7600, 2.71, 0.314, 264, 242, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
2393, d3vrzB3, 0.7600, 2.56, 0.247, 269, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
2394, d3lmgA_, 0.7600, 2.60, 0.208, 268, 240, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2395, d3ggfB_, 0.7600, 2.75, 0.283, 270, 247, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
2396, d3bhhA1, 0.7600, 2.66, 0.321, 287, 240, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2397, d1zwsF_, 0.7600, 2.65, 0.285, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2398, d1eh4A_, 0.7600, 3.15, 0.190, 293, 252, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2399, d1ad5A3, 0.7600, 2.54, 0.243, 271, 239, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
2400, d5w5oC_, 0.7599, 2.86, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2401, d4cegA_, 0.7599, 2.71, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
2402, d4c8bA_, 0.7599, 2.74, 0.230, 279, 244, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
2403, d3q32B1, 0.7599, 2.80, 0.262, 293, 244, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
2404, d3dcvA_, 0.7599, 2.57, 0.287, 273, 240, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
2405, d2hckB3, 0.7599, 2.52, 0.247, 271, 239, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
2406, d3vs3A3, 0.7598, 2.58, 0.251, 269, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
2407, d5o21B_, 0.7597, 2.64, 0.247, 273, 239, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
2408, d3vryA3, 0.7597, 2.56, 0.247, 269, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
2409, d5v24B_, 0.7596, 2.75, 0.300, 263, 240, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2410, d5ih4A_, 0.7596, 2.98, 0.198, 286, 248, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
2411, d5dn3A_, 0.7596, 2.71, 0.314, 264, 242, AURORA A IN COMPLEX WITH ATP AND AA35.
2412, d2gs7B_, 0.7596, 2.64, 0.220, 288, 241, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2413, d4rpvA_, 0.7595, 2.56, 0.286, 273, 241, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
2414, d3p86A_, 0.7595, 2.29, 0.229, 250, 236, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
2415, d3c4eA_, 0.7595, 2.58, 0.278, 273, 241, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2416, d5ar7A_, 0.7594, 2.94, 0.226, 278, 248, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
2417, d4lm5A_, 0.7594, 2.57, 0.279, 264, 240, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
2418, d4enyA_, 0.7594, 2.40, 0.274, 261, 237, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
2419, d2w4kA_, 0.7594, 2.78, 0.284, 301, 243, X-RAY STRUCTURE OF A DAP-KINASE 2-302
2420, d2bziB_, 0.7594, 2.53, 0.279, 272, 240, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
2421, d5orsA_, 0.7593, 2.70, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2422, d5ng2B_, 0.7593, 2.97, 0.238, 278, 248, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
2423, d5he2A2, 0.7593, 2.88, 0.256, 353, 246, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
2424, d4o0rA_, 0.7593, 2.88, 0.264, 293, 246, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2425, d4m7iA1, 0.7593, 2.35, 0.288, 246, 233, CRYSTAL STRUCTURE OF GSK6157 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.34A RESOLUTION
2426, d4i41A_, 0.7593, 2.55, 0.287, 272, 240, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
2427, d3vs6B3, 0.7593, 2.58, 0.251, 269, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
2428, d1ywvA_, 0.7593, 2.61, 0.270, 274, 241, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
2429, d1xwsA_, 0.7593, 2.49, 0.275, 273, 240, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
2430, d3pvwA2, 0.7592, 2.84, 0.248, 343, 246, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
2431, d3kexB_, 0.7592, 2.58, 0.208, 283, 240, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
2432, d3e64A_, 0.7592, 2.78, 0.262, 291, 244, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2433, d2a2aB_, 0.7592, 2.79, 0.280, 303, 243, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2434, d1yxsA_, 0.7592, 2.61, 0.274, 274, 241, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
2435, d1eh4B_, 0.7592, 3.16, 0.187, 293, 252, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2436, d5o21A_, 0.7591, 2.58, 0.252, 272, 238, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
2437, d5auuA_, 0.7591, 2.58, 0.289, 274, 239, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
2438, d4qmtA_, 0.7591, 2.97, 0.291, 284, 247, MST3 IN COMPLEX WITH HESPERADIN
2439, d3d14A1, 0.7591, 2.60, 0.307, 257, 241, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
2440, d2yaaA_, 0.7591, 2.65, 0.289, 300, 242, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2441, d1zwsH_, 0.7591, 2.68, 0.285, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2442, d5v19B_, 0.7590, 2.68, 0.305, 260, 239, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2443, d5o13A_, 0.7590, 2.52, 0.285, 270, 239, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2444, d5gnkA_, 0.7590, 2.60, 0.217, 277, 240, CRYSTAL STRUCTURE OF EGFR 696-988 T790M IN COMPLEX WITH LXX-6-34
2445, d3db6A_, 0.7590, 2.83, 0.286, 287, 245, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
2446, d1ckjB_, 0.7590, 3.01, 0.198, 293, 248, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
2447, d5oq8A_, 0.7589, 2.61, 0.282, 261, 241, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2448, d5mrdA_, 0.7589, 2.92, 0.293, 283, 246, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
2449, d3ppzA_, 0.7589, 2.63, 0.250, 264, 240, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2450, d2x4fB_, 0.7589, 2.65, 0.290, 288, 241, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2451, d4y95C1, 0.7588, 2.57, 0.192, 265, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
2452, d4rc2A_, 0.7588, 2.56, 0.283, 272, 240, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2453, d4qmwA_, 0.7588, 2.99, 0.291, 286, 247, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
2454, d3ikaB_, 0.7588, 2.90, 0.167, 310, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
2455, d2yabB_, 0.7588, 2.77, 0.288, 299, 243, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2456, d2fumC_, 0.7588, 2.44, 0.266, 254, 237, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2457, d2clqB_, 0.7588, 2.67, 0.296, 259, 240, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2458, d5itaA_, 0.7587, 2.35, 0.221, 250, 235, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
2459, d5aadA_, 0.7587, 2.55, 0.318, 252, 239, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
2460, d4yomB1, 0.7587, 2.65, 0.286, 320, 241, STRUCTURE OF SAD KINASE
2461, d4y95B1, 0.7587, 2.57, 0.192, 265, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
2462, d4pnkA2, 0.7587, 2.95, 0.244, 350, 246, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
2463, d4bn1A_, 0.7587, 2.68, 0.307, 261, 241, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
2464, d4aw0A_, 0.7587, 2.86, 0.294, 283, 245, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
2465, d3pp0A_, 0.7587, 2.78, 0.223, 286, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
2466, d1zwsB_, 0.7587, 2.70, 0.285, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2467, d5jsmD1, 0.7586, 2.54, 0.219, 255, 237, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2468, d5hu3A_, 0.7586, 2.54, 0.345, 266, 238, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2469, d5aepA_, 0.7586, 2.75, 0.263, 287, 243, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
2470, p4d28B_, 0.7586, 2.71, 0.339, 277, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
2471, d4d0xA_, 0.7586, 2.79, 0.262, 291, 244, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
2472, d3vs4B3, 0.7586, 2.58, 0.247, 269, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
2473, d3krrA1, 0.7586, 2.81, 0.262, 290, 244, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
2474, d3c4eB_, 0.7586, 2.59, 0.278, 273, 241, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2475, d2c0tB3, 0.7586, 2.66, 0.247, 268, 239, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
2476, d4lg4B_, 0.7585, 2.92, 0.296, 284, 247, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2477, d3nrmA_, 0.7585, 2.67, 0.315, 263, 241, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
2478, d5dosA_, 0.7584, 2.85, 0.309, 259, 243, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2479, d4rx5A1, 0.7584, 2.56, 0.200, 264, 240, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
2480, d4a07A_, 0.7584, 2.84, 0.294, 282, 245, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
2481, d3vs2B3, 0.7584, 2.53, 0.252, 268, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
2482, d3we8A_, 0.7583, 2.60, 0.282, 273, 241, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
2483, d2c0oA3, 0.7583, 2.48, 0.241, 268, 237, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
2484, d5autA_, 0.7582, 2.58, 0.289, 274, 239, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
2485, d4nfmA_, 0.7582, 3.16, 0.192, 293, 250, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
2486, d3vs6A3, 0.7582, 2.59, 0.247, 269, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
2487, d3vryB3, 0.7582, 2.58, 0.251, 269, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
2488, d2o63A_, 0.7582, 2.62, 0.270, 274, 241, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
2489, d2c0oB3, 0.7582, 2.46, 0.241, 268, 237, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
2490, d1xr1A_, 0.7582, 2.70, 0.278, 277, 241, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
2491, d5lohA_, 0.7581, 2.50, 0.309, 248, 236, KINASE DOMAIN OF HUMAN GREATWALL
2492, d4ivaA_, 0.7581, 2.79, 0.258, 290, 244, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
2493, d1ckiB_, 0.7581, 3.04, 0.202, 286, 248, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
2494, d5w5oN_, 0.7580, 2.71, 0.231, 272, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2495, d5u6bC_, 0.7580, 2.79, 0.226, 270, 243, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2496, d4wnpA_, 0.7580, 2.67, 0.312, 273, 240, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2497, d4d0wA_, 0.7580, 2.86, 0.262, 289, 244, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
2498, d5uoxA_, 0.7579, 2.76, 0.300, 263, 240, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2499, d5cf4B_, 0.7579, 2.81, 0.262, 291, 244, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2500, d3vs4A3, 0.7579, 2.58, 0.247, 270, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
2501, d3o7lD_, 0.7579, 2.87, 0.283, 333, 247, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
2502, d3f69A_, 0.7579, 2.53, 0.269, 270, 238, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
2503, d4rioA_, 0.7578, 2.86, 0.255, 285, 243, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
2504, d4jajA_, 0.7578, 2.79, 0.306, 265, 242, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
2505, d3q32A_, 0.7578, 2.79, 0.262, 291, 244, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
2506, d3pvuA2, 0.7578, 2.88, 0.248, 340, 246, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
2507, d3plsA_, 0.7578, 2.76, 0.219, 298, 242, RON IN COMPLEX WITH LIGAND AMP-PNP
2508, d3lmgB_, 0.7578, 2.63, 0.208, 268, 240, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2509, d3a4pA_, 0.7578, 2.95, 0.220, 285, 245, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
2510, d5ttvA_, 0.7577, 2.97, 0.254, 280, 244, JAK3 WITH COVALENT INHIBITOR 6
2511, d5objA_, 0.7577, 2.68, 0.314, 260, 242, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
2512, d4otwA_, 0.7577, 2.60, 0.208, 272, 240, HER3 PSEUDOKINASE DOMAIN BOUND TO BOSUTINIB
2513, d2c0iB3, 0.7577, 2.55, 0.248, 268, 238, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
2514, d2c0iA3, 0.7577, 2.55, 0.248, 268, 238, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
2515, d5ortA_, 0.7576, 2.72, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2516, d4prjA_, 0.7576, 2.56, 0.315, 251, 238, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
2517, d3vs0B3, 0.7576, 2.55, 0.248, 268, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
2518, d3ocsA1, 0.7576, 2.57, 0.200, 262, 240, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
2519, d1ckiA_, 0.7576, 3.03, 0.198, 292, 248, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
2520, d2yaaB_, 0.7575, 2.68, 0.289, 299, 242, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2521, d5deyA_, 0.7574, 2.95, 0.294, 295, 248, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2522, d4ynzA1, 0.7574, 2.39, 0.291, 306, 237, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
2523, d4y95D_, 0.7574, 2.49, 0.192, 265, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
2524, d4g31A1, 0.7574, 2.38, 0.292, 247, 233, CRYSTAL STRUCTURE OF GSK6414 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.28 A RESOLUTION
2525, d3ikaA_, 0.7574, 2.98, 0.224, 310, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
2526, d4y95A1, 0.7573, 2.49, 0.192, 265, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
2527, d3vs2A3, 0.7573, 2.56, 0.252, 268, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
2528, d3m11A_, 0.7573, 2.64, 0.315, 256, 241, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
2529, d2c0tA3, 0.7573, 2.56, 0.248, 268, 238, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
2530, d1zwsG_, 0.7573, 2.69, 0.285, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2531, d1ckjA_, 0.7573, 3.04, 0.194, 296, 248, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
2532, d5eakB_, 0.7572, 2.62, 0.325, 300, 240, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
2533, d4wsqB_, 0.7572, 2.66, 0.255, 310, 239, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2534, d3dj7A_, 0.7572, 2.63, 0.307, 257, 241, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
2535, d2o65A_, 0.7572, 2.62, 0.270, 274, 241, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
2536, d5oneA_, 0.7571, 2.72, 0.314, 257, 242, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
2537, d5nttA1, 0.7571, 2.66, 0.306, 268, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
2538, d3vs5B3, 0.7571, 2.56, 0.248, 268, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
2539, d3uixA_, 0.7571, 2.54, 0.280, 266, 239, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2540, d3rvgA_, 0.7571, 2.74, 0.263, 285, 243, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
2541, d3r22A_, 0.7571, 2.67, 0.315, 255, 241, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
2542, d6bqpA1, 0.7570, 2.62, 0.297, 262, 239, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
2543, d5he1A2, 0.7570, 2.90, 0.271, 342, 247, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
2544, d4yhfA_, 0.7570, 2.64, 0.200, 268, 240, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
2545, d4o0sA_, 0.7570, 2.74, 0.314, 265, 242, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2546, d4e6qA_, 0.7570, 2.79, 0.266, 296, 244, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
2547, d3jy0A_, 0.7570, 2.66, 0.275, 275, 240, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2548, d2x6dA_, 0.7570, 2.74, 0.307, 255, 241, AURORA-A BOUND TO AN INHIBITOR
2549, d2bikB_, 0.7570, 2.55, 0.279, 272, 240, HUMAN PIM1 PHOSPHORYLATED ON SER261
2550, d5vgoA1, 0.7569, 2.57, 0.200, 264, 240, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
2551, d5u6bA_, 0.7569, 2.80, 0.226, 270, 243, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2552, d5orlA_, 0.7569, 2.72, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2553, d5jsmB1, 0.7569, 2.63, 0.214, 259, 238, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2554, d5cf5A1, 0.7569, 2.76, 0.263, 286, 243, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2555, d4qmlA_, 0.7569, 3.02, 0.287, 280, 247, MST3 IN COMPLEX WITH AMP-PNP
2556, d4i6hA_, 0.7569, 2.80, 0.262, 285, 244, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2557, d4g34A1, 0.7569, 2.39, 0.292, 247, 233, CRYSTAL STRUCTURE OF GSK6924 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.70 A RESOLUTION
2558, d1mq4A_, 0.7569, 2.76, 0.307, 261, 241, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
2559, d5k00A_, 0.7568, 2.41, 0.342, 311, 237, MELK IN COMPLEX WITH NVS-MELK5
2560, d4otqA_, 0.7568, 2.62, 0.196, 263, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
2561, d4otfA1, 0.7568, 2.58, 0.200, 261, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
2562, d4i6bA_, 0.7568, 2.80, 0.258, 285, 244, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2563, d3vrzA3, 0.7568, 2.57, 0.248, 268, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
2564, d1jktA_, 0.7568, 2.78, 0.285, 276, 242, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2565, d5n93A1, 0.7567, 2.47, 0.310, 256, 239, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
2566, d5jsmC1, 0.7567, 2.55, 0.215, 259, 237, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2567, d4h58A_, 0.7567, 2.72, 0.217, 263, 240, BRAF IN COMPLEX WITH COMPOUND 3
2568, d3d4qB_, 0.7567, 2.80, 0.212, 264, 241, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
2569, d2xruA_, 0.7567, 2.69, 0.307, 253, 241, AURORA-A T288E COMPLEXED WITH PHA-828300
2570, d5texA_, 0.7566, 2.65, 0.274, 274, 241, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2571, d5obrA_, 0.7566, 2.64, 0.315, 255, 241, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
2572, d5da3A1, 0.7566, 2.63, 0.258, 261, 240, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN WITH INHIBITOR
2573, d5cf6A_, 0.7566, 2.76, 0.263, 285, 243, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2574, d4zimB1, 0.7566, 2.83, 0.262, 292, 244, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
2575, d4x7nA_, 0.7566, 2.90, 0.270, 259, 241, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-[2-AMINO-4-METHYL-3-(2- METHYLQUINOLIN-6-YL)BENZOYL]-1-METHYL-25-DIPHENYL-12-DIHYDRO-3H- PYRAZOL-3-ONE INHIBITOR
2576, d3naxA_, 0.7566, 2.82, 0.287, 278, 244, PDK1 IN COMPLEX WITH INHIBITOR MP7
2577, d1jktB_, 0.7566, 2.76, 0.285, 276, 242, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2578, d5kupA1, 0.7565, 2.58, 0.200, 264, 240, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
2579, d5bpyA1, 0.7565, 2.64, 0.200, 262, 240, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
2580, d4wsqA_, 0.7565, 2.67, 0.264, 317, 239, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2581, d4otrA_, 0.7565, 2.62, 0.196, 263, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
2582, d3vs5A3, 0.7565, 2.57, 0.248, 268, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
2583, d3d4qA_, 0.7565, 2.81, 0.216, 264, 241, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
2584, d3cikA2, 0.7565, 2.97, 0.260, 347, 246, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
2585, d4deeA_, 0.7564, 2.78, 0.314, 271, 242, AURORA A IN COMPLEX WITH ADP
2586, d4aqcA_, 0.7564, 2.81, 0.262, 289, 244, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
2587, d3uo5A_, 0.7564, 2.75, 0.314, 267, 242, AURORA A IN COMPLEX WITH YL1-038-31
2588, d3ppkB_, 0.7564, 2.84, 0.216, 264, 241, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
2589, d3is5E1, 0.7564, 1.82, 0.308, 243, 227, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
2590, d5ng0A_, 0.7563, 2.77, 0.238, 274, 244, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
2591, d4wnpD_, 0.7563, 2.74, 0.312, 272, 240, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2592, d4wnpC_, 0.7563, 2.68, 0.314, 271, 239, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2593, d4twcB_, 0.7563, 3.01, 0.194, 292, 248, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
2594, d4i5pA_, 0.7563, 2.81, 0.258, 284, 244, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2595, d1zwsA_, 0.7563, 2.73, 0.285, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2596, d5j87B_, 0.7562, 2.63, 0.200, 274, 240, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2597, d4qpsC_, 0.7562, 2.74, 0.261, 276, 241, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
2598, d4f08B_, 0.7562, 2.82, 0.262, 288, 244, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
2599, d4bkjB1, 0.7562, 2.97, 0.223, 296, 247, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
2600, d1o6yA_, 0.7562, 2.59, 0.271, 260, 240, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
2601, d4zegA_, 0.7561, 2.67, 0.311, 260, 241, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2602, d4medA_, 0.7561, 2.58, 0.287, 272, 240, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
2603, d5p9fA_, 0.7560, 2.63, 0.200, 266, 240, BTK IN COMPLEX WITH GDC-0834
2604, d5he3A2, 0.7560, 2.86, 0.245, 346, 245, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
2605, d4f08A_, 0.7560, 2.82, 0.262, 288, 244, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
2606, d4bicB_, 0.7560, 2.75, 0.303, 259, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2607, d4bhnA_, 0.7560, 2.65, 0.304, 256, 237, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2608, d3vs0A3, 0.7560, 2.59, 0.248, 268, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
2609, d2yakA_, 0.7560, 2.73, 0.285, 277, 242, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
2610, d2bcjA3, 0.7560, 2.85, 0.249, 348, 245, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
2611, d5ar2A_, 0.7559, 2.86, 0.237, 277, 245, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
2612, d4rc3A_, 0.7559, 2.56, 0.289, 271, 239, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2613, d3r21A_, 0.7559, 2.69, 0.311, 254, 241, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
2614, d3otuA_, 0.7559, 2.89, 0.295, 276, 244, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
2615, d2wzjB_, 0.7559, 2.43, 0.316, 310, 237, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2616, d2gdoA_, 0.7559, 2.90, 0.294, 269, 245, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
2617, d5lohB_, 0.7558, 2.74, 0.317, 250, 240, KINASE DOMAIN OF HUMAN GREATWALL
2618, d5j87D_, 0.7558, 2.65, 0.200, 263, 240, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2619, d4dhfA_, 0.7558, 2.79, 0.314, 258, 242, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2620, d4aqcB_, 0.7558, 2.86, 0.262, 295, 244, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
2621, d3uytC_, 0.7558, 3.04, 0.198, 286, 248, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2622, d3d15A_, 0.7558, 2.61, 0.308, 256, 240, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
2623, d2h8hA3, 0.7558, 2.71, 0.242, 280, 240, SRC KINASE IN COMPLEX WITH A QUINAZOLINE INHIBITOR
2624, d4i6fA_, 0.7557, 2.82, 0.262, 285, 244, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2625, d4dhfB_, 0.7557, 2.80, 0.314, 258, 242, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2626, d6bleA1, 0.7556, 2.64, 0.297, 263, 239, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
2627, d5hesA_, 0.7556, 2.64, 0.254, 287, 236, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
2628, d4rfyA_, 0.7556, 2.64, 0.196, 263, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
2629, d3t9iA_, 0.7556, 2.58, 0.276, 273, 239, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
2630, d1yi4A_, 0.7556, 2.55, 0.285, 267, 239, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
2631, d5ng0B_, 0.7555, 3.04, 0.238, 282, 248, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
2632, d5j79A_, 0.7555, 2.89, 0.229, 283, 245, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
2633, d4ntsB_, 0.7555, 2.88, 0.268, 341, 246, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2634, d3vs1B3, 0.7555, 2.51, 0.241, 268, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
2635, d3mygA_, 0.7555, 2.63, 0.318, 252, 239, AURORA A KINASE COMPLEXED WITH SCH 1473759
2636, d2qu5A_, 0.7555, 2.85, 0.222, 292, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
2637, d2f57A1, 0.7555, 2.96, 0.253, 290, 245, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
2638, d4x7kA_, 0.7554, 2.92, 0.270, 260, 241, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-3-[5-FLUORO-2- (METHYLAMINO)QUINAZOLIN-6-YL]-4-METHYLBENZOYL}-1-METHYL-25-DIPHENYL- 12-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
2639, d4hvgA_, 0.7554, 2.75, 0.261, 281, 241, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
2640, d4f09A_, 0.7554, 2.82, 0.258, 288, 244, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
2641, d3a7jA_, 0.7554, 3.03, 0.264, 286, 246, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
2642, d5dr9A_, 0.7553, 2.74, 0.314, 257, 242, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
2643, d5cswA_, 0.7553, 2.67, 0.206, 254, 238, B-RAF IN COMPLEX WITH DABRAFENIB
2644, d4iaaA_, 0.7553, 2.58, 0.287, 272, 240, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
2645, d2ya9A_, 0.7553, 2.70, 0.289, 299, 242, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2646, d2wzjD_, 0.7553, 2.44, 0.316, 313, 237, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2647, d5mrbA1, 0.7552, 2.42, 0.315, 259, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
2648, d3lxlA_, 0.7552, 2.88, 0.256, 281, 242, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
2649, d3a99A_, 0.7552, 2.76, 0.282, 273, 241, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
2650, d2xngA_, 0.7552, 2.65, 0.308, 253, 240, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
2651, d1ym7C3, 0.7552, 3.01, 0.232, 346, 246, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2652, d5oq7A_, 0.7551, 2.64, 0.299, 259, 241, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2653, d4x7lA_, 0.7551, 2.93, 0.270, 260, 241, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-4-METHYL-3-[2- (METHYLAMINO)-13-BENZOTHIAZOL-6-YL]BENZOYL}-1-METHYL-25-DIPHENYL-1 2-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
2654, d4wnpB_, 0.7551, 2.72, 0.317, 272, 240, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2655, d5h0hA3, 0.7550, 2.69, 0.250, 281, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
2656, d5h0eA3, 0.7550, 2.70, 0.250, 281, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
2657, d4ytfA_, 0.7550, 2.76, 0.260, 283, 242, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
2658, d4tl0A_, 0.7550, 2.81, 0.284, 300, 243, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
2659, d4ot6A_, 0.7550, 2.65, 0.196, 265, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
2660, d3vs7A3, 0.7550, 2.58, 0.256, 267, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
2661, d3vs1A3, 0.7550, 2.59, 0.252, 268, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
2662, d3mj2A_, 0.7550, 2.48, 0.231, 259, 238, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
2663, d3eyhA_, 0.7550, 2.89, 0.259, 285, 243, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
2664, d1ym7A3, 0.7550, 3.01, 0.232, 347, 246, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2665, d5up3A_, 0.7549, 2.76, 0.310, 258, 239, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2666, d5h09A3, 0.7549, 2.70, 0.250, 281, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
2667, d5dt0A_, 0.7549, 2.91, 0.313, 259, 243, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
2668, d3d2iA_, 0.7549, 2.65, 0.307, 255, 241, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
2669, d5hznG_, 0.7548, 2.87, 0.217, 296, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2670, d4kbkB_, 0.7548, 3.05, 0.198, 289, 248, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2671, d4e6qB_, 0.7548, 2.82, 0.266, 296, 244, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
2672, d3pjcA_, 0.7548, 2.84, 0.260, 286, 242, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
2673, d1ym7D3, 0.7548, 3.01, 0.232, 340, 246, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2674, d1ym7B3, 0.7548, 3.01, 0.232, 347, 246, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2675, d1wvwA_, 0.7548, 2.60, 0.292, 275, 240, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2676, d5tozA_, 0.7547, 2.87, 0.260, 278, 242, JAK3 WITH COVALENT INHIBITOR PF-06651600
2677, d5hznC_, 0.7547, 2.87, 0.217, 296, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2678, d5cf6B1, 0.7547, 2.77, 0.264, 288, 242, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2679, d5ap7A1, 0.7547, 2.37, 0.308, 253, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2680, d4rblA_, 0.7547, 2.57, 0.285, 271, 239, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2681, d3ppkA_, 0.7547, 2.59, 0.214, 262, 238, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
2682, d2v7oA1, 0.7547, 2.68, 0.320, 297, 241, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
2683, d2qvsE_, 0.7547, 2.90, 0.249, 323, 245, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
2684, d5p9gA_, 0.7546, 2.63, 0.200, 265, 240, STRUCTURE OF BTK WITH RN486
2685, d5hznE_, 0.7546, 2.88, 0.217, 296, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2686, d5dewA_, 0.7546, 3.02, 0.294, 295, 248, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
2687, d3uzpA_, 0.7546, 3.16, 0.183, 292, 251, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
2688, d2y7jA_, 0.7546, 2.72, 0.295, 284, 241, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2689, d5jt2B1, 0.7545, 2.54, 0.219, 250, 237, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
2690, d5hznA_, 0.7545, 2.88, 0.217, 296, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2691, d4jbqA_, 0.7545, 2.76, 0.314, 257, 242, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2692, d4at4A1, 0.7545, 2.93, 0.239, 289, 247, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
2693, d3uodA_, 0.7545, 2.83, 0.314, 266, 242, AURORA A IN COMPLEX WITH RPM1693
2694, d3lzbC_, 0.7545, 2.66, 0.217, 259, 240, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
2695, d3kckA_, 0.7545, 2.76, 0.260, 285, 242, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
2696, d4yhtB_, 0.7544, 2.67, 0.209, 258, 239, BRAF COMPLEXED WITH AN INHIBITOR
2697, d4yhtA_, 0.7544, 2.61, 0.206, 256, 238, BRAF COMPLEXED WITH AN INHIBITOR
2698, d2srcA3, 0.7544, 2.69, 0.246, 284, 240, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC IN COMPLEX WITH AMP-PNP
2699, d5j87A_, 0.7543, 2.65, 0.200, 263, 240, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2700, d4jjrA_, 0.7543, 2.92, 0.200, 284, 245, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
2701, d4h58B_, 0.7543, 2.79, 0.216, 262, 241, BRAF IN COMPLEX WITH COMPOUND 3
2702, d4e4mA_, 0.7543, 2.88, 0.266, 296, 244, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2703, d5eymB_, 0.7542, 2.47, 0.270, 292, 237, MEK1 IN COMPLEX WITH BI 847325
2704, d5eymA_, 0.7542, 2.49, 0.270, 292, 237, MEK1 IN COMPLEX WITH BI 847325
2705, d5aaeA_, 0.7542, 2.65, 0.317, 252, 240, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
2706, d4wnoA_, 0.7542, 2.79, 0.317, 272, 240, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
2707, d3uytA_, 0.7542, 3.03, 0.189, 287, 249, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2708, d1zycB1, 0.7542, 2.88, 0.286, 252, 241, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
2709, d1zy5A1, 0.7542, 2.92, 0.277, 269, 242, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT COMPLEXED WITH AMPPNP.
2710, d5ihcA_, 0.7541, 2.27, 0.325, 305, 234, MELK IN COMPLEX WITH NVS-MELK12B
2711, d5h0bA3, 0.7541, 2.71, 0.250, 281, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
2712, d4ytcA_, 0.7541, 2.77, 0.260, 284, 242, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
2713, d3pscA2, 0.7541, 2.99, 0.248, 344, 246, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
2714, d3hmiA_, 0.7541, 2.78, 0.224, 268, 241, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
2715, d2fb8A_, 0.7541, 2.76, 0.208, 259, 240, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
2716, d2dwbA_, 0.7541, 2.69, 0.318, 259, 239, AURORA-A KINASE COMPLEXED WITH AMPPNP
2717, d2cgxA_, 0.7541, 2.97, 0.293, 265, 246, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2718, d5uorB_, 0.7540, 2.79, 0.301, 262, 239, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2719, d5ap1A1, 0.7540, 2.60, 0.311, 264, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2720, d4k11A3, 0.7540, 2.72, 0.242, 282, 240, THE STRUCTURE OF 1NA IN COMPLEX WITH SRC T338G
2721, d4e4mE_, 0.7540, 2.88, 0.262, 296, 244, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2722, d3uysC_, 0.7540, 3.02, 0.194, 286, 247, CRYSTAL STRUCTURE OF APO HUMAN CK1D
2723, d3h0yA_, 0.7540, 2.62, 0.310, 250, 239, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
2724, d3f66B_, 0.7540, 2.72, 0.228, 269, 241, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
2725, d2qnjB1, 0.7540, 2.67, 0.331, 321, 242, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
2726, d1snuB_, 0.7540, 2.41, 0.230, 241, 235, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
2727, d5x17B_, 0.7539, 3.04, 0.194, 289, 247, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
2728, d5dr6A_, 0.7539, 2.78, 0.314, 257, 242, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
2729, d4zy4A_, 0.7539, 2.85, 0.266, 288, 244, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2730, d4tw9B_, 0.7539, 3.04, 0.194, 289, 248, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
2731, d3vs7B3, 0.7539, 2.51, 0.245, 266, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
2732, d3fdnA_, 0.7539, 2.79, 0.310, 261, 242, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
2733, d4ztrA_, 0.7538, 2.49, 0.314, 249, 239, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
2734, d4mnfB_, 0.7538, 2.57, 0.215, 257, 237, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
2735, d3zosB1, 0.7538, 3.13, 0.221, 301, 249, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
2736, d3uytD_, 0.7538, 3.02, 0.194, 268, 248, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2737, d5h0gA3, 0.7537, 2.71, 0.250, 281, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
2738, d3dlsD_, 0.7537, 2.68, 0.262, 284, 240, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2739, d2w1iB_, 0.7537, 2.80, 0.264, 284, 242, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2740, d5ng2A_, 0.7536, 2.86, 0.234, 274, 244, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
2741, d4zs0A_, 0.7536, 2.61, 0.318, 257, 239, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
2742, d4ji9A_, 0.7536, 2.77, 0.264, 284, 242, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
2743, d2wzjF_, 0.7535, 2.46, 0.321, 310, 237, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2744, d5mqvC_, 0.7534, 2.98, 0.195, 288, 246, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
2745, d5hznF_, 0.7534, 2.89, 0.217, 296, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2746, p4d28D_, 0.7534, 2.48, 0.331, 271, 236, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
2747, d4btkA_, 0.7534, 3.03, 0.191, 287, 246, TTBK1 IN COMPLEX WITH INHIBITOR
2748, d4b0gA_, 0.7534, 2.52, 0.308, 247, 237, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
2749, d3v5wA2, 0.7534, 3.05, 0.232, 355, 246, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
2750, d3d5xA_, 0.7534, 2.70, 0.286, 279, 241, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
2751, d2w1iA_, 0.7534, 2.79, 0.264, 284, 242, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2752, d2vz6A1, 0.7534, 2.73, 0.314, 285, 239, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
2753, d2cgvA_, 0.7534, 2.90, 0.294, 264, 245, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2754, d5hznB_, 0.7533, 2.89, 0.217, 296, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2755, d5e8wA1, 0.7533, 2.78, 0.221, 302, 240, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
2756, d4bkjA1, 0.7533, 3.01, 0.223, 294, 247, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
2757, d1zycC1, 0.7533, 2.94, 0.276, 269, 243, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
2758, d6bkuA1, 0.7532, 2.68, 0.293, 264, 239, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
2759, d5o11A_, 0.7532, 2.51, 0.283, 268, 237, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2760, d4riyA_, 0.7532, 2.59, 0.206, 269, 238, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
2761, d4hctA_, 0.7532, 2.61, 0.233, 265, 240, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
2762, d4e26A_, 0.7532, 2.78, 0.212, 270, 240, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
2763, d3prfA_, 0.7532, 2.82, 0.217, 262, 240, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
2764, d1zltA_, 0.7532, 3.06, 0.293, 272, 246, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
2765, d5uyjA1, 0.7531, 2.74, 0.292, 279, 240, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2766, d4rfzA_, 0.7531, 2.68, 0.192, 263, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
2767, d4g5pA_, 0.7531, 2.81, 0.227, 299, 242, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
2768, d4deaA_, 0.7531, 2.77, 0.314, 266, 242, AURORA A IN COMPLEX WITH YL1-038-18
2769, d4bibA_, 0.7531, 2.54, 0.306, 254, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2770, d3k5uA_, 0.7531, 2.79, 0.314, 260, 242, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
2771, d1zy4A1, 0.7531, 3.04, 0.276, 269, 243, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT IN APO FORM.
2772, d1sm2B_, 0.7531, 2.45, 0.230, 241, 235, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
2773, d5e8uA1, 0.7530, 2.78, 0.220, 303, 241, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
2774, d4e26B_, 0.7530, 2.80, 0.216, 264, 241, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
2775, d3iokA_, 0.7530, 2.79, 0.264, 285, 242, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
2776, d3dlsC_, 0.7530, 2.66, 0.258, 281, 240, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2777, d1kswA3, 0.7530, 2.81, 0.249, 284, 241, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
2778, d4ludB3, 0.7529, 2.61, 0.252, 264, 238, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
2779, d5dpvA_, 0.7528, 2.80, 0.314, 257, 242, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
2780, d4x7hA_, 0.7528, 2.81, 0.268, 256, 239, CO-CRYSTAL STRUCTURE OF PERK BOUND TO N-{5-[(67-DIMETHOXYQUINOLIN-4- YL)OXY]PYRIDIN-2-YL}-1-METHYL-3-OXO-2-PHENYL-5-(PYRIDIN-4-YL)-23- DIHYDRO-1H-PYRAZOLE-4-CARBOXAMIDE INHIBITOR
2781, d4rg0A_, 0.7528, 2.69, 0.192, 263, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
2782, d4deiA_, 0.7528, 2.84, 0.227, 287, 242, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
2783, d3nyxA1, 0.7528, 2.85, 0.227, 285, 242, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
2784, d3lzbB_, 0.7528, 2.64, 0.217, 265, 240, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
2785, d3h0zC_, 0.7528, 2.39, 0.315, 246, 235, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
2786, d3eygA_, 0.7528, 2.80, 0.270, 280, 241, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
2787, d5x17A_, 0.7527, 3.08, 0.194, 290, 247, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
2788, d5uklA2, 0.7527, 3.07, 0.232, 353, 246, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
2789, d5opuA_, 0.7527, 2.67, 0.296, 261, 240, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2790, d4bbfD_, 0.7527, 2.89, 0.258, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2791, d1zwsE_, 0.7527, 2.76, 0.289, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2792, d1iasB_, 0.7527, 2.88, 0.220, 324, 241, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
2793, d4nwmA_, 0.7526, 2.63, 0.201, 261, 239, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
2794, d4bbfA_, 0.7526, 2.90, 0.258, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2795, d2vn9B_, 0.7526, 2.76, 0.310, 301, 242, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
2796, d2cguA_, 0.7526, 2.87, 0.295, 263, 244, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2797, d5jrsA1, 0.7525, 2.48, 0.203, 257, 236, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
2798, d5ci7A_, 0.7525, 2.78, 0.318, 276, 239, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
2799, d4j8mA_, 0.7525, 2.65, 0.303, 265, 241, AURORA A IN COMPLEX WITH CD532
2800, d4aszA1, 0.7525, 2.87, 0.237, 286, 245, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
2801, d4hvhA_, 0.7524, 2.91, 0.261, 278, 241, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
2802, d3zzeA_, 0.7524, 2.79, 0.223, 286, 242, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
2803, d3lxnA_, 0.7524, 3.13, 0.245, 287, 245, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
2804, d5tq5A_, 0.7523, 2.98, 0.262, 291, 244, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2805, d4rixA_, 0.7523, 2.59, 0.206, 269, 238, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2806, d5ig1A_, 0.7522, 2.87, 0.296, 300, 243, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2807, d4ckrA1, 0.7522, 3.00, 0.223, 294, 247, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
2808, d4bieA_, 0.7522, 2.61, 0.309, 257, 236, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2809, d3dlsA_, 0.7522, 2.66, 0.262, 285, 240, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2810, d5e8xA_, 0.7521, 2.80, 0.216, 304, 241, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
2811, d4x7jA_, 0.7521, 2.86, 0.268, 257, 239, CO-CRYSTAL STRUCTURE OF PERK WITH 2-AMINO-N-[4-METHOXY-3- (TRIFLUOROMETHYL)PHENYL]-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6- YL]BENZAMIDE INHIBITOR
2812, d4uv0A_, 0.7521, 2.83, 0.284, 300, 243, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
2813, d4riyC_, 0.7521, 2.57, 0.214, 275, 238, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
2814, d4rixC_, 0.7521, 2.62, 0.213, 275, 239, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2815, d4ji9B_, 0.7521, 2.82, 0.264, 288, 242, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
2816, d4fg8B_, 0.7521, 2.74, 0.287, 268, 237, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
2817, d4bkiA1, 0.7521, 3.00, 0.223, 294, 247,  
2818, d3zosA_, 0.7521, 3.18, 0.221, 301, 249, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
2819, d1sm2A_, 0.7521, 2.47, 0.225, 245, 236, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
2820, d4ot5A_, 0.7520, 2.69, 0.196, 263, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
2821, d3up2A_, 0.7520, 2.80, 0.314, 266, 242, AURORA A IN COMPLEX WITH RPM1686
2822, d3lxkA_, 0.7520, 2.90, 0.256, 279, 242, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
2823, d2qohB2, 0.7520, 3.07, 0.242, 280, 244, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
2824, d4zimA_, 0.7519, 2.83, 0.263, 285, 243, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
2825, d4e5wB_, 0.7519, 2.79, 0.270, 278, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
2826, d4e4mD_, 0.7519, 2.89, 0.262, 296, 244, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2827, d3qgyB1, 0.7519, 2.52, 0.228, 244, 237, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
2828, d3prfB_, 0.7519, 2.64, 0.214, 262, 238, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
2829, d2np8A_, 0.7519, 2.63, 0.310, 256, 239, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
2830, d2hz0A_, 0.7519, 2.86, 0.241, 265, 241, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
2831, d1zysA_, 0.7519, 2.97, 0.290, 271, 245, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
2832, d1vjyA_, 0.7519, 2.81, 0.220, 299, 241, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
2833, d5mqvF_, 0.7518, 3.03, 0.195, 286, 246, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
2834, d5cf4A_, 0.7518, 2.79, 0.264, 283, 242, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2835, d4usfB1, 0.7518, 3.12, 0.285, 283, 249, HUMAN SLK WITH SB-440719
2836, d3vbwA_, 0.7518, 2.54, 0.274, 264, 237, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2837, d3io7A_, 0.7518, 2.76, 0.261, 282, 241, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
2838, d2vn9A_, 0.7518, 2.77, 0.314, 301, 242, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
2839, d1zycD1, 0.7518, 2.77, 0.283, 254, 240, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
2840, d1k2pA_, 0.7518, 2.58, 0.202, 258, 238, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
2841, d5ih9A_, 0.7517, 2.66, 0.331, 308, 239, MELK IN COMPLEX WITH NVS-MELK8A
2842, d4ztsA_, 0.7517, 2.56, 0.318, 249, 239, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
2843, d3ppzB_, 0.7517, 2.55, 0.246, 264, 236, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2844, d2wqnA_, 0.7517, 2.59, 0.304, 259, 237, STRUCTURE OF ADP-BOUND HUMAN NEK7
2845, d2fb8B_, 0.7517, 2.72, 0.222, 259, 239, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
2846, d5aagA_, 0.7516, 2.68, 0.317, 253, 240, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
2847, d4l7sA1, 0.7516, 2.55, 0.235, 248, 238, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
2848, d4hvdA_, 0.7516, 2.82, 0.258, 276, 240, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
2849, d3nlbA_, 0.7516, 2.78, 0.295, 261, 241, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
2850, d3dlsF_, 0.7516, 2.73, 0.262, 281, 240, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2851, d3dlsE_, 0.7516, 2.72, 0.262, 282, 240, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2852, d5uy6A1, 0.7515, 2.72, 0.293, 280, 239, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2853, d5ukmA2, 0.7515, 3.07, 0.232, 353, 246, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
2854, d4e4mB_, 0.7515, 2.89, 0.262, 296, 244, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2855, d3dbqA_, 0.7515, 2.71, 0.307, 259, 241, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
2856, d1zydA1, 0.7515, 3.04, 0.278, 268, 245, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE COMPLEXED WITH ATP.
2857, d5p9hA_, 0.7514, 2.62, 0.201, 264, 239, BTK1 COCRYSTALLIZED WITH RN983
2858, d4byiA_, 0.7514, 2.66, 0.317, 254, 240, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
2859, d3jy9A_, 0.7514, 2.77, 0.257, 282, 241, JANUS KINASE 2 INHIBITORS
2860, d2hakF_, 0.7514, 2.58, 0.328, 318, 241, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
2861, d1qcfA3, 0.7514, 2.73, 0.246, 281, 240, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
2862, d1mrvA_, 0.7514, 2.31, 0.305, 261, 233, CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN
2863, d4hcuA_, 0.7513, 2.65, 0.229, 263, 240, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
2864, d4bibB_, 0.7513, 2.77, 0.300, 258, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2865, d3dlsB_, 0.7513, 2.63, 0.259, 280, 239, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2866, d5op7A_, 0.7512, 2.71, 0.286, 261, 241, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
2867, d5eydA_, 0.7512, 2.85, 0.219, 289, 242, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
2868, d4o0wA_, 0.7512, 2.80, 0.310, 259, 242, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2869, d2ydiA_, 0.7512, 2.99, 0.302, 279, 245, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
2870, d4nwmB_, 0.7511, 2.67, 0.201, 261, 239, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
2871, d4hyhA_, 0.7511, 2.80, 0.298, 263, 242, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
2872, d4fg9B_, 0.7511, 2.83, 0.283, 279, 237, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
2873, d2wzjC_, 0.7511, 2.50, 0.321, 310, 237, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
2874, d1snxB_, 0.7511, 2.46, 0.229, 245, 236, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
2875, d5hznH_, 0.7510, 2.93, 0.217, 303, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2876, d4mnfA_, 0.7510, 2.69, 0.214, 257, 238, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
2877, d4kbaC_, 0.7510, 3.17, 0.192, 277, 250, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
2878, d4e5wA1, 0.7510, 2.85, 0.269, 291, 242, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
2879, d1iasD_, 0.7510, 3.00, 0.224, 330, 241, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
2880, d5ttsA_, 0.7509, 2.81, 0.258, 274, 240, JAK3 WITH COVALENT INHIBITOR 4
2881, d5tq8A_, 0.7509, 2.99, 0.262, 291, 244, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2882, d5tq3A_, 0.7509, 3.00, 0.258, 282, 244, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2883, d5kbqA_, 0.7509, 3.05, 0.275, 289, 247, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
2884, d4qt1A_, 0.7509, 2.63, 0.265, 277, 238, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
2885, d3lzbD_, 0.7509, 2.76, 0.220, 261, 241, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
2886, d2y7jC_, 0.7509, 2.76, 0.295, 284, 241, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2887, d5tq3B_, 0.7508, 3.02, 0.258, 285, 244, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2888, d5o23B1, 0.7508, 2.74, 0.238, 276, 239, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
2889, d5hznD_, 0.7508, 2.93, 0.217, 304, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2890, d3vw6A_, 0.7508, 2.68, 0.308, 255, 237, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
2891, d2ya9B_, 0.7508, 2.76, 0.289, 299, 242, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2892, d2fo0A3, 0.7508, 3.03, 0.226, 291, 243, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
2893, d1snxA_, 0.7508, 2.47, 0.229, 245, 236, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
2894, d1lufA_, 0.7508, 2.67, 0.242, 275, 240, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
2895, d5oorA_, 0.7507, 2.85, 0.298, 273, 242, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
2896, d5ig1B_, 0.7507, 2.89, 0.296, 304, 243, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2897, d5e1eB_, 0.7507, 2.87, 0.269, 280, 242, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
2898, d4riwA_, 0.7507, 2.63, 0.210, 269, 238, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
2899, d4kb8A_, 0.7507, 3.08, 0.202, 265, 247, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
2900, d5w4wC_, 0.7506, 3.21, 0.191, 284, 251, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2901, d4i6qA_, 0.7506, 2.86, 0.258, 277, 240, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
2902, d2jitA_, 0.7506, 2.75, 0.232, 299, 241, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
2903, d5walA1, 0.7505, 2.98, 0.235, 285, 243, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
2904, d5j87C_, 0.7505, 2.70, 0.200, 261, 240, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2905, d4riwC_, 0.7505, 2.65, 0.213, 275, 239, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
2906, d4jiaA_, 0.7505, 2.91, 0.258, 298, 244, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
2907, d3l8pA_, 0.7505, 2.44, 0.261, 292, 234, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
2908, d2x8dA_, 0.7505, 3.00, 0.294, 279, 245, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
2909, d1mruA_, 0.7505, 2.71, 0.270, 269, 241, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
2910, d5hieC_, 0.7504, 2.87, 0.204, 253, 240, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2911, d5aafA_, 0.7504, 2.73, 0.317, 254, 240, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
2912, d2ptkA3, 0.7504, 2.43, 0.251, 259, 235, CHICKEN SRC TYROSINE KINASE
2913, d1j3hA_, 0.7504, 2.90, 0.261, 329, 245, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2914, d5mqvA_, 0.7503, 3.05, 0.200, 286, 245, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
2915, d4dfyE_, 0.7503, 3.07, 0.282, 312, 248, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
2916, d3qgwA_, 0.7503, 2.50, 0.220, 244, 236, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
2917, d3fupB_, 0.7503, 2.84, 0.264, 287, 242, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
2918, d2a27C_, 0.7503, 2.78, 0.281, 303, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2919, d5cf8B1, 0.7502, 2.80, 0.266, 287, 241, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2920, d4bbeC_, 0.7502, 2.92, 0.262, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2921, d3zclA_, 0.7502, 2.76, 0.224, 289, 241, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
2922, d3umxA_, 0.7502, 2.49, 0.284, 261, 236, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
2923, d1ia8A_, 0.7502, 2.99, 0.294, 272, 245, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
2924, d5w5jB_, 0.7501, 2.52, 0.212, 257, 236, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
2925, d5nadA1, 0.7501, 2.71, 0.310, 253, 239, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
2926, d4zogA_, 0.7501, 3.00, 0.230, 269, 243, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
2927, d4hyiA_, 0.7501, 3.02, 0.293, 269, 246, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
2928, d2b7aB_, 0.7501, 2.84, 0.264, 287, 242, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
2929, d2a27A_, 0.7501, 2.78, 0.281, 304, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2930, d1iasA_, 0.7501, 2.99, 0.224, 330, 241, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
2931, d5oq7B_, 0.7500, 2.59, 0.294, 256, 238, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2932, d5e1eA_, 0.7500, 2.85, 0.261, 279, 241, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
2933, d4gmyA_, 0.7500, 2.91, 0.258, 298, 244, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
2934, d4fk6B_, 0.7500, 2.94, 0.258, 284, 244, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
2935, d2hxlA_, 0.7500, 3.11, 0.293, 272, 246, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
2936, d5d9hB_, 0.7499, 3.30, 0.273, 293, 245, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
2937, d5d9hA_, 0.7499, 3.19, 0.275, 290, 244, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
2938, d4kbcB_, 0.7499, 2.88, 0.197, 277, 244, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
2939, d2a27E_, 0.7499, 2.78, 0.281, 303, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2940, d4py1A_, 0.7498, 3.07, 0.242, 289, 244, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
2941, d4kb8C_, 0.7498, 3.19, 0.192, 277, 250, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
2942, d3mdyA_, 0.7498, 2.84, 0.228, 320, 241, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
2943, d2g2hA_, 0.7498, 2.95, 0.223, 272, 242, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2944, d2chlA_, 0.7498, 3.23, 0.208, 298, 250, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
2945, d5eycA_, 0.7497, 2.76, 0.221, 288, 240, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
2946, d4ewhA_, 0.7497, 2.90, 0.252, 274, 242, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
2947, d3vquA_, 0.7497, 2.67, 0.312, 258, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
2948, d5friA1, 0.7496, 2.62, 0.224, 299, 237, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
2949, d4z3vA_, 0.7496, 2.71, 0.200, 271, 240, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
2950, d4hcvA_, 0.7496, 2.69, 0.229, 263, 240, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
2951, d4bidB_, 0.7496, 2.82, 0.300, 258, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2952, d2wotA_, 0.7496, 2.91, 0.221, 303, 240, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
2953, d2wotA1, 0.7496, 2.91, 0.221, 301, 240, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
2954, d2w1fA1, 0.7496, 2.75, 0.315, 253, 241, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2955, d5op5A_, 0.7495, 2.66, 0.289, 259, 239, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
2956, d5hx8A_, 0.7495, 2.89, 0.269, 291, 242, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
2957, d5hesB_, 0.7495, 2.58, 0.261, 278, 234, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
2958, d4aoiA_, 0.7495, 2.77, 0.224, 289, 241, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
2959, d3dk7B_, 0.7495, 3.08, 0.235, 268, 243, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
2960, d2y7jB_, 0.7495, 2.77, 0.295, 281, 241, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2961, d4x2fA1, 0.7494, 2.83, 0.221, 302, 240, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2962, d4fg9A_, 0.7494, 2.85, 0.278, 278, 237, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
2963, d3tjcB_, 0.7494, 2.85, 0.264, 287, 242, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
2964, d3iecD_, 0.7494, 2.62, 0.325, 311, 237, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2965, d1snuA_, 0.7494, 2.50, 0.225, 245, 236, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
2966, d4lg4F_, 0.7493, 2.95, 0.296, 276, 247, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2967, d4debA_, 0.7493, 2.79, 0.315, 264, 241, AURORA A IN COMPLEX WITH RK2-17-01
2968, d2a27F_, 0.7493, 2.78, 0.281, 303, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2969, d6babB_, 0.7492, 2.74, 0.324, 285, 238, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2970, d5tq7A_, 0.7492, 2.97, 0.263, 275, 243, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2971, d5cf8A1, 0.7492, 2.79, 0.266, 284, 241, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2972, d4bbeB_, 0.7492, 2.94, 0.258, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2973, d3u6iA_, 0.7492, 2.95, 0.206, 281, 243, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
2974, d3lpbB1, 0.7492, 2.82, 0.266, 283, 241, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
2975, d2y0aA_, 0.7492, 2.89, 0.284, 300, 243, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
2976, d2a27H_, 0.7492, 2.79, 0.281, 304, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2977, d1iasC_, 0.7492, 2.92, 0.225, 330, 240, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
2978, d5n87A1, 0.7491, 2.55, 0.301, 252, 239, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
2979, d3wzkA_, 0.7491, 2.61, 0.310, 258, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
2980, d3kulA_, 0.7491, 2.64, 0.205, 267, 239, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
2981, d3iecB_, 0.7491, 2.69, 0.326, 313, 239, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2982, d1k9aB3, 0.7491, 2.73, 0.238, 267, 239, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
2983, d4zlzA_, 0.7490, 2.73, 0.200, 270, 240, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
2984, d4p7eB_, 0.7490, 2.90, 0.264, 285, 242, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
2985, d3wzjA_, 0.7490, 2.53, 0.303, 257, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
2986, d3u6hA_, 0.7490, 2.91, 0.207, 280, 242, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
2987, d3lpbA_, 0.7490, 2.84, 0.266, 278, 241, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
2988, d3hmpA_, 0.7490, 2.57, 0.310, 258, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
2989, d3dk3B_, 0.7490, 3.09, 0.235, 269, 243, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
2990, d1rw8A_, 0.7490, 2.79, 0.222, 301, 239, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
2991, d1omwA3, 0.7490, 3.08, 0.232, 344, 246, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
2992, d5hieB_, 0.7489, 2.70, 0.218, 259, 238, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
2993, d3iecC_, 0.7489, 2.61, 0.325, 311, 237, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2994, d2c3kA_, 0.7489, 2.86, 0.293, 262, 242, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2995, d5wo4A_, 0.7488, 2.91, 0.269, 292, 242, JAK1 COMPLEXED WITH COMPOUND 28
2996, d4bidA_, 0.7488, 2.67, 0.302, 254, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2997, d2w1gA1, 0.7488, 2.78, 0.315, 254, 241, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2998, d2hziA_, 0.7488, 2.96, 0.240, 268, 242, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
2999, d2a27G_, 0.7488, 2.80, 0.281, 303, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3000, d1kobA_, 0.7488, 2.89, 0.251, 352, 243, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
3001, d4itjB_, 0.7487, 2.97, 0.222, 276, 243, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
3002, p4d28A_, 0.7487, 2.56, 0.329, 274, 237, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
3003, d3tjcA_, 0.7487, 2.85, 0.264, 284, 242, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
3004, d2a27D_, 0.7487, 2.80, 0.281, 304, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3005, d4usfA1, 0.7486, 3.25, 0.285, 275, 249, HUMAN SLK WITH SB-440719
3006, d3t9tA_, 0.7486, 2.60, 0.202, 263, 238, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
3007, d2hxqA_, 0.7486, 3.02, 0.294, 272, 245, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
3008, d2b7aA_, 0.7486, 2.86, 0.264, 284, 242, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
3009, d1iasE_, 0.7486, 2.92, 0.225, 330, 240, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3010, d4qygB_, 0.7485, 2.89, 0.293, 264, 242, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
3011, d3fupA_, 0.7485, 2.85, 0.264, 284, 242, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3012, d1tkiB_, 0.7485, 3.27, 0.223, 321, 247, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
3013, d4qyhB_, 0.7484, 2.90, 0.293, 264, 242, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
3014, d4hgeA_, 0.7484, 2.83, 0.264, 284, 242, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
3015, d4bbfC_, 0.7484, 2.97, 0.258, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3016, d4bbfB_, 0.7484, 2.96, 0.258, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3017, d2x4fA_, 0.7484, 2.68, 0.286, 289, 238, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
3018, d2j0mB_, 0.7484, 2.67, 0.243, 257, 239, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
3019, d5n84A1, 0.7483, 2.59, 0.310, 253, 239, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
3020, d5e90A1, 0.7483, 2.83, 0.222, 300, 239, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
3021, d4hviA_, 0.7483, 2.79, 0.259, 274, 239, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
3022, d4ewhB_, 0.7483, 2.83, 0.253, 273, 241, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
3023, d2yexA_, 0.7483, 2.92, 0.288, 269, 243, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
3024, d2wd1A_, 0.7483, 2.86, 0.224, 289, 241, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
3025, d5e8tA1, 0.7482, 2.88, 0.221, 300, 240, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
3026, d4x2nA1, 0.7482, 2.84, 0.221, 302, 240, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3027, d4x0mA1, 0.7482, 2.84, 0.221, 302, 240, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3028, d3sxsA1, 0.7482, 2.73, 0.221, 261, 240, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
3029, d3lzbA_, 0.7482, 2.69, 0.217, 265, 240, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
3030, d2x9eA_, 0.7482, 2.50, 0.312, 253, 237, HUMAN MPS1 IN COMPLEX WITH NMS-P715
3031, d2j7tA_, 0.7482, 2.67, 0.324, 285, 238, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
3032, d4x2gA1, 0.7481, 2.84, 0.221, 302, 240, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3033, d3kcfC_, 0.7481, 2.94, 0.225, 330, 240, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3034, d3eqrB_, 0.7481, 2.79, 0.254, 271, 240, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
3035, d5te0A_, 0.7480, 2.80, 0.255, 316, 239, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
3036, d4xyfA_, 0.7480, 2.87, 0.220, 290, 241, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
3037, d4gj2A1, 0.7480, 3.00, 0.239, 287, 243, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
3038, d4fsnA_, 0.7480, 2.85, 0.290, 270, 241, CRYSTAL STRUCTURE OF THE CHK1
3039, d2z8cA1, 0.7480, 3.08, 0.209, 297, 244, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
3040, d1ol5A_, 0.7480, 2.76, 0.318, 263, 239, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
3041, d5fbnD_, 0.7479, 2.67, 0.201, 255, 239, BTK KINASE DOMAIN WITH INHIBITOR 1
3042, d5ap0A1, 0.7479, 2.51, 0.307, 250, 238, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3043, d4ivbB_, 0.7479, 2.87, 0.266, 280, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
3044, d4fg8A_, 0.7479, 2.45, 0.289, 263, 232, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
3045, d3eqrA_, 0.7479, 2.98, 0.251, 270, 243, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
3046, d2a27B_, 0.7479, 2.81, 0.281, 303, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3047, d5ap4A1, 0.7478, 2.49, 0.308, 253, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3048, d4gihA1, 0.7478, 3.00, 0.239, 287, 243, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
3049, d4e6dB_, 0.7478, 2.83, 0.270, 286, 241, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
3050, d3zxzA_, 0.7478, 2.78, 0.224, 289, 241, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
3051, d3wyxA_, 0.7478, 2.71, 0.312, 258, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
3052, d2wzjE_, 0.7478, 2.52, 0.316, 310, 237, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3053, d5fbnC_, 0.7477, 2.71, 0.200, 256, 240, BTK KINASE DOMAIN WITH INHIBITOR 1
3054, d5cswB_, 0.7477, 2.57, 0.217, 252, 235, B-RAF IN COMPLEX WITH DABRAFENIB
3055, d4p7eA_, 0.7477, 2.86, 0.264, 281, 242, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
3056, d4hgeB_, 0.7477, 2.88, 0.264, 288, 242, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
3057, d3zbxA_, 0.7477, 2.78, 0.224, 282, 241, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
3058, d2rfsA_, 0.7477, 2.76, 0.228, 264, 237, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
3059, d2cgwA_, 0.7477, 2.87, 0.292, 262, 243, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3060, d1tkiA_, 0.7477, 3.19, 0.224, 321, 246, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
3061, d1fmkA3, 0.7477, 2.75, 0.250, 270, 240, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC
3062, d5hieA_, 0.7476, 2.68, 0.219, 258, 237, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3063, d5f1zA1, 0.7476, 2.74, 0.231, 280, 238, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
3064, d1csnA_, 0.7476, 3.22, 0.189, 293, 249, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
3065, d1bygA_, 0.7476, 2.59, 0.230, 246, 235, KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
3066, d5usqA_, 0.7475, 2.75, 0.223, 299, 238, ALK-5 KINASE INHIBITOR COMPLEX
3067, d5o12A_, 0.7475, 2.43, 0.278, 264, 234, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3068, d4zy5A_, 0.7475, 2.84, 0.270, 283, 241, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
3069, d4l7sB1, 0.7475, 2.53, 0.232, 248, 237, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
3070, d4bf2A_, 0.7475, 2.54, 0.313, 253, 233, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3071, d2yerA_, 0.7475, 2.87, 0.289, 268, 242, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
3072, d2w1eA1, 0.7475, 2.78, 0.315, 252, 241, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3073, d2hziB_, 0.7475, 2.95, 0.241, 264, 241, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
3074, d1koaA2, 0.7475, 3.14, 0.245, 350, 245, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
3075, d5ukkA2, 0.7474, 3.16, 0.232, 348, 246, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
3076, d4ymjA1, 0.7474, 2.88, 0.240, 267, 242, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3077, d4hgtA_, 0.7474, 2.91, 0.198, 283, 243, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
3078, d4bbeD_, 0.7474, 2.95, 0.258, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3079, d3f66A_, 0.7474, 2.93, 0.210, 288, 243, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
3080, d3dk7A_, 0.7474, 2.93, 0.237, 265, 241, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3081, d3d7uC1, 0.7474, 2.75, 0.243, 255, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3082, d3d7uA1, 0.7474, 2.75, 0.243, 255, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3083, d2e9oA_, 0.7474, 2.93, 0.293, 269, 242, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
3084, d1k9aA3, 0.7474, 2.75, 0.238, 267, 239, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3085, d4g16A1, 0.7473, 3.30, 0.188, 301, 250, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
3086, d4bbeA_, 0.7473, 2.96, 0.258, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3087, d3gqiA_, 0.7473, 3.06, 0.238, 304, 244, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3088, d3fe3B_, 0.7473, 2.77, 0.331, 317, 242, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
3089, d2wgjA_, 0.7473, 2.79, 0.224, 289, 241, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
3090, d4qo9B_, 0.7472, 2.99, 0.235, 285, 243, MST3 IN COMPLEX WITH DANUSERTIB
3091, d4ivcB_, 0.7472, 2.87, 0.266, 280, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
3092, d4e6dA_, 0.7472, 2.82, 0.270, 286, 241, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
3093, d4ap7A_, 0.7472, 2.79, 0.224, 289, 241, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
3094, d3zhpD_, 0.7472, 2.94, 0.254, 264, 244, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3095, d3nz0A1, 0.7472, 2.95, 0.237, 283, 241, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
3096, d2g2hB_, 0.7472, 3.05, 0.235, 272, 243, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3097, d5jfsA_, 0.7471, 2.76, 0.229, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
3098, d4x2kA1, 0.7471, 2.86, 0.221, 302, 240, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3099, d4x2jA1, 0.7471, 2.86, 0.221, 302, 240, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3100, d4w9wA_, 0.7471, 2.80, 0.268, 306, 239, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
3101, d4rfmA1, 0.7471, 2.58, 0.214, 248, 238, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
3102, d3w1fA_, 0.7471, 2.69, 0.308, 259, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
3103, d2aypA_, 0.7471, 2.87, 0.293, 268, 242, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
3104, d5mqvB_, 0.7470, 3.05, 0.196, 287, 245, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3105, d5imeA1, 0.7470, 2.77, 0.293, 279, 239, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
3106, d5grnA_, 0.7470, 3.08, 0.216, 285, 245, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
3107, d5e8sA1, 0.7470, 2.65, 0.224, 299, 237, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
3108, d4zogB_, 0.7470, 3.06, 0.230, 268, 243, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
3109, d4ft3A_, 0.7470, 2.75, 0.296, 269, 240, CRYSTAL STRUCTURE OF THE CHK1
3110, d4e4lD_, 0.7470, 2.91, 0.264, 281, 242, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3111, d3kcfB_, 0.7470, 2.85, 0.226, 324, 239, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3112, d1kobB_, 0.7470, 2.93, 0.251, 352, 243, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
3113, d4w9xA_, 0.7469, 2.76, 0.269, 300, 238, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
3114, d4rvkA_, 0.7469, 2.90, 0.293, 264, 242, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
3115, d4r1vA_, 0.7469, 2.82, 0.220, 289, 241, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
3116, d4qygA_, 0.7469, 2.95, 0.293, 264, 242, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
3117, d4qyeA_, 0.7469, 2.90, 0.293, 271, 242, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
3118, d4js8A_, 0.7469, 2.62, 0.310, 259, 239, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
3119, d3hmmA_, 0.7469, 2.67, 0.224, 293, 237, STRUCTURE OF ALK5 + GW855857
3120, d2c6dA_, 0.7469, 2.88, 0.303, 254, 241, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
3121, d6b16A_, 0.7468, 2.85, 0.269, 285, 242, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
3122, d5w4wD_, 0.7468, 3.11, 0.194, 287, 248, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3123, d5usyA_, 0.7468, 2.93, 0.267, 287, 243, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
3124, d4k6zA_, 0.7468, 2.91, 0.261, 279, 241, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
3125, d4cqeA_, 0.7468, 2.58, 0.216, 250, 236, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
3126, d3vapA_, 0.7468, 2.73, 0.305, 249, 239, SYNTHESIS AND SAR STUDIES OF IMIDAZO-[12-A]-PYRAZINE AURORA KINASE INHIBITORS WITH IMPROVED OFF TARGET KINASE SELECTIVITY
3127, d6eimB_, 0.7467, 2.74, 0.322, 295, 239, HUMAN STK10 BOUND TO GW683134A
3128, d3qgyA1, 0.7467, 2.49, 0.221, 244, 235, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
3129, d2z60A1, 0.7467, 3.12, 0.239, 280, 243, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
3130, d1zycA1, 0.7467, 3.09, 0.266, 259, 244, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
3131, d5ih8A_, 0.7466, 2.59, 0.331, 306, 236, MELK IN COMPLEX WITH NVS-MELK1
3132, d4hgsA1, 0.7466, 3.30, 0.188, 301, 250, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
3133, d4gj3A1, 0.7466, 3.02, 0.235, 287, 243, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
3134, d3kcfD_, 0.7466, 3.06, 0.224, 330, 241, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3135, d3dk3A_, 0.7466, 2.95, 0.237, 266, 241, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3136, d2xzsA_, 0.7466, 2.82, 0.285, 301, 242, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3137, d1m52A_, 0.7466, 3.06, 0.235, 271, 243, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
3138, d4j8nB_, 0.7465, 2.89, 0.314, 266, 242, AURORA A KINASE APO
3139, d3kulB_, 0.7465, 2.84, 0.203, 271, 241, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
3140, d2qohA2, 0.7465, 3.04, 0.236, 270, 242, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
3141, d4kbaA_, 0.7464, 3.03, 0.200, 263, 245, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3142, d4j8nC_, 0.7464, 2.89, 0.314, 266, 242, AURORA A KINASE APO
3143, d4ehzA_, 0.7464, 2.97, 0.259, 290, 243, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3144, d3og7A_, 0.7464, 2.48, 0.215, 247, 233, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
3145, d2wqmA_, 0.7464, 2.58, 0.306, 258, 235, STRUCTURE OF APO HUMAN NEK7
3146, d2brnA_, 0.7464, 3.08, 0.273, 268, 245, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3147, d5mqvE_, 0.7463, 3.06, 0.196, 287, 245, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3148, d4qrcA_, 0.7463, 2.86, 0.256, 297, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
3149, d4k77B_, 0.7463, 2.89, 0.266, 280, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
3150, d4j8nD_, 0.7463, 2.90, 0.314, 265, 242, AURORA A KINASE APO
3151, d4j8nA_, 0.7463, 2.89, 0.314, 266, 242, AURORA A KINASE APO
3152, d4g17A1, 0.7463, 3.30, 0.188, 301, 250, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
3153, d1zydB1, 0.7463, 2.89, 0.283, 251, 240, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE COMPLEXED WITH ATP.
3154, d5l3aA_, 0.7462, 2.98, 0.258, 290, 244, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
3155, d4ivbA1, 0.7462, 2.90, 0.266, 290, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
3156, d4e20A_, 0.7462, 3.13, 0.239, 282, 243, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
3157, d1u4dB_, 0.7462, 2.52, 0.264, 262, 235, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
3158, d1f3mC_, 0.7462, 3.22, 0.266, 287, 248, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
3159, d4hglA1, 0.7461, 3.31, 0.188, 301, 250, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
3160, d3zhpC1, 0.7461, 2.93, 0.255, 267, 243, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3161, d6babC_, 0.7460, 2.66, 0.321, 284, 237, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3162, d5p9jA_, 0.7460, 2.75, 0.200, 263, 240, BTK1 COCRYSTALLIZED WITH IBRUTINIB
3163, d5mqvD_, 0.7460, 3.07, 0.196, 287, 245, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3164, d4ivdB_, 0.7460, 2.89, 0.261, 280, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
3165, d3zc5A_, 0.7460, 2.81, 0.224, 289, 241, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
3166, d5wo4B_, 0.7459, 2.91, 0.266, 280, 241, JAK1 COMPLEXED WITH COMPOUND 28
3167, d5jrqB1, 0.7459, 2.33, 0.222, 245, 230, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
3168, d5e8zA1, 0.7459, 2.86, 0.222, 300, 239, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
3169, d3zepD_, 0.7459, 2.88, 0.264, 272, 239, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3170, d1x8bA_, 0.7459, 2.49, 0.239, 259, 234, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
3171, d5ehlA1, 0.7458, 2.70, 0.320, 254, 241, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3172, d5csxA_, 0.7458, 2.88, 0.203, 261, 241, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
3173, d4c3rA_, 0.7458, 2.77, 0.317, 252, 240, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
3174, d4z16B_, 0.7457, 2.90, 0.267, 276, 240, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3175, d3q4uB1, 0.7457, 2.90, 0.247, 298, 239, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3176, d3ma3A_, 0.7457, 2.56, 0.280, 266, 236, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
3177, d2ywpA_, 0.7457, 2.96, 0.293, 269, 242, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
3178, d3wyyA_, 0.7456, 2.75, 0.317, 258, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
3179, d1m52B_, 0.7456, 3.17, 0.230, 272, 244, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
3180, d5p9kA_, 0.7455, 2.76, 0.200, 271, 240, CRYSTAL STRUCTURE OF BTK WITH CNX 774
3181, d5ootA_, 0.7455, 2.80, 0.296, 260, 240, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3182, d5oq5A_, 0.7454, 2.93, 0.305, 265, 243, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3183, d4rwiA_, 0.7454, 3.08, 0.241, 305, 245, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
3184, d4pmmA1, 0.7454, 2.80, 0.232, 281, 241, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
3185, d4i5cA_, 0.7454, 2.91, 0.261, 279, 241, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3186, d3a7gB_, 0.7454, 3.09, 0.287, 290, 247, HUMAN MST3 KINASE
3187, d2fgaA_, 0.7454, 2.96, 0.293, 269, 242,  
3188, d2csnA_, 0.7454, 3.18, 0.194, 293, 248, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
3189, d1u4dA_, 0.7454, 2.69, 0.257, 258, 237, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
3190, d5jznA_, 0.7453, 2.61, 0.297, 268, 236, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
3191, d4giiA1, 0.7453, 3.03, 0.235, 287, 243, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
3192, d3uo4A_, 0.7453, 2.87, 0.314, 266, 242, AURORA A IN COMPLEX WITH RPM1680
3193, d4ftuA_, 0.7452, 2.91, 0.303, 270, 241, CRYSTAL STRUCTURE OF THE CHK1
3194, d4dfyA_, 0.7452, 3.04, 0.285, 310, 246, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
3195, d4dehA_, 0.7452, 2.83, 0.222, 286, 239, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
3196, d3tkiA_, 0.7452, 2.94, 0.293, 272, 242, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
3197, d3sv0A_, 0.7452, 3.25, 0.190, 294, 247, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
3198, d2wzjA_, 0.7452, 2.47, 0.322, 310, 236, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3199, d2vz6B1, 0.7452, 2.83, 0.312, 288, 240, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3200, d5opsA_, 0.7451, 2.63, 0.287, 258, 237, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3201, d5hieD_, 0.7451, 2.80, 0.211, 253, 237, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3202, d4rwkA1, 0.7451, 3.10, 0.241, 307, 245, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
3203, d4ludA3, 0.7451, 2.47, 0.249, 261, 233, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
3204, d4d1sA_, 0.7451, 2.89, 0.260, 280, 242, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3205, d3up7A_, 0.7451, 2.80, 0.317, 264, 240, AURORA A IN COMPLEX WITH YL1-038-09
3206, d3ha6A1, 0.7451, 2.84, 0.308, 262, 240, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
3207, d2iztA_, 0.7451, 3.26, 0.205, 296, 249, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3208, d1t46A_, 0.7451, 3.00, 0.239, 297, 243, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
3209, d1p4fA_, 0.7451, 2.53, 0.295, 269, 234, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
3210, d1oplB2, 0.7451, 2.95, 0.237, 267, 241, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3211, d1opkA3, 0.7451, 3.10, 0.231, 291, 242, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3212, d5w4wA_, 0.7450, 3.32, 0.191, 291, 251, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3213, d5tq6A_, 0.7450, 2.91, 0.266, 274, 241, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3214, d5hibA_, 0.7450, 3.22, 0.210, 314, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3215, d4rvmA_, 0.7450, 2.93, 0.293, 264, 242, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
3216, d4qyhA_, 0.7450, 2.98, 0.293, 264, 242, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
3217, d2z2wA_, 0.7450, 2.56, 0.238, 260, 235, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
3218, d5w4wB_, 0.7449, 3.33, 0.191, 291, 251, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3219, d5fqdF_, 0.7449, 3.18, 0.201, 294, 249, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
3220, d5f20A_, 0.7449, 2.69, 0.237, 274, 236, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
3221, d4zsaA_, 0.7449, 3.07, 0.237, 289, 245, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
3222, d4ymjB1, 0.7449, 2.87, 0.241, 272, 241, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3223, d4ftiA_, 0.7449, 2.94, 0.293, 270, 242, CRYSTAL STRUCTURE OF THE CHK1
3224, d3mdyC_, 0.7449, 2.76, 0.227, 320, 238, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
3225, d3kcfA_, 0.7449, 2.92, 0.226, 328, 239, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3226, d3cqeA_, 0.7449, 2.56, 0.238, 258, 235, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
3227, d2x0gA_, 0.7449, 2.83, 0.285, 318, 242, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
3228, d2p2iA2, 0.7449, 2.92, 0.231, 283, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
3229, d2e9vA_, 0.7449, 2.88, 0.295, 268, 241, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
3230, d5usyB_, 0.7448, 2.94, 0.263, 287, 243, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
3231, d5oopA_, 0.7448, 2.87, 0.298, 261, 242, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
3232, d4gu6A_, 0.7447, 2.79, 0.249, 271, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
3233, d5opvA_, 0.7446, 2.76, 0.289, 261, 239, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3234, d5jfvA_, 0.7446, 2.78, 0.229, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
3235, d4u0iA_, 0.7446, 3.02, 0.239, 297, 243, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
3236, d4tn6B_, 0.7446, 3.22, 0.188, 285, 250, CK1D IN COMPLEX WITH INHIBITOR
3237, d4bieB_, 0.7446, 2.80, 0.307, 257, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3238, d3og7B_, 0.7446, 2.70, 0.223, 254, 238, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
3239, d2c30A_, 0.7446, 3.05, 0.248, 289, 242, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
3240, d4uwcB_, 0.7445, 3.07, 0.237, 301, 245, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
3241, d4knbA_, 0.7445, 2.73, 0.223, 273, 238, C-MET IN COMPLEX WITH OSI LIGAND
3242, d4ei4B_, 0.7445, 2.92, 0.266, 280, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
3243, d2brbA_, 0.7445, 3.17, 0.293, 272, 246, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3244, d5ehoA1, 0.7444, 2.58, 0.315, 255, 238, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3245, d4o6lB_, 0.7444, 2.58, 0.304, 256, 237, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
3246, d4hniA_, 0.7444, 2.86, 0.203, 284, 241, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
3247, d3uytB_, 0.7444, 3.17, 0.197, 286, 249, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3248, d3kfaB1, 0.7444, 3.16, 0.230, 283, 244, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3249, d2e9uA_, 0.7444, 2.96, 0.293, 269, 242, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
3250, d5p9mA_, 0.7443, 2.73, 0.201, 271, 239, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
3251, d5ei6A1, 0.7443, 2.65, 0.317, 261, 240, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3252, d5ar8A_, 0.7443, 2.42, 0.241, 255, 232, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
3253, d4k77A_, 0.7443, 2.93, 0.266, 282, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
3254, d4fk6A_, 0.7443, 2.93, 0.256, 285, 242, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
3255, d3tzmA_, 0.7443, 2.64, 0.225, 295, 236, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
3256, d3cr0A_, 0.7443, 2.52, 0.239, 257, 234, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
3257, d2welA_, 0.7443, 2.83, 0.321, 304, 240, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
3258, d2dq7X_, 0.7443, 2.76, 0.249, 262, 237, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
3259, d2br1A_, 0.7443, 3.10, 0.294, 272, 245, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3260, d5k9iA_, 0.7442, 2.62, 0.249, 258, 237, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
3261, d5fqdC_, 0.7442, 3.19, 0.201, 294, 249, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
3262, d4fgbA_, 0.7442, 2.87, 0.287, 282, 240, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I APO FORM
3263, d4bggB_, 0.7442, 2.74, 0.242, 293, 236, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3264, d3iecA_, 0.7442, 2.69, 0.329, 311, 237, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3265, d2w1dA1, 0.7442, 2.80, 0.317, 251, 240, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3266, d5vndB_, 0.7441, 3.08, 0.237, 295, 245, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
3267, d5u9dA_, 0.7441, 2.80, 0.200, 271, 240, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
3268, d5jznB_, 0.7441, 2.58, 0.309, 266, 236, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
3269, d4e4nB_, 0.7441, 2.93, 0.266, 280, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
3270, d4czuD1, 0.7441, 2.87, 0.307, 296, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
3271, d4bggA_, 0.7441, 2.73, 0.242, 296, 236, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3272, d3dk6A_, 0.7441, 2.90, 0.243, 262, 239, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3273, d2ivsA_, 0.7441, 3.10, 0.252, 284, 242, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
3274, d1uwjA_, 0.7441, 2.97, 0.203, 264, 241, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
3275, d1fotA_, 0.7441, 3.05, 0.233, 299, 245, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
3276, d5jfxA_, 0.7440, 2.78, 0.229, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
3277, d5ew8A_, 0.7440, 3.09, 0.237, 291, 245, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
3278, d5am6B_, 0.7440, 2.97, 0.239, 280, 243, NATIVE FGFR1 WITH AN INHIBITOR
3279, d4ntsA_, 0.7440, 3.02, 0.266, 341, 244, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
3280, d4m15A_, 0.7440, 2.73, 0.209, 263, 239, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
3281, d3tjdB_, 0.7440, 3.09, 0.262, 287, 244, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
3282, d3tjdA_, 0.7440, 2.91, 0.264, 284, 242, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
3283, d3kfaA1, 0.7440, 3.16, 0.234, 283, 244, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3284, d3gqlA_, 0.7440, 3.07, 0.237, 287, 245, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3285, d3e5aA_, 0.7440, 2.87, 0.308, 264, 240, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
3286, d5p9iA_, 0.7439, 2.75, 0.197, 271, 239, BTK1 SOAKED WITH IBRUTINIB-REV
3287, d5jt2A1, 0.7439, 2.46, 0.224, 253, 232, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
3288, d5ihaA_, 0.7439, 2.58, 0.333, 303, 234, MELK IN COMPLEX WITH NVS-MELK8F
3289, d5ct7B_, 0.7439, 2.66, 0.203, 254, 236, BRAF IN COMPLEX WITH RAF265
3290, d4pmpA1, 0.7439, 2.89, 0.232, 276, 241, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
3291, d4kbaB_, 0.7439, 3.06, 0.195, 285, 246, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3292, d4bi0A1, 0.7439, 2.53, 0.312, 251, 237, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3293, d4bf2B_, 0.7439, 2.66, 0.315, 252, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3294, d3txoA_, 0.7439, 2.65, 0.292, 317, 236, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
3295, d3mvjB_, 0.7439, 3.03, 0.258, 320, 244, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
3296, d2r0iB_, 0.7439, 2.63, 0.325, 300, 237, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
3297, d2brmA_, 0.7439, 3.14, 0.273, 263, 245, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3298, d5tq7B_, 0.7438, 2.91, 0.267, 269, 240, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3299, d5hx8B_, 0.7438, 2.94, 0.261, 279, 241, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
3300, d4uwbB_, 0.7438, 3.09, 0.237, 299, 245, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
3301, d4fszA_, 0.7438, 2.89, 0.283, 268, 240, CRYSTAL STRUCTURE OF THE CHK1
3302, d3ugcA_, 0.7438, 3.04, 0.262, 274, 244, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
3303, d3tt0A_, 0.7438, 3.07, 0.237, 305, 245, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
3304, d3q4uD_, 0.7438, 3.03, 0.242, 299, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3305, d5tq6B_, 0.7437, 2.89, 0.267, 271, 240, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3306, d4o0uA_, 0.7437, 2.86, 0.310, 259, 242, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3307, d4m13A_, 0.7437, 2.73, 0.209, 264, 239, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
3308, d4kbkC_, 0.7437, 3.08, 0.196, 280, 245, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3309, d4cv9A1, 0.7437, 2.62, 0.307, 250, 238, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3310, d3lxpA_, 0.7437, 3.11, 0.235, 285, 243, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3311, d3kcfE_, 0.7437, 3.00, 0.221, 330, 240, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3312, d3dajA_, 0.7437, 2.52, 0.311, 245, 235, CRYSTAL STRUCTURE OF AURORA A COMPLEXED WITH AN INHIBITOR DISCOVERED THROUGH SITE-DIRECTED DYNAMIC TETHERING
3313, d2izsA_, 0.7437, 3.38, 0.188, 298, 250, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3314, d2e9nA_, 0.7437, 2.98, 0.293, 269, 242, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
3315, d5ikwA_, 0.7436, 2.83, 0.268, 297, 239, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3316, d5ew8B_, 0.7436, 3.09, 0.237, 290, 245, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
3317, d4kioC1, 0.7436, 2.63, 0.223, 249, 238, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
3318, d3q4zA1, 0.7436, 2.86, 0.267, 281, 240, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
3319, d3oriB_, 0.7436, 2.87, 0.271, 267, 240, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3320, d5tehB_, 0.7435, 2.67, 0.245, 262, 237, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
3321, d4useA_, 0.7435, 2.96, 0.320, 286, 241, HUMAN STK10 (LOK) WITH SB-633825
3322, d2xa4A_, 0.7435, 2.85, 0.271, 276, 240, INHIBITORS OF JAK2 KINASE DOMAIN
3323, d2bdwB_, 0.7435, 2.95, 0.322, 309, 242, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
3324, d1oplA3, 0.7435, 2.99, 0.232, 291, 241, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3325, d5n7vA1, 0.7434, 2.61, 0.314, 257, 239, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
3326, d4dedA_, 0.7434, 2.92, 0.315, 265, 241, AURORA A IN COMPLEX WITH YL1-038-21
3327, d3u4wA_, 0.7434, 2.83, 0.262, 275, 240, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
3328, d3dkfA1, 0.7434, 2.97, 0.223, 293, 242, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
3329, d2hogA_, 0.7434, 3.00, 0.302, 272, 242, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
3330, d2c3lA_, 0.7434, 2.99, 0.293, 265, 242, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3331, d5itaB_, 0.7433, 2.74, 0.208, 252, 236, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
3332, d5b2lA_, 0.7433, 3.30, 0.222, 288, 252, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
3333, d4zy6A_, 0.7433, 2.86, 0.270, 284, 241, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
3334, d4ivcA1, 0.7433, 2.94, 0.266, 290, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
3335, d3q4uC_, 0.7433, 3.00, 0.242, 296, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3336, d3lcdA_, 0.7433, 2.84, 0.221, 290, 240, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
3337, d5l8lA_, 0.7432, 2.83, 0.283, 263, 240, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
3338, d4riyD_, 0.7432, 2.99, 0.223, 297, 242, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
3339, d1py5A_, 0.7432, 3.08, 0.220, 301, 241, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
3340, d6b4wA_, 0.7431, 2.57, 0.315, 259, 238, TTK IN COMPLEX WITH INHIBITOR
3341, d4xmoA_, 0.7431, 2.81, 0.209, 289, 239, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
3342, d5na0A1, 0.7430, 2.61, 0.304, 250, 237, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
3343, d4z16A_, 0.7430, 2.83, 0.265, 271, 238, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3344, d4rwlB_, 0.7430, 3.04, 0.234, 285, 244, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
3345, d4qyfA_, 0.7430, 2.99, 0.302, 269, 242, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
3346, d4ft9A_, 0.7430, 2.89, 0.292, 270, 240, CRYSTAL STRUCTURE OF THE CHK1
3347, d4ehzB_, 0.7430, 2.97, 0.269, 280, 242, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3348, d2x2kA1, 0.7430, 3.09, 0.252, 284, 242, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3349, d5jfwA_, 0.7429, 2.80, 0.229, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
3350, d4m12A_, 0.7429, 2.76, 0.205, 264, 239, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
3351, d4m0zA_, 0.7429, 2.75, 0.209, 264, 239, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
3352, d4m0yA_, 0.7429, 2.75, 0.209, 263, 239, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
3353, d3repA_, 0.7429, 2.74, 0.168, 268, 238, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
3354, d3js2A_, 0.7429, 3.09, 0.237, 295, 245, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
3355, d1u59A1, 0.7429, 3.03, 0.230, 276, 243, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3356, d5ehyA1, 0.7428, 2.60, 0.311, 251, 238, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3357, d4riwD_, 0.7428, 2.99, 0.219, 297, 242, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
3358, d4j98B_, 0.7428, 3.20, 0.239, 304, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
3359, d4c4jA1, 0.7428, 2.73, 0.308, 258, 240, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3360, d4bhnB_, 0.7428, 2.83, 0.303, 257, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3361, d3js2B_, 0.7428, 3.00, 0.238, 291, 244, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
3362, d1nvqA_, 0.7428, 2.97, 0.293, 264, 242, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
3363, d4lg4C_, 0.7427, 3.16, 0.301, 288, 249, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3364, d4hniB_, 0.7427, 2.81, 0.205, 284, 239, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
3365, d4gg7A_, 0.7427, 2.82, 0.216, 278, 241, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
3366, d4degA_, 0.7427, 2.82, 0.223, 286, 238, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
3367, d4ckiA1, 0.7427, 3.12, 0.252, 288, 242, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
3368, d3uzpB_, 0.7427, 2.84, 0.196, 284, 240, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
3369, d3u51A_, 0.7427, 2.59, 0.242, 256, 236, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
3370, d3oriA_, 0.7427, 2.81, 0.272, 267, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3371, d3f3zA_, 0.7427, 2.86, 0.262, 271, 240, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
3372, d3c4fA_, 0.7427, 3.06, 0.230, 290, 244, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
3373, d2bvaB_, 0.7427, 2.78, 0.256, 274, 238, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
3374, d1uwhA_, 0.7427, 3.13, 0.218, 264, 243, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
3375, d5eobA_, 0.7426, 2.96, 0.219, 288, 242, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
3376, d4cv8A1, 0.7426, 2.63, 0.311, 252, 238, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3377, d4asxA1, 0.7426, 2.73, 0.237, 295, 236, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
3378, d3socB1, 0.7426, 2.76, 0.237, 294, 236, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
3379, d3a7hB_, 0.7426, 3.13, 0.264, 290, 246, HUMAN MST3 KINASE IN COMPLEX WITH ATP
3380, d2hy0A_, 0.7426, 2.99, 0.293, 272, 242, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
3381, d5a46B_, 0.7425, 3.11, 0.237, 297, 245, FGFR1 IN COMPLEX WITH DOVITINIB
3382, d4rixD_, 0.7425, 3.02, 0.223, 297, 242, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
3383, d4rixB_, 0.7425, 2.92, 0.220, 293, 241, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
3384, d4i5cB1, 0.7425, 2.96, 0.261, 290, 241, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3385, d4byjA_, 0.7425, 2.53, 0.315, 246, 235, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
3386, d5ljjA1, 0.7424, 2.73, 0.314, 260, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
3387, d5kmjA_, 0.7424, 2.91, 0.236, 300, 242, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
3388, d4fsrA_, 0.7424, 2.90, 0.292, 269, 240, CRYSTAL STRUCTURE OF THE CHK1
3389, d4lueA3, 0.7423, 2.65, 0.256, 261, 234, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
3390, d4equB_, 0.7423, 2.96, 0.315, 282, 241, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
3391, d3fe3A_, 0.7423, 2.84, 0.331, 317, 242, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
3392, d2xzsB_, 0.7423, 3.00, 0.284, 293, 243, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3393, d2izuA_, 0.7423, 3.21, 0.206, 297, 248, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3394, d5khwB_, 0.7422, 2.90, 0.271, 276, 240, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
3395, d5flfD_, 0.7422, 3.24, 0.238, 290, 244, DISEASE LINKED MUTATION IN FGFR
3396, d3kmwA_, 0.7422, 2.73, 0.168, 268, 238, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
3397, d3aqvA_, 0.7422, 2.80, 0.283, 267, 240, HUMAN AMP-ACTIVATED PROTEIN KINASE ALPHA 2 SUBUNIT KINASE DOMAIN (T172D) COMPLEXED WITH COMPOUND C
3398, d2in6A_, 0.7422, 2.59, 0.239, 256, 234, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
3399, d1uwhB_, 0.7422, 3.14, 0.214, 264, 243, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
3400, d1nvsA_, 0.7422, 2.98, 0.293, 264, 242, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
3401, d5w86D_, 0.7421, 2.88, 0.264, 272, 239, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3402, d5a4cB1, 0.7421, 3.12, 0.237, 284, 245, FGFR1 LIGAND COMPLEX
3403, d4jjrB_, 0.7421, 3.13, 0.192, 283, 245, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3404, d4c4fA1, 0.7421, 2.56, 0.304, 250, 237, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3405, d3c4fB_, 0.7421, 3.10, 0.237, 290, 245, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
3406, d2wouA_, 0.7421, 2.68, 0.225, 299, 236, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
3407, d2wouA1, 0.7421, 2.68, 0.225, 297, 236, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
3408, d2bujB1, 0.7421, 2.95, 0.254, 277, 240, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
3409, d2broA_, 0.7421, 3.23, 0.272, 272, 246, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3410, d5op4A_, 0.7420, 2.72, 0.290, 259, 238, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
3411, d2j4zA_, 0.7420, 2.73, 0.317, 263, 240, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3412, d5oxgB_, 0.7419, 2.77, 0.242, 296, 236, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3413, d5am7A_, 0.7419, 2.95, 0.232, 294, 241, FGFR1 MUTANT WITH AN INHIBITOR
3414, d4zlyA_, 0.7419, 2.81, 0.200, 270, 240, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
3415, d4czuA1, 0.7419, 2.94, 0.311, 291, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
3416, d4bi1A1, 0.7419, 2.50, 0.314, 249, 236, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3417, d4bc6A_, 0.7419, 2.97, 0.320, 285, 241, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
3418, d2ivtA1, 0.7419, 3.09, 0.252, 283, 242, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
3419, d5ap3A1, 0.7418, 2.56, 0.308, 250, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3420, d4asxB1, 0.7418, 2.97, 0.238, 296, 239, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
3421, d3ue4A_, 0.7418, 3.14, 0.239, 270, 243, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
3422, d6brcA1, 0.7417, 2.78, 0.303, 263, 238, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
3423, d5e8yA_, 0.7417, 2.91, 0.238, 298, 239, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
3424, d4zsaB_, 0.7417, 2.87, 0.236, 282, 242, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
3425, d4mneB_, 0.7417, 2.88, 0.215, 270, 237, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3426, d4li5A1, 0.7417, 2.98, 0.224, 303, 241, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
3427, d3ky2A1, 0.7417, 3.07, 0.243, 305, 243, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
3428, d3dtcA_, 0.7417, 2.03, 0.283, 245, 226, CRYSTAL STRUCTURE OF MIXED-LINEAGE KINASE MLK1 COMPLEXED WITH COMPOUND 16
3429, d3a7gA_, 0.7417, 3.21, 0.272, 289, 246, HUMAN MST3 KINASE
3430, d4kb8B_, 0.7416, 3.10, 0.199, 285, 246, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3431, d2j4zB_, 0.7416, 2.79, 0.315, 269, 241, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3432, d2c6eA_, 0.7416, 2.77, 0.315, 251, 241, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3433, d5vamB_, 0.7415, 2.90, 0.217, 260, 240, BRAF IN COMPLEX WITH RAF709
3434, d4m14A_, 0.7415, 2.77, 0.209, 263, 239, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
3435, d4j96B_, 0.7415, 3.22, 0.239, 305, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
3436, d3vw6B_, 0.7415, 2.80, 0.312, 253, 237, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3437, d3q6wA1, 0.7415, 3.19, 0.217, 293, 244, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
3438, d3q4tB1, 0.7415, 2.76, 0.237, 293, 236, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
3439, d1uwjB_, 0.7415, 3.01, 0.207, 263, 241, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
3440, d5wevA_, 0.7414, 2.91, 0.257, 293, 241, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
3441, d4ft7A_, 0.7414, 2.95, 0.295, 270, 241, CRYSTAL STRUCTURE OF THE CHK1
3442, d4cvaA1, 0.7414, 2.63, 0.307, 250, 238, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3443, d3v8tB1, 0.7414, 2.55, 0.230, 242, 235, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
3444, d3hmoA_, 0.7414, 2.60, 0.319, 257, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
3445, d2e9vB_, 0.7414, 2.94, 0.295, 268, 241, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
3446, d5wr7A_, 0.7413, 3.00, 0.235, 301, 243, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
3447, d5flfA_, 0.7413, 3.19, 0.239, 296, 243, DISEASE LINKED MUTATION IN FGFR
3448, d4z16C_, 0.7413, 2.88, 0.252, 271, 238, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3449, d4pp9B1, 0.7413, 2.56, 0.225, 246, 236, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
3450, d3q4uA_, 0.7413, 2.87, 0.241, 298, 237, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3451, d4cnhB_, 0.7412, 2.91, 0.187, 293, 241, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
3452, d5drbA_, 0.7411, 2.90, 0.256, 273, 238, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH WNK463
3453, d4c4eA1, 0.7411, 2.60, 0.308, 253, 237, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3454, d3rhkA_, 0.7411, 2.94, 0.207, 298, 241, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
3455, d3et7A_, 0.7411, 2.86, 0.212, 261, 241, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
3456, d5w86C_, 0.7410, 2.89, 0.265, 273, 238, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3457, d4ybkA_, 0.7410, 2.85, 0.254, 266, 240, C-HELIX-OUT DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
3458, d4o2pA_, 0.7410, 2.79, 0.248, 265, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
3459, d4cztA1, 0.7410, 2.94, 0.311, 289, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
3460, d3w8qA_, 0.7410, 2.66, 0.275, 318, 236, STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1)
3461, d1sykA_, 0.7410, 3.14, 0.250, 348, 244, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
3462, p6c3eA_, 0.7409, 2.76, 0.221, 258, 235, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
3463, d5hcxA_, 0.7409, 3.24, 0.202, 298, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
3464, d5ew3A_, 0.7409, 2.92, 0.217, 274, 240, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
3465, d4riyB_, 0.7409, 2.94, 0.220, 293, 241, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
3466, d4bi2A1, 0.7409, 2.57, 0.312, 250, 237, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3467, d3zz2A_, 0.7409, 2.95, 0.325, 281, 240,  
3468, d2y7jD_, 0.7409, 2.90, 0.295, 281, 241, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
3469, d5vndA_, 0.7408, 3.12, 0.237, 302, 245, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
3470, d5ct7A_, 0.7408, 2.92, 0.213, 257, 239, BRAF IN COMPLEX WITH RAF265
3471, d4uwcA_, 0.7408, 3.13, 0.237, 300, 245, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
3472, d3qgwB_, 0.7408, 2.58, 0.226, 240, 234, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
3473, d5jt2C1, 0.7407, 2.48, 0.221, 247, 231, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
3474, d4rwjA1, 0.7407, 3.13, 0.241, 306, 245, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
3475, d1t45A_, 0.7407, 2.99, 0.240, 331, 242, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
3476, d1sykB_, 0.7407, 3.14, 0.254, 323, 244, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
3477, d1nvrA_, 0.7407, 3.01, 0.302, 264, 242, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
3478, d5u6bB1, 0.7406, 3.06, 0.226, 289, 243, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
3479, d5am6A1, 0.7406, 3.03, 0.236, 294, 242, NATIVE FGFR1 WITH AN INHIBITOR
3480, d4yneA1, 0.7406, 2.82, 0.237, 276, 241, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3481, d4qqtA_, 0.7406, 2.88, 0.250, 283, 240, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
3482, d4e4lE_, 0.7406, 2.92, 0.262, 280, 240, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3483, d3q4tA1, 0.7406, 3.01, 0.238, 294, 239, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
3484, d1pkgB_, 0.7406, 3.04, 0.237, 277, 241, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
3485, d5ui0B_, 0.7405, 3.24, 0.235, 304, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
3486, d4tn6A_, 0.7405, 3.31, 0.198, 292, 248, CK1D IN COMPLEX WITH INHIBITOR
3487, d4pmsA1, 0.7405, 2.87, 0.232, 279, 241, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
3488, d4gvjA1, 0.7405, 3.11, 0.243, 288, 243, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
3489, d4ft0A_, 0.7405, 2.85, 0.297, 266, 239, CRYSTAL STRUCTURE OF THE CHK1
3490, d4cztD1, 0.7405, 2.91, 0.311, 296, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
3491, d3zepA_, 0.7405, 2.94, 0.265, 274, 238, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3492, d3rhxB_, 0.7405, 2.95, 0.240, 275, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
3493, d3qtiA_, 0.7405, 2.99, 0.224, 292, 241, C-MET KINASE IN COMPLEX WITH NVP-BVU972
3494, d3ik3A1, 0.7405, 3.21, 0.230, 279, 244, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
3495, d3fzrA_, 0.7405, 2.91, 0.212, 261, 241, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
3496, d3d94A_, 0.7405, 2.93, 0.221, 288, 240, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
3497, d3bi6A_, 0.7405, 2.63, 0.238, 258, 235, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
3498, d2xneA_, 0.7405, 2.64, 0.308, 246, 237, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
3499, d2x8eA_, 0.7405, 2.89, 0.292, 259, 240, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3500, d5oxgD_, 0.7404, 2.85, 0.241, 293, 237, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3501, d4ivdA1, 0.7404, 2.94, 0.262, 289, 240, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
3502, d4ithB_, 0.7404, 2.89, 0.218, 270, 238, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
3503, d2izrA_, 0.7404, 3.36, 0.185, 298, 249, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3504, d1fgiA_, 0.7404, 3.03, 0.238, 283, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
3505, d5e91A_, 0.7403, 3.05, 0.233, 297, 240, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
3506, d4uwbA_, 0.7403, 3.14, 0.237, 299, 245, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
3507, d3wzeA_, 0.7403, 3.11, 0.226, 298, 243, KDR IN COMPLEX WITH LIGAND SORAFENIB
3508, d3ot3A_, 0.7403, 2.85, 0.293, 259, 239, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
3509, d3geqB1, 0.7403, 2.73, 0.257, 270, 237, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
3510, d5oprA_, 0.7402, 2.76, 0.290, 258, 238, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
3511, d4qo9A_, 0.7402, 3.20, 0.290, 280, 245, MST3 IN COMPLEX WITH DANUSERTIB
3512, d3u51B_, 0.7402, 2.58, 0.243, 255, 235, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
3513, d3eqpB_, 0.7402, 3.09, 0.251, 270, 243, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
3514, d2v7aA_, 0.7402, 3.23, 0.234, 269, 244, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
3515, d3p86B_, 0.7401, 2.29, 0.236, 239, 229, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
3516, d5hu9A1, 0.7400, 3.13, 0.227, 262, 242, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
3517, d5cenA_, 0.7400, 2.83, 0.270, 281, 237, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
3518, d4nk9B_, 0.7400, 3.05, 0.230, 282, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
3519, d4e4nA1, 0.7400, 2.99, 0.261, 290, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
3520, d4e1zA_, 0.7400, 3.04, 0.236, 288, 242, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
3521, d4ag8A_, 0.7400, 3.11, 0.218, 296, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
3522, d3geqA1, 0.7400, 2.74, 0.257, 269, 237, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
3523, d5jzjA_, 0.7399, 2.61, 0.311, 271, 235, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
3524, d4z16D_, 0.7399, 2.91, 0.256, 271, 238, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3525, d4fsuA_, 0.7399, 2.88, 0.293, 260, 239, CRYSTAL STRUCTURE OF THE CHK1
3526, d4ehzD_, 0.7399, 2.98, 0.266, 280, 241, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3527, d3ik3B1, 0.7399, 3.22, 0.234, 285, 244, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
3528, d3c4dB1, 0.7399, 2.80, 0.206, 256, 238,  
3529, d2zmcA_, 0.7399, 2.72, 0.296, 260, 240, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
3530, d1muoA_, 0.7399, 2.85, 0.310, 251, 239, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
3531, d1k2pB_, 0.7399, 2.78, 0.206, 258, 238, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
3532, d5vo6A_, 0.7398, 2.81, 0.262, 271, 237, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
3533, d4u5jB_, 0.7398, 2.77, 0.252, 267, 238, C-SRC IN COMPLEX WITH RUXOLITINIB
3534, d3rhxA_, 0.7398, 3.13, 0.237, 289, 245, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
3535, d3r7oA1, 0.7398, 3.22, 0.221, 295, 244, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
3536, d3oy3B1, 0.7398, 3.22, 0.230, 283, 244, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
3537, d2i1mA_, 0.7398, 3.09, 0.222, 311, 243, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
3538, d5xp7B_, 0.7397, 2.81, 0.252, 267, 238, C-SRC IN COMPLEX WITH ATP-CHCL
3539, d5t3qA1, 0.7397, 2.91, 0.201, 277, 239, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
3540, d4p90A_, 0.7397, 2.56, 0.274, 272, 234, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
3541, d4kspA_, 0.7397, 2.87, 0.210, 257, 238, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
3542, d4hnfA_, 0.7397, 3.22, 0.189, 289, 249, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
3543, d4aojC_, 0.7397, 3.01, 0.230, 261, 243, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3544, d2zv2A_, 0.7397, 2.67, 0.294, 256, 235, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
3545, d2wkmA_, 0.7397, 2.96, 0.219, 286, 242, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
3546, d2r0iA_, 0.7397, 2.80, 0.324, 300, 238, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
3547, d5oq6A_, 0.7396, 2.80, 0.294, 257, 238, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3548, d5khwA_, 0.7395, 2.95, 0.271, 276, 240, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
3549, d4aojA_, 0.7395, 2.97, 0.231, 260, 242, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3550, d5oxgA_, 0.7394, 2.84, 0.242, 293, 236, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3551, d5o26A_, 0.7394, 3.06, 0.242, 271, 240, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
3552, d5am7B_, 0.7394, 2.86, 0.237, 287, 240, FGFR1 MUTANT WITH AN INHIBITOR
3553, d4xliA_, 0.7394, 3.05, 0.241, 264, 241, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
3554, d4x7oA_, 0.7394, 2.39, 0.281, 246, 228, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 1-[5-(4-AMINO-27-DIMETHYL-7H- PYRROLO[23-D]PYRIMIDIN-5-YL)-23-DIHYDRO-1H-INDOL-1-YL]-2-[3-FLUORO- 5-(TRIFLUOROMETHYL)PHENYL]ETHANONE INHIBITOR
3555, d4qpsA_, 0.7394, 2.63, 0.264, 270, 235, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
3556, d4o6lA_, 0.7394, 2.81, 0.311, 257, 238, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
3557, d3vntA_, 0.7394, 3.11, 0.222, 301, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3558, d3tkhA_, 0.7394, 2.88, 0.297, 269, 239, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
3559, d5gtzA_, 0.7393, 3.34, 0.214, 317, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
3560, d4fsyA_, 0.7393, 2.85, 0.286, 267, 238, CRYSTAL STRUCTURE OF THE CHK1
3561, d3uysD_, 0.7393, 3.10, 0.184, 284, 245, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3562, d3oriD_, 0.7393, 2.99, 0.271, 267, 240, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3563, d5eg3A_, 0.7392, 3.17, 0.234, 301, 244, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
3564, d3g0fB_, 0.7392, 3.08, 0.244, 293, 242, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
3565, d3alnA_, 0.7392, 2.62, 0.262, 270, 233, CRYSTAL STRUCTURE OF HUMAN NON-PHOSPHORYLATED MKK4 KINASE DOMAIN COMPLEXED WITH AMP-PNP
3566, d2xa4B_, 0.7392, 2.81, 0.277, 275, 238, INHIBITORS OF JAK2 KINASE DOMAIN
3567, d1zxeC1, 0.7392, 2.91, 0.272, 265, 239, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
3568, d5t18A1, 0.7391, 2.66, 0.208, 259, 236, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
3569, d4f0iA_, 0.7391, 3.02, 0.236, 284, 242, CRYSTAL STRUCTURE OF APO TRKA
3570, d4asdA_, 0.7391, 3.10, 0.218, 305, 243, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
3571, d2x2lA1, 0.7391, 3.14, 0.252, 282, 242, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3572, d2c3jA_, 0.7391, 2.80, 0.290, 257, 238, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3573, d1f3mD_, 0.7391, 3.32, 0.271, 285, 247, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
3574, d5hicA_, 0.7390, 3.20, 0.203, 302, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
3575, d4f0iB_, 0.7390, 3.05, 0.235, 294, 243, CRYSTAL STRUCTURE OF APO TRKA
3576, d3bu6A_, 0.7390, 3.16, 0.213, 294, 244, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
3577, d6bqqA1, 0.7389, 2.83, 0.294, 269, 238, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
3578, d6b8uA_, 0.7389, 2.94, 0.214, 253, 238, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
3579, d5u6bD1, 0.7389, 3.09, 0.226, 289, 243, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
3580, d4twpB_, 0.7389, 3.10, 0.231, 271, 242, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
3581, d4knbC_, 0.7389, 2.78, 0.226, 271, 235, C-MET IN COMPLEX WITH OSI LIGAND
3582, d4dbnB_, 0.7389, 2.83, 0.210, 263, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3583, d3beaA_, 0.7389, 3.09, 0.222, 310, 243, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
3584, d3b2wA_, 0.7389, 2.85, 0.243, 261, 239, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
3585, d2qnjA1, 0.7389, 2.86, 0.331, 317, 242, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
3586, d2ghgA1, 0.7389, 3.09, 0.292, 269, 243, H-CHK1 COMPLEXED WITH A431994
3587, d5hcyA_, 0.7388, 3.20, 0.203, 302, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
3588, d4twpA_, 0.7388, 3.04, 0.233, 266, 240, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
3589, d4riwB_, 0.7388, 2.97, 0.220, 293, 241, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
3590, d3zmmA_, 0.7388, 2.83, 0.273, 273, 238, INHIBITORS OF JAK2 KINASE DOMAIN
3591, d3v5lC1, 0.7388, 2.51, 0.231, 242, 234, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
3592, d3i5nA_, 0.7388, 2.88, 0.223, 280, 238, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
3593, d3genA_, 0.7388, 2.73, 0.198, 264, 237, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
3594, d3g0eA1, 0.7388, 3.00, 0.236, 330, 242, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
3595, d2ivuA1, 0.7388, 3.11, 0.253, 283, 241, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
3596, d2f4jA_, 0.7388, 3.12, 0.231, 287, 242, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
3597, d5k9iB_, 0.7387, 2.75, 0.256, 262, 238, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
3598, d5bpyB1, 0.7387, 2.66, 0.204, 246, 235, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
3599, d3vo3A_, 0.7387, 3.11, 0.218, 303, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
3600, d3ag9A_, 0.7387, 3.17, 0.258, 323, 244, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
3601, d6bu6D_, 0.7386, 3.31, 0.153, 318, 249, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3602, d5ttuA_, 0.7386, 2.82, 0.263, 271, 236, JAK3 WITH COVALENT INHIBITOR 7
3603, d4kbcA_, 0.7386, 3.18, 0.193, 288, 244, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3604, d3zepC_, 0.7386, 3.03, 0.259, 276, 239, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3605, d2c47D1, 0.7386, 3.17, 0.203, 289, 246, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3606, d4v05B_, 0.7385, 3.18, 0.233, 286, 245, FGFR1 IN COMPLEX WITH AZD4547.
3607, d4hvsA1, 0.7385, 3.10, 0.231, 323, 242, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
3608, d3eqpA_, 0.7385, 2.99, 0.253, 268, 241, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
3609, d5capA_, 0.7384, 3.18, 0.211, 303, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
3610, d5a46A_, 0.7384, 3.11, 0.238, 289, 244, FGFR1 IN COMPLEX WITH DOVITINIB
3611, d4gt4B_, 0.7384, 2.85, 0.226, 273, 239, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
3612, d4c62A_, 0.7384, 2.84, 0.273, 273, 238, INHIBITORS OF JAK2 KINASE DOMAIN
3613, d4bggC_, 0.7384, 3.00, 0.244, 279, 238, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3614, d3v5lD1, 0.7384, 2.61, 0.233, 244, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
3615, d3oriC_, 0.7384, 2.87, 0.269, 267, 238, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3616, d3d2kA_, 0.7384, 2.60, 0.308, 245, 234, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH [7-(2-{2-[3-(3-CHLORO- PHENYL)-UREIDO]-THIAZOL-5-YL}-ETHYLAMINO)-PYRAZOLO[43- D]PYRIMIDIN-1-YL]-ACETIC ACID
3617, d3a60A_, 0.7384, 2.49, 0.320, 263, 231, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED P70S6K1 (FORM I)
3618, d1pkgA_, 0.7384, 3.03, 0.242, 290, 240, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
3619, d5kmkA1, 0.7383, 2.97, 0.236, 302, 242, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
3620, d5i4nA1, 0.7383, 2.83, 0.209, 273, 239, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
3621, d4ftjA_, 0.7383, 2.85, 0.298, 266, 238, CRYSTAL STRUCTURE OF THE CHK1
3622, d3oy3A1, 0.7383, 3.23, 0.234, 283, 244, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
3623, d3ormA_, 0.7383, 2.93, 0.268, 266, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN D76A MUTANT
3624, d3a7hA_, 0.7383, 3.27, 0.272, 289, 246, HUMAN MST3 KINASE IN COMPLEX WITH ATP
3625, d5oy6B_, 0.7382, 3.03, 0.243, 292, 239, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3626, d5o23A_, 0.7382, 2.76, 0.242, 269, 236, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
3627, d5jzjB_, 0.7382, 2.52, 0.309, 261, 233, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
3628, d4u5jA_, 0.7382, 2.93, 0.255, 267, 239, C-SRC IN COMPLEX WITH RUXOLITINIB
3629, d3gxjA_, 0.7382, 2.75, 0.216, 288, 236,  
3630, d2vwiD_, 0.7382, 3.09, 0.272, 284, 239, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
3631, d2pvfA_, 0.7382, 3.17, 0.239, 285, 243, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
3632, d6bu6B_, 0.7381, 3.28, 0.141, 307, 248, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3633, d5hczA_, 0.7381, 3.27, 0.202, 300, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
3634, d5cy3A1, 0.7381, 2.90, 0.208, 274, 240, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
3635, d3gvuA1, 0.7381, 3.08, 0.232, 261, 241, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
3636, d3c4cB1, 0.7381, 2.82, 0.210, 256, 238, B-RAF KINASE IN COMPLEX WITH PLX4720
3637, d1fvrB_, 0.7381, 2.94, 0.245, 300, 241, TIE2 KINASE DOMAIN
3638, d5oxgC1, 0.7380, 3.08, 0.242, 299, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3639, d3cekA1, 0.7380, 2.71, 0.305, 252, 239, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
3640, d6brcB_, 0.7379, 2.89, 0.303, 260, 238, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
3641, d5kmoA1, 0.7379, 2.88, 0.232, 290, 241, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
3642, d4lqmA_, 0.7379, 3.36, 0.210, 305, 248, EGFR L858R IN COMPLEX WITH PD168393
3643, d3ii5A_, 0.7379, 3.02, 0.207, 262, 241, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
3644, d3hmnA_, 0.7379, 2.68, 0.311, 255, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
3645, d3eflA1, 0.7379, 2.74, 0.224, 279, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
3646, d1zmwB_, 0.7379, 2.78, 0.316, 302, 237, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
3647, d5calA_, 0.7378, 3.26, 0.202, 300, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
3648, d5c9cA_, 0.7378, 3.00, 0.209, 254, 239, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
3649, d4f64B_, 0.7378, 3.01, 0.240, 272, 242, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
3650, d2gs6A2, 0.7378, 3.24, 0.211, 308, 246, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
3651, d5canA_, 0.7377, 3.26, 0.202, 301, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
3652, d5ap6A1, 0.7377, 2.71, 0.318, 259, 239, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3653, d4rj7A_, 0.7377, 3.27, 0.203, 295, 246, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
3654, d4hgtB_, 0.7377, 2.77, 0.190, 280, 237, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
3655, d2jfmA_, 0.7377, 2.63, 0.288, 287, 236, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
3656, d6eimA_, 0.7376, 2.59, 0.322, 286, 233, HUMAN STK10 BOUND TO GW683134A
3657, d2gqgB1, 0.7376, 3.11, 0.244, 270, 242, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
3658, d1qpjA_, 0.7376, 3.05, 0.246, 265, 240, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
3659, d5n9sA1, 0.7375, 2.71, 0.298, 256, 238, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
3660, d4qqjA_, 0.7375, 2.85, 0.251, 282, 239, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
3661, d4dbnA_, 0.7375, 2.98, 0.209, 257, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3662, d4fg7A_, 0.7374, 2.49, 0.293, 250, 232, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
3663, d4ei4A1, 0.7374, 2.90, 0.259, 288, 239, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
3664, d3socA1, 0.7374, 3.06, 0.238, 296, 239, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
3665, d3dakB_, 0.7374, 3.28, 0.272, 278, 239, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
3666, d5bvkA_, 0.7373, 3.28, 0.223, 278, 247, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3667, d4c4gA1, 0.7373, 2.57, 0.318, 247, 236, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3668, d3wzuA_, 0.7373, 2.99, 0.239, 270, 243, THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-OXOZEAENOL
3669, d5khxA_, 0.7372, 2.89, 0.252, 276, 238, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
3670, d4v05A_, 0.7372, 3.16, 0.237, 287, 245, FGFR1 IN COMPLEX WITH AZD4547.
3671, d4e4lB_, 0.7372, 2.97, 0.262, 279, 240, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3672, d4ckjA1, 0.7372, 3.20, 0.252, 287, 242, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
3673, d3gxlA_, 0.7372, 2.67, 0.218, 285, 234, ALK-5 KINASE COMPLEX WITH GW857175
3674, d3en5B_, 0.7372, 2.69, 0.254, 261, 236, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
3675, d2ydkA_, 0.7372, 3.06, 0.286, 263, 241, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3676, d2j50B_, 0.7372, 2.69, 0.301, 249, 236, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3677, d2j50A_, 0.7372, 2.69, 0.301, 249, 236, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3678, d2ivsB1, 0.7372, 3.21, 0.256, 272, 242, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
3679, d5em7A_, 0.7371, 3.32, 0.206, 300, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3680, d5ei2A_, 0.7371, 2.75, 0.314, 256, 239, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3681, d3h9rA_, 0.7371, 3.06, 0.247, 312, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
3682, d3g0fA_, 0.7371, 3.17, 0.243, 291, 243, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
3683, d1opjA1, 0.7371, 3.18, 0.227, 282, 242, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3684, d5valB_, 0.7370, 2.89, 0.203, 254, 237, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
3685, d5ugbA_, 0.7370, 3.20, 0.212, 307, 245, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
3686, d4nkaB_, 0.7370, 3.16, 0.226, 287, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
3687, d4lg4A_, 0.7370, 3.15, 0.260, 289, 246, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3688, d4gh2A_, 0.7370, 2.78, 0.300, 266, 237, CRYSTAL STRUCTURE OF THE CHK1
3689, d3zewA_, 0.7370, 2.91, 0.221, 269, 240, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
3690, d2x9fA_, 0.7370, 2.94, 0.220, 265, 241, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3691, d2hznA2, 0.7370, 3.12, 0.237, 268, 240, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
3692, d4mneG_, 0.7369, 2.79, 0.209, 259, 235, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3693, p5x02A_, 0.7368, 2.90, 0.225, 305, 240, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
3694, d5nkgA_, 0.7368, 2.99, 0.207, 292, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
3695, d4uxlA_, 0.7368, 3.06, 0.239, 288, 243, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
3696, d4ehzC_, 0.7368, 2.98, 0.267, 278, 240, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3697, d2g15A_, 0.7368, 2.92, 0.205, 301, 239, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
3698, d1zmwA_, 0.7368, 2.79, 0.316, 302, 237, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
3699, d5ukfA_, 0.7367, 3.20, 0.137, 322, 248, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
3700, d4fvrA_, 0.7367, 2.87, 0.209, 274, 239, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN MUTANT V617F (MG- ATP-BOUND FORM)
3701, d4e4lA_, 0.7367, 2.93, 0.264, 277, 239, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3702, d4ae6B_, 0.7367, 3.09, 0.260, 321, 242, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
3703, d3zfxI_, 0.7367, 2.85, 0.229, 263, 240, CRYSTAL STRUCTURE OF EPHB1
3704, d3v8wB1, 0.7367, 2.51, 0.227, 240, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
3705, d3efkA_, 0.7367, 3.00, 0.195, 276, 241, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
3706, d2x8iA_, 0.7367, 2.84, 0.290, 261, 238, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3707, d1agwB_, 0.7367, 2.94, 0.241, 272, 241, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
3708, d2pwlA_, 0.7366, 3.19, 0.236, 284, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
3709, d3cohB_, 0.7365, 2.70, 0.308, 247, 237, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3710, d2c47B_, 0.7365, 3.20, 0.196, 289, 245, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3711, d1b6cD_, 0.7365, 3.06, 0.222, 326, 239, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3712, d6bu6A_, 0.7364, 3.21, 0.137, 322, 248, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3713, d5gmpA_, 0.7364, 3.39, 0.219, 305, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
3714, d4pqnA_, 0.7364, 2.46, 0.237, 240, 232, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
3715, d4kspB_, 0.7364, 2.91, 0.210, 256, 238, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
3716, d2e2bA1, 0.7364, 3.25, 0.236, 266, 242, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
3717, d5i3oA_, 0.7363, 2.93, 0.276, 302, 239, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3718, d4ztqA_, 0.7363, 2.67, 0.318, 247, 236, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK932
3719, d4p90B_, 0.7363, 2.70, 0.314, 262, 236, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
3720, d1iepB1, 0.7363, 3.05, 0.237, 270, 241, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
3721, d1fpuB1, 0.7363, 3.11, 0.232, 266, 241, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3722, d1fgkB_, 0.7363, 2.95, 0.241, 272, 241, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
3723, d5p9lA_, 0.7362, 2.72, 0.195, 252, 236, BTK1 IN COMPLEX WITH CC 292
3724, d5kmnA1, 0.7362, 2.99, 0.236, 290, 242, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
3725, d4xi2A2, 0.7362, 2.90, 0.201, 274, 239, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
3726, d4iwdA1, 0.7362, 3.19, 0.222, 295, 243, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
3727, d4czuC_, 0.7362, 3.04, 0.308, 281, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
3728, d3cd8A_, 0.7362, 2.82, 0.229, 278, 236, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
3729, d2hyyA_, 0.7362, 3.06, 0.237, 263, 241, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3730, d5flfB_, 0.7361, 3.28, 0.239, 292, 243, DISEASE LINKED MUTATION IN FGFR
3731, d4mf1A1, 0.7361, 2.52, 0.236, 241, 233, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
3732, d3v5lA1, 0.7361, 2.50, 0.232, 238, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
3733, d2zmdA_, 0.7361, 2.72, 0.310, 259, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
3734, d5t0pA_, 0.7360, 2.78, 0.253, 264, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
3735, d5l8kA_, 0.7360, 2.91, 0.264, 266, 239, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
3736, d5ia2A_, 0.7360, 3.10, 0.206, 287, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
3737, d5cauA_, 0.7360, 3.27, 0.203, 297, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
3738, d4aojB_, 0.7360, 2.82, 0.230, 258, 239, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3739, d3pxkB_, 0.7360, 2.87, 0.243, 258, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
3740, d3kf4A_, 0.7360, 3.22, 0.236, 281, 242, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3741, d3ii5B_, 0.7360, 3.03, 0.217, 257, 240, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
3742, d3gfwA1, 0.7360, 2.74, 0.311, 249, 238, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
3743, d3b8qA1, 0.7360, 2.96, 0.225, 285, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
3744, d4nksB_, 0.7359, 2.99, 0.241, 271, 241, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
3745, d4lg4D_, 0.7359, 2.37, 0.252, 250, 230, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3746, p4e3cC1, 0.7359, 3.04, 0.289, 290, 242, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3747, d4c61B_, 0.7359, 2.79, 0.280, 274, 236, INHIBITORS OF JAK2 KINASE DOMAIN
3748, d4bhzA1, 0.7359, 2.50, 0.312, 248, 234, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3749, d3oxzA1, 0.7359, 3.16, 0.233, 267, 240, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
3750, d3efjA_, 0.7359, 3.03, 0.199, 276, 241, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
3751, d3ckwA_, 0.7359, 2.90, 0.273, 255, 238, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
3752, d1opjB1, 0.7359, 3.18, 0.236, 284, 242, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3753, d5v19A_, 0.7358, 2.76, 0.312, 250, 234, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3754, d5hlwA_, 0.7358, 3.00, 0.218, 284, 239, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
3755, d5em6A_, 0.7358, 3.30, 0.202, 301, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3756, d4f63B_, 0.7358, 3.01, 0.241, 271, 241, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
3757, p4e3cF1, 0.7358, 3.14, 0.276, 290, 243, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3758, d4dggA_, 0.7358, 2.70, 0.246, 261, 236, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
3759, d3idpA_, 0.7358, 3.13, 0.212, 255, 240, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
3760, d2jkmA_, 0.7358, 2.89, 0.246, 260, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3761, d5y8uA_, 0.7357, 2.94, 0.233, 267, 240, CRYSTAL STRUCTURE OF THE C276S MUTANT OF MAP2K7
3762, d5wfjA_, 0.7357, 2.94, 0.257, 265, 237, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
3763, d4nk9A_, 0.7357, 3.12, 0.230, 281, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
3764, d3wj6A_, 0.7357, 3.04, 0.232, 282, 241,  
3765, d3uqfB_, 0.7357, 2.48, 0.251, 253, 231, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
3766, d2wmrA_, 0.7357, 2.75, 0.297, 254, 236, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3767, d2j5fA_, 0.7357, 3.38, 0.222, 308, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
3768, d5casA_, 0.7356, 3.27, 0.203, 299, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
3769, d5b7vA_, 0.7356, 3.04, 0.232, 282, 241, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
3770, d4v04B_, 0.7356, 3.07, 0.227, 287, 242, FGFR1 IN COMPLEX WITH PONATINIB.
3771, d4nt4A1, 0.7356, 3.26, 0.198, 299, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
3772, d3cohA_, 0.7356, 2.71, 0.308, 247, 237, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3773, d2c6eB_, 0.7356, 2.68, 0.314, 246, 236, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3774, d4c61A_, 0.7355, 2.85, 0.274, 272, 237, INHIBITORS OF JAK2 KINASE DOMAIN
3775, d3ms9B1, 0.7355, 3.04, 0.242, 267, 240, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
3776, d3k5vB1, 0.7355, 3.24, 0.231, 279, 242, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
3777, d3efjB_, 0.7355, 2.99, 0.196, 275, 240, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
3778, d3cp9B_, 0.7355, 2.95, 0.222, 269, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
3779, d2w5aA1, 0.7355, 2.53, 0.284, 259, 236, HUMAN NEK2 KINASE ADP-BOUND
3780, d2qluA1, 0.7355, 2.94, 0.228, 295, 237, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
3781, d2bdjA_, 0.7355, 2.85, 0.256, 254, 238, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
3782, d5vo1A_, 0.7354, 2.60, 0.284, 269, 232, DLK IN COMPLEX WITH COMPOUND 10 (5-(1-ISOPROPYL-5-(3-(OXETAN-3-YL)-3- AZABICYCLO[3.1.0]HEXAN-6-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL) PYRIDIN-2-AMINE)
3783, d5ui0A_, 0.7354, 3.29, 0.235, 301, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
3784, d5nk1A_, 0.7354, 3.08, 0.202, 284, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
3785, d5i9yA_, 0.7354, 3.11, 0.206, 287, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
3786, d4uzhA1, 0.7354, 2.70, 0.314, 250, 236, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
3787, d3wj6B_, 0.7354, 3.01, 0.237, 277, 241,  
3788, d2xynA_, 0.7354, 3.02, 0.233, 264, 240, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
3789, d2v7aB_, 0.7354, 3.32, 0.237, 268, 245, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
3790, d2j51A_, 0.7354, 2.69, 0.288, 288, 236, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
3791, d1fvrA_, 0.7354, 2.93, 0.246, 299, 240, TIE2 KINASE DOMAIN
3792, d5cepA_, 0.7353, 2.58, 0.284, 269, 232, DLK IN COMPLEX WITH INHIBITOR N-(1-ISOPROPYL-5-(PIPERIDIN-4-YL)-1H- PYRAZOL-3-YL)-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE
3793, d5caoA_, 0.7353, 3.24, 0.207, 300, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
3794, d3zfxH_, 0.7353, 2.88, 0.229, 266, 240, CRYSTAL STRUCTURE OF EPHB1
3795, d3dakA_, 0.7353, 3.38, 0.271, 279, 240, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
3796, d5x18A_, 0.7352, 3.41, 0.184, 294, 250, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
3797, d4ypsA1, 0.7352, 2.78, 0.228, 275, 237, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3798, d4jt3A_, 0.7352, 2.69, 0.312, 254, 237, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 400740
3799, d3en4B_, 0.7352, 2.95, 0.255, 266, 239, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
3800, d3ccnA_, 0.7352, 2.82, 0.226, 275, 235, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
3801, d2brgA_, 0.7352, 2.93, 0.293, 257, 239, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3802, d5kmmA1, 0.7351, 3.02, 0.236, 300, 242, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
3803, d5caqA_, 0.7351, 3.26, 0.203, 301, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
3804, d4xeyA_, 0.7351, 3.17, 0.232, 269, 241, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
3805, d4mneC_, 0.7351, 2.82, 0.209, 260, 235, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3806, d4czuB1, 0.7351, 3.13, 0.311, 283, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
3807, d4aseA_, 0.7351, 3.13, 0.222, 305, 243, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
3808, d3oroA_, 0.7351, 2.86, 0.266, 272, 237, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 4)
3809, d3cs9A_, 0.7351, 3.16, 0.237, 264, 241, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
3810, d2qhmA_, 0.7351, 2.92, 0.286, 268, 238, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
3811, d1b6cH_, 0.7351, 3.10, 0.222, 326, 239, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3812, d6eixA_, 0.7350, 3.21, 0.241, 312, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
3813, d4pp9A1, 0.7350, 2.61, 0.226, 245, 235, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
3814, d3efkB_, 0.7350, 2.98, 0.200, 272, 240, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
3815, d3bqrA1, 0.7350, 2.85, 0.263, 273, 236, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH AN IMIDAZO-PYRIDAZINE LIGAND
3816, d5e92A_, 0.7349, 3.06, 0.238, 298, 239, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
3817, d5ceqA_, 0.7349, 2.60, 0.284, 269, 232, DLK IN COMPLEX WITH INHIBITOR 2-((1-CYCLOPENTYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)AMINO)ISONICOTINONITRILE
3818, d5ceoA_, 0.7349, 2.64, 0.292, 269, 233, DLK IN COMPLEX WITH INHIBITOR 2-((6-(33-DIFLUOROPYRROLIDIN-1-YL)-4- (1-(OXETAN-3-YL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)ISONICOTINONITRILE
3819, d5ap5A1, 0.7349, 2.65, 0.316, 248, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3820, d4ftcA_, 0.7349, 2.88, 0.287, 266, 237, CRYSTAL STRUCTURE OF THE CHK1
3821, d3nsvA_, 0.7349, 3.04, 0.233, 264, 240,  
3822, d3mtfB_, 0.7349, 3.16, 0.242, 298, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
3823, d3gqlB_, 0.7349, 3.12, 0.238, 276, 244, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3824, d6bruA_, 0.7348, 3.23, 0.137, 322, 248, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3825, d5vdkA_, 0.7348, 2.67, 0.266, 260, 233, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
3826, d5nkfA_, 0.7348, 3.04, 0.207, 291, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
3827, d5i9xA_, 0.7348, 3.00, 0.207, 284, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
3828, d5i9wA_, 0.7348, 2.82, 0.197, 267, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
3829, d5i3rA_, 0.7348, 2.94, 0.280, 302, 239, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3830, d4xliB_, 0.7348, 3.06, 0.230, 264, 239, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
3831, d4l00A_, 0.7348, 2.98, 0.229, 277, 240, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
3832, d4fswA_, 0.7348, 2.87, 0.295, 265, 237, CRYSTAL STRUCTURE OF THE CHK1
3833, d3zepB_, 0.7348, 2.79, 0.260, 268, 235, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3834, d3dqwD_, 0.7348, 2.93, 0.256, 276, 238, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
3835, d3dakD_, 0.7348, 3.30, 0.272, 284, 239, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
3836, d3bu3A_, 0.7348, 3.14, 0.214, 294, 243, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
3837, d2jflA_, 0.7348, 2.69, 0.284, 286, 236, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-12 4-TRIAZOLE-1-CARBOTHIOAMIDE
3838, d4c4iA1, 0.7347, 2.60, 0.309, 250, 236, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3839, d4agcA_, 0.7347, 3.14, 0.214, 304, 243, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
3840, d1iepA1, 0.7347, 3.07, 0.237, 270, 241, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
3841, d5uafA_, 0.7346, 2.83, 0.234, 291, 235, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
3842, d5uadA_, 0.7346, 2.83, 0.234, 291, 235, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
3843, d4itiB_, 0.7346, 2.93, 0.224, 270, 237, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
3844, d4itiA_, 0.7346, 2.92, 0.219, 272, 237, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
3845, d2fgiB_, 0.7346, 2.97, 0.241, 272, 241, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
3846, d5vamA_, 0.7345, 3.05, 0.216, 269, 241, BRAF IN COMPLEX WITH RAF709
3847, d5l4qB_, 0.7345, 2.61, 0.257, 287, 230, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3848, d5e1sA_, 0.7345, 3.04, 0.211, 284, 242, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
3849, d5b7vB_, 0.7345, 2.95, 0.237, 277, 240, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
3850, d4fc0B_, 0.7345, 2.89, 0.210, 263, 238, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
3851, d1fgiB_, 0.7345, 3.05, 0.240, 272, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
3852, d5v24A_, 0.7344, 2.89, 0.302, 249, 235, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3853, d5oy6A_, 0.7344, 3.09, 0.243, 291, 239, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3854, d5kmiA_, 0.7344, 3.02, 0.236, 300, 242, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
3855, d3p9jA_, 0.7344, 2.78, 0.321, 249, 237, AURORA A KINASE DOMAIN WITH PHTHALAZINONE PYRAZOLE INHIBITOR
3856, d3k5vA1, 0.7344, 3.29, 0.235, 281, 243, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
3857, d3bceB_, 0.7344, 3.12, 0.223, 286, 242, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
3858, d2wtvD_, 0.7344, 2.95, 0.279, 262, 240, AURORA-A INHIBITOR STRUCTURE
3859, d5nk9A_, 0.7343, 3.09, 0.202, 285, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
3860, d5c8kA_, 0.7343, 3.32, 0.202, 300, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
3861, d4v0gA_, 0.7343, 3.01, 0.265, 267, 238, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
3862, d4rwkB_, 0.7343, 3.09, 0.227, 282, 242, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
3863, d4k33A_, 0.7343, 3.17, 0.240, 293, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
3864, d4gt4A_, 0.7343, 2.77, 0.232, 274, 237, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
3865, d3ue4B_, 0.7343, 3.18, 0.236, 268, 242, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
3866, d3o50A_, 0.7343, 2.66, 0.303, 246, 234, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
3867, d3f6xC_, 0.7343, 2.89, 0.262, 265, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3868, d2ivvA1, 0.7343, 3.07, 0.255, 277, 239, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
3869, d4rj8A_, 0.7342, 3.28, 0.203, 298, 246, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
3870, d4r7hA_, 0.7342, 3.09, 0.227, 308, 242, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
3871, d4c02A_, 0.7342, 2.88, 0.246, 313, 236, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
3872, d3rhkB_, 0.7342, 3.02, 0.212, 299, 241, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
3873, d3lw0C_, 0.7342, 3.01, 0.220, 292, 241, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3874, d3lw0A_, 0.7342, 3.01, 0.220, 292, 241, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3875, d3clyA_, 0.7342, 3.35, 0.235, 289, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
3876, d2oiqA_, 0.7342, 2.96, 0.256, 265, 238, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
3877, d2etmB_, 0.7342, 3.06, 0.248, 263, 242, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
3878, d1ol6A_, 0.7342, 2.57, 0.283, 245, 233, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
3879, d5c8nA_, 0.7341, 3.31, 0.202, 300, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
3880, d4rlpA_, 0.7341, 2.31, 0.317, 261, 227, HUMAN P70S6K1 WITH RUTHENIUM-BASED INHIBITOR FL772
3881, d4kbkA_, 0.7341, 3.12, 0.201, 283, 244, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3882, d3zmmB_, 0.7341, 2.81, 0.284, 274, 236, INHIBITORS OF JAK2 KINASE DOMAIN
3883, d3op5A_, 0.7341, 3.21, 0.138, 320, 247, HUMAN VACCINIA-RELATED KINASE 1
3884, d5o26B_, 0.7340, 3.04, 0.252, 265, 238, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
3885, d4fsmA_, 0.7340, 2.85, 0.292, 265, 236, CRYSTAL STRUCTURE OF THE CHK1
3886, d3mtfA_, 0.7340, 3.12, 0.243, 296, 239, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
3887, d3lw0D_, 0.7340, 3.01, 0.220, 292, 241, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3888, d2wtvA_, 0.7340, 2.95, 0.279, 262, 240, AURORA-A INHIBITOR STRUCTURE
3889, d2qhnA_, 0.7340, 2.96, 0.294, 268, 238, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A
3890, d2pwlB_, 0.7340, 3.21, 0.236, 286, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
3891, d5nk7A_, 0.7339, 3.00, 0.203, 284, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
3892, d4h58C_, 0.7339, 3.01, 0.205, 272, 239, BRAF IN COMPLEX WITH COMPOUND 3
3893, d4cqeB_, 0.7339, 2.65, 0.215, 248, 233, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
3894, d3zfxD_, 0.7339, 2.84, 0.230, 265, 239, CRYSTAL STRUCTURE OF EPHB1
3895, d3lw0B_, 0.7339, 3.01, 0.220, 292, 241, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3896, d3h9fA1, 0.7339, 2.84, 0.312, 256, 240, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
3897, d5vo2A_, 0.7338, 2.63, 0.284, 269, 232, DLK IN COMPLEX WITH INHIBITOR 5-(1-ISOPROPYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE (COMPOUND 7)
3898, d5nk6A_, 0.7338, 3.01, 0.203, 284, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
3899, d5cxzA1, 0.7338, 2.95, 0.209, 267, 239, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
3900, d5amnA1, 0.7338, 3.27, 0.252, 282, 242, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
3901, d4xg3B_, 0.7338, 2.98, 0.204, 267, 240, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3902, d4mf1B1, 0.7338, 2.70, 0.216, 244, 236, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
3903, d4l00B_, 0.7338, 3.01, 0.217, 278, 240, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
3904, d4fttA_, 0.7338, 2.89, 0.291, 266, 237, CRYSTAL STRUCTURE OF THE CHK1
3905, d3zfxA_, 0.7338, 2.84, 0.230, 267, 239, CRYSTAL STRUCTURE OF EPHB1
3906, d3cc6A_, 0.7338, 2.83, 0.221, 269, 240, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
3907, d1zmuB_, 0.7338, 2.67, 0.321, 296, 234, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
3908, d5em8A_, 0.7337, 3.34, 0.211, 303, 246, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
3909, d4cztB1, 0.7337, 3.06, 0.308, 283, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
3910, d3g6gB_, 0.7337, 2.91, 0.253, 263, 237, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
3911, d2uv2A1, 0.7337, 2.63, 0.282, 286, 234, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 4-(4-( 5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)-QUINAZOLIN-2-YLAMINO)- PHENYL)-ACETONITRILE
3912, d2ja0A_, 0.7337, 2.63, 0.282, 285, 234,  
3913, d2c47A_, 0.7337, 3.18, 0.193, 288, 244, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3914, d1xbcA1, 0.7337, 2.98, 0.205, 267, 239, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
3915, d4v0gB_, 0.7336, 2.98, 0.265, 272, 238, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
3916, d4mxzA_, 0.7336, 2.88, 0.261, 266, 238, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3917, d4mxyA_, 0.7336, 2.88, 0.261, 266, 238, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3918, d4itjA_, 0.7336, 2.92, 0.225, 261, 236, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
3919, d4fc0A_, 0.7336, 3.04, 0.213, 254, 239, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
3920, d3f6xA_, 0.7336, 2.89, 0.262, 264, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3921, d3dakC_, 0.7336, 3.16, 0.270, 281, 237, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
3922, d5ugxB_, 0.7335, 3.19, 0.231, 282, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
3923, d5nkbA_, 0.7335, 3.12, 0.202, 285, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
3924, d4fvqA_, 0.7335, 2.93, 0.205, 274, 239, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (MG-ATP-BOUND FORM)
3925, d3p08A_, 0.7335, 2.89, 0.203, 252, 236, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
3926, d3lauA1, 0.7335, 2.70, 0.314, 250, 236, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
3927, d4ftaA_, 0.7334, 2.85, 0.292, 264, 236, CRYSTAL STRUCTURE OF THE CHK1
3928, d4cztC_, 0.7334, 3.09, 0.308, 286, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
3929, d3q96B_, 0.7334, 2.94, 0.206, 262, 238, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
3930, d4ft5A_, 0.7333, 2.85, 0.284, 265, 236, CRYSTAL STRUCTURE OF THE CHK1
3931, d3v5lB1, 0.7333, 2.51, 0.228, 239, 232, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
3932, d2wtvB_, 0.7333, 2.96, 0.283, 261, 240, AURORA-A INHIBITOR STRUCTURE
3933, d2hiwA1, 0.7333, 3.10, 0.242, 270, 240, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
3934, d5oy6C_, 0.7332, 3.08, 0.243, 291, 239, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3935, d5nk2A_, 0.7332, 3.01, 0.203, 290, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
3936, d5bvwA_, 0.7332, 3.35, 0.223, 274, 247, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3937, d4i0sA1, 0.7332, 3.13, 0.199, 263, 241, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
3938, d3zewB_, 0.7332, 2.78, 0.211, 252, 237, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
3939, d3w16A_, 0.7332, 2.79, 0.312, 249, 237, STRUCTURE OF AURORA KINASE A COMPLEXED TO PYRAZOLE-AMINOQUINOLINE INHIBITOR III
3940, d3tucA_, 0.7332, 2.86, 0.210, 257, 238, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
3941, d3qupA_, 0.7332, 2.60, 0.237, 241, 232, INHIBITOR BOUND STRUCTURE OF THE KINASE DOMAIN OF THE MURINE RECEPTOR TYROSINE KINASE TYRO3 (SKY)
3942, d3oomA_, 0.7332, 3.16, 0.237, 297, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
3943, d2ym6A_, 0.7332, 2.77, 0.298, 253, 235, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3944, d2wtvC_, 0.7332, 2.96, 0.283, 261, 240, AURORA-A INHIBITOR STRUCTURE
3945, d4ftrA_, 0.7331, 2.82, 0.297, 258, 236, CRYSTAL STRUCTURE OF THE CHK1
3946, d3g6hA_, 0.7331, 2.98, 0.259, 266, 239, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
3947, d4uxqA_, 0.7330, 3.17, 0.252, 286, 242, FGFR4 IN COMPLEX WITH PONATINIB
3948, d4othA_, 0.7330, 2.47, 0.294, 305, 231, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH RO-31-8220
3949, d3eflB_, 0.7330, 2.89, 0.218, 263, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
3950, d1r0pA_, 0.7330, 2.87, 0.224, 301, 237, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
3951, d5oy6D_, 0.7329, 3.13, 0.242, 292, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3952, d4rwjB_, 0.7329, 3.18, 0.234, 282, 244, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
3953, d2w5bA1, 0.7329, 2.60, 0.275, 263, 236, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
3954, d1k9aE3, 0.7329, 2.94, 0.238, 268, 239, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3955, d5lmbA_, 0.7328, 3.00, 0.201, 264, 239, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3956, d5i9zA_, 0.7328, 3.01, 0.208, 273, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
3957, d5cxhA1, 0.7328, 3.06, 0.204, 273, 240, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
3958, d3p08B_, 0.7328, 2.88, 0.199, 258, 236, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
3959, d5kbrB_, 0.7327, 2.58, 0.315, 260, 232, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
3960, d4rwlA_, 0.7327, 3.08, 0.232, 282, 241, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
3961, d4mneF_, 0.7327, 2.97, 0.212, 258, 236, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3962, d5hhwA_, 0.7326, 3.11, 0.209, 306, 244, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
3963, d4uwyA_, 0.7326, 2.99, 0.230, 296, 239, FGFR1 APO STRUCTURE
3964, d4dggB_, 0.7326, 2.83, 0.254, 259, 236, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
3965, d3u9nA_, 0.7326, 2.94, 0.297, 257, 239, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
3966, d3b2tA_, 0.7326, 3.34, 0.238, 288, 244, STRUCTURE OF PHOSPHOTRANSFERASE
3967, d2x2mA1, 0.7326, 3.15, 0.251, 281, 239, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3968, d5l4qA_, 0.7325, 2.53, 0.258, 293, 229, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3969, d5kmlA1, 0.7325, 3.03, 0.236, 290, 242, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
3970, d4rj4A_, 0.7325, 3.32, 0.203, 299, 246, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
3971, d3ky2B_, 0.7325, 3.10, 0.241, 280, 241, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
3972, d3bceC_, 0.7325, 3.14, 0.223, 286, 242, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
3973, d2j5eA_, 0.7325, 3.30, 0.200, 309, 245, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
3974, d5j5sA_, 0.7324, 2.68, 0.247, 258, 235, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
3975, d5hezB_, 0.7324, 3.00, 0.270, 289, 237, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
3976, d5a4cA_, 0.7324, 3.24, 0.230, 294, 243, FGFR1 LIGAND COMPLEX
3977, d4l01A_, 0.7324, 3.03, 0.229, 274, 240, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
3978, d2itzA_, 0.7324, 3.25, 0.212, 302, 245, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
3979, d1u46B_, 0.7324, 2.51, 0.265, 257, 230, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
3980, d1fpuA1, 0.7324, 3.14, 0.237, 271, 241, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3981, d5nkcA_, 0.7323, 3.02, 0.203, 286, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
3982, d5j5sB_, 0.7323, 2.61, 0.245, 258, 233, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
3983, d5edqA_, 0.7323, 3.32, 0.219, 298, 247, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
3984, d5c8mA_, 0.7323, 3.31, 0.211, 302, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
3985, d4gg5A_, 0.7323, 2.88, 0.218, 274, 238, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
3986, d2i0yA_, 0.7323, 3.07, 0.225, 289, 240, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
3987, d2b4sB_, 0.7323, 3.33, 0.213, 294, 244, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
3988, d1qpdA_, 0.7323, 3.21, 0.245, 270, 241, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
3989, d5valA_, 0.7322, 2.93, 0.211, 254, 237, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
3990, d5uoxB_, 0.7322, 2.79, 0.303, 252, 234, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3991, d5ia3A_, 0.7322, 3.07, 0.207, 275, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
3992, d4v01B_, 0.7322, 3.00, 0.230, 275, 239, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
3993, d4j99B_, 0.7322, 3.19, 0.236, 291, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
3994, d4d4sB_, 0.7322, 3.09, 0.249, 260, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3995, d3h3cA_, 0.7322, 3.00, 0.220, 263, 241, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
3996, d1rqqA_, 0.7322, 3.33, 0.213, 294, 244, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
3997, d5njzA_, 0.7321, 3.12, 0.207, 273, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
3998, d4j99C_, 0.7321, 3.31, 0.235, 291, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
3999, d4j98A_, 0.7321, 3.32, 0.239, 304, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
4000, d2a19B1, 0.7321, 2.79, 0.266, 261, 233, PKR KINASE DOMAIN- EIF2ALPHA- AMP-PNP COMPLEX.
4001, d1rqqB_, 0.7321, 3.29, 0.213, 294, 244, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
4002, d4rj6A_, 0.7320, 3.34, 0.211, 297, 246, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
4003, d4j96A_, 0.7320, 3.34, 0.239, 302, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
4004, d4f65A_, 0.7320, 3.08, 0.224, 279, 241, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
4005, d3krjA_, 0.7320, 3.10, 0.224, 304, 241, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
4006, d3dqwC_, 0.7320, 3.02, 0.255, 275, 239, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
4007, d2rfnB_, 0.7320, 2.91, 0.203, 269, 237, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4008, d2ofuA_, 0.7320, 3.12, 0.246, 272, 240, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
4009, d2hakD_, 0.7320, 3.01, 0.336, 309, 241, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4010, d5jrsB1, 0.7319, 2.40, 0.210, 239, 229, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
4011, d5i3oB_, 0.7319, 3.02, 0.280, 302, 239, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4012, d4knbB_, 0.7319, 2.71, 0.233, 256, 232, C-MET IN COMPLEX WITH OSI LIGAND
4013, d3qlfB_, 0.7319, 2.82, 0.241, 258, 237, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
4014, d3gqlC_, 0.7319, 3.20, 0.239, 275, 243, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4015, d2vgoB_, 0.7319, 3.01, 0.283, 277, 240, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
4016, d5xy1A1, 0.7318, 3.03, 0.237, 252, 240, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
4017, d5jkgA_, 0.7318, 3.09, 0.245, 266, 241, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
4018, d4j97A_, 0.7318, 3.33, 0.237, 282, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
4019, d4fvpA_, 0.7318, 2.94, 0.205, 274, 239, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (APO FORM)
4020, d2a1aB1, 0.7318, 2.76, 0.263, 266, 232, PKR KINASE DOMAIN-EIF2ALPHA COMPLEX
4021, d5w86B_, 0.7317, 2.85, 0.261, 267, 234, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4022, d5lmbB_, 0.7317, 2.81, 0.211, 261, 237, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
4023, d4j95B_, 0.7316, 3.24, 0.236, 282, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
4024, d3q96A_, 0.7316, 3.06, 0.210, 253, 238, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4025, d3my0M1, 0.7316, 2.96, 0.245, 297, 237, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4026, d2xynC_, 0.7316, 3.06, 0.233, 262, 240, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
4027, d2psqA_, 0.7316, 3.22, 0.240, 287, 242, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
4028, d2e9pA_, 0.7316, 3.15, 0.289, 269, 242, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
4029, d5owrA_, 0.7315, 2.80, 0.318, 282, 236, HUMAN STK10 BOUND TO DASATINIB
4030, d5dlsA_, 0.7315, 2.94, 0.303, 257, 238, IDENTIFICATION OF NOVEL IN VIVO ACTIVE CHK1 INHIBITORS UTILIZING STRUCTURE GUIDED DRUG DESIGN
4031, d4j97C_, 0.7315, 3.22, 0.229, 283, 240, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
4032, d3v8wA1, 0.7315, 2.56, 0.233, 241, 232, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
4033, d3v5jB1, 0.7315, 2.49, 0.229, 239, 231, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
4034, d1y57A3, 0.7315, 2.95, 0.252, 285, 238, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
4035, d5nkdA_, 0.7314, 2.99, 0.204, 287, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
4036, d3b8rB_, 0.7314, 2.90, 0.223, 267, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4037, d2rfnA_, 0.7314, 2.91, 0.203, 268, 237, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4038, d1zxeA1, 0.7314, 2.90, 0.275, 259, 236, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
4039, d1xbaA1, 0.7314, 3.17, 0.199, 265, 241, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
4040, d5ugxA_, 0.7313, 3.21, 0.231, 297, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
4041, d4rwiB_, 0.7313, 3.12, 0.241, 280, 241, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
4042, d4lueB3, 0.7313, 2.49, 0.258, 256, 229, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
4043, d4jikA_, 0.7313, 2.88, 0.297, 256, 236, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22A (R)-2-(4-CHLOROPHENYL)-8- (PIPERIDIN-3-YLAMINO)IMIDAZO[12-C]PYRIMIDINE-5-CARBOXAMIDE BOUND TO HUMAN CHK1 KINASE DOMAIN
4044, d4ae9B_, 0.7313, 3.13, 0.261, 321, 241, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
4045, d2hz4A_, 0.7313, 3.06, 0.235, 262, 238, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
4046, d4l01B_, 0.7312, 2.92, 0.218, 274, 238, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
4047, d4j95D_, 0.7312, 3.19, 0.237, 271, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
4048, d4hw7A_, 0.7312, 3.05, 0.225, 289, 240, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
4049, d3zfxE_, 0.7312, 2.84, 0.231, 262, 238, CRYSTAL STRUCTURE OF EPHB1
4050, d3v5jA1, 0.7312, 2.63, 0.236, 239, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
4051, d3my0N1, 0.7312, 2.93, 0.246, 299, 236, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4052, d2eb3A_, 0.7312, 3.15, 0.218, 294, 243, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
4053, d2c47C_, 0.7312, 3.08, 0.194, 282, 242, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4054, d4kioD1, 0.7311, 2.61, 0.222, 240, 234, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4055, d1oecA_, 0.7311, 3.31, 0.240, 280, 242, FGFR2 KINASE DOMAIN
4056, d4fnyA_, 0.7310, 2.86, 0.182, 273, 236, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4057, d4c2vA_, 0.7310, 3.00, 0.314, 270, 242, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
4058, d3my0V1, 0.7310, 2.90, 0.247, 281, 235, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4059, d3dk6B_, 0.7310, 3.02, 0.237, 259, 236, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4060, d3b8qB_, 0.7310, 3.00, 0.218, 271, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4061, d4lg4E_, 0.7309, 3.11, 0.296, 275, 243, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4062, d4d58B_, 0.7309, 3.12, 0.249, 261, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4063, d3qlgB_, 0.7309, 2.81, 0.258, 260, 236, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
4064, d3my0L1, 0.7309, 2.94, 0.246, 295, 236, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4065, d3bymA_, 0.7309, 3.24, 0.245, 271, 241, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
4066, d2gqgA1, 0.7309, 3.19, 0.236, 271, 242, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
4067, d1b6cB_, 0.7309, 3.32, 0.219, 326, 242, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4068, d5vc6A_, 0.7308, 2.91, 0.233, 259, 236, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
4069, d5kbrA_, 0.7308, 2.47, 0.314, 259, 229, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4070, d5ia0C_, 0.7308, 2.86, 0.205, 269, 239, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4071, d3srvB_, 0.7308, 3.03, 0.209, 263, 239, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
4072, d3ri1A_, 0.7308, 3.29, 0.239, 285, 243, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
4073, d1u54A_, 0.7308, 2.68, 0.256, 262, 234, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
4074, d4r7iA_, 0.7307, 3.08, 0.228, 290, 241, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
4075, d3qtiB_, 0.7307, 2.90, 0.233, 280, 236, C-MET KINASE IN COMPLEX WITH NVP-BVU972
4076, d3oezB_, 0.7307, 2.83, 0.246, 261, 236, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
4077, d3nsvC_, 0.7307, 3.07, 0.233, 262, 240,  
4078, d2xvdA_, 0.7307, 3.01, 0.220, 270, 241, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4079, d5xdkA_, 0.7306, 3.36, 0.215, 307, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
4080, d5t0pB_, 0.7306, 2.86, 0.262, 263, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4081, d5ia1A_, 0.7306, 2.94, 0.205, 261, 239, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
4082, d5b2kA_, 0.7306, 2.84, 0.223, 264, 238, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4083, d4xcuA1, 0.7306, 2.88, 0.248, 287, 238, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
4084, d4rj5A_, 0.7306, 3.37, 0.211, 296, 246, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
4085, d3ztxA_, 0.7306, 2.99, 0.283, 269, 240, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
4086, d5hezA_, 0.7305, 3.00, 0.264, 287, 235, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4087, d4i23A_, 0.7305, 3.16, 0.215, 304, 242, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
4088, d4agdA_, 0.7305, 3.18, 0.214, 303, 243, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
4089, d3my0U1, 0.7305, 2.90, 0.247, 284, 235, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4090, d2py3A_, 0.7305, 3.32, 0.225, 282, 240, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4091, d5edrA_, 0.7304, 3.34, 0.215, 299, 246, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
4092, d4rvlA_, 0.7304, 2.89, 0.284, 258, 236, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 7: 3-(2- HYDROXYPHENYL)-9H-PYRROLO[23-B:54-C ]DIPYRIDINE-6-CARBONITRILE
4093, d4d55A_, 0.7304, 2.99, 0.246, 260, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4094, d3h10D_, 0.7304, 2.94, 0.280, 255, 239, AURORA A INHIBITOR COMPLEX
4095, d4c7tA_, 0.7303, 3.06, 0.245, 259, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
4096, d3idpB_, 0.7303, 3.03, 0.209, 256, 239, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4097, d4jq8A_, 0.7302, 3.10, 0.220, 303, 241, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
4098, d4bggD_, 0.7302, 2.79, 0.245, 286, 233, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4099, d3eknA_, 0.7302, 3.15, 0.201, 297, 244, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
4100, d3dtwA1, 0.7302, 2.95, 0.235, 281, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
4101, d3dqwA_, 0.7302, 3.07, 0.255, 278, 239, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
4102, d2io6A_, 0.7302, 2.57, 0.235, 252, 230, WEE1 KINASE COMPLEXED WITH INHIBITOR PD330961
4103, d5hx6A_, 0.7301, 2.89, 0.225, 259, 236, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
4104, d4yfiA_, 0.7301, 2.76, 0.222, 268, 230, TNNI3K COMPLEXED WITH INHIBITOR 1
4105, d4xg4A_, 0.7301, 3.04, 0.208, 264, 240, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4106, d4wnmA1, 0.7300, 3.08, 0.200, 269, 240, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
4107, d3oezA_, 0.7300, 2.92, 0.245, 261, 237, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
4108, d3jvrA_, 0.7300, 2.85, 0.298, 258, 235, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
4109, d2wmvA_, 0.7300, 2.68, 0.283, 251, 233, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4110, d2fh9A_, 0.7300, 2.85, 0.332, 255, 235, STRUCTURE AND DIMERIZATION OF THE KINASE DOMAIN FROM YEAST SNF1
4111, d2b4sD_, 0.7300, 3.35, 0.213, 294, 244, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
4112, d5uvfC_, 0.7299, 3.31, 0.143, 301, 245, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4113, d5nk4A_, 0.7299, 3.02, 0.204, 290, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
4114, d5e8vA_, 0.7299, 3.00, 0.241, 296, 237, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
4115, d5c9cB_, 0.7299, 2.99, 0.203, 251, 237, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4116, d3pa3A_, 0.7299, 3.00, 0.297, 259, 239, X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN
4117, d2ittA_, 0.7299, 3.36, 0.229, 302, 245, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
4118, d1b6cF_, 0.7299, 3.12, 0.213, 326, 239, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4119, d4kbaD_, 0.7298, 3.10, 0.190, 274, 242, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4120, d3tudA1, 0.7298, 2.89, 0.210, 255, 238, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
4121, d3mssD1, 0.7298, 2.96, 0.245, 260, 237, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4122, d3kf4B_, 0.7298, 3.38, 0.235, 270, 243, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
4123, d2x7fE_, 0.7298, 2.40, 0.275, 251, 229, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4124, d2og8A_, 0.7298, 2.87, 0.233, 246, 236, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
4125, d2itnA_, 0.7298, 3.32, 0.220, 304, 245, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
4126, d2ijmB_, 0.7298, 3.03, 0.249, 261, 241, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
4127, d5xdlA_, 0.7297, 3.30, 0.205, 292, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
4128, d4yznA_, 0.7297, 3.05, 0.239, 269, 238, HUMANIZED ROCO4 BOUND TO COMPOUND 19
4129, d1u54B_, 0.7297, 2.77, 0.261, 261, 234, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
4130, d1mqbB_, 0.7297, 3.07, 0.212, 265, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
4131, d4mxxB_, 0.7296, 2.90, 0.232, 260, 237, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4132, d3vf8A_, 0.7296, 3.06, 0.201, 265, 239, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
4133, d3fzpA_, 0.7296, 2.99, 0.217, 259, 240, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
4134, d2yn8B_, 0.7296, 2.77, 0.212, 260, 236, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4135, d2r0uA_, 0.7296, 3.09, 0.297, 269, 239, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
4136, d2py3B_, 0.7296, 3.22, 0.230, 284, 239, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4137, d1zmvB_, 0.7296, 2.75, 0.316, 296, 234, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4138, d5tq4A_, 0.7295, 3.32, 0.266, 290, 244, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4139, d5ek7B_, 0.7295, 2.95, 0.204, 286, 240, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
4140, d4px6A1, 0.7295, 3.03, 0.205, 261, 239, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
4141, d3daeB_, 0.7295, 3.06, 0.300, 246, 237, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
4142, d2cmwA_, 0.7295, 3.37, 0.195, 294, 246, STRUCTURE OF HUMAN CASEIN KINASE 1 GAMMA-1 IN COMPLEX WITH 2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9- ISOPROPYLPURINE (CASP TARGET)
4143, d5tf9A_, 0.7294, 2.69, 0.245, 262, 229, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
4144, d5tehA_, 0.7294, 2.92, 0.241, 261, 237, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
4145, d5hezD_, 0.7294, 3.04, 0.266, 289, 237, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4146, d5ghvB_, 0.7294, 3.16, 0.207, 265, 242, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4147, d4xg5B_, 0.7294, 3.16, 0.207, 265, 242,  
4148, d4xeyB2, 0.7294, 3.04, 0.219, 264, 237, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
4149, d4tyjA1, 0.7294, 3.03, 0.248, 275, 238, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4150, d3mssB1, 0.7294, 2.97, 0.245, 260, 237, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4151, d2itpA_, 0.7294, 3.26, 0.218, 305, 243, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
4152, d1zmuA_, 0.7294, 2.71, 0.309, 293, 233, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4153, d5tr6A1, 0.7293, 3.05, 0.201, 268, 239, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
4154, d4yfiC_, 0.7293, 2.85, 0.225, 269, 231, TNNI3K COMPLEXED WITH INHIBITOR 1
4155, d4fyoA1, 0.7293, 3.07, 0.205, 263, 239, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
4156, d3dqwB_, 0.7293, 3.08, 0.255, 278, 239, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
4157, d1gjoA_, 0.7293, 3.33, 0.240, 280, 242, THE FGFR2 TYROSINE KINASE DOMAIN
4158, d5tobA_, 0.7292, 2.72, 0.214, 245, 234, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
4159, d5k3yB_, 0.7292, 3.07, 0.283, 277, 240, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
4160, d2bfyB_, 0.7292, 3.07, 0.283, 278, 240, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
4161, d1zxeE1, 0.7292, 2.81, 0.284, 254, 232, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
4162, d1irkA_, 0.7292, 3.13, 0.202, 303, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
4163, d5flfC_, 0.7291, 3.52, 0.237, 283, 245, DISEASE LINKED MUTATION IN FGFR
4164, d4mwiA_, 0.7291, 2.82, 0.205, 266, 239, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
4165, d5ur1A_, 0.7290, 3.04, 0.233, 278, 240, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
4166, d5i3rB_, 0.7290, 3.06, 0.280, 302, 239, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4167, d5ghvA_, 0.7290, 3.16, 0.207, 265, 242, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4168, d4xg5A_, 0.7290, 3.16, 0.207, 265, 242,  
4169, d4pwnA_, 0.7290, 2.50, 0.250, 245, 228, CRYSTAL STRUCTURE OF ACTIVE WNK1 KINASE
4170, d4j99D_, 0.7290, 3.16, 0.237, 281, 240, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
4171, d3etaB_, 0.7290, 3.21, 0.211, 292, 242, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
4172, d2hakE_, 0.7290, 2.90, 0.332, 318, 241, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4173, d2e2bB1, 0.7290, 2.92, 0.237, 258, 236, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
4174, d5imxA_, 0.7289, 2.87, 0.191, 266, 236, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
4175, d5i8aA1, 0.7289, 2.61, 0.237, 265, 232, TRKA WITH (6~{R})-3-METHYLSULFANYL-6-PHENYL-1-(1~{H}-PYRAZOL-3-YL)-6 7-DIHYDRO-5~{H}-THIENO[34-C]PYRIDIN-4-ONE
4176, d3tt0B_, 0.7289, 3.15, 0.241, 272, 241, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
4177, d3is5D1, 0.7289, 1.78, 0.317, 230, 218, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4178, d3byuA_, 0.7289, 3.14, 0.234, 256, 239, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE REVERSE AMIDE 23
4179, d2brhA_, 0.7289, 2.95, 0.298, 257, 238, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4180, d1fgkA_, 0.7289, 2.99, 0.230, 278, 239, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
4181, d4j97B_, 0.7288, 3.27, 0.237, 283, 240, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
4182, d3dtwB_, 0.7288, 3.15, 0.212, 269, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
4183, d3bceA_, 0.7288, 3.19, 0.223, 285, 242, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
4184, d5owqB_, 0.7287, 2.65, 0.325, 254, 231, HUMAN STK10 BOUND TO DOVITINIB
4185, d4mxzB_, 0.7287, 3.00, 0.256, 264, 238, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4186, d4mxyB_, 0.7287, 3.00, 0.256, 264, 238, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4187, d4jrvA_, 0.7287, 3.14, 0.216, 300, 241, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
4188, d3svvB_, 0.7287, 2.73, 0.245, 257, 233, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
4189, d3bysA_, 0.7287, 2.97, 0.236, 255, 237, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE AMIDE 10B
4190, d1szmB_, 0.7287, 3.05, 0.264, 320, 239, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
4191, d1agwA_, 0.7287, 3.00, 0.230, 278, 239, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
4192, d5w86A_, 0.7286, 2.88, 0.265, 269, 234, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4193, d5vc4A_, 0.7286, 2.94, 0.228, 261, 237, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
4194, d5dg5B_, 0.7286, 3.13, 0.217, 297, 240, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
4195, d4d4yB_, 0.7286, 3.15, 0.249, 260, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4196, d4bb4A_, 0.7286, 3.06, 0.220, 265, 241, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4197, d3orkA1, 0.7286, 3.04, 0.265, 272, 238, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 2)
4198, d5j7hA_, 0.7285, 3.19, 0.185, 291, 243, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
4199, d4uynA_, 0.7285, 2.80, 0.316, 249, 237, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4200, d3w18A_, 0.7285, 2.36, 0.310, 234, 226, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4201, d3o50B_, 0.7285, 2.90, 0.298, 249, 235, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4202, d4puzA_, 0.7284, 3.09, 0.208, 263, 240, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
4203, d4fsqA_, 0.7284, 2.82, 0.291, 263, 234, CRYSTAL STRUCTURE OF THE CHK1
4204, d4b8mA_, 0.7284, 3.01, 0.283, 270, 240, AURORA B KINASE IN COMPLEX WITH VX-680
4205, d3w10A_, 0.7284, 2.89, 0.270, 263, 237, AURORA KINASE A COMPLEXED TO PYRAZOLE AMINOQUINOLINE I
4206, d3my0A1, 0.7284, 3.17, 0.238, 295, 239, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4207, d3mssA1, 0.7284, 2.99, 0.245, 260, 237, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4208, d6bp0B_, 0.7283, 3.27, 0.148, 304, 244, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4209, d5lpvA_, 0.7283, 2.96, 0.228, 282, 237, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
4210, d4uwyB_, 0.7283, 3.09, 0.237, 273, 240, FGFR1 APO STRUCTURE
4211, d3svvA_, 0.7283, 2.88, 0.258, 261, 236, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
4212, d3kk8A_, 0.7283, 3.27, 0.321, 283, 243, CAMKII SUBSTRATE COMPLEX A
4213, d3fzoA_, 0.7283, 2.85, 0.222, 262, 239, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
4214, d1u46A_, 0.7283, 2.74, 0.258, 255, 233, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
4215, d5w5jA_, 0.7282, 2.46, 0.232, 251, 228, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
4216, d5fboA_, 0.7282, 2.95, 0.192, 255, 239, BTK-INHIBITOR CO-STRUCTURE
4217, d4kioA1, 0.7282, 2.54, 0.229, 238, 231, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4218, d3el8B_, 0.7282, 2.82, 0.264, 259, 235, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
4219, d4ybjB_, 0.7281, 2.78, 0.248, 253, 234, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4220, d3kmmA_, 0.7281, 3.17, 0.246, 270, 240, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
4221, d3f6xD_, 0.7281, 3.10, 0.255, 267, 239, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4222, d2j6mA_, 0.7281, 3.14, 0.228, 306, 241, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
4223, d2j0lA_, 0.7281, 3.11, 0.249, 274, 241, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
4224, d5ut4A_, 0.7280, 2.96, 0.205, 273, 239, JAK2 JH2 IN COMPLEX WITH NVP-BSK805
4225, d5i9vA_, 0.7280, 3.14, 0.207, 279, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
4226, d3sxrA1, 0.7280, 2.79, 0.217, 257, 235, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
4227, d3my0W1, 0.7280, 2.88, 0.248, 280, 234, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4228, d3bizA_, 0.7280, 2.61, 0.235, 250, 230, WEE1 KINASE COMPLEX WITH INHIBITOR PD331618
4229, d2wtkC1, 0.7280, 2.87, 0.300, 261, 237, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
4230, d2nryB_, 0.7280, 3.06, 0.249, 286, 237, CRYSTAL STRUCTURE OF IRAK-4
4231, d5lmaA_, 0.7279, 3.00, 0.209, 267, 239, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
4232, d5ew3B_, 0.7279, 2.91, 0.225, 266, 236, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
4233, d5edpA_, 0.7279, 3.40, 0.215, 295, 247, EGFR KINASE (T790M/L858R) APO
4234, d4rx7A1, 0.7279, 3.11, 0.212, 270, 240, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
4235, d4oa9A_, 0.7279, 3.02, 0.233, 280, 236,  
4236, d6bp0D_, 0.7278, 3.26, 0.139, 311, 244, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4237, d4ftkA_, 0.7278, 2.85, 0.286, 263, 234, CRYSTAL STRUCTURE OF THE CHK1
4238, d3pa4A_, 0.7278, 2.99, 0.294, 257, 238, X-RAY CRYSTAL STRUCTURE OF COMPOUND 2A BOUND TO HUMAN CHK1 KINASE DOMAIN
4239, d3my0B_, 0.7278, 3.14, 0.238, 295, 239, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4240, d2vgoA_, 0.7278, 3.02, 0.283, 268, 240, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
4241, d2of4A_, 0.7278, 3.16, 0.246, 271, 240, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
4242, d1m17A_, 0.7278, 3.27, 0.222, 312, 243, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
4243, d6b8uB_, 0.7277, 2.86, 0.205, 248, 234, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4244, d5up3B_, 0.7277, 2.72, 0.312, 243, 231, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4245, d4mkcA_, 0.7277, 3.14, 0.182, 303, 242, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
4246, d4hzrB_, 0.7277, 2.69, 0.254, 258, 232, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
4247, d4d5hB_, 0.7277, 3.16, 0.249, 260, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4248, d3mssC1, 0.7277, 3.00, 0.245, 260, 237, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4249, d3ms9A1, 0.7277, 3.01, 0.245, 261, 237, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
4250, d2ituA_, 0.7277, 3.37, 0.215, 304, 246, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
4251, d2hiwB1, 0.7277, 3.18, 0.237, 270, 241, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
4252, d2bfyA_, 0.7277, 3.03, 0.283, 270, 240, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
4253, d4hzrA_, 0.7276, 2.76, 0.256, 261, 234, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
4254, d4c4hA1, 0.7276, 2.61, 0.316, 245, 234, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4255, d4b8lA_, 0.7276, 2.90, 0.284, 249, 236, AURORA B KINASE P353G MUTANT
4256, d3miyA1, 0.7276, 2.50, 0.230, 237, 230, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
4257, d3f6xB_, 0.7276, 3.03, 0.256, 267, 238, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4258, d2xf0A_, 0.7276, 2.63, 0.286, 251, 231, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4259, d2oiqB_, 0.7276, 2.97, 0.261, 265, 238, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
4260, d1rjbA_, 0.7276, 3.07, 0.234, 298, 239, CRYSTAL STRUCTURE OF FLT3
4261, d4ztlA_, 0.7275, 3.15, 0.248, 280, 238, IRAK4-INHIBITOR CO-STRUCTURE
4262, d4id7A_, 0.7275, 3.07, 0.249, 268, 241, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
4263, d4cd0A_, 0.7275, 3.09, 0.183, 295, 241, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
4264, d3my0Q1, 0.7275, 2.89, 0.244, 293, 234, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4265, d3db8A_, 0.7275, 2.77, 0.283, 261, 233, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 041
4266, d2ityA1, 0.7275, 3.26, 0.234, 299, 244, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
4267, d2i0vA_, 0.7275, 3.20, 0.224, 303, 241, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
4268, d4f64A_, 0.7274, 3.02, 0.230, 278, 239, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
4269, d4c62B_, 0.7274, 2.76, 0.279, 271, 233, INHIBITORS OF JAK2 KINASE DOMAIN
4270, d4b8mB_, 0.7274, 3.08, 0.283, 279, 240, AURORA B KINASE IN COMPLEX WITH VX-680
4271, d3op5B_, 0.7274, 3.36, 0.134, 319, 247, HUMAN VACCINIA-RELATED KINASE 1
4272, d3f82A_, 0.7274, 3.11, 0.221, 278, 240, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
4273, d2hakC_, 0.7274, 3.05, 0.308, 310, 240, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4274, d2fgiA_, 0.7274, 3.01, 0.230, 274, 239, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
4275, d2bfxA_, 0.7274, 3.03, 0.283, 269, 240, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
4276, d4dymA_, 0.7273, 3.07, 0.245, 293, 237, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
4277, d3v5qB1, 0.7273, 2.90, 0.233, 262, 236, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
4278, d3kxzA_, 0.7273, 3.15, 0.246, 263, 240, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
4279, d2jkkA_, 0.7273, 3.16, 0.245, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4280, d4jq7A_, 0.7272, 3.16, 0.220, 303, 241, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
4281, d3orpA_, 0.7272, 3.08, 0.269, 274, 238, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 5)
4282, d3my0F1, 0.7272, 2.90, 0.244, 293, 234, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4283, d2yjrA_, 0.7272, 2.96, 0.193, 278, 238, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
4284, d2x81A_, 0.7272, 2.60, 0.306, 242, 232, STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054
4285, d2qu6B_, 0.7272, 2.84, 0.217, 260, 235, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4286, d2itxA_, 0.7272, 3.33, 0.229, 307, 245, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
4287, d2hz4C_, 0.7272, 3.11, 0.232, 259, 237, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
4288, d5v5yA_, 0.7271, 2.93, 0.243, 259, 235, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
4289, d5ew9A_, 0.7271, 3.07, 0.265, 257, 238, CRYSTAL STRUCTURE OF AURORA A KINASE DOMAIN BOUND TO MK-5108
4290, d4i0tA1, 0.7271, 2.99, 0.202, 262, 238, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
4291, d4gfgA1, 0.7271, 3.09, 0.204, 273, 240, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
4292, d4ftqA_, 0.7271, 2.76, 0.296, 254, 233, CRYSTAL STRUCTURE OF THE CHK1
4293, d4c2vB_, 0.7271, 3.09, 0.283, 280, 240, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
4294, d3srvA_, 0.7271, 2.98, 0.198, 262, 237, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
4295, d3qlgA_, 0.7271, 2.87, 0.242, 259, 236, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
4296, d2jkqA_, 0.7271, 3.13, 0.245, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4297, d5k3yA_, 0.7270, 3.05, 0.271, 267, 240, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
4298, d4h1jA_, 0.7270, 3.04, 0.207, 263, 241, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
4299, d3w2qA1, 0.7270, 3.44, 0.215, 306, 247, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
4300, d3my0C1, 0.7270, 2.94, 0.247, 298, 235, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4301, d3ac5A_, 0.7270, 3.19, 0.246, 270, 240, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4302, d2qu6A1, 0.7270, 2.82, 0.214, 276, 234, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4303, d6bruD_, 0.7269, 3.28, 0.139, 311, 244, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4304, d5owqA_, 0.7269, 2.56, 0.326, 255, 230, HUMAN STK10 BOUND TO DOVITINIB
4305, d5hezC_, 0.7269, 3.10, 0.270, 289, 237, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4306, d4jr3A_, 0.7269, 3.16, 0.220, 303, 241, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
4307, d3uqgA_, 0.7269, 2.93, 0.262, 263, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
4308, d3tz8B_, 0.7269, 3.01, 0.244, 263, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
4309, d3miyB1, 0.7269, 2.51, 0.226, 238, 230, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
4310, d3h10A_, 0.7269, 3.18, 0.287, 268, 240, AURORA A INHIBITOR COMPLEX
4311, d2xeyA_, 0.7269, 2.85, 0.286, 252, 234, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4312, d1p14A_, 0.7269, 3.04, 0.212, 287, 240, CRYSTAL STRUCTURE OF A CATALYTIC-LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
4313, d5x18B_, 0.7268, 3.52, 0.181, 294, 249, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
4314, d5d12A_, 0.7268, 2.92, 0.263, 260, 236, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
4315, d4c2wB_, 0.7268, 3.11, 0.283, 277, 240, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
4316, d3my0G1, 0.7268, 2.90, 0.248, 293, 234, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4317, d3en4A_, 0.7268, 2.89, 0.246, 257, 236, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
4318, d3ac1A_, 0.7268, 3.10, 0.247, 270, 239, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4319, d2vwiC_, 0.7268, 2.90, 0.276, 270, 232, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4320, d4rloA_, 0.7267, 2.39, 0.319, 259, 226, HUMAN P70S6K1 WITH RUTHENIUM-BASED INHIBITOR EM5
4321, d4otiA_, 0.7267, 2.44, 0.297, 303, 229, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH TOFACITINIB
4322, d4kb8D_, 0.7267, 3.14, 0.190, 278, 242, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4323, d1zmvA_, 0.7267, 2.75, 0.305, 293, 233, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4324, d4j95C_, 0.7266, 3.30, 0.237, 281, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
4325, d4gt5A_, 0.7266, 3.20, 0.235, 290, 243, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
4326, d4ftmA_, 0.7266, 2.85, 0.286, 263, 234, CRYSTAL STRUCTURE OF THE CHK1
4327, d4f63A_, 0.7266, 3.05, 0.230, 278, 239, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
4328, d3my0E1, 0.7266, 2.91, 0.244, 293, 234, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4329, d3f3tB_, 0.7266, 2.82, 0.256, 259, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
4330, d3dj6A_, 0.7266, 2.59, 0.296, 252, 230, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 823.
4331, d2zm1A_, 0.7266, 3.19, 0.246, 270, 240, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4332, d5uhnA_, 0.7265, 3.44, 0.230, 282, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
4333, d4i4fA_, 0.7265, 3.03, 0.248, 255, 238, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH AN ALLOSTERIC BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
4334, d3uc3A_, 0.7265, 3.11, 0.276, 272, 239, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.3
4335, d3my0S1, 0.7265, 2.91, 0.248, 293, 234, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4336, d3cp9A1, 0.7265, 2.91, 0.217, 281, 235, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4337, d5ut1A_, 0.7264, 2.96, 0.206, 272, 238, JAK2 JH2 IN COMPLEX WITH BI-D1870
4338, d5uszA_, 0.7264, 2.96, 0.206, 272, 238, JAK2 JH2 IN COMPLEX WITH JNJ-7706621
4339, d5uabA_, 0.7264, 2.86, 0.236, 288, 233, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4340, d5ek7A_, 0.7264, 2.98, 0.204, 286, 240, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
4341, d4mxoA_, 0.7264, 3.01, 0.256, 266, 238, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
4342, d3g6gA_, 0.7264, 3.00, 0.249, 264, 237, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
4343, d3bu5A_, 0.7264, 3.23, 0.212, 291, 241, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
4344, d3b8rA1, 0.7264, 2.98, 0.219, 282, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4345, d2gs2A_, 0.7264, 3.35, 0.216, 305, 245, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
4346, d2etmA_, 0.7264, 3.12, 0.249, 262, 241, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
4347, d1zxeD1, 0.7264, 2.65, 0.283, 246, 230, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
4348, d1yomA_, 0.7264, 2.78, 0.235, 260, 234, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
4349, d4rx8A1, 0.7263, 3.08, 0.205, 266, 239, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
4350, d3zbfA_, 0.7263, 2.94, 0.231, 281, 238, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
4351, d3my0R1, 0.7263, 2.91, 0.244, 293, 234, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4352, d3my0H1, 0.7263, 2.91, 0.248, 293, 234, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4353, d2xynB_, 0.7263, 3.26, 0.240, 264, 242, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
4354, d1qpcA_, 0.7263, 3.10, 0.247, 270, 239, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
4355, d5ut5A_, 0.7262, 2.95, 0.206, 272, 238, JAK2 JH2 IN COMPLEX WITH GLPG0634
4356, d5swhB_, 0.7262, 2.86, 0.243, 261, 235, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4357, d4ftlA_, 0.7262, 2.86, 0.286, 263, 234, CRYSTAL STRUCTURE OF THE CHK1
4358, d3zuuA_, 0.7262, 3.07, 0.271, 281, 240, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
4359, d2vrxA_, 0.7262, 3.03, 0.283, 268, 240, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
4360, d2itvA_, 0.7262, 3.32, 0.225, 303, 244, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
4361, d4z55A_, 0.7261, 3.21, 0.182, 294, 242, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
4362, d4j99A_, 0.7261, 3.33, 0.236, 280, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
4363, d4j97D_, 0.7261, 3.23, 0.231, 285, 238, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
4364, d3f9nA_, 0.7261, 2.83, 0.282, 253, 234, CRYSTAL STRUCTURE OF CHK1 KINASE IN COMPLEX WITH INHIBITOR 38
4365, d3cpcB_, 0.7261, 2.88, 0.213, 262, 235, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4366, d3cpcA1, 0.7261, 2.85, 0.222, 277, 234, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4367, d4xlvA_, 0.7260, 3.39, 0.217, 307, 244, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
4368, d4x7qB_, 0.7260, 2.29, 0.271, 243, 225, PIM2 KINASE IN COMPLEX WITH COMPOUND 1S
4369, d4puzB_, 0.7260, 3.17, 0.200, 265, 240, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
4370, d4oa6A_, 0.7260, 2.99, 0.230, 279, 235,  
4371, d4c2wA_, 0.7260, 3.04, 0.283, 268, 240, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
4372, d3f3uB_, 0.7260, 2.93, 0.246, 259, 236, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
4373, d2zvaA1, 0.7260, 3.10, 0.233, 260, 240, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
4374, d4j95A_, 0.7259, 3.33, 0.236, 279, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
4375, d3my0D1, 0.7259, 2.91, 0.248, 297, 234, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4376, d3kc3E_, 0.7259, 3.03, 0.263, 287, 232, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4377, d3fqeA1, 0.7259, 3.09, 0.205, 265, 239, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
4378, d2p2iB_, 0.7259, 3.00, 0.216, 263, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
4379, d2ofvA2, 0.7259, 2.71, 0.239, 243, 230, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
4380, d2itqA_, 0.7259, 3.15, 0.220, 300, 241, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
4381, d6btwD_, 0.7258, 3.27, 0.140, 307, 243, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4382, d5tx5A_, 0.7258, 2.96, 0.229, 259, 236, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4383, d5ap2A1, 0.7258, 2.84, 0.312, 253, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4384, d4nkaA_, 0.7258, 3.09, 0.226, 279, 239, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
4385, d4kbkD_, 0.7258, 3.15, 0.190, 281, 242, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4386, d5uq0A_, 0.7257, 3.13, 0.230, 266, 239, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
4387, d4ztmD_, 0.7257, 3.14, 0.257, 282, 237, IRAK4-INHIBITOR CO-STRUCTURE
4388, d4wunA_, 0.7257, 3.09, 0.233, 282, 240, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
4389, d4brxA_, 0.7257, 3.09, 0.246, 259, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
4390, d3dbdA_, 0.7257, 2.79, 0.283, 261, 233, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 094
4391, d2pl0A_, 0.7257, 3.06, 0.235, 268, 238, LCK BOUND TO IMATINIB
4392, d2jc6A_, 0.7257, 2.90, 0.274, 278, 234, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4393, d1i44A_, 0.7257, 3.19, 0.206, 282, 243, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
4394, d5cavA_, 0.7256, 3.23, 0.227, 306, 242, EGFR KINASE DOMAIN WITH COMPOUND 41A
4395, d4d2sA_, 0.7256, 2.55, 0.323, 249, 232, HUMAN TTK IN COMPLEX WITH A DYRK1B INHIBITOR
4396, d3lcsA_, 0.7256, 3.24, 0.180, 304, 244, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4397, d3ac2A_, 0.7256, 3.12, 0.247, 270, 239, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4398, d2psqB_, 0.7256, 3.31, 0.236, 286, 242, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
4399, d5ut6A_, 0.7255, 2.98, 0.206, 272, 238, JAK2 JH2 IN COMPLEX WITH A DIAMINOPYRIMIDINE
4400, d5tf9B_, 0.7255, 2.54, 0.243, 266, 226, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
4401, d4ztlD_, 0.7255, 3.17, 0.256, 285, 238, IRAK4-INHIBITOR CO-STRUCTURE
4402, d4useB_, 0.7255, 2.96, 0.315, 278, 235, HUMAN STK10 (LOK) WITH SB-633825
4403, d4mxcA_, 0.7255, 3.24, 0.215, 290, 242, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4404, d3u6jA1, 0.7255, 3.20, 0.219, 305, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
4405, d3acjA_, 0.7255, 3.11, 0.247, 270, 239, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4406, d2of2A_, 0.7255, 3.19, 0.246, 271, 240, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
4407, d5htiA_, 0.7254, 3.25, 0.219, 290, 242, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
4408, d3nsvB_, 0.7254, 3.27, 0.240, 264, 242,  
4409, d3ewhA1, 0.7254, 3.34, 0.208, 295, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
4410, d3ac3A_, 0.7254, 3.11, 0.247, 270, 239, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4411, d2zybA_, 0.7254, 3.11, 0.247, 270, 239, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4412, d5ut2A_, 0.7253, 2.98, 0.206, 273, 238, JAK2 JH2 IN COMPLEX WITH PRT062607
4413, d5mjbA_, 0.7253, 3.13, 0.228, 276, 241, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
4414, d3vf9A_, 0.7253, 3.11, 0.201, 265, 239, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
4415, d3g6hB_, 0.7253, 2.90, 0.246, 259, 236, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
4416, d3ad4A_, 0.7253, 3.11, 0.247, 270, 239, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4417, d5swhA_, 0.7252, 2.88, 0.238, 258, 235, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4418, d4oa2A_, 0.7252, 3.05, 0.229, 280, 236,  
4419, d4d4vA_, 0.7252, 3.01, 0.243, 256, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4420, d3cs9B_, 0.7252, 3.09, 0.231, 247, 238, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4421, d2vgpB_, 0.7252, 3.11, 0.283, 277, 240, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
4422, d5we8A_, 0.7251, 2.65, 0.246, 270, 228, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4423, d5em5A_, 0.7251, 3.43, 0.211, 298, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4424, d3bhhD1, 0.7251, 2.96, 0.331, 285, 236, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
4425, d5ut3A_, 0.7250, 2.98, 0.206, 272, 238, JAK2 JH2 IN COMPLEX WITH IKK-2 INHIBITOR VI
4426, d5ut0A_, 0.7250, 2.99, 0.206, 272, 238, JAK2 JH2 IN COMPLEX WITH AT9283
4427, d4yffB_, 0.7250, 2.99, 0.220, 264, 232, TNNI3K COMPLEXED WITH INHIBITOR 2
4428, d4v04A_, 0.7250, 3.10, 0.226, 290, 239, FGFR1 IN COMPLEX WITH PONATINIB.
4429, d3uqfA_, 0.7250, 2.90, 0.257, 260, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
4430, d2xb7A_, 0.7250, 3.20, 0.186, 286, 242, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
4431, d2bfxB_, 0.7250, 2.99, 0.287, 275, 237, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
4432, d1r1wA_, 0.7250, 3.04, 0.228, 287, 237, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET
4433, d5vc5A_, 0.7249, 2.95, 0.236, 261, 237, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
4434, d4mxxA_, 0.7249, 3.03, 0.252, 266, 238, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4435, d3my0I1, 0.7249, 2.89, 0.245, 292, 233, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4436, d3fqsA1, 0.7249, 3.16, 0.204, 264, 240, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
4437, d3ad5A_, 0.7249, 3.13, 0.247, 270, 239, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4438, d3ac8A_, 0.7249, 3.12, 0.247, 270, 239, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4439, d2hz0B_, 0.7249, 2.75, 0.235, 243, 230, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
4440, d4xg3A_, 0.7248, 3.07, 0.202, 262, 238, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4441, d4v01A_, 0.7248, 3.02, 0.219, 273, 237, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
4442, d4focA_, 0.7248, 3.17, 0.182, 296, 242, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
4443, d3zuuB_, 0.7248, 3.19, 0.260, 282, 242, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
4444, d3op5C_, 0.7248, 3.31, 0.143, 308, 245, HUMAN VACCINIA-RELATED KINASE 1
4445, d3dj5A_, 0.7248, 2.61, 0.296, 252, 230, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 290.
4446, d3ac4A_, 0.7248, 3.12, 0.247, 270, 239, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4447, d2qi8B_, 0.7248, 2.58, 0.258, 249, 229, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
4448, d5sysA_, 0.7247, 2.88, 0.238, 258, 235, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
4449, d4wo5B1, 0.7247, 2.21, 0.211, 241, 223, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
4450, d4r1yA_, 0.7247, 2.81, 0.223, 265, 233, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITOR
4451, d4kioB1, 0.7247, 2.54, 0.222, 237, 230, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4452, d3ackA_, 0.7247, 3.11, 0.247, 270, 239, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4453, d2zm4A_, 0.7247, 3.12, 0.247, 270, 239, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
4454, d2yn8A_, 0.7247, 2.78, 0.214, 253, 234, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4455, d2q0bA_, 0.7247, 3.24, 0.223, 280, 238, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4456, d4wunB_, 0.7246, 3.19, 0.236, 268, 242, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
4457, d4d5kB_, 0.7246, 3.03, 0.244, 256, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4458, d3lckA_, 0.7246, 3.13, 0.247, 270, 239, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
4459, d5d11A_, 0.7245, 2.78, 0.245, 254, 233, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
4460, d4yffA_, 0.7245, 2.93, 0.225, 264, 231, TNNI3K COMPLEXED WITH INHIBITOR 2
4461, d4d4vB_, 0.7245, 3.02, 0.244, 255, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4462, d4ccbA_, 0.7245, 3.08, 0.183, 287, 240, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
4463, d3jvsA_, 0.7245, 2.83, 0.300, 256, 233, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
4464, d3h10B_, 0.7245, 3.11, 0.289, 267, 239, AURORA A INHIBITOR COMPLEX
4465, d3efwB_, 0.7245, 2.62, 0.307, 242, 231, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4466, d3ad6A_, 0.7245, 3.12, 0.247, 272, 239, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
4467, d2ydjA_, 0.7245, 2.85, 0.285, 252, 235, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4468, d2reiA1, 0.7245, 2.95, 0.202, 274, 238, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
4469, d5tt7A1, 0.7244, 3.13, 0.202, 270, 238, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
4470, d4xg9B_, 0.7244, 3.08, 0.201, 265, 239, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4471, d3zutA_, 0.7244, 3.09, 0.271, 281, 240, THE STRUCTURE OF OST1 (D160A) KINASE
4472, d2eb2A_, 0.7244, 3.22, 0.211, 305, 242, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
4473, d5uorA_, 0.7243, 2.80, 0.307, 249, 231, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4474, d4rzvA1, 0.7243, 2.37, 0.213, 245, 225, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
4475, d3l8vA_, 0.7243, 3.34, 0.218, 293, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
4476, d3el8A_, 0.7243, 2.99, 0.261, 263, 238, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
4477, d5l8jA_, 0.7242, 2.97, 0.262, 253, 237, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 S93R
4478, d5eykB_, 0.7242, 3.15, 0.283, 275, 240, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
4479, d5dg5A_, 0.7242, 3.19, 0.208, 297, 240, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
4480, d3v5qA1, 0.7242, 2.96, 0.229, 260, 236, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
4481, d3qriB_, 0.7242, 3.13, 0.244, 262, 238, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
4482, d3of0B_, 0.7242, 2.62, 0.252, 251, 230, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
4483, d3f3vB_, 0.7242, 2.98, 0.245, 262, 237, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4484, d6btwB_, 0.7241, 3.20, 0.140, 301, 242, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4485, d5d12B_, 0.7241, 2.82, 0.245, 253, 233, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
4486, d4gfoA1, 0.7241, 2.84, 0.241, 270, 232, TYK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
4487, d3of0A_, 0.7241, 2.92, 0.246, 260, 236, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
4488, d3fztA_, 0.7241, 3.01, 0.208, 259, 240, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
4489, d2dylA_, 0.7241, 3.09, 0.224, 272, 241, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 ACTIVATED MUTANT (S287D T291D)
4490, d5j9yA_, 0.7240, 3.17, 0.216, 300, 241, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
4491, d5c26A1, 0.7240, 3.08, 0.205, 271, 239, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
4492, d4wkqA1, 0.7240, 3.17, 0.218, 294, 238, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
4493, d4trlA_, 0.7240, 3.00, 0.210, 268, 238, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4494, d3zfxB_, 0.7240, 2.74, 0.226, 254, 234, CRYSTAL STRUCTURE OF EPHB1
4495, d3w18B_, 0.7240, 2.59, 0.313, 236, 230, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4496, d2x2mB1, 0.7240, 3.06, 0.251, 274, 235, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
4497, d4xs2B_, 0.7239, 3.11, 0.258, 278, 236, IRAK4-INHIBITOR CO-STRUCTURE
4498, d4nifD_, 0.7239, 2.65, 0.310, 313, 229, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4499, d4fobA_, 0.7239, 3.18, 0.182, 295, 242, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
4500, d3uysA_, 0.7239, 3.17, 0.182, 281, 242, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4501, d3mpmA_, 0.7239, 2.96, 0.235, 257, 238, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
4502, d2ijmA_, 0.7239, 3.17, 0.245, 260, 241, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
4503, d5wdyA_, 0.7238, 2.56, 0.256, 260, 227, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH 1-CYCLOHEXYL-N-({6-FLUORO-1- [2-(3-METHOXYPHENYL)PYRIDIN-4-YL]-1H-INDOL-3-YL}METHYL)METHANAMINE (COMPOUND 6)
4504, d3qriA1, 0.7238, 3.25, 0.237, 270, 241, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
4505, d3dqxB_, 0.7238, 3.13, 0.259, 268, 239, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
4506, d3byoA_, 0.7238, 3.13, 0.247, 270, 239, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
4507, d2og8B2, 0.7238, 3.10, 0.235, 247, 238, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
4508, d5j9zA_, 0.7237, 3.13, 0.224, 291, 241, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
4509, d4jg8A_, 0.7237, 2.69, 0.304, 300, 230, STRUCTURE OF RSK2 T493M CTD MUTANT BOUND TO 2-CYANO-N-(1-HYDROXY-2- METHYLPROPAN-2-YL)-3-(3-(345-TRIMETHOXYPHENYL)-1H-INDAZOL-5-YL) ACRYLAMIDE
4510, d4fynA1, 0.7237, 3.17, 0.200, 263, 240, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
4511, d1yomB_, 0.7237, 2.89, 0.243, 261, 235, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
4512, d3dkgA_, 0.7236, 3.07, 0.219, 281, 237, STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
4513, d3daeA_, 0.7236, 3.04, 0.301, 248, 236, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
4514, d6bruB_, 0.7235, 3.21, 0.140, 301, 242, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4515, d5uvfA_, 0.7235, 3.23, 0.135, 317, 244, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4516, d5uhnB_, 0.7235, 3.34, 0.232, 269, 241, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
4517, d4o2pB_, 0.7235, 2.98, 0.262, 265, 237, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
4518, d4ftnA_, 0.7235, 2.79, 0.289, 253, 232, CRYSTAL STRUCTURE OF THE CHK1
4519, d3zfxF_, 0.7235, 2.71, 0.227, 254, 233, CRYSTAL STRUCTURE OF EPHB1
4520, d4m8tA_, 0.7234, 2.64, 0.306, 303, 229, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH 3-(3-(1H-PYRAZOL- 4-YL)PHENYL)-2-CYANOACRYLAMIDE
4521, d3g5dA_, 0.7234, 2.82, 0.262, 256, 233, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
4522, d2yzaA_, 0.7234, 2.89, 0.289, 258, 235, CRYSTAL STRUCTURE OF KINASE DOMAIN OF HUMAN 5 -AMP-ACTIVATED PROTEIN KINASE ALPHA-2 SUBUNIT MUTANT (T172D)
4523, d2oh4A1, 0.7234, 3.31, 0.214, 296, 243, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
4524, d1qpeA_, 0.7234, 3.23, 0.246, 270, 240, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
4525, d1m14A_, 0.7234, 3.25, 0.227, 307, 242, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
4526, d5lpwA_, 0.7233, 2.95, 0.231, 280, 234, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
4527, d4k8aB_, 0.7233, 3.01, 0.251, 258, 239, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
4528, d3b2tB_, 0.7233, 3.27, 0.230, 287, 239, STRUCTURE OF PHOSPHOTRANSFERASE
4529, d2zv8A1, 0.7233, 3.10, 0.230, 256, 239, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
4530, d2pz5B_, 0.7233, 3.23, 0.228, 280, 237, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4531, d5uglA_, 0.7232, 3.42, 0.235, 285, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
4532, d4oacA_, 0.7232, 3.12, 0.232, 280, 237,  
4533, d1p4oB_, 0.7232, 3.28, 0.214, 314, 243, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
4534, d5nk3A_, 0.7231, 3.20, 0.207, 281, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
4535, d4yc8B_, 0.7231, 3.10, 0.236, 264, 237, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
4536, d4maoA_, 0.7231, 2.74, 0.304, 298, 230, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH RMM58
4537, d3f3uA_, 0.7231, 3.01, 0.245, 261, 237, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
4538, d2pzpB_, 0.7231, 3.24, 0.228, 282, 237, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
4539, d6btwA_, 0.7230, 3.24, 0.135, 317, 244, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4540, d4gu6B_, 0.7230, 3.27, 0.248, 258, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
4541, d4hokI_, 0.7229, 3.47, 0.178, 291, 247, CRYSTAL STRUCTURE OF APO CK1E
4542, d4f65B_, 0.7229, 3.20, 0.220, 279, 241, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
4543, d4d5kA_, 0.7229, 3.00, 0.244, 255, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4544, d4d4yA_, 0.7229, 3.01, 0.244, 255, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4545, d4c3fA_, 0.7229, 2.97, 0.235, 257, 238, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
4546, d3my0P_, 0.7229, 2.92, 0.240, 290, 233, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4547, d2vwiB_, 0.7229, 3.00, 0.273, 264, 231, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4548, d2q0bB_, 0.7229, 3.16, 0.224, 282, 237, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4549, d6bp0A_, 0.7228, 3.24, 0.135, 317, 244, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4550, d5c03B_, 0.7228, 2.78, 0.223, 260, 233, CRYSTAL STRUCTURE OF KINASE
4551, d3zfxG_, 0.7228, 2.72, 0.227, 253, 233, CRYSTAL STRUCTURE OF EPHB1
4552, d2pvyC_, 0.7228, 3.14, 0.225, 285, 236, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
4553, d2iwiB_, 0.7228, 2.47, 0.269, 249, 227, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4554, d4fstA_, 0.7227, 2.80, 0.289, 253, 232, CRYSTAL STRUCTURE OF THE CHK1
4555, d2wmtA_, 0.7227, 2.66, 0.283, 248, 230, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4556, d2pz5A_, 0.7227, 3.26, 0.228, 280, 237, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4557, d4equA_, 0.7226, 2.95, 0.316, 274, 234, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
4558, d3my0T1, 0.7226, 2.88, 0.246, 291, 232, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4559, d3lctA_, 0.7226, 3.28, 0.180, 308, 244, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4560, d2pvyB_, 0.7226, 3.13, 0.225, 286, 236, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
4561, d1xbbA1, 0.7226, 3.09, 0.213, 266, 239, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
4562, d4r5sA_, 0.7225, 3.40, 0.216, 299, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
4563, d1p4oA_, 0.7225, 3.32, 0.197, 308, 244, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
4564, d5lpzA_, 0.7224, 3.10, 0.229, 283, 236, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
4565, d3f61A_, 0.7224, 3.00, 0.272, 271, 235, CRYSTAL STRUCTURE OF M. TUBERCULOSIS PKNB LEU33ASP/VAL222ASP DOUBLE MUTANT IN COMPLEX WITH ADP
4566, d4xg6A1, 0.7223, 3.12, 0.205, 270, 239, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4567, d2pzpA_, 0.7223, 3.26, 0.228, 280, 237, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
4568, d4xg9A_, 0.7222, 2.87, 0.212, 259, 236, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4569, d4hokM_, 0.7221, 3.47, 0.185, 291, 248, CRYSTAL STRUCTURE OF APO CK1E
4570, d3ri1B_, 0.7221, 3.36, 0.236, 283, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
4571, d3ot8A_, 0.7221, 2.80, 0.303, 251, 231, X-RAY CRYSTAL STRUCTURE OF COMPOUND 17R BOUND TO HUMAN CHK1 KINASE DOMAIN
4572, d3o23A_, 0.7221, 3.30, 0.202, 293, 243, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
4573, d3g5dB_, 0.7221, 2.92, 0.255, 257, 235, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
4574, d3dqxA_, 0.7221, 3.18, 0.259, 267, 239, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
4575, d3cpbA1, 0.7221, 2.98, 0.217, 278, 235, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
4576, d2pzrA_, 0.7221, 3.13, 0.220, 280, 236, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4577, d1a06A_, 0.7221, 3.09, 0.274, 279, 234, CALMODULIN-DEPENDENT PROTEIN KINASE FROM RAT
4578, d5ia0B_, 0.7220, 3.20, 0.207, 266, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4579, d4yc8A_, 0.7220, 3.08, 0.229, 259, 236, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
4580, d4mxoB_, 0.7220, 3.08, 0.256, 264, 238, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
4581, d3zutB_, 0.7220, 3.25, 0.259, 282, 243, THE STRUCTURE OF OST1 (D160A) KINASE
4582, d3w2oA1, 0.7220, 3.41, 0.215, 304, 246, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
4583, d2jboA_, 0.7220, 2.87, 0.260, 295, 231, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-1 SOAKING)
4584, d5k7gD_, 0.7219, 3.18, 0.257, 283, 237, IRAK4 IN COMPLEX WITH AZ3862
4585, d5eykA_, 0.7219, 3.09, 0.283, 263, 240, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
4586, d4d5hA_, 0.7219, 3.02, 0.244, 255, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4587, d3f3wA_, 0.7219, 3.01, 0.245, 261, 237, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4588, d4fodA_, 0.7218, 3.21, 0.182, 308, 242, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
4589, d3my0O1, 0.7218, 2.94, 0.253, 296, 233, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4590, d3bz3A_, 0.7218, 3.20, 0.249, 259, 241, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
4591, d2w5hA1, 0.7218, 2.63, 0.279, 257, 233, HUMAN NEK2 KINASE APO
4592, d5ur1B_, 0.7217, 3.17, 0.229, 265, 240, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
4593, d5t1sB_, 0.7217, 3.17, 0.267, 282, 236, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4594, d4xs2A_, 0.7217, 3.21, 0.248, 283, 238, IRAK4-INHIBITOR CO-STRUCTURE
4595, d4kabB_, 0.7217, 3.19, 0.245, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
4596, d2vgpA_, 0.7217, 2.96, 0.287, 265, 237, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
4597, d1zy5B1, 0.7217, 2.76, 0.286, 247, 231, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT COMPLEXED WITH AMPPNP.
4598, d5ukfC_, 0.7216, 3.35, 0.143, 317, 245, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
4599, d5nkiA_, 0.7216, 3.09, 0.197, 268, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
4600, d5ftoA1, 0.7216, 3.26, 0.169, 297, 243, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
4601, d4d58A_, 0.7216, 2.97, 0.245, 255, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4602, d3bhhC1, 0.7216, 3.01, 0.326, 284, 236, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
4603, d2xezA_, 0.7216, 2.77, 0.286, 249, 231, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4604, d1zy4B1, 0.7216, 2.83, 0.284, 247, 232, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT IN APO FORM.
4605, d5mjbB_, 0.7215, 3.09, 0.225, 278, 240, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
4606, d5bvnA_, 0.7215, 3.40, 0.224, 278, 246, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4607, d4ybjA_, 0.7215, 2.82, 0.253, 255, 233, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4608, d4m67A_, 0.7215, 2.84, 0.207, 264, 237, CRYSTAL STRUCTURE OF THE HUMAN MLKL KINASE-LIKE DOMAIN
4609, d3ug1A_, 0.7215, 3.16, 0.214, 296, 238, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
4610, d3sxrB1, 0.7215, 2.79, 0.215, 255, 233, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
4611, d5uvfB_, 0.7214, 3.40, 0.143, 316, 245, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4612, d5h3qA_, 0.7214, 3.14, 0.229, 302, 240, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
4613, d5c27A1, 0.7214, 3.20, 0.204, 271, 240, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
4614, d4tygA1, 0.7214, 3.29, 0.252, 290, 242, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4615, d4gu9B_, 0.7214, 3.18, 0.245, 255, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
4616, d4d9uA_, 0.7214, 2.71, 0.304, 307, 230, RSK2 C-TERMINAL KINASE DOMAIN (E)-TERT-BUTYL 3-(4-AMINO-7-(3- HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4617, d3alnB_, 0.7214, 2.38, 0.262, 263, 225, CRYSTAL STRUCTURE OF HUMAN NON-PHOSPHORYLATED MKK4 KINASE DOMAIN COMPLEXED WITH AMP-PNP
4618, d5xgmA_, 0.7213, 3.30, 0.215, 288, 242, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
4619, d4oabA_, 0.7213, 3.03, 0.230, 279, 235,  
4620, d4i0rA1, 0.7213, 2.97, 0.212, 260, 236, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
4621, d3kc3I_, 0.7213, 2.86, 0.265, 295, 230, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4622, d2vrxB_, 0.7213, 2.99, 0.288, 274, 236, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
4623, d5kx7B_, 0.7212, 3.22, 0.256, 286, 238, IRAK4-INHIBITOR CO-STRUCTURE
4624, d3zfxC_, 0.7212, 2.74, 0.227, 248, 233, CRYSTAL STRUCTURE OF EPHB1
4625, d3etaA_, 0.7212, 3.32, 0.215, 293, 242, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
4626, d3ekkA_, 0.7212, 3.19, 0.212, 285, 241, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
4627, d2itwA_, 0.7212, 3.23, 0.228, 300, 241, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
4628, d4d9tA_, 0.7210, 2.74, 0.304, 299, 230, RSK2 C-TERMINAL KINASE DOMAIN WITH INHIBITOR (E)-METHYL 3-(4-AMINO-7- (3-HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4629, d1y8gB_, 0.7209, 2.83, 0.315, 292, 232, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
4630, d1gagA_, 0.7209, 3.48, 0.209, 300, 244, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
4631, d5we8B_, 0.7208, 2.67, 0.260, 272, 227, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4632, d5kx8D_, 0.7208, 3.22, 0.256, 283, 238, IRAK4-INHIBITOR CO-STRUCTURE
4633, d5i9uA_, 0.7208, 3.21, 0.207, 281, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
4634, d2rl5A1, 0.7208, 3.30, 0.207, 290, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
4635, d2pvyD_, 0.7208, 3.16, 0.225, 283, 236, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
4636, d2p2hA1, 0.7208, 3.19, 0.221, 289, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
4637, d6bqlA1, 0.7207, 3.22, 0.297, 276, 239, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
4638, d5uglB_, 0.7207, 3.34, 0.233, 271, 240, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
4639, d5sysB_, 0.7207, 2.94, 0.243, 258, 235, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
4640, d3comB_, 0.7207, 3.28, 0.263, 279, 243, CRYSTAL STRUCTURE OF MST1 KINASE
4641, d5uvfD_, 0.7206, 3.41, 0.144, 296, 243, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4642, d5c03A_, 0.7206, 2.76, 0.224, 260, 232, CRYSTAL STRUCTURE OF KINASE
4643, d4rssA_, 0.7206, 3.16, 0.204, 269, 240, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
4644, d4ibmA_, 0.7206, 3.29, 0.218, 301, 243, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
4645, d4hokU_, 0.7206, 3.50, 0.194, 289, 247, CRYSTAL STRUCTURE OF APO CK1E
4646, d4h1mA_, 0.7206, 3.10, 0.221, 256, 240, CRYSTAL STRUCTURE OF PYK2 WITH THE INDOLE 10C
4647, d2ofvB2, 0.7206, 2.50, 0.235, 243, 226, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
4648, d2nryD_, 0.7206, 3.24, 0.257, 282, 237, CRYSTAL STRUCTURE OF IRAK-4
4649, d1zxeB1, 0.7206, 2.76, 0.287, 242, 230, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
4650, d5mo4A3, 0.7205, 3.25, 0.222, 271, 239, ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB
4651, d4wo5A1, 0.7205, 2.30, 0.215, 250, 223, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
4652, d3zxtA_, 0.7205, 2.64, 0.286, 249, 227, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4653, d5t68B_, 0.7204, 3.21, 0.216, 264, 241, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
4654, d3kc3F_, 0.7204, 2.60, 0.263, 293, 228, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4655, d3fqhB_, 0.7204, 2.99, 0.200, 258, 235, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
4656, d3emgA_, 0.7204, 3.01, 0.215, 255, 237, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
4657, d2qg5B1, 0.7204, 3.08, 0.249, 275, 237, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
4658, d3fqhA_, 0.7203, 2.95, 0.204, 262, 235, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
4659, d2nryC_, 0.7203, 3.08, 0.265, 280, 234, CRYSTAL STRUCTURE OF IRAK-4
4660, d2bvaA_, 0.7203, 2.92, 0.261, 272, 234, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4661, d5lpyA_, 0.7202, 3.09, 0.230, 282, 235, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ATP FROM ARABIDOPSIS THALIANA
4662, d3vjnA_, 0.7202, 3.11, 0.210, 297, 238, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
4663, d2pzrB_, 0.7202, 3.16, 0.220, 282, 236, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
4664, d5nkeA_, 0.7201, 3.20, 0.203, 292, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
4665, d3f3tA_, 0.7201, 3.05, 0.245, 261, 237, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
4666, d3d5vA_, 0.7201, 2.78, 0.281, 260, 231, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
4667, d2zm3B2, 0.7201, 3.36, 0.217, 295, 244, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
4668, d1yi6B_, 0.7201, 3.07, 0.236, 274, 237, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
4669, d5xp7A_, 0.7200, 3.09, 0.261, 265, 238, C-SRC IN COMPLEX WITH ATP-CHCL
4670, d5t68A1, 0.7200, 3.20, 0.217, 264, 240, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
4671, d4hokW_, 0.7200, 3.45, 0.180, 289, 245, CRYSTAL STRUCTURE OF APO CK1E
4672, d4f1tA1, 0.7200, 3.18, 0.227, 267, 238, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
4673, d4ebvA1, 0.7200, 3.12, 0.248, 261, 238, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
4674, d3op5D_, 0.7200, 3.23, 0.140, 302, 242, HUMAN VACCINIA-RELATED KINASE 1
4675, d2pvyA_, 0.7200, 3.16, 0.225, 288, 236, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
4676, d4pv0A1, 0.7199, 3.08, 0.203, 266, 237, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
4677, d4nifA_, 0.7199, 2.72, 0.306, 313, 229, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4678, d3w2pA1, 0.7199, 3.47, 0.207, 307, 246, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
4679, d3uiuB_, 0.7199, 2.59, 0.261, 255, 226, CRYSTAL STRUCTURE OF APO-PKR KINASE DOMAIN
4680, d3uiuA_, 0.7199, 2.59, 0.261, 255, 226, CRYSTAL STRUCTURE OF APO-PKR KINASE DOMAIN
4681, d2h6dA_, 0.7199, 2.91, 0.286, 256, 234, PROTEIN KINASE DOMAIN OF THE HUMAN 5 -AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2 (AMPK ALPHA-2 CHAIN)
4682, d5vt1A1, 0.7198, 3.17, 0.298, 264, 238, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
4683, d5mjaA_, 0.7198, 3.05, 0.230, 271, 239, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
4684, d4d4sA_, 0.7198, 3.05, 0.244, 255, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4685, d3vjoA_, 0.7198, 3.40, 0.215, 298, 242, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
4686, d2qr8A_, 0.7198, 2.75, 0.304, 298, 230, 2.0A X-RAY STRUCTURE OF C-TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2 (RSK2)
4687, d3f3vA_, 0.7197, 3.06, 0.241, 261, 237, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4688, d5ko1A_, 0.7196, 2.95, 0.205, 265, 239, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 4.
4689, d3comA_, 0.7196, 3.22, 0.299, 264, 241, CRYSTAL STRUCTURE OF MST1 KINASE
4690, d2ym5A_, 0.7196, 2.74, 0.291, 248, 230, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4691, d1vr2A_, 0.7196, 3.34, 0.207, 275, 242, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
4692, d1m7nB_, 0.7196, 3.32, 0.214, 299, 243, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
4693, d5aaaA_, 0.7195, 3.21, 0.187, 294, 241, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4694, d4agwA_, 0.7195, 2.90, 0.248, 258, 234, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
4695, d3dpkA_, 0.7195, 2.96, 0.230, 279, 235, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
4696, d1m7nA_, 0.7195, 3.32, 0.214, 299, 243, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
4697, d4cmoA_, 0.7194, 3.23, 0.183, 295, 241, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
4698, d2hz4B1, 0.7194, 2.75, 0.236, 248, 229, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
4699, d5iuhA_, 0.7193, 3.14, 0.186, 285, 237, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
4700, d5fedA_, 0.7193, 3.18, 0.214, 288, 238, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
4701, d4g5jA_, 0.7193, 2.95, 0.222, 307, 234, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
4702, d3kc3L_, 0.7193, 2.66, 0.272, 291, 228, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4703, d3cpbB_, 0.7193, 2.97, 0.217, 263, 235, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
4704, d4hokO_, 0.7192, 3.49, 0.175, 290, 246, CRYSTAL STRUCTURE OF APO CK1E
4705, d2ym7A_, 0.7192, 2.77, 0.291, 248, 230, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4706, d2oicC_, 0.7192, 3.33, 0.249, 277, 237, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4707, d4f1mA1, 0.7191, 3.17, 0.224, 274, 237, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
4708, d3l9pA_, 0.7191, 3.33, 0.168, 303, 244, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4709, d1yolB_, 0.7191, 2.75, 0.238, 253, 231, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
4710, d1yolA_, 0.7191, 2.80, 0.242, 256, 231, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
4711, d5nkhA_, 0.7190, 3.22, 0.203, 295, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
4712, d5iugA_, 0.7190, 3.15, 0.190, 285, 237, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
4713, d4f1oA1, 0.7190, 3.21, 0.239, 274, 238, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
4714, d3lvpA_, 0.7190, 3.31, 0.198, 289, 242, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
4715, d3kc3H_, 0.7190, 2.81, 0.271, 290, 229, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4716, d2wmxA_, 0.7190, 2.75, 0.287, 248, 230, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4717, d2ogvA_, 0.7190, 3.42, 0.213, 317, 244, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
4718, d2helA_, 0.7190, 3.15, 0.192, 256, 240, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
4719, d5t1tD_, 0.7189, 3.25, 0.256, 283, 238, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4720, d4ztmA_, 0.7189, 3.34, 0.251, 287, 239, IRAK4-INHIBITOR CO-STRUCTURE
4721, d4k8aA_, 0.7189, 3.03, 0.244, 251, 238, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
4722, d3ztxB_, 0.7189, 2.98, 0.289, 272, 235, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
4723, d3qlfA_, 0.7189, 2.65, 0.249, 249, 229, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
4724, d2r2pA1, 0.7189, 3.24, 0.216, 276, 241, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
4725, d1ir3A_, 0.7189, 3.48, 0.213, 300, 244, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
4726, d5k7gC_, 0.7188, 3.32, 0.254, 283, 240, IRAK4 IN COMPLEX WITH AZ3862
4727, d4dfnA1, 0.7188, 3.20, 0.204, 268, 240, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
4728, d3uqgB_, 0.7188, 2.82, 0.254, 257, 232, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
4729, d3tz8A_, 0.7188, 3.06, 0.245, 261, 237, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
4730, d5jt2D1, 0.7187, 2.14, 0.232, 232, 220, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4731, d5ia0A_, 0.7187, 3.11, 0.201, 263, 239, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4732, d3kc3A_, 0.7187, 2.68, 0.269, 288, 227, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4733, d2zv9A1, 0.7187, 3.17, 0.234, 255, 239, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
4734, d2iwiA_, 0.7187, 2.52, 0.284, 244, 225, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4735, d2bdfA_, 0.7187, 3.12, 0.256, 261, 238, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
4736, d5a6nA1, 0.7186, 2.65, 0.274, 270, 230, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4737, d4ztmB_, 0.7186, 3.13, 0.261, 280, 234, IRAK4-INHIBITOR CO-STRUCTURE
4738, d4yo6D_, 0.7186, 3.27, 0.256, 285, 238, IRAK4-INHIBITOR CO-STRUCTURE
4739, d4wa9B1, 0.7186, 3.14, 0.224, 263, 237, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
4740, d4ficA_, 0.7186, 2.59, 0.250, 251, 228, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
4741, d3mj1A1, 0.7186, 2.14, 0.231, 226, 221, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR RO5191614
4742, d3kc3B_, 0.7186, 2.78, 0.262, 290, 229, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4743, d3ug2A_, 0.7185, 3.30, 0.220, 299, 241, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
4744, d3uc4A_, 0.7185, 3.23, 0.253, 295, 241, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.6
4745, d3h0zB_, 0.7185, 2.71, 0.306, 240, 229, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4746, d3be2A1, 0.7185, 3.22, 0.216, 285, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
4747, d5kz0A_, 0.7184, 3.24, 0.183, 293, 241, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
4748, d5ftqA1, 0.7184, 3.19, 0.183, 292, 240, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
4749, d4ithA_, 0.7184, 2.75, 0.225, 247, 227, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
4750, d4fz7A1, 0.7184, 3.13, 0.203, 261, 237, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
4751, d4cljA_, 0.7184, 3.27, 0.182, 295, 242, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4752, d3lvpB_, 0.7184, 3.29, 0.198, 295, 242, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
4753, d3fpqA_, 0.7184, 2.88, 0.268, 262, 231, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF WNK1
4754, d5lpbA_, 0.7183, 3.08, 0.230, 280, 235, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
4755, d4ztnA_, 0.7183, 3.34, 0.251, 286, 239, IRAK4-INHIBITOR CO-STRUCTURE
4756, d3tz9B_, 0.7183, 2.95, 0.247, 259, 235, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
4757, d5vd2A_, 0.7182, 2.94, 0.238, 258, 235, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PF- 03814735
4758, d4yffD_, 0.7182, 2.71, 0.211, 257, 227, TNNI3K COMPLEXED WITH INHIBITOR 2
4759, d3efwA_, 0.7182, 2.52, 0.286, 240, 227, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4760, d2bdfB_, 0.7182, 3.21, 0.255, 265, 239, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
4761, d4knbD_, 0.7181, 2.76, 0.224, 247, 228, C-MET IN COMPLEX WITH OSI LIGAND
4762, d1y8gA_, 0.7181, 2.91, 0.313, 292, 233, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
4763, d2ydjB_, 0.7180, 2.90, 0.286, 251, 234, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4764, d5nkaA_, 0.7179, 3.17, 0.197, 271, 239, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
4765, d4hokE_, 0.7179, 3.58, 0.174, 291, 247, CRYSTAL STRUCTURE OF APO CK1E
4766, d4ebwA_, 0.7179, 3.23, 0.247, 259, 239, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
4767, d2vx0A_, 0.7179, 3.21, 0.216, 273, 241, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4768, d3wi6C_, 0.7178, 2.74, 0.269, 283, 227, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4769, d3qrkA1, 0.7178, 3.22, 0.243, 268, 239, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
4770, d3ohtB_, 0.7178, 3.79, 0.292, 331, 250, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
4771, d5w84A_, 0.7177, 3.25, 0.257, 279, 237, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
4772, d5o2bA1, 0.7177, 3.07, 0.229, 268, 231, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN A COMPLEX WITH THE INHIBITOR PP-121
4773, d4zauA_, 0.7177, 3.11, 0.224, 283, 237, AZD9291 COMPLEX WITH WILD TYPE EGFR
4774, d4f0fA1, 0.7177, 3.18, 0.232, 274, 237, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
4775, d3pxkA_, 0.7177, 3.13, 0.243, 256, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
4776, d2wmuA_, 0.7177, 2.66, 0.285, 246, 228, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4777, d2oibC_, 0.7177, 3.29, 0.253, 278, 237, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4778, d4ztnD_, 0.7176, 3.34, 0.251, 285, 239, IRAK4-INHIBITOR CO-STRUCTURE
4779, d4dflA1, 0.7176, 3.08, 0.203, 262, 236, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
4780, d2ym4A_, 0.7176, 2.80, 0.309, 251, 230, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4781, d2vwyA_, 0.7176, 3.21, 0.216, 274, 241, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4782, d2j90A1, 0.7176, 2.69, 0.275, 259, 229, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4783, d5t1sD_, 0.7175, 3.31, 0.265, 281, 238, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4784, d4yjoA_, 0.7175, 3.07, 0.210, 267, 238, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
4785, d4yffC_, 0.7175, 2.62, 0.212, 258, 226, TNNI3K COMPLEXED WITH INHIBITOR 2
4786, d4p2wB_, 0.7175, 2.99, 0.204, 253, 235,  
4787, d4nksA_, 0.7175, 3.15, 0.227, 265, 238, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
4788, d3wi6E_, 0.7175, 2.75, 0.269, 283, 227, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4789, d3wi6B_, 0.7175, 2.75, 0.269, 283, 227, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4790, d3octA_, 0.7175, 2.95, 0.191, 244, 236, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE MUTANT V555R IN COMPLEX WITH DASATINIB
4791, d3fzsA_, 0.7175, 2.96, 0.219, 254, 237, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH BIRB796
4792, d2jc6C_, 0.7175, 2.87, 0.276, 277, 232, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4793, d4tt7A_, 0.7174, 3.06, 0.181, 291, 237, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
4794, d3wi6F_, 0.7174, 2.75, 0.269, 283, 227, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4795, d3pa5A_, 0.7174, 2.97, 0.305, 255, 233, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
4796, d3wzdA_, 0.7173, 3.11, 0.227, 278, 238, KDR IN COMPLEX WITH LIGAND LENVATINIB
4797, d3ujgA_, 0.7173, 3.19, 0.289, 290, 239, CRYSTAL STRUCTURE OF SNRK2.6 IN COMPLEX WITH HAB1
4798, d2ym3A_, 0.7173, 2.70, 0.284, 247, 229, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4799, d2hyyD1, 0.7173, 2.98, 0.245, 251, 233, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4800, d5hx6B_, 0.7172, 3.11, 0.226, 264, 234, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
4801, d5aabA_, 0.7172, 3.16, 0.188, 293, 239, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4802, d4wovA_, 0.7172, 2.79, 0.234, 258, 231, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
4803, d4fl1A_, 0.7172, 3.17, 0.218, 268, 239, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
4804, d2ym8A_, 0.7172, 2.66, 0.285, 246, 228, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4805, d2hwoA_, 0.7172, 2.60, 0.250, 251, 228, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
4806, d5vc3A_, 0.7171, 3.01, 0.233, 260, 236, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
4807, d5o1vA_, 0.7171, 3.14, 0.224, 278, 232, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE (A-LOOP SWAPPED)
4808, d4xg8A_, 0.7171, 3.10, 0.211, 258, 237, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4809, d4ccuA_, 0.7171, 3.08, 0.181, 292, 237, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
4810, d5mjaB_, 0.7170, 3.17, 0.225, 274, 240, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
4811, d5bvoA_, 0.7170, 3.42, 0.224, 276, 245, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4812, d5a6oA_, 0.7170, 2.66, 0.274, 265, 230, CRYSTAL STRUCTURE OF THE APO FORM OF THE UNPHOSPHORYLATED HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3)
4813, d4cliA_, 0.7170, 3.25, 0.183, 294, 241, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
4814, d3ortA_, 0.7170, 3.09, 0.261, 271, 234, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 6)
4815, d2bmcA_, 0.7170, 2.89, 0.293, 256, 232, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4816, d5c01B_, 0.7169, 2.81, 0.224, 260, 232, CRYSTAL STRUCTURE OF KINASE
4817, d3uysB_, 0.7169, 3.16, 0.183, 279, 240, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4818, d6bu6C_, 0.7168, 3.25, 0.132, 315, 242, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4819, d4rx9A1, 0.7168, 3.09, 0.203, 264, 236, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
4820, d4kaoB_, 0.7168, 3.08, 0.248, 254, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
4821, d4fz6A1, 0.7168, 3.11, 0.203, 262, 237, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
4822, d5uitB_, 0.7167, 3.30, 0.252, 283, 238, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
4823, d5kx8C_, 0.7167, 3.34, 0.251, 287, 239, IRAK4-INHIBITOR CO-STRUCTURE
4824, d5aa9A_, 0.7167, 3.26, 0.187, 295, 241, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4825, d4cmuA_, 0.7167, 3.26, 0.183, 294, 241, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
4826, d2rioA_, 0.7167, 2.82, 0.315, 396, 232, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4827, d4kabA_, 0.7166, 3.13, 0.244, 255, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
4828, d2vwzA_, 0.7166, 3.23, 0.216, 274, 241, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4829, d2oicD_, 0.7166, 3.39, 0.262, 284, 237, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4830, d1k9aF3, 0.7166, 3.01, 0.220, 264, 236, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4831, d4rzvB1, 0.7165, 2.46, 0.210, 254, 224, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
4832, d4p2wA_, 0.7165, 2.89, 0.219, 250, 233,  
4833, d4gk3A_, 0.7165, 3.26, 0.216, 275, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
4834, d3f3wB_, 0.7165, 3.10, 0.241, 260, 237, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4835, d2vx1A_, 0.7165, 3.23, 0.216, 274, 241, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4836, d5kx8A_, 0.7164, 3.31, 0.256, 285, 238, IRAK4-INHIBITOR CO-STRUCTURE
4837, d4mcvB_, 0.7164, 3.08, 0.245, 265, 237, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
4838, d3v8tA1, 0.7164, 2.64, 0.232, 236, 228, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
4839, d3cs9C_, 0.7164, 3.00, 0.248, 243, 234, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4840, d2hyyB1, 0.7164, 3.02, 0.239, 252, 234, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4841, d1k3aA_, 0.7164, 3.44, 0.198, 288, 242, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
4842, d4ztnC_, 0.7163, 3.35, 0.251, 284, 239, IRAK4-INHIBITOR CO-STRUCTURE
4843, d4agwB_, 0.7163, 2.96, 0.252, 257, 234, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
4844, d2xp2A_, 0.7163, 3.12, 0.181, 285, 238, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
4845, d4u97B_, 0.7162, 3.20, 0.249, 270, 233, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4846, d5nk5A_, 0.7161, 3.09, 0.202, 287, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
4847, d5k7gA_, 0.7161, 3.12, 0.265, 277, 234, IRAK4 IN COMPLEX WITH AZ3862
4848, d4gk2A_, 0.7160, 3.07, 0.206, 265, 238, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
4849, d3tz9A_, 0.7160, 3.09, 0.241, 261, 237, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
4850, d1mqbA_, 0.7160, 3.24, 0.199, 263, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
4851, d6bruC_, 0.7159, 3.26, 0.136, 315, 242, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4852, d4yo6A_, 0.7159, 3.29, 0.252, 286, 238, IRAK4-INHIBITOR CO-STRUCTURE
4853, d4u9aB_, 0.7159, 3.20, 0.249, 270, 233, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4854, d2rioB_, 0.7159, 2.79, 0.316, 395, 231, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4855, d4yfiB_, 0.7158, 3.03, 0.212, 262, 231, TNNI3K COMPLEXED WITH INHIBITOR 1
4856, d4pmtA1, 0.7158, 2.98, 0.225, 269, 236, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N~4~-(4-MORPHOLIN- 4-YLPHENYL)-N~6~-(PYRIDIN-3-YLMETHYL)PYRIDO[32-D]PYRIMIDINE-46- DIAMINE
4857, d3wi6D_, 0.7158, 2.73, 0.270, 282, 226, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4858, d3vw8A_, 0.7158, 3.28, 0.213, 303, 239, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
4859, d5t1tA_, 0.7157, 3.35, 0.251, 283, 239, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4860, d2vwxA_, 0.7157, 3.24, 0.216, 274, 241, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4861, d1zxeF1, 0.7157, 2.75, 0.281, 239, 228, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
4862, d4ztlC_, 0.7156, 3.20, 0.251, 282, 235, IRAK4-INHIBITOR CO-STRUCTURE
4863, d4lghB_, 0.7156, 2.68, 0.250, 247, 228, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4864, d4jg7A_, 0.7156, 2.76, 0.298, 307, 228, STRUCTURE OF RSK2 CTD BOUND TO 3-(3-(1H-PYRROLO[23-B]PYRIDINE-3- CARBONYL)PHENYL)-2-CYANOACRYLAMIDE
4865, d4hokS_, 0.7156, 3.51, 0.184, 286, 245, CRYSTAL STRUCTURE OF APO CK1E
4866, d4fk3A1, 0.7156, 2.41, 0.215, 238, 223, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4867, d4aw5A_, 0.7156, 3.07, 0.210, 261, 238, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
4868, d6btwC_, 0.7155, 3.26, 0.136, 315, 242, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4869, d4yfiD_, 0.7155, 3.08, 0.221, 261, 231, TNNI3K COMPLEXED WITH INHIBITOR 1
4870, d4gu9A_, 0.7155, 3.14, 0.244, 252, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
4871, d2wmwA_, 0.7155, 2.75, 0.288, 247, 229, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4872, d2bmcB_, 0.7155, 3.08, 0.295, 258, 234, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4873, d4xs2D_, 0.7154, 3.22, 0.258, 277, 236, IRAK4-INHIBITOR CO-STRUCTURE
4874, d4ftoA_, 0.7154, 2.83, 0.291, 252, 230, CRYSTAL STRUCTURE OF THE CHK1
4875, d2zv7A1, 0.7154, 3.21, 0.230, 256, 239, LYN TYROSINE KINASE DOMAIN APO FORM
4876, d2zm3D2, 0.7154, 3.35, 0.215, 292, 242, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
4877, d4tyeA_, 0.7153, 3.48, 0.242, 292, 244, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4878, d2bmcE_, 0.7153, 2.80, 0.294, 256, 231, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4879, d4hokA_, 0.7152, 3.53, 0.179, 290, 246, CRYSTAL STRUCTURE OF APO CK1E
4880, d3pixA_, 0.7152, 3.18, 0.196, 268, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
4881, d2hyyC1, 0.7152, 3.05, 0.235, 249, 234, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4882, d6bp0C_, 0.7151, 3.41, 0.135, 315, 244, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4883, d5t1sA_, 0.7151, 3.41, 0.251, 280, 239, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4884, d3zzwA_, 0.7151, 3.17, 0.198, 269, 237, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
4885, d3wi6A_, 0.7151, 2.74, 0.270, 282, 226, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4886, d5nk0A_, 0.7150, 3.11, 0.202, 273, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
4887, d4pdoB_, 0.7150, 3.04, 0.204, 261, 235, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4888, d4g2fA_, 0.7150, 3.29, 0.212, 275, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
4889, d3cs9D_, 0.7150, 3.31, 0.235, 263, 238, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4890, d2bmcD_, 0.7149, 2.91, 0.293, 256, 232, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4891, d5t1tC_, 0.7148, 3.35, 0.251, 286, 239, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4892, d4xg2A1, 0.7148, 3.11, 0.203, 258, 236, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
4893, d4pdoA_, 0.7148, 3.05, 0.204, 261, 235, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4894, d5iuiA_, 0.7147, 3.35, 0.173, 303, 243, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
4895, d5d11B_, 0.7147, 2.88, 0.267, 255, 232, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
4896, d3cjgA_, 0.7147, 3.28, 0.222, 280, 239, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
4897, d4qq5A1, 0.7146, 3.34, 0.249, 272, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4898, d3kc3K_, 0.7146, 2.75, 0.270, 280, 226, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4899, d2hakA_, 0.7146, 3.18, 0.304, 309, 240, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4900, d2oibA_, 0.7145, 3.06, 0.236, 280, 233, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4901, d4ztnB_, 0.7144, 3.20, 0.268, 282, 235, IRAK4-INHIBITOR CO-STRUCTURE
4902, d3lvpC_, 0.7144, 3.39, 0.198, 293, 242, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
4903, d2xyuA_, 0.7144, 3.03, 0.190, 260, 237, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
4904, p5osjA2, 0.7143, 0.45, 0.995, 214, 201, CDK2(WT) WITH COVALENT ADDUCT AT C177
4905, d5feeA_, 0.7143, 3.21, 0.211, 287, 237, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
4906, d4mcvA_, 0.7143, 3.03, 0.246, 267, 236, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
4907, d2y4pC_, 0.7143, 2.66, 0.286, 264, 227, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN
4908, d5c01A_, 0.7142, 2.80, 0.225, 258, 231, CRYSTAL STRUCTURE OF KINASE
4909, d4y73C_, 0.7142, 3.38, 0.251, 290, 239, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4910, d2y6oA_, 0.7142, 3.04, 0.190, 263, 237, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
4911, d4gk4A_, 0.7140, 3.37, 0.215, 275, 242, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
4912, d3udbB_, 0.7140, 3.35, 0.244, 278, 242, CRYSTAL STRUCTURE OF SNRK2.6
4913, d3c1xA_, 0.7140, 3.35, 0.203, 290, 241, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
4914, d4dceB_, 0.7138, 3.03, 0.183, 284, 235, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
4915, d3lq8A_, 0.7138, 3.22, 0.223, 278, 238, STRUCTURE OF THE KINASE DOMAIN OF C-MET BOUND TO XL880 (GSK1363089)
4916, d1ywnA_, 0.7138, 3.33, 0.204, 279, 240, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
4917, d4y73A_, 0.7137, 3.39, 0.251, 289, 239, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4918, d4hokK_, 0.7136, 3.61, 0.179, 290, 246, CRYSTAL STRUCTURE OF APO CK1E
4919, d2xkdA1, 0.7136, 2.46, 0.289, 243, 228, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 12
4920, d2nruA_, 0.7136, 3.33, 0.252, 293, 238, CRYSTAL STRUCTURE OF IRAK-4
4921, d2jamA_, 0.7136, 3.18, 0.288, 279, 233, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE I G
4922, d5ia4A_, 0.7135, 3.34, 0.207, 269, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
4923, d4anqA_, 0.7135, 3.22, 0.184, 293, 239, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4924, d2qq7A_, 0.7135, 2.71, 0.268, 251, 228, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
4925, d4yjuA_, 0.7134, 3.22, 0.206, 262, 238, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
4926, d3d7tA_, 0.7134, 3.02, 0.233, 249, 236, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4927, d4yp8A_, 0.7133, 3.43, 0.251, 284, 239, IRAK4-INHIBITOR CO-STRUCTURE
4928, d3tubA_, 0.7133, 3.16, 0.202, 253, 238, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
4929, d2hk5A2, 0.7133, 3.07, 0.263, 268, 236, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
4930, d5m08B_, 0.7132, 3.06, 0.188, 253, 234, CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS PKNI KINASE DOMAIN C20A_R136A DOUBLE MUTANT
4931, d5k72A_, 0.7132, 3.28, 0.271, 277, 236, IRAK4 IN COMPLEX WITH COMPOUND 21
4932, d4f0gA1, 0.7131, 3.11, 0.234, 260, 235, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM
4933, d4cmtA_, 0.7131, 3.06, 0.182, 284, 236, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
4934, d5to8A_, 0.7130, 2.89, 0.214, 250, 234, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
4935, d5fm3A_, 0.7130, 3.28, 0.249, 276, 237, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
4936, p5osmA2, 0.7129, 0.52, 0.990, 214, 201, CDK2(F80C C177A) WITH COVALENT ADDUCT AT C80
4937, d4rmzB_, 0.7129, 3.38, 0.256, 282, 238, CRYSTAL STRUCTURE OF IRAK-4
4938, d3ohtA_, 0.7129, 3.73, 0.315, 331, 251, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
4939, d3el7A_, 0.7128, 2.87, 0.251, 254, 231, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 3
4940, d2zm3A2, 0.7128, 3.44, 0.213, 299, 244, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
4941, d5tiuA1, 0.7127, 3.08, 0.201, 262, 234, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
4942, d2jkoA_, 0.7127, 3.33, 0.241, 256, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4943, d2ac3A1, 0.7127, 2.71, 0.265, 275, 226, STRUCTURE OF HUMAN MNK2 KINASE DOMAIN
4944, d4ansA_, 0.7126, 3.23, 0.184, 293, 239, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4945, d3zonA_, 0.7126, 2.86, 0.225, 261, 231, HUMAN TYK2 PSEUDOKINASE DOMAIN BOUND TO A KINASE INHIBITOR
4946, d5tx5B_, 0.7125, 3.03, 0.224, 263, 232, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4947, d5a9uA_, 0.7125, 3.20, 0.181, 292, 238, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4948, d4rmzA_, 0.7125, 3.35, 0.252, 284, 238, CRYSTAL STRUCTURE OF IRAK-4
4949, d3krlA_, 0.7125, 3.21, 0.224, 281, 237, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
4950, d5k76B_, 0.7124, 3.39, 0.252, 281, 238, IRAK4 IN COMPLEX WITH COMPOUND 28
4951, d4p5qA_, 0.7124, 3.31, 0.216, 275, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4952, d3q6uA1, 0.7124, 3.45, 0.215, 281, 242, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
4953, d3pyyB1, 0.7124, 3.03, 0.238, 244, 231, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
4954, d3pyyA1, 0.7123, 3.09, 0.236, 251, 233, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
4955, d5t1sC_, 0.7122, 3.40, 0.251, 284, 239, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4956, d4dceA_, 0.7122, 3.24, 0.185, 288, 238, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
4957, d2vwvA_, 0.7122, 3.12, 0.211, 255, 237, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4958, d4yo6C_, 0.7121, 3.39, 0.251, 286, 239, IRAK4-INHIBITOR CO-STRUCTURE
4959, d4y73B_, 0.7121, 3.44, 0.251, 289, 239, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4960, d4fnzA_, 0.7121, 3.22, 0.181, 287, 238, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
4961, d5o1vB_, 0.7120, 3.06, 0.217, 270, 230, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE (A-LOOP SWAPPED)
4962, d5k7gB_, 0.7120, 3.21, 0.251, 275, 235, IRAK4 IN COMPLEX WITH AZ3862
4963, d3cthA_, 0.7120, 3.54, 0.207, 295, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
4964, d4xg8C_, 0.7119, 2.94, 0.215, 254, 233, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4965, d3lvpD_, 0.7119, 3.08, 0.220, 282, 236, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
4966, d2x7fD_, 0.7119, 2.54, 0.258, 236, 225, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4967, d2qi8A_, 0.7119, 2.89, 0.255, 255, 231, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
4968, d5uiqC_, 0.7118, 3.21, 0.254, 280, 236, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4969, d5aa8A_, 0.7118, 3.21, 0.185, 292, 238, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
4970, d4u9aA_, 0.7118, 3.22, 0.253, 272, 233, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4971, d4hokQ_, 0.7117, 3.52, 0.184, 290, 245, CRYSTAL STRUCTURE OF APO CK1E
4972, d5fd2B_, 0.7116, 2.50, 0.212, 234, 222, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
4973, d4zloB_, 0.7116, 2.67, 0.283, 263, 226, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
4974, d4wovB_, 0.7116, 2.75, 0.228, 256, 228, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
4975, d4hokC_, 0.7116, 3.56, 0.179, 289, 246, CRYSTAL STRUCTURE OF APO CK1E
4976, d2cn5A1, 0.7116, 3.17, 0.293, 281, 229, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH ADP
4977, d2qg5A1, 0.7115, 3.20, 0.253, 268, 237, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
4978, d2pzyB_, 0.7115, 3.04, 0.268, 283, 228, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4979, d2nruB_, 0.7115, 3.36, 0.256, 294, 238, CRYSTAL STRUCTURE OF IRAK-4
4980, d4ctcA_, 0.7114, 3.12, 0.182, 288, 236, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
4981, d2y6mA_, 0.7114, 3.01, 0.191, 262, 236, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN
4982, d2wmqA_, 0.7114, 2.76, 0.298, 246, 228, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4983, d4hokG_, 0.7113, 3.60, 0.179, 290, 246, CRYSTAL STRUCTURE OF APO CK1E
4984, d2y4pA_, 0.7112, 2.61, 0.284, 251, 225, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN
4985, d2nruD_, 0.7112, 3.37, 0.252, 293, 238, CRYSTAL STRUCTURE OF IRAK-4
4986, d4p2kA_, 0.7111, 3.23, 0.185, 259, 238, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4987, d2pzyC_, 0.7109, 3.01, 0.266, 307, 229, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4988, d4xg7A1, 0.7108, 3.15, 0.203, 265, 236, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4989, d4u97A_, 0.7108, 3.23, 0.258, 272, 233, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4990, d4f4pA1, 0.7108, 3.20, 0.203, 260, 236, SYK IN COMPLEX WITH LIGAND LASW836
4991, d3piyA_, 0.7108, 3.13, 0.199, 262, 236, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
4992, d3famB_, 0.7108, 3.16, 0.303, 239, 234,  
4993, d3c7qA_, 0.7108, 3.36, 0.204, 286, 240, STRUCTURE OF VEGFR2 KINASE DOMAIN IN COMPLEX WITH BIBF1120
4994, d2eueB_, 0.7108, 3.16, 0.303, 239, 234,  
4995, d4qqcA1, 0.7107, 3.37, 0.249, 271, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4996, d4i4eA_, 0.7107, 3.27, 0.243, 254, 239, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH HINGE BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
4997, d3ce3A_, 0.7107, 3.53, 0.203, 293, 241, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
4998, d5t1tB_, 0.7106, 3.20, 0.269, 280, 234, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4999, d5fdxA_, 0.7106, 3.56, 0.224, 280, 245, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
5000, d2wqeA_, 0.7106, 2.77, 0.288, 241, 229, STRUCTURE OF S155R AURORA-A SOMATIC MUTANT
